azathioprine has been researched along with Crohn Disease in 1279 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2." | 9.12 | 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007) |
| "To evaluate, in a prospective, open-label study, the influence of antibiotics and azathioprine on the clinical outcome of perianal fistulas in patients with Crohn's disease." | 9.10 | Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. ( Dejaco, C; Harrer, M; Miehsler, W; Reinisch, W; Vogelsang, H; Waldhoer, T, 2003) |
| "The study included 20 consecutive patients with Crohn's colitis or ileocolitis in clinical remission while taking azathioprine for at least 9 months and no corticosteroids for at least 3 months who had had an ileocolonoscopy less than 1 year before the start of azathioprine." | 9.09 | Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. ( D'Haens, G; Geboes, K; Rutgeerts, P, 1999) |
| "Our aim was to report the clinical experience with combination treatment using tacrolimus and either azathioprine (AZA) or 6-mercaptopurine (6MP) in patients with Crohn's disease (CD) perianal fistulae." | 9.09 | Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. ( Lowry, PW; Sandborn, WJ; Tremaine, WJ; Weaver, AL, 1999) |
| " We report a case of disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under steroids and azathioprine." | 8.90 | Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under azathioprine and steroids: First case report and literature review. ( Abreu, C; Andrade, P; Coelho, R; Lopes, S; Macedo, G; Magro, F; Santos-Antunes, J; Vilas-Boas, F, 2014) |
| "A case of acute pancreatitis induced by azathioprine presented in a 22-year-old patient with Crohn's disease is reported." | 8.80 | [Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease]. ( Caro-Paton, A; Fernández, P; González, JM; Goyeneche, ML; Martín, MA; Remacha, B; Sánchez, G; Velicia, MR, 1999) |
| "To assess the effectiveness of azathioprine and 6-mercaptopurine in inducing remission of active Crohn disease and the effectiveness of azathioprine in maintaining remission of quiescent disease." | 8.79 | Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. ( Fick, GH; May, GR; Pearson, DC; Sutherland, LR, 1995) |
| "The immunosuppressant drug azathioprine is associated with a 4% risk of acute pancreatitis in patients with inflammatory bowel disease (IBD)." | 8.12 | HLA variants associated with azathioprine-induced pancreatitis in patients with Crohn's disease. ( Ås, J; Bertulyte, I; Eriksson, N; Hallberg, P; Magnusson, PKE; Wadelius, M, 2022) |
| "Azathioprine (AZA)-induced leukopenia is a common but life-threatening complication of inflammatory bowel disease." | 8.12 | A rare case of Azathioprine-induced leukopenia in an European woman. ( Jean-Charles, C; Séverine, W; Xavier, K, 2022) |
| "A 52-year-old woman was treated for colorectal diffuse large B-cell lymphoma (DLBCL) after a prolonged treatment period of azathioprine (AZA) and infliximab (IFX) for Crohn's disease (CD)." | 7.96 | Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. ( Daikuhara, S; Hirayama, A; Sato, K; Suga, T; Tanaka, E; Uehara, T, 2020) |
| "We describe two children with CD in whom MP were successfully trialled after a confirmed azathioprine-induced pancreatitis, being well tolerated in both cases." | 7.81 | Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn's Disease. ( Bartosova, L; Blasco-Alonso, J; Fernández-Crehuet, FG; Gallego-Gutiérrez, S; García-Galán, P; Kolorz, M; Lukac, K; Luque-Pérez, S; Navas-López, VM; Núñez-Caro, L; Serrano-Nieto, MJ; Sierra-Salinas, C, 2015) |
| " To our knowledge this is the first reported case of LYG related to azathioprine therapy in Crohn disease." | 7.80 | Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. ( Belletrutti, PJ; Connors, W; Griffiths, C; Patel, J, 2014) |
| " We present a case of disseminated histoplasmosis presenting as Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine." | 7.79 | Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine. ( Abou Zahr, A; Saad Aldin, E; Yunyongying, P, 2013) |
| "We report a case of a Crohn's disease patient who developed pulmonary cryptococcosis following chicken manure exposition while he received adalimumab and azathioprine." | 7.79 | Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination. ( Fraison, JB; Guilpain, P; Le Moing, V; Le Quellec, A; Rispail, P; Schiffmann, A; Veyrac, M, 2013) |
| "We report the case of a 53-year-old man with Crohn's disease who developed azathioprine-induced nodular regenerative hyperplasia of the liver." | 7.77 | [Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease]. ( Corbatón, P; de la Fuente-Fernández, E; Gisbert, JP; López-Martín, C; Sánchez, MC, 2011) |
| " In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administer azathioprine during pregnancy." | 7.77 | The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. ( Oussalah, A; Peyrin-Biroulet, L; Roblin, X; Sparrow, MP, 2011) |
| "We describe a case of 36-year-old Japanese man with Crohn's disease, complicated by Bacillus cereus bacteremia on maintenance azathioprine therapy." | 7.75 | [Bacillus cereus bacteremia in Crohn's disease with multiple ileal stricture on maintenance azathioprine therapy]. ( Hizawa, K; Iida, M; Matsumoto, T; Nagata, Y; Nakamori, M; Taniguchi, M, 2009) |
| "In a retrospective multicenter study, efficacy of methotrexate in inducing and maintaining remission or response was assessed by Harvey-Bradshaw activity index, paediatric Crohn disease activity index and steroid use, in 25 children with Crohn disease, refractory or intolerant to thiopurine analogues." | 7.75 | Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. ( Broide, E; Bujanover, Y; Fradkin, A; Lerner, A; Levine, A; Shapiro, R; Weiss, B, 2009) |
| "This was a cross-sectional study of 51 pediatric patients with Crohn disease who were prescribed maintenance therapy with a thiopurine immunomodulator (6-mercaptopurine or azathioprine) and/or mesalamine during a 180-day period." | 7.74 | Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. ( Abadom, V; Cuffari, C; Oliva-Hemker, MM; Thompson, RE, 2007) |
| " We describe a patient with Crohn's disease, treated with azathioprine, who developed peliosis hepatis after three epsiodes of alcohol binging." | 7.74 | Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease. ( Elsing, C; Herrmann, T; Placke, J, 2007) |
| "To determine whether long-term low-dose prednisone (LTLDP) therapy has a decelerating effect on growth velocity and whether this therapy is effective in the maintenance of remission in the subgroup of pediatric patients with Crohn disease (CD) who had previously experienced flares on more than 1 occasion when prednisone was discontinued." | 7.74 | Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. ( Hanauer, SB; Kirschner, BS; Navarro, FA, 2007) |
| "We hypothesized that the presence of pancreatic autoantibodies in Crohn's disease patients is associated with the development of azathioprine-induced pancreatitis." | 7.74 | Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease? ( Batstra, MR; Kleibeuker, JH; van Dullemen, HM; Weersma, RK, 2008) |
| " constellatus chorioamnionitis in a pregnant Crohn's disease patient who was taking azathioprine." | 7.73 | Chorioamnionitis associated with Crohn's disease and azathioprine treatment: a case report. ( Gutman, G; Helpman, L; Kupferminc, MJ; Lessing, JB; Pauzner, D, 2005) |
| "The use of azathioprine (AZA) in the treatment of autoimmune diseases during pregnancy are believed to be relatively safe, particularly taking into account the potential risks for mother and fetus should the underlying disease become active due to withdrawal of this thiopurine." | 7.73 | Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. ( de Boer, NK; de Graaf, P; Jarbandhan, SV; Mulder, CJ; van Bodegraven, AA; van Elburg, RM, 2006) |
| "6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn disease (CD)." | 7.71 | Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. ( Belaiche, J; Desager, JP; Horsmans, Y; Louis, E, 2001) |
| "A patient is presented with Crohn disease who developed tuberculous pleurisy while treated with azathioprine." | 7.71 | Tuberculous pleurisy: an unusual complication during treatment of Crohn disease with azathioprine. ( Meijssen, MA; van Wijngaarden, P, 2001) |
| "A 22-year-old woman without predisposing liver disease developed focal hepatic glycogenosis and hepatocellular carcinoma after 6 years of azathioprine therapy for Crohn's disease." | 7.70 | Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. ( Cattan, S; Chazouilleres, O; Gendre, JP; Schmitz, J; Wendum, D, 2000) |
| "Azathioprine is an immunosuppressive drug widely used in the treatment of chronic inflammatory diseases, including Multiple Sclerosis (MS)." | 7.70 | Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases. ( Blumhardt, LD; Constantinescu, CS; Whiteley, A, 2000) |
| "Of the 19 patients treated with azathioprine for recurrent ileitis, 15 could be reevaluated by endoscopy or radiological examination." | 7.69 | Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. ( D'Haens, G; Geboes, K; Penninckx, F; Ponette, E; Rutgeerts, P, 1997) |
| "The combination of cyclosporine, azathioprine and low-dose prednisolone leads to marked improvement of perianal fistulas in Crohn's disease." | 7.69 | Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. ( Aichbichler, B; Fickert, P; Hinterleitner, TA; Krejs, GJ; Petritsch, W; Ranner, G, 1997) |
| "Azathioprine therapy in a patient with granulomatous ileocolitis was associated with an attack of acute pancreatitis, which was confirmed by laparotomy." | 7.65 | Azathioprine-associated acute pancreatitis. ( Levin, B; Paloyan, D; Simonowitz, D, 1977) |
| "We report here a case of Crohn's disease in which there is strong circumstantial evidence that azathioprine precipitated the development of an intraabdominal abscess on two separate occasions." | 7.65 | Intraabdominal abscesses due to azathioprine for Crohn's disease. ( Northfield, TC; Roberts, CI, 1972) |
| "We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients." | 6.84 | Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine. ( Bronsky, J; Copova, I; Hradsky, O; Pos, L; Rouskova, B; Skaba, R; Zarubova, K, 2017) |
| "Azathioprine (aza) therapy is beneficial in the treatment of inflammatory bowel disease, but 10%-30% of patients cannot tolerate aza therapy because of adverse drug reactions." | 6.71 | Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2005) |
| "Azathioprine is commonly used in Crohn's disease." | 5.48 | A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. ( Audrain, M; Caldari, D; Dert, C; Hémont, C; Joyau, C; Léger, A; Mirallié, S; Monteil-Ganiere, C; Thomas, C, 2018) |
| "AZA-induced acute pancreatitis is a common adverse event in IBD patients, but in this study had a mild course in all patients." | 5.43 | Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. ( Bokemeyer, B; Bündgens, B; Büning, J; Drabik, A; Helwig, U; Hüppe, D; Klugmann, T; Kruis, W; Maaser, C; Miehlke, S; Mohl, W; Siegmund, B; Stallmach, A; Teich, N; Weismüller, J, 2016) |
| "She developed an encephalopathy which resolved after discontinuation of ganciclovir." | 5.43 | Ganciclovir-induced ataxia and encephalopathy. ( Kramer, MH; Möhlmann, MC; Stiksma, J, 2016) |
| "He was diagnosed with Crohn's disease 3 years ago after suffering from abdominal pain and hematochezia for 12 years." | 5.39 | [A case of pleomorphic liposarcoma in a patient with Crohn's disease taking azathioprine]. ( Ahn, SM; Bae, JY; Oh, YM; Park, CA; Sim, HH; Song, CM; Suh, SO; Yun, CY, 2013) |
| "Neutropenia was ameliorated with use of granulocyte colony-stimulating factor." | 5.37 | Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn's disease. ( Alkim, C; Alkim, H; Altinkaya, E; Boğa, S; Buğdaci, MS; Köksal, AR; Özdoğan, O; Sökmen, M, 2011) |
| " The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia." | 5.35 | Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine. ( de Boer, NK; Kanis, BM; van Asseldonk, DP; van Bodegraven, AA, 2009) |
| "Azathioprine dosage was adjusted according to clinical response and occurrence of adverse events." | 5.35 | Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. ( Chebli, JM; Chebli, LA; do Amaral, FJ; Gaburri, PD; Meirelles de Souza, AF; Moraes, JP; Pace, FH; Pinto, AL; Ribeiro, MS, 2009) |
| "In addition, acute pancreatitis is one of the extra-intestinal manifestations of acute exacerbation of CD without the previous use of azathioprine." | 5.35 | [Acute pancreatitis following azathioprine therapy of crohn's disease--a case report and the overview of the literature]. ( Koren, M; Potrc, S; Sinkovic, A; Skok, P, 2008) |
| "Hepatocellular carcinoma is known to be associated with underlying liver diseases, such as cirrhosis, hemochromatosis, and chronic viral hepatitis." | 5.33 | Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. ( Chen, SC; Cho, WK; Cummings, OW; Filomena, CA; Hartley, MP, 2006) |
| " These observations suggest that the development of muscular weakness in patients on azathioprine should be considered as an adverse effect of the drug." | 5.33 | Severe muscular weakness: an unusual adverse effect of azathioprine therapy. ( Arora, M; Dutta, SK; Karhadkar, AS; Schwartz, HJ, 2006) |
| "Acute pancreatitis is rarely seen when azathioprine is used for other diseases than Crohn's disease." | 5.32 | Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. ( Homan van der Heide, JJ; Jansen, PL; Oostenbrug, LE; Peters, FT; Ploeg, RJ; Posthumus, MD; van den Berg, AP; van Dullemen, HM; van Haastert, M; Weersma, RK, 2004) |
| "A 19 year old man with a history of Crohn's disease treated with azathioprine and prednisone, died after a primary infection with Epstein-Barr virus." | 5.29 | Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. ( Kluin, PM; Kluin-Nelemans, JC; Lamers, CB; Posthuma, EF; van der Sluys Veer, A; Westendorp, RG, 1995) |
| "A patient with Crohn's disease and alopecia totalis is described." | 5.28 | Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine. ( August, PJ; Goddard, CJ; Whorwell, PJ, 1989) |
| " The recommendations encompass pretreatment evaluation; medical management of active IBD; medical management of IBD in remission; management of IBD during the periconception period and pregnancy; surveillance strategies for colitis-associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD." | 5.12 | Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. ( Ahuja, V; Andoh, A; Chen, M; Han, DS; Hibi, T; Hilmi, IN; Hu, PJ; Jeen, YT; Kim, HJ; Leung, WK; Matsuoka, K; Ng, SC; Ooi, CJ; Qian, J; Ran, Z; Sollano, J; Suzuki, Y; Watanabe, M; Wei, SC; Wu, K; Yang, SK, 2021) |
| "A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2." | 5.12 | 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007) |
| "To evaluate, in a prospective, open-label study, the influence of antibiotics and azathioprine on the clinical outcome of perianal fistulas in patients with Crohn's disease." | 5.10 | Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. ( Dejaco, C; Harrer, M; Miehsler, W; Reinisch, W; Vogelsang, H; Waldhoer, T, 2003) |
| "The study included 20 consecutive patients with Crohn's colitis or ileocolitis in clinical remission while taking azathioprine for at least 9 months and no corticosteroids for at least 3 months who had had an ileocolonoscopy less than 1 year before the start of azathioprine." | 5.09 | Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. ( D'Haens, G; Geboes, K; Rutgeerts, P, 1999) |
| "Our aim was to report the clinical experience with combination treatment using tacrolimus and either azathioprine (AZA) or 6-mercaptopurine (6MP) in patients with Crohn's disease (CD) perianal fistulae." | 5.09 | Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. ( Lowry, PW; Sandborn, WJ; Tremaine, WJ; Weaver, AL, 1999) |
| " The thiopurine drugs, azathioprine and 6-mercaptopurine, are commonly used to maintain remission in Crohn's disease and ulcerative colitis; however, the use of these drugs may be limited by the development of pancreatitis in some individuals." | 4.91 | Thiopurine-induced pancreatitis in inflammatory bowel diseases. ( Day, AS; Ledder, O; Lemberg, DA, 2015) |
| " We report a case of disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under steroids and azathioprine." | 4.90 | Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under azathioprine and steroids: First case report and literature review. ( Abreu, C; Andrade, P; Coelho, R; Lopes, S; Macedo, G; Magro, F; Santos-Antunes, J; Vilas-Boas, F, 2014) |
| "A case of acute pancreatitis induced by azathioprine presented in a 22-year-old patient with Crohn's disease is reported." | 4.80 | [Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease]. ( Caro-Paton, A; Fernández, P; González, JM; Goyeneche, ML; Martín, MA; Remacha, B; Sánchez, G; Velicia, MR, 1999) |
| "To assess the effectiveness of azathioprine and 6-mercaptopurine in inducing remission of active Crohn disease and the effectiveness of azathioprine in maintaining remission of quiescent disease." | 4.79 | Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. ( Fick, GH; May, GR; Pearson, DC; Sutherland, LR, 1995) |
| "The immunosuppressant drug azathioprine is associated with a 4% risk of acute pancreatitis in patients with inflammatory bowel disease (IBD)." | 4.12 | HLA variants associated with azathioprine-induced pancreatitis in patients with Crohn's disease. ( Ås, J; Bertulyte, I; Eriksson, N; Hallberg, P; Magnusson, PKE; Wadelius, M, 2022) |
| "Azathioprine (AZA)-induced leukopenia is a common but life-threatening complication of inflammatory bowel disease." | 4.12 | A rare case of Azathioprine-induced leukopenia in an European woman. ( Jean-Charles, C; Séverine, W; Xavier, K, 2022) |
| "A total of N = 42 pediatric IBD patients (Crohn disease, n = 30; ulcerative colitis, n = 12) for whom an anti-TNFα therapy with and without a concomitant azathioprine (AZA) medication was administered were recruited." | 4.02 | Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy. ( Allabauer, I; Christoph, J; Ehrsam, C; Hess, M; Hoerning, A; Kaspar, S; Metzler, M; Rascher, W; Rechenauer, T; Rieger, D; Rückel, A; Schmidt, H; Schnell, A; Schwarz, B; Siebenlist, G; Wahlbuhl, M; Weber, S; Werner, F; Woelfle, J, 2021) |
| "A 52-year-old woman was treated for colorectal diffuse large B-cell lymphoma (DLBCL) after a prolonged treatment period of azathioprine (AZA) and infliximab (IFX) for Crohn's disease (CD)." | 3.96 | Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. ( Daikuhara, S; Hirayama, A; Sato, K; Suga, T; Tanaka, E; Uehara, T, 2020) |
| "We report on a 25-year-old female patient with Crohn's disease and profound lymphocytopenia while receiving corticosteroids and azathioprine." | 3.88 | [Severe lymphopenia in a patient with Crohn's disease]. ( Hasselblatt, P; Kreisel, W; Monasterio, C, 2018) |
| "In this paper, we describe a case of an acute cytomegalovirus (CMV) infection in a 35-year-old male patient with Crohn's disease being in remission while receiving azathioprine therapy." | 3.88 | Severe complication during remission of Crohn's disease: hemophagocytic lymphohistiocytosis due to acute cytomegalovirus infection. ( Aichinger, W; Kirchgatterer, A; Miechowiecki, J; Prammer, W; Stainer, W; Tuppy, H; Wallner, G, 2018) |
| "We report a rare case of chronic paracoccidioidomycosis(PCM) in a woman with Crohn disease in the setting of treatment with azathioprine and mesalazine." | 3.85 | Chronic paracoccidioidmycosis in a woman with Crohn Disease. ( Augusto Benevenuto de Andrade, B; Bufalino, A; Caxias Travassos, D; Fernandes, D; Tavares Dos Santos, H, 2017) |
| " We report a case of a 13-year-old girl who presented with orofacial swelling and arthralgia, who eventually was diagnosed with Crohn's disease, which was successfully treated with infliximab and azathioprine combination therapy." | 3.83 | Case report of cheilitis granulomatosa and joint complaints as presentation of Crohn's disease. ( Benninga, MA; D'Haens, GR; Hoekman, DR; Roelofs, JJ; Schonenberg-Meinema, D; van Schuppen, J, 2016) |
| "6-TGN measurement is a helpful method of preventing disease relapse and avoiding leukopenia in individual azathioprine maintenance therapy." | 3.83 | Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients. ( Han, W; Hu, J; Hu, N; Liu, Q; Mei, Q; Wang, Y, 2016) |
| "A cost-utility analysis was performed comparing five smoking cessation strategies: No Program, Counseling, Nicotine Replacement Therapy (NRT), NRT+Counseling, and Varenicline." | 3.81 | Funding a smoking cessation program for Crohn's disease: an economic evaluation. ( Barkema, HW; Clement, F; Coward, S; Ghosh, S; Heitman, SJ; Kaplan, GG; Leung, YP; Negron, M; Panaccione, R; Seow, C, 2015) |
| "We describe two children with CD in whom MP were successfully trialled after a confirmed azathioprine-induced pancreatitis, being well tolerated in both cases." | 3.81 | Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn's Disease. ( Bartosova, L; Blasco-Alonso, J; Fernández-Crehuet, FG; Gallego-Gutiérrez, S; García-Galán, P; Kolorz, M; Lukac, K; Luque-Pérez, S; Navas-López, VM; Núñez-Caro, L; Serrano-Nieto, MJ; Sierra-Salinas, C, 2015) |
| "Thiopurines (azathioprine, 6-mercaptopurine) are a mainstay of treatment in Crohn disease (CD)." | 3.80 | Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease. ( Amre, D; Deslandres, C; Kopylov, U; Seidman, EG; Theoret, Y, 2014) |
| " To our knowledge this is the first reported case of LYG related to azathioprine therapy in Crohn disease." | 3.80 | Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. ( Belletrutti, PJ; Connors, W; Griffiths, C; Patel, J, 2014) |
| "An 81-year-old woman with Crohn disease presented with fever and an acute eruption of plaques on her extremities within 2 weeks of starting treatment with azathioprine." | 3.79 | Neutrophilic dermatosis after azathioprine exposure. ( Choi, JN; Cyrus, N; Ko, CJ; Mason, AR; Stavert, R, 2013) |
| " We present a case of disseminated histoplasmosis presenting as Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine." | 3.79 | Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine. ( Abou Zahr, A; Saad Aldin, E; Yunyongying, P, 2013) |
| " Four cases are presented of TIP appropriately related temporally to azathioprine commencement, with no other apparent cause of pancreatitis identified." | 3.79 | Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? ( Day, AS; Ledder, OD; Lemberg, DA; Ooi, CY, 2013) |
| "We report a case of a Crohn's disease patient who developed pulmonary cryptococcosis following chicken manure exposition while he received adalimumab and azathioprine." | 3.79 | Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination. ( Fraison, JB; Guilpain, P; Le Moing, V; Le Quellec, A; Rispail, P; Schiffmann, A; Veyrac, M, 2013) |
| "A 39-year-old Afro-Caribbean man with Crohn disease with recurrent deep vein thromboses and pulmonary emboli was commenced on lifelong warfarin treatment." | 3.77 | Exacerbation of hereditary warfarin resistance by azathioprine. ( Campbell, S; Gambhir, N; Hadfield, KD; Latif, A; Newman, WG; Pushpakom, SP, 2011) |
| "We report the case of a 53-year-old man with Crohn's disease who developed azathioprine-induced nodular regenerative hyperplasia of the liver." | 3.77 | [Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease]. ( Corbatón, P; de la Fuente-Fernández, E; Gisbert, JP; López-Martín, C; Sánchez, MC, 2011) |
| " In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administer azathioprine during pregnancy." | 3.77 | The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. ( Oussalah, A; Peyrin-Biroulet, L; Roblin, X; Sparrow, MP, 2011) |
| "To assess the risk of infections in offspring breastfed by mothers receiving azathioprine (AZA) for inflammatory bowel disease (IBD)." | 3.77 | Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. ( Angelberger, S; Dejaco, C; Messerschmidt, A; Miehsler, W; Novacek, G; Reinisch, W; Vogelsang, H, 2011) |
| "We describe a case of 36-year-old Japanese man with Crohn's disease, complicated by Bacillus cereus bacteremia on maintenance azathioprine therapy." | 3.75 | [Bacillus cereus bacteremia in Crohn's disease with multiple ileal stricture on maintenance azathioprine therapy]. ( Hizawa, K; Iida, M; Matsumoto, T; Nagata, Y; Nakamori, M; Taniguchi, M, 2009) |
| "In a retrospective multicenter study, efficacy of methotrexate in inducing and maintaining remission or response was assessed by Harvey-Bradshaw activity index, paediatric Crohn disease activity index and steroid use, in 25 children with Crohn disease, refractory or intolerant to thiopurine analogues." | 3.75 | Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. ( Broide, E; Bujanover, Y; Fradkin, A; Lerner, A; Levine, A; Shapiro, R; Weiss, B, 2009) |
| "Reported herein is a case of hepatocellular carcinoma (HCC) occurring in a 25-year-old Japanese man who was diagnosed with Crohn's disease (CD) at 14 years of age; treatment included predonisolone, azathioprine, and infliximab." | 3.75 | Hepatocellular carcinoma occurring in a young Crohn's disease patient. ( Enaka, M; Kawachi, K; Kunisaki, R; Morimoto, M; Murakami, A; Nagano, Y; Nozawa, A; Sasaki, T; Tanabe, M; Tanaka, Y; Ueda, M, 2009) |
| "Although azathioprine usually is reserved for inflammatory bowel disease that proves difficult to control, routine early use has recently been advocated for children with Crohn disease." | 3.74 | Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. ( Davies, P; Mossop, H; Murphy, MS, 2008) |
| "Pancytopenia was most likely azathioprine-related." | 3.74 | [Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease]. ( Günther, U; Loddenkemper, C; Preiss, JC; Schumann, M; Siegmund, B; Somasundaram, R; Zeitz, M, 2008) |
| "This was a cross-sectional study of 51 pediatric patients with Crohn disease who were prescribed maintenance therapy with a thiopurine immunomodulator (6-mercaptopurine or azathioprine) and/or mesalamine during a 180-day period." | 3.74 | Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. ( Abadom, V; Cuffari, C; Oliva-Hemker, MM; Thompson, RE, 2007) |
| " We describe a patient with Crohn's disease, treated with azathioprine, who developed peliosis hepatis after three epsiodes of alcohol binging." | 3.74 | Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease. ( Elsing, C; Herrmann, T; Placke, J, 2007) |
| "To determine whether long-term low-dose prednisone (LTLDP) therapy has a decelerating effect on growth velocity and whether this therapy is effective in the maintenance of remission in the subgroup of pediatric patients with Crohn disease (CD) who had previously experienced flares on more than 1 occasion when prednisone was discontinued." | 3.74 | Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. ( Hanauer, SB; Kirschner, BS; Navarro, FA, 2007) |
| "We hypothesized that the presence of pancreatic autoantibodies in Crohn's disease patients is associated with the development of azathioprine-induced pancreatitis." | 3.74 | Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease? ( Batstra, MR; Kleibeuker, JH; van Dullemen, HM; Weersma, RK, 2008) |
| "Azathioprine and 6-mercaptopurine are useful therapies in inflammatory bowel diseases." | 3.73 | 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. ( Domènech, E; Garcia-Planella, E; Gassull, MA; López-San Román, A; Nos, P; Papo, M, 2005) |
| " Azathioprine has a significant early adverse reaction (EAR) profile, which includes an acute syndrome of constitutional symptoms, fever, rash, and acute pancreatitis and often requires discontinuation of drug." | 3.73 | Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. ( Bajaj, JS; Binion, DG; Emmons, J; Franco, J; Knox, JF; Levy, M; Podoll, J; Saeian, K; Varma, RR, 2005) |
| " constellatus chorioamnionitis in a pregnant Crohn's disease patient who was taking azathioprine." | 3.73 | Chorioamnionitis associated with Crohn's disease and azathioprine treatment: a case report. ( Gutman, G; Helpman, L; Kupferminc, MJ; Lessing, JB; Pauzner, D, 2005) |
| "The use of azathioprine (AZA) in the treatment of autoimmune diseases during pregnancy are believed to be relatively safe, particularly taking into account the potential risks for mother and fetus should the underlying disease become active due to withdrawal of this thiopurine." | 3.73 | Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. ( de Boer, NK; de Graaf, P; Jarbandhan, SV; Mulder, CJ; van Bodegraven, AA; van Elburg, RM, 2006) |
| "Studies on azathioprine (Aza) treatment in Crohn disease have indicated a positive correlation between clinical remission and a concentration in erythrocytes of the metabolites 6-thioguanine nucleotides (E-6-TGN) above 230 pmol/8 x 10(8) RBC." | 3.72 | Pharmacological monitoring of azathioprine therapy. ( Christensen, S; Haaber, A; Johansen, N; Kjeldsen, J; Larsen, B; Larsen, NE; Rasmussen, SN; Reuther, LO; Schmiegelow, K; Sonne, J; Tofteng, F, 2003) |
| "Asymptomatic man receiving maintenance azathioprine therapy for Crohn disease whose wife had multidrug-resistant pulmonary tuberculosis." | 3.72 | Early diagnosis of subclinical multidrug-resistant tuberculosis. ( Ewer, K; Fabbri, LM; Hansell, DM; Lalvani, A; Losi, M; Richeldi, L; Roversi, P, 2004) |
| "although azathioprine (AZA) is an effective immunomodulator in treating Crohn's disease, some patients develop leukopenia and risk severe infections." | 3.71 | Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. ( Mardini, H; Regueiro, M, 2002) |
| "6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn disease (CD)." | 3.71 | Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. ( Belaiche, J; Desager, JP; Horsmans, Y; Louis, E, 2001) |
| "A patient is presented with Crohn disease who developed tuberculous pleurisy while treated with azathioprine." | 3.71 | Tuberculous pleurisy: an unusual complication during treatment of Crohn disease with azathioprine. ( Meijssen, MA; van Wijngaarden, P, 2001) |
| " They developed leukopenia or thrombocytopenia during azathioprine or 6-mercaptopurine treatment." | 3.70 | Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. ( Bonaz, B; Broly, F; Catala, P; Colombel, JF; Debuysere, H; Ferrari, N; Gendre, JP; Libersa, C; Marteau, P; Modigliani, R; Soulé, JC; Touze, Y, 2000) |
| "A 22-year-old woman without predisposing liver disease developed focal hepatic glycogenosis and hepatocellular carcinoma after 6 years of azathioprine therapy for Crohn's disease." | 3.70 | Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. ( Cattan, S; Chazouilleres, O; Gendre, JP; Schmitz, J; Wendum, D, 2000) |
| "Azathioprine is an immunosuppressive drug widely used in the treatment of chronic inflammatory diseases, including Multiple Sclerosis (MS)." | 3.70 | Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases. ( Blumhardt, LD; Constantinescu, CS; Whiteley, A, 2000) |
| "Of the 19 patients treated with azathioprine for recurrent ileitis, 15 could be reevaluated by endoscopy or radiological examination." | 3.69 | Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. ( D'Haens, G; Geboes, K; Penninckx, F; Ponette, E; Rutgeerts, P, 1997) |
| "The combination of cyclosporine, azathioprine and low-dose prednisolone leads to marked improvement of perianal fistulas in Crohn's disease." | 3.69 | Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. ( Aichbichler, B; Fickert, P; Hinterleitner, TA; Krejs, GJ; Petritsch, W; Ranner, G, 1997) |
| "A prospective study in the United Kingdom of 1,634 patients without transplants treated with immunosuppressive drugs (68 percent with azathioprine, 28 percent with cyclophosphamide) found an excess of non-Hodgkin's lymphoma and squamous cell skin cancer, suggesting that the excesses (although larger) of the same malignancies found among transplant recipients are not due solely to the foreign antigens of the graft." | 3.67 | Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. ( Kinlen, LJ, 1985) |
| "Azathioprine therapy in a patient with granulomatous ileocolitis was associated with an attack of acute pancreatitis, which was confirmed by laparotomy." | 3.65 | Azathioprine-associated acute pancreatitis. ( Levin, B; Paloyan, D; Simonowitz, D, 1977) |
| "We report here a case of Crohn's disease in which there is strong circumstantial evidence that azathioprine precipitated the development of an intraabdominal abscess on two separate occasions." | 3.65 | Intraabdominal abscesses due to azathioprine for Crohn's disease. ( Northfield, TC; Roberts, CI, 1972) |
| "Adult patients with Crohn's disease in steroid-free clinical remission for more than 6 months, on combination therapy of infliximab and immunosuppressant therapy for at least 8 months were randomly assigned (1:1:1) to either continue combination therapy (combination group), discontinue infliximab (infliximab withdrawal group), or discontinue immunosuppressant therapy (immunosuppressant withdrawal group)." | 3.30 | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. ( Almer, S; Baert, F; Ben-Horin, S; Bossuyt, P; Bouhnik, Y; Colombel, JF; D'Haens, G; Ding, N; Fumery, M; Gilletta, C; Hertervig, E; Irving, P; Laharie, D; Lamb, CA; Louis, E; Nachury, M; Picon, L; Pollok, R; Resche-Rigon, M; Satsangi, J; Siegmund, B; Viennot, S; Vuitton, L, 2023) |
| "Among Chinese patients with Crohn's disease, dose optimisation by NUDT15 C415T reduced the rate of thiopurine-induced leucopenia, without significant influence on efficacy." | 3.01 | Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. ( Cao, Q; Chao, K; Gao, X; Guo, H; Hu, P; Huang, J; Huang, M; Huang, Y; Li, M; Lin, L; Tang, J; Wang, X; Yang, Q; Ye, L; Zhang, C; Zhu, X, 2021) |
| "The impact of severity and location of Crohn's disease (CD) endoscopic ulcers on endoscopic remission in patients treated with antitumor necrosis factor is poorly known." | 3.01 | Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. ( Baert, F; Bossuyt, P; Buisson, A; D'Haens, G; Laharie, D; Lambrecht, G; Oldenburg, B; Pariente, B; Peyrin-Biroulet, L; Rivière, P; Vermeire, S, 2021) |
| "Curcumin has anti-inflammatory properties and induces endoscopic remission in patients with ulcerative colitis." | 2.94 | Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. ( Bommelaer, G; Buisson, A; Fumery, M; Goutte, M; Hebuterne, X; Laharie, D; Nachury, M; Nancey, S; Pereira, B; Peyrin-Biroulet, L; Richard, D; Roblin, X, 2020) |
| "Clinical failure was defined for Crohn's disease (CD) as a Harvey-Bradshaw index ≥5 associated with a faecal calprotectin level >250 µg/g stool and for UC as a Mayo score >5 with endoscopic subscore >1 or as the occurrence of adverse events requiring to stop treatment." | 2.94 | Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. ( Berger, AE; Boschetti, G; Del Tedesco, E; Duru, G; Flourie, B; Nancey, S; Paul, S; Peyrin-Biroulet, L; Phelip, JM; Roblin, X; Vedrines, P; Williet, N, 2020) |
| "Early prediction of postoperative recurrence (POR) remains a major concern in Crohn's disease (CD)." | 2.94 | Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. ( Bommelaer, G; Boube, M; Buisson, A; Fumery, M; Hebuterne, X; Laharie, D; Minet-Quinard, R; Nancey, S; Pariente, B; Pereira, B; Peyrin-Biroulet, L; Roblin, X, 2020) |
| "The recurrence of Crohn's Disease after ileo-colonic resection is a crucial issue." | 2.94 | Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. ( Angelucci, E; Annese, V; Aratari, A; Biancone, L; Bossa, F; Cappello, M; Castiglione, F; Cottone, M; Di Mitri, R; Giunta, M; Kohn, A; Macaluso, FS; Mocciaro, F; Onali, S; Orlando, A; Papi, C; Renna, S; Rispo, A; Scimeca, D; Scribano, ML; Testa, A; Ventimiglia, M, 2020) |
| " Combination therapy with azathioprine appears to improve efficacy by increasing pharmacokinetic features of infliximab." | 2.90 | Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. ( Adedokun, OJ; Colombel, JF; Cornillie, FJ; D'Haens, GR; Gao, LL; Gasink, C; Hanauer, SB; Reinisch, W; Rutgeerts, PJ; Sandborn, WJ, 2019) |
| "In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA)." | 2.90 | Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. ( Alba, C; Barrio, J; Bermejo, F; Calvet, X; Castro, L; Ceballos, D; Domènech, E; Echarri, A; Esteve, M; Gisbert, JP; Guardiola, J; Hinojosa, J; Iglesias, E; López-Sanromán, A; Marín-Jiménez, I; Márquez-Mosquera, L; Martín-Arranz, MD; Martínez-Montiel, P; Mínguez, M; Nos, P; Pons, V; Rimola, J; Ruiz, VV; Taxonera, C; Vera-Mendoza, I, 2019) |
| " The main reason for study dropout was active CD in the monotherapy group, whereas it was adverse effects in the combination group [Fisher's exact test, p <0." | 2.90 | Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. ( Esaki, M; Hibi, T; Hisamatsu, T; Ishida, T; Kanai, T; Kato, S; Matsui, T; Matsumoto, T; Motoya, S; Nagahori, M; Naito, Y; Nakagawa, T; Nakase, H; Nojima, M; Suzuki, Y; Watanabe, K; Watanabe, M; Yoshimura, N, 2019) |
| "Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered." | 2.84 | Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial. ( Barrio, J; Bermejo, F; Calvet, X; Castro, L; Ceballos, D; Domènech, E; Echarri, A; Esteve, M; Gisbert, JP; Guardiola, J; Hinojosa, J; Iglesias, E; López-Sanromán, A; Marín-Jiménez, I; Márquez-Mosquera, L; Martín-Arranz, MD; Martínez-Montiel, P; Mínguez, M; Nos, P; Pons, V; Rimola, J; Taxonera, C; Vega Ruiz, V; Vera-Mendoza, I, 2017) |
| "We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients." | 2.84 | Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine. ( Bronsky, J; Copova, I; Hradsky, O; Pos, L; Rouskova, B; Skaba, R; Zarubova, K, 2017) |
| "The risk of acute pancreatitis in patients with IBD is increased due to the higher incidence of cholelithiasis and drug-induced pancreatitis in this population." | 2.82 | Pancreatic Disorders in Patients with Inflammatory Bowel Disease. ( Bi, Y; Corral, JE; Farraye, FA; Ji, B; Kröner, PT; Lukens, FJ; Montenegro, ML, 2022) |
| "The efficacy of azathioprine for Crohn's disease under adalimumab treatment remains obscure." | 2.82 | Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. ( Esaki, M; Hibi, T; Hisamatsu, T; Ishida, T; Kanai, T; Kato, S; Matsui, T; Matsumoto, T; Motoya, S; Nagahori, M; Naito, Y; Nakagawa, T; Nakase, H; Nojima, M; Suzuki, Y; Watanabe, K; Watanabe, M; Yoshimura, N, 2016) |
| " Exome data for 100 patients were assessed against biochemically measured TPMT enzyme activity, clinical response and adverse effects." | 2.82 | Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. ( Afzal, NA; Andreoletti, G; Ashton, JJ; Batra, A; Beattie, RM; Coelho, T; Ennis, S; Gao, Y; Williams, AP, 2016) |
| "Many patients with quiescent Crohn's disease are maintained on long-term treatment with azathioprine (AZA), but controlled data are limited." | 2.80 | Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. ( Högenauer, C; Novacek, G; Öfferlbauer-Ernst, A; Petritsch, W; Primas, C; Reinisch, W; Teml, A; Vogelsang, H; Wenzl, HH, 2015) |
| "The primary endpoint was clinical recurrence, and the secondary endpoint was endoscopic recurrence." | 2.80 | Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. ( Cao, L; Gong, J; Gu, L; Guo, Z; Li, J; Li, N; Li, Y; Zhang, W; Zhu, W; Zuo, L, 2015) |
| "Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery." | 2.80 | Crohn's disease management after intestinal resection: a randomised trial. ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Sparrow, M; Woods, R, 2015) |
| "As treatment goals in Crohn's disease (CD) evolve, targets now include clinical remission (CR), mucosal healing (MH) and biological remission [C-reactive protein normalisation (CRPnorm )]." | 2.80 | Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. ( Bevelander, GS; Colombel, JF; Cornillie, FJ; Kornbluth, A; Mantzaris, GJ; Oortwijn, A; Reinisch, W; Rutgeerts, P; Sandborn, WJ; Tang, KL, 2015) |
| " The disease activity was determined by Crohn's Disease Activity Index and serum C-reactive protein dosage and dietary intake by 24h dietary recalls." | 2.80 | Whey and soy protein supplements changes body composition in patients with Crohn's disease undergoing azathioprine and anti-TNF-alpha therapy. ( Coy, CS; Machado, JF; Morcillo, AM; Oya, V; Severino, SD; Sgarbieri, VC; Vilela, MM; Wu, C, 2015) |
| "A high proportion of Crohn's disease (CD) patients lose response to antitumor necrosis factor (anti-TNF) and therapy needs to be intensified." | 2.80 | Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. ( Anastasiou, J; Giakoumis, M; Karamanolis, DG; Koukouratos, T; Theocharis, G; Triantos, C; Tsolias, C; Viazis, N, 2015) |
| "Endoscopic recurrence (Rutgeerts score i2-i4) occurred in 33 of 73 (45%) thiopurine vs." | 2.80 | Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Jakobovits, S; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Woods, R, 2015) |
| "Conventional management of Crohn's disease features incremental use of therapies." | 2.80 | Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. ( Bitton, A; Bressler, B; D'Haens, G; Donner, A; Feagan, BG; Greenberg, GR; Khanna, R; Levesque, BG; MacIntosh, D; Morris, JC; Panaccione, R; Paré, P; Sandborn, WJ; Stitt, LW; Vandervoort, MK; Vermeire, S; Zou, G, 2015) |
| "To investigate whether AZA therapy is optimised by individualised dosing based on thiopurine methyltransferase (TPMT) activity and 6TGN concentrations." | 2.79 | Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. ( Bentsen, JL; Dassopoulos, T; Dubinsky, MC; Galanko, JA; Hanauer, SB; Martin, CF; Sandler, RS; Seidman, EG, 2014) |
| " This analysis reports the results of a cohort of Japanese patients with moderate to severe Crohn's disease who were evaluated for up to 3years to assess the long-term use of adalimumab." | 2.79 | Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. ( Arora, V; Camez, A; Chao, J; Hibi, T; Mostafa, NM; Petersson, J; Thakkar, R; Watanabe, M, 2014) |
| "Patients with subocclusive Crohn's disease (CD) who received azathioprine (AZA) therapy had lower re-hospitalization rates due to all causes and for surgical management of CD compared to those treated with mesalazine during a 3-year period." | 2.79 | Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. ( Castro, AC; Chebli, JM; Chebli, LA; da Rocha Ribeiro, TC; de Lima Pace, FH; de Oliveira Zanini, KA; de Souza, GS; do Valle Pinheiro, B; Furtado, MC; Gaburri, PD; Machado de Oliveira, J; Pinto, AL; Ribeiro, LC; Vidigal, FM; Zanini, A, 2014) |
| "The rates of relapse (defined as Crohn's Disease Activity Index score >175) and corticosteroid requirements were similar between groups." | 2.78 | Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. ( Bermejo, F; Domènech, E; Esteve, M; García-Sánchez, V; Gomez-García, M; Gutiérrez, A; López-Sanromán, A; Panés, J; Piqueras, M; Sans, M; Taxonera, C; Torres, Y, 2013) |
| "Patients with Crohn's disease (CD) often require surgery over their clinical course." | 2.78 | Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. ( Andrisani, G; Armuzzi, A; De Vitis, I; Federico, F; Felice, C; Guidi, L; Marzo, M; Papa, A; Pugliese, D; Rapaccini, GL, 2013) |
| "Postsurgical recurrence of Crohn's disease (CD) is very frequent and, to date, only infliximab has been shown to be useful in preventing it." | 2.78 | Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. ( Assandri, L; Bodini, G; Bruzzone, L; Dulbecco, P; Fazio, V; Frigo, AC; Marabotto, E; Mazza, F; Savarino, E; Savarino, V, 2013) |
| " Adverse events were monitored and therapeutic adherence was assessed." | 2.78 | Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. ( Bouma, G; de Boer, NK; Hanauer, SB; Harrell, LE; Hoentjen, F; Rubin, DT; Seinen, ML; van Bodegraven, AA, 2013) |
| "Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma." | 2.78 | Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. ( Ammendola, A; Diculescu, M; Dietrich, B; Fellermann, K; Hartmann, H; Hentsch, B; Herrlinger, KR; Howaldt, S; Nikolov, R; Otte, JM; Petrov, A; Reindl, W; Stange, EF; Stoynov, S; Strauch, U; Sturm, A; Voiosu, R, 2013) |
| "Fifty-one patients with Crohn's disease (38 female; median age: 42 years) were included: 18 receiving MTX, 18 AZA and 15 IFX." | 2.76 | Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. ( Belleannée, G; Capdepont, M; Chabrun, E; de Lédinghen, V; Laharie, D; Razaire, S; Reffet, A; Subtil, C, 2011) |
| "Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or infliximab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azathioprine monotherapy." | 2.75 | Infliximab, azathioprine, or combination therapy for Crohn's disease. ( Broussard, DL; Colombel, JF; D'Haens, G; Diamond, RH; Kornbluth, A; Lichtiger, S; Mantzaris, GJ; Rachmilewitz, D; Reinisch, W; Rutgeerts, P; Sandborn, WJ; Tang, KL; van der Woude, CJ, 2010) |
| "Azathioprine (AZA) withdrawal in Crohn's disease after long-term remission under treatment is controversial." | 2.74 | Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. ( Bouhnik, Y; Colombel, JF; Cosnes, J; Duclos, B; Lemann, M; Lerebours, E; Mary, JY; Soule, JC; Treton, X, 2009) |
| "Patients with Crohn's disease who underwent an ileocolic resection were randomized to side-to-side anastomosis or end-to-end anastomosis." | 2.74 | Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. ( McKenzie, M; McLeod, RS; Parkes, R; Ross, S; Wolff, BG, 2009) |
| "Eighty-three patients with Crohn's disease (n = 42) and ulcerative colitis (n = 41) were enrolled." | 2.73 | Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. ( Andoh, A; Bamba, S; Ban, H; Fujiyama, Y; Hashimoto, T; Ogawa, A; Saito, Y; Sasaki, M; Tsujikawa, T, 2008) |
| "More than 80% of Crohn's disease (CD) patients undergoing resection suffer recurrence of their disease." | 2.73 | Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. ( Aerden, I; D'Haens, GR; Noman, M; Rutgeerts, P; Van Assche, G; Van Olmen, G; Vermeire, S, 2008) |
| "Treatment with azathioprine (AZA) may be beneficial in such patients." | 2.73 | Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. ( Chebli, JM; Chebli, LA; De Souza, AF; Felga, GE; Forn, CG; Gaburri, PD; Pimentel, CF; Pinto, AL, 2007) |
| "Most patients who have active Crohn's disease are treated initially with corticosteroids." | 2.73 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. ( Baert, F; Caenepeel, P; Coche, JR; D'Haens, G; De Vos, M; Donner, A; Feagan, BG; Hommes, D; Lambrecht, GL; Mana, F; Ochsenkühn, T; Rutgeerts, P; Stitt, L; Tuynman, H; van Assche, G; van Bodegraven, AA; Van De Mierop, FJ; van der Woude, J; van Deventer, S; Van Hootegem, PP; Vergauwe, P; Vermeire, S, 2008) |
| "Azathioprine is an effective agent which controls the relapse of Crohn's disease in most patients." | 2.73 | Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China. ( Chu, XQ; Seng, BW; Shi, XH; Zheng, JJ; Zhou, CL, 2008) |
| " Primary end point was the proportion of patients who required a decrease in IFX dosing interval or stopped IFX therapy." | 2.73 | Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. ( Baert, F; D'Haens, G; Magdelaine-Beuzelin, C; Noman, M; Paintaud, G; Rutgeerts, P; Ternant, D; Van Assche, G; Vermeire, S; Watier, H, 2008) |
| "All Crohn's disease patients and 3 of 4 ulcerative colitis patients achieved complete remission." | 2.72 | Pulse cyclophosphamide therapy for inflammatory bowel disease. ( Barta, Z; Tóth, L; Zeher, M, 2006) |
| "Patients with chronic active Crohn's disease were admitted to this investigator-blind study." | 2.71 | Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. ( Ardizzone, S; Bianchi Porro, G; Bollani, S; Colombo, E; Imbesi, V; Manzionna, G, 2003) |
| "To investigate whether patients kept in remission by azathioprine treatment for >2 years benefit from further treatment, and to explore dose-response relationship." | 2.71 | Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. ( Dahlerup, JF; Fallingborg, J; Grønbaek, K; Munck, LK; Nørregaard, P; Vilien, M, 2004) |
| "Mesalamine was investigated for the prevention of postoperative relapse, with disappointing results." | 2.71 | Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. ( Ardizzone, S; Bianchi Porro, G; Colombo, E; Danelli, PG; Imbesi, V; Maconi, G; Molteni, M; Radice, E; Russo, A; Sampietro, GM; Taschieri, AM, 2004) |
| "Azathioprine (aza) therapy is beneficial in the treatment of inflammatory bowel disease, but 10%-30% of patients cannot tolerate aza therapy because of adverse drug reactions." | 2.71 | Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2005) |
| "Azathioprine has variable efficacy in inflammatory bowel disease." | 2.71 | The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. ( Daczo, J; Folwaczny, C; Folwaczny, M; Glas, J; Tonenchi, L; Török, HP, 2005) |
| "Azathioprine is an effective agent in the management of chronic active Crohn's disease leading to long term remission of disease activity." | 2.69 | Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. ( Krummenauer, F; Meyer zum Büschenfelde, KH; Neurath, MF; Peters, M; Schlaak, JF; Wanitschke, R, 1999) |
| "Prednisone was tapered over 5 weeks." | 2.69 | Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. ( Feagan, BG; Fedorak, RN; Gordon, S; Hanauer, SB; Isaacs, KL; Kleoudis, CS; Lipsky, JJ; Mays, DC; McDonald, JW; Murdock, RH; Pike, MG; Sandborn, WJ; Sninsky, CA; Sutherland, LR; Targan, SR; Tremaine, WJ; Wolf, DC, 1999) |
| "Azathioprine has been found effective in chronic active Crohn's disease." | 2.69 | Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. German Imurek Study Group. ( Ludwig, D; Stange, EF, 1999) |
| "Tacrolimus was continued for 2 to 3 months in the responders, except for 1 patient who was given tacrolimus for 11 months." | 2.69 | Oral tacrolimus treatment of severe colitis in children. ( Balint, JP; Bousvaros, A; Daum, F; Day, AS; Ferry, GD; Freeman, KB; Griffiths, AM; Kirschner, BS; Leichtner, AM; Parker-Hartigan, L; Werlin, SL; Zurakowski, D, 2000) |
| "Azathioprine, an effective therapy for Crohn's disease, is limited by a prolonged time to response." | 2.68 | An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. ( Lipsky, JJ; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van O, EC; Zins, BJ, 1995) |
| "Sixty three patients with active Crohn's disease were treated with a 12 weeks diminishing dose of prednisolone and at the same time entered into a randomised, double blind 15 month trial of either azathioprine (2." | 2.68 | A controlled double blind study of azathioprine in the management of Crohn's disease. ( Adams, G; Candy, S; Gerber, M; Gerig, M; Goodman, R; Wright, J, 1995) |
| "Two boys and six girls (six with ulcerative colitis and two with Crohn's disease; ages 3-17 years) received 100-200 micrograms/kg/day cyclosporine intravenously and then 4-10 mg/kg/day orally." | 2.68 | Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. ( Calenda, K; Grand, RJ; Langhans, N; Ramakrishna, J; Verhave, M, 1996) |
| " This study examined whether AZA combined with standard prednisolone therapy improved the therapeutic outcome compared with monotherapy with prednisolone." | 2.67 | Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. ( Ewe, K; Hommel, G; Meyer zum Büschenfelde, KH; Press, AG; Singe, CC; Stufler, M; Ueberschaer, B, 1993) |
| "Conventional medications for Crohn's disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids." | 2.66 | Adalimumab for maintenance of remission in Crohn's disease. ( Abbass, M; Cepek, J; Feagan, BG; Jairath, V; Khanna, R; MacDonald, JK; Nguyen, TM; Parker, CE; Townsend, CM, 2020) |
| "About half of patients with Crohn's disease (CD) require surgery within 10 years of diagnosis." | 2.66 | Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. ( Bravo-Soto, GA; Candia, R; Hernandez, C; Monrroy, H; Nguyen, GC, 2020) |
| " Metronidazole and azathioprin are considered to be reserve drugs and can be used in the treatment of fistulae or in order to cut down the dosage of prednisolone during remission." | 2.66 | [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid]. ( Gerok, W; Schölmerich, J, 1986) |
| "A standard clinical grading system, the Crohn's Disease Activity Index (CDAI) was developed to allow uniform decentralized clinical evaluation and decision-making throughout the 5 yr of the study." | 2.65 | National Cooperative Crohn's Disease Study: study design and conduct of the study. ( Becktel, JM; Best, WR; Kern, F; Lenk, LF; Singleton, JW; Summers, RW; Winship, DH, 1979) |
| "The response of active and quiescent Crohn's disease to prednisone, sulfasalazine, or azathioprine has been studied in 569 patients in a placebo-controlled, randomized, multicenter cooperative trial." | 2.65 | National Cooperative Crohn's Disease Study: results of drug treatment. ( Becktel, JM; Best, WR; Kern, F; Sessions, JT; Singleton, JW; Summers, RW; Switz, DM, 1979) |
| "Azathioprine was approximately as toxic as prednisone but no more effective than placebo in suppressing active disease." | 2.65 | National Cooperative Crohn's Disease Study: adverse reactions to study drugs. ( Kelley, ML; Law, DH; Mekhjian, HS; Singleton, JW; Sturdevant, RA, 1979) |
| "51 patients with Crohn's disease who were in good health while taking azathiprine, 2 mg/kg body-weight/day, for at least six months were allocated either to a group in which azathioprine was continued or to one in which a control tablet was substituted." | 2.64 | Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. ( Bown, RL; Dawson, AM; Lennard-Jones, JE; O'Donoghue, DP; Powell-Tuck, J, 1978) |
| " The mean reduction in steriod dosage in the azathioprine group at the end of the trial (-15." | 2.64 | A controlled trial of azathioprine in Crohn's disease. ( Kirsner, JB; Levin, B; Rosenberg, JL; Wall, AJ, 1975) |
| "The main role of therapy in Crohn's disease (CD) is to achieve long-term clinical remission, and to allow for normal growth and development of children." | 2.58 | Therapeutic role of methotrexate in pediatric Crohn's disease. ( Budić, I; Djordjević, J; Djurić, Z; Pavlović, V; Šaranac, L, 2018) |
| "Significant increases in Crohn's disease incidence have been noticed in recent decades." | 2.58 | [Inflammatory Bowel Diseases - Diagnosis and Therapy in Practice]. ( Klugmann, T; Teich, N, 2018) |
| "Recent findings do support optimized drug dosing for infliximab based on early trough levels, but question the utility of checking these values in patients doing well in maintenance therapy." | 2.53 | Therapeutic drug monitoring in inflammatory bowel disease. ( Dubinsky, M; Jossen, J, 2016) |
| "Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission." | 2.53 | Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. ( Chande, N; MacDonald, JK; Parker, CE; Townsend, CM, 2016) |
| " Fortunately, the absolute incidence of serious toxicity remains low, and an improved understanding of how best to minimize risk and the recognition of groups of patients at higher risk of toxicity from thiopurines means that they remain a relatively safe therapy in the majority of patients." | 2.52 | Toxicity and response to thiopurines in patients with inflammatory bowel disease. ( Goldberg, R; Irving, PM, 2015) |
| "Three cases of basal cell carcinoma in Crohn's disease patients treated with azathioprine are described." | 2.52 | Crohn's Disease treated with azathioprine and basal cell carcinoma : three cases and literature review. ( Borgies, P; Dubois, A; El Nawar, A; Gallez, JF; Moreels, T; Nakad, A; Patris, A; Rahier, JF; Tennstedt, D; Vandenbulcke, H, 2015) |
| "The incidence and prevalence of Crohn's disease are increasing, particularly in the Western world and Asia." | 2.50 | Steroid use in Crohn's disease. ( Rogler, G; Scharl, M; Schoepfer, AM; Vavricka, SR, 2014) |
| "The therapy of Crohn's disease is constantly evolving." | 2.50 | Positioning therapy for Crohn's disease. ( Dassopoulos, T; Gutierrez, A, 2014) |
| "Post-operative recurrence of Crohn's disease is an important management challenge, with 2-year recurrence rates defined by clinical, endoscopic and radiological parameters of up to 77%, 64% and 49%." | 2.50 | Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance--progress and prospects. ( Arnott, ID; Jones, GR; Kennedy, NA; Lees, CW; Satsangi, J, 2014) |
| "Crohn's disease is a chronic incurable condition that normally requires lifelong treatment." | 2.50 | Can we get more from our current treatments? ( Irving, PM, 2014) |
| "New therapeutic goals have emerged in Crohn's disease such as the need to look beyond symptoms by achieving mucosal healing that is known to be associated with better outcomes." | 2.50 | Treatment algorithms in Crohn's - up, down or something else? ( Antunes, O; Filippi, J; Hébuterne, X; Peyrin-Biroulet, L, 2014) |
| "Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission." | 2.49 | Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. ( Chande, N; MacDonald, JK; Tsoulis, DJ, 2013) |
| "The natural history of Crohn's disease is associated with several factors that affect the prognostic of the patients." | 2.49 | Prognostic factors in Crohn's disease: a systematic review. ( Boubaker, J; Dachraoui, A; Filali, A; Karoui, S; Serghini, M, 2013) |
| "Mercaptopurine was tolerated by 58% of azathioprine-intolerant patients in the Edinburgh cohort." | 2.49 | A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. ( Arnott, ID; Kennedy, NA; Lees, CW; Noble, CL; Rhatigan, E; Satsangi, J; Shand, AG, 2013) |
| "Crohn's disease and ulcerative colitis are highly related genetically." | 2.49 | Update on idiopathic colitides. ( Abreu, MT; Strobel, S, 2013) |
| "Up to 75% of patients with Crohn's disease (CD) will have intestinal resection during their life." | 2.48 | Prevention of postoperative recurrence of Crohn's disease. ( Dijkstra, G; Nieuwenhuijs, VB; Ploeg, RJ; van Loo, ES, 2012) |
| "The majority of patients diagnosed with Crohn's disease eventually require surgical intervention." | 2.47 | Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field. ( Borowiec, AM; Fedorak, RN, 2011) |
| "Crohn's disease and ulcerative colitis, together popularly known as inflammatory bowel disease (IBD), are characterized by a number of extraintestinal manifestations." | 2.46 | Pancreatitis in inflammatory bowel diseases. ( Das, K; Pitchumoni, CS; Rubin, A, 2010) |
| "Crohn's disease is a chronic, progressive disabling condition ultimately leading to stricturing and/or penetrating complications." | 2.46 | [Postoperative recurrence of Crohn's disease, and its prevention]. ( Lakatos, L; Lakatos, PL, 2010) |
| "The therapy of Crohn's disease depends on its disease activity." | 2.45 | [Treatment of Crohn's disease]. ( Rogler, G; Vavricka, SR, 2009) |
| "Complex perianal fistulas have a negative impact on the quality of life of sufferers and should be treated." | 2.45 | Emerging treatments for complex perianal fistula in Crohn's disease. ( García-Olmo, D; Schwartz, DA; Taxonera, C, 2009) |
| "Step-up therapy in Crohn's disease refers to the classic therapeutic approach resulting in progressive increase of therapies with the increasing severity of the disease." | 2.45 | Mild to moderate Crohn's disease: still room for step-up therapies? ( Bar-Meir, S, 2009) |
| "In inflammatory bowel disease, such as Crohn's disease, certain immunological abnormalities are considered as its cause, but the fundamental mechanism remains unclear." | 2.44 | [New therapy in inflammatory bowel disease (infliximab)]. ( Hibi, T; Yoshizawa, S, 2008) |
| " Pharmacogenetically guided dosing is recommended for safe use of thiopurines but ongoing routine laboratory monitoring remains important." | 2.44 | Laboratory evaluation of inflammatory bowel disease. ( Bass, D; Wong, A, 2008) |
| "Crohn's disease is a long-term chronic condition of the gastrointestinal tract." | 2.44 | Crohn's disease. ( Orchard, TR; Reese, GE; Tekkis, PP; von Roon, AC, 2007) |
| "The therapy of inflammatory bowel diseases is based on 5-aminosalicylates (5-ASAs) that are the forefront of treatment of mild-to-moderate active disease and maintenance; steroids are used for the treatment of moderate-to-severe active disease; immunosuppressives and sometimes antibiotics in moderate-to-severe disease; maintenance and for the treatment of selected complications." | 2.44 | [Medical therapy of inflammatory bowel diseases: Crohn's disease]. ( Lakatos, L; Lakatos, PL, 2007) |
| " Azathioprine/6-MP-related pulmonary toxicity is a rare but serious side effect, and it is important for clinicians to have a high index of suspicion for this adverse reaction which occurs within 1 month after initiation of treatment for IBD." | 2.44 | Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. ( Ananthakrishnan, AN; Attila, T; Binion, DG; Komorowski, RA; Lipchik, RJ; Massey, BT; Otterson, MF, 2007) |
| "Search terms included 'Crohn's disease or synonyms', 'remission or synonyms' and the names of specific interventions." | 2.44 | Review article: the evidence base for interventions used to maintain remission in Crohn's disease. ( Akobeng, AK, 2008) |
| " For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported." | 2.44 | Optimizing drug therapy in inflammatory bowel disease. ( Kornbluth, A; Swaminath, A, 2007) |
| "Pediatric ulcerative colitis tends to present with more severe and more extensive involvement than in adults." | 2.44 | IBD in children: lessons for adults. ( Haller, CA; Markowitz, J, 2007) |
| "Care of patients with Crohn's disease requires interdisciplinary cooperation between gastroenterologists and surgeons." | 2.43 | [Crohn's disease--standards of treatment 2004]. ( Kruis, W, 2005) |
| " Additionally, established therapies are attracting renewed interest with novel dosage regimens and new formulations offering improved efficacy whilst maintaining an excellent tolerance profile." | 2.43 | What's new: innovative concepts in inflammatory bowel disease. ( Sandborn, WJ, 2006) |
| "Current therapy for moderate to severe Crohn's disease is based on 'step-up' algorithms, which initiate treatment with corticosteroids followed by immunomodulatory agents, and defer therapy with biological agents until patients become refractory to conventional therapeutics." | 2.43 | Biological therapy in the management of recent-onset Crohn's disease: why, when and how? ( Hommes, D; Löwenberg, M; Peppelenbosch, M, 2006) |
| "Crohn's disease and ulcerative colitis are the most frequent inflammatory bowel diseases (IBD) with a prevalence of approximately one out of 500." | 2.42 | [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy]. ( Göke, B; Ochsenkühn, T; Sackmann, M, 2003) |
| "Therapy for Crohn's disease must involve treating comorbid conditions to improve the quality of life of patients." | 2.42 | Management of Crohn's disease--a practical approach. ( Cronau, H; Greenberg, G; Knutson, D, 2003) |
| "The clinical management of Crohn's disease can be considered in relation to the treatment of acute disease and the maintenance of remission." | 2.42 | Review article: chronic active disease and maintaining remission in Crohn's disease. ( Kamm, MA, 2004) |
| "Therapeutic research in Crohn's disease has been intensified in recent years." | 2.42 | Advances in medical therapy for Crohn's disease. ( D'Haens, G; Hlavaty, T, 2004) |
| "Management of Crohn's disease has changed considerably in recent years." | 2.41 | Advances in medical therapy for Crohn's disease. ( D'Haens, G; Daperno, M, 2002) |
| "It describes the treatment of ulcerative colitis according to the different groups of patients and the degree of activity." | 2.41 | [Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002) |
| "CROHN'S DISEASE: In Crohn's disease, these are the induction of remission in chronic active Crohn's disease, steroid-dependent Crohn's disease, fistulizing Crohn's disease and the maintenance of remission in Crohn's disease." | 2.41 | [Azathioprine in chronic inflammatory bowel diseases. Evidence base]. ( Herrlinger, K; Stange, EF, 2000) |
| "Important observations in ulcerative colitis (UC) over the past year include evidence of a protective effect of 5-aminosalicylic acid (5-ASA) with respect to colorectal cancer, negative results from a study for heparin monotherapy, and results from a comparison of mycophenolate mofetil versus azathioprine as maintenance therapy." | 2.41 | Medical therapies for ulcerative colitis and Crohn's disease. ( Baert, FJ; Rutgeerts, PJ, 2000) |
| " Oral controlled-release budesonide has demonstrated comparable efficacy to prednisolone with less risk for adverse effects, although many questions remain regarding the long-term use of this agent." | 2.41 | Conventional treatment of Crohn's disease: objectives and outcomes. ( Rutgeerts, PJ, 2001) |
| "Whereas the incidence of ulcerative colitis has remained stable at around 8-9/10(5), the incidence of Crohn's disease has increased from below 1 to more than 5/10(5) per year during the last three decades." | 2.41 | [Therapeutic principles for chronic inflammatory bowel disease]. ( Binder, V; Munkholm, P, 2001) |
| "Fistulas are common in patients with Crohn's disease and, when associated with inflammatory disease and established for several weeks, tend to be chronic." | 2.41 | Management of fistulas in patients with Crohn's disease: antibiotic to antibody. ( Paré, P, 2001) |
| "Ulcerative colitis and Crohn's disease are chronic relapsing inflammatory disorders of the bowel that affect 2-4 per 1,000 people in Northern Europe." | 2.41 | Maintenance drugs for inflammatory bowel disease. ( , 2001) |
| "The medical management of Crohn's disease has changed in recent years, but the mainstay of treatment is still prednisone." | 2.40 | [Drug treatment of Crohn's disease]. ( Tytgat, GN; van Deventer, SJ, 1998) |
| "Crohn's disease is inevitably characterized by episodes of relapse followed by remission." | 2.40 | The case against routine post-operative therapy for prevention of recurrence in Crohn's disease. ( Breslin, NP; Sutherland, LR, 1998) |
| "Azathioprine is a drug commonly used for the treatment of inflammatory bowel disease, organ transplantation and various autoimmune diseases." | 2.40 | Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. ( Jewell, L; Lalor, E; Romagnuolo, J; Sadowski, DC; Thomson, AB, 1998) |
| "In view of a high recurrence rate of Crohn's disease after surgical resection prophylaxis is desirable." | 2.39 | [Crohn disease: prevention and drug therapy]. ( Andus, T; Gross, V; Schölmerich, J, 1995) |
| "In both ulcerative colitis and Crohn's disease 5-ASA has proved effective in the acute phase of the disease." | 2.39 | Medical management of patients with difficult-to-treat inflammatory bowel disease. ( van Hogezand, RA, 1994) |
| "Crohn's disease is a chronic relapsing inflammatory disorder primarily affecting the gastrointestinal system." | 2.39 | [Myositis--a rare complication of Crohn disease]. ( Druschky, A; Engelhardt, A; Heckmann, J, 1996) |
| "Crohn's disease is a chronic inflammatory intestinal disorder characterized in most patients by repeated episodes of diminished and exacerbated symptoms." | 2.38 | Maintenance of symptomatic remission in patients with Crohn's disease. ( Stark, ME; Tremaine, WJ, 1993) |
| "The standard therapy of ulcerative colitis and Crohn's disease is based on the treatment with corticosteroids, sulfasalazine and 5-aminosalicylic acid (mesalazine)." | 2.38 | [Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments]. ( Fischbach, W, 1992) |
| "Of a total 44 patients with Crohn's disease, 10 patients with 9 internal and 15 external fistulae, some of which were recurrent, were analyzed at the Department of Surgery, Yokohama City University between 1973 and 1988." | 2.38 | The medical, nutritional and surgical treatment of fistulae in Crohn's disease. ( Fukushima, T; Sugita, A; Takemura, H; Tsuchiya, S; Yamazaki, Y, 1990) |
| "For patients with more extensive ulcerative colitis with moderate symptoms, prednisone and/or sulfasalazine will result in improvement in about 80% of patients." | 2.37 | Current status of drug therapy for inflammatory bowel disease. ( Peppercorn, MA, 1985) |
| " Side effects can be serious but are usually manageable and, to some extent, preventable by appropriate dosage schedules." | 2.37 | Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. ( Goldstein, F, 1987) |
| "Crohn's disease is a perplexing disease with a high rate of morbidity and complications." | 2.35 | The protean manifestations of Crohn's disease. ( Farmer, RG, 1975) |
| "It is important to distinguish between ulcerative colitis and Crohn's colitis because response to treatment and prognosis are different." | 2.35 | Inflammatory disease of the colon: ulcerative colitis and Crohn's colitis. ( Ament, ME, 1975) |
| "Acenocoumarol is an anticoagulant with numerous drug reactions." | 1.91 | Azathioprine and Acenocoumarol Drug Interaction in Patients with Crohn's Disease: A Case Report. ( Belhadj, A; Ben-Hammamia, S; Bouchrika, A; Charfi, O; Chebbi, F; El Aidli, S; Lakhoua, G, 2023) |
| "Clinical relapse was defined as necessity of re-induction of remission." | 1.91 | Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN. ( Bronsky, J; de Meij, T; Dias, JA; Escher, JC; Hradsky, O; Kolacek, S; Kolho, KL; Kulich, M; Lerchova, T; Melek, J; Schwarz, J; Serban, DE; Sładek, M; Van Biervliet, S; Veres, G; Winther, K, 2023) |
| "A 35-year-old patient with Crohn's disease in clinical remission on azathioprine 150 mg daily and infliximab 5 mg/kg every 8 weeks was used for base-case analysis." | 1.91 | Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine. ( Almario, CV; Melmed, GY; Spiegel, BMR; Syal, G, 2023) |
| " With these data we generated a population pharmacokinetic model using non-linear mixed effects modeling and calculated infliximab clearance for each patient over time." | 1.91 | Early Infliximab Clearance Predicts Remission in Children with Crohn's Disease. ( Almeida, P; Carroll, M; Chung, A; Huynh, H; Isaac, D; Mould, D; Petrova, A; Wine, E, 2023) |
| "Treatment with azathioprine had a negative impact on recurrence rates." | 1.91 | [Effectiveness of Mucosal Advancement Flaps in Surgery of Perianal Fistulas from Crohn´s Disease and Cryptoglandular Fistulas - a Long-term Follow-up Study]. ( Bruder, L; Kamphues, C; Kreis, M; Lauscher, JC; Schineis, C; Warschkow, R; Weixler, B, 2023) |
| "Azathioprine, which is an immunosuppressive agent commonly used for chronic inflammatory bowel disease, may be associated with an increased risk of certain cancers such as hematologic malignancies." | 1.91 | Acute myeloid leukemia after 10 years of azathioprine treatment for Crohn's disease. ( Asma, M; Emna, BM; Nadia, B; Nouha, T; Yosra, S; Yosra, Z, 2023) |
| "Azathioprine was added to her regimen due to lack of response; however, despite 6 weeks of this therapy, the ulcerations did not heal thus infliximab was initiated." | 1.91 | Successful multidisciplinary treatment of the rare pathology of vulvar Crohn's disease. ( Al Yacoub, R; Brown, K; Ladna, M, 2023) |
| " The TPMT*2 (defined by rs1800462), *3A (defined by rs1800460 and rs1142345), *3B (defined by rs1800460), *3C (defined by rs1142345), *6 (defined by rs75543815), and NUDT15 rs116855232 genetic variant have been associated, with the highest level of evidence, with the response to azathioprine, and, the approved drug label for azathioprine and main pharmacogenetic dosing guidelines recommend starting with reduced initial doses in TPMT intermediate metabolizer (IM) patients and considering an alternative treatment in TPMT poor metabolizer (PM) patients." | 1.91 | Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation. ( Cabeza-Barrera, J; Callejas-Rubio, JL; Díaz-Villamarín, X; Fernández-Varón, E; Gálvez, J; Morón, R; Rodríguez-Nogales, A; Rojas Romero, MC, 2023) |
| "Among these, 218 (ulcerative colitis (UC) = 179; Crohn's disease (CD) = 39) patients were in clinical remission and were continued on mesalamine." | 1.72 | Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease. ( Ahuja, V; Das, P; Golla, R; Kante, B; Kedia, S; Kumar, P; Makharia, G; Mundhra, SK; Ranjan, MK; Sahni, P; Sharma, R; Vuyyuru, SK, 2022) |
| "Stricturing Crohn's disease (CD) is difficult to manage medically with limited treatment options, anti-tumor necrosis factor (TNF) therapy being the first-line therapy." | 1.72 | Monotherapy with thiopurines in stricturing Crohn's disease: A real-life experience from low- and middle-income countries. ( Ahuja, V; Das, P; Kante, B; Kedia, S; Kumar, P; Madhusudhan, KS; Makharia, G; Panwar, R; Ranjan, MK; Sahu, P; Sharma, R; Virmani, S; Vuyyuru, SK, 2022) |
| "We assessed the incidence and predictive factors of thiopurine-induced adverse events (AE) resulting in therapy cessation in pediatric inflammatory bowel disease (IBD), related to thiopurine metabolites and biochemical abnormalities, and determined overall drug survival." | 1.72 | Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. ( Benninga, MA; Buiter, HJC; de Boer, NKH; de Meij, TGJ; Jagt, JZ; Pothof, CD; van Limbergen, JE; van Wijk, MP, 2022) |
| "Of these, 448 (53." | 1.72 | Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center. ( Galanis, P; Galanopoulos, M; Giakoumis, M; Karatzas, P; Kyriakos, N; Liatsos, C; Mantzaris, G; Mylonas, I; Papaefthymiou, A, 2022) |
| "Clinical remission was defined as Crohn's Disease Activity Index [CDAI] < 150 in Crohn´s disease [CD], partial Mayo score <2 in ulcerative colitis [UC], and faecal calprotectin values <150 µg/g and C-reactive protein <5 mg/dl." | 1.62 | Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. ( Aden, K; Adolph, TE; Bronowski, C; Effenberger, M; Enrich, B; Koch, R; Moschen, AR; Reider, S; Rosenstiel, P; Tilg, H; Waschina, S, 2021) |
| "Combination therapy dosed with an optimized thiopurine was superior to infliximab monotherapy for induction of response, durability of response, and clinical outcomes in the first 6 months following induction." | 1.62 | Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. ( Dawson, L; Gibson, PR; Kariyawasam, VC; Luber, RP; Martin, C; Munari, S; Sparrow, MP; Ward, MG, 2021) |
| "In paediatric patients with Crohn's disease, the role of combination therapy, infliximab plus immunomodulators [thiopurine or methotrexate], is debated and data are sparse." | 1.62 | Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study. ( Kjeldsen, J; Knudsen, T; Larsen, MD; Lund, K; Mertz Nørgård, B; Nielsen, RG, 2021) |
| "CR was defined as a Crohn's Disease Activity Index [CDAI] <150, clinical response as a CDAI reduction of ≥100 points, and ER as SES-CD score <3." | 1.62 | Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. ( Colombel, JF; Dulai, PS; Marshall, JK; Narula, N; Reinisch, W; Wong, ECL, 2021) |
| "CMV pneumonitis was initially suspected on CT chest images and confirmed by PCR for CMV." | 1.62 | CMV pneumonitis in a patient with Crohn's disease taking azathioprine. ( Chambers, L; Devereux, G; Hawthorne, TZ; Shellien, R, 2021) |
| "Azathioprine (AZA) has been widely used for the treatment of various immune-related diseases and has become a mainstay in the treatment of inflammatory bowel disease." | 1.62 | Azathioprine-induced toxoplasma gondii infection in a patient with Crohn's disease with NUDT15 variation: A case report. ( Ou, D; Tan, Y; Wang, X; Wang, Y; Wu, Y, 2021) |
| "Preventing postoperative recurrence (POR) is a major concern in Crohn's disease (CD)." | 1.62 | Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. ( Bommelaer, G; Buisson, A; Fumery, M; Hebuterne, X; Laharie, D; Manlay, L; Nancey, S; Pariente, B; Pereira, B; Peyrin-Biroulet, L; Roblin, X; Rubin, DT; Vuitton, L, 2021) |
| "Pulmonary lymphomatoid granulomatosis (PLG) is a rare angiocentric and angiodestructive EBV-associated lymphoproliferative disorder which almost always affects the lungs." | 1.56 | An atypical case of a pulmonary mass in an immunocompromised patient. ( Bode, H; Bos, S; Cardinaels, N; Tousseyn, T; Van Bleyenbergh, P; Van Rompaey, W, 2020) |
| " The attributes included efficacy and withdrawals due to adverse events, as well as dosing and other rare risks of treatment." | 1.56 | Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. ( Bombardier, C; Deardon, R; Hazlewood, GS; Kaplan, GG; Ma, C; Marshall, DA; Panaccione, R; Pokharel, G; Seow, CH; Tomlinson, G, 2020) |
| "A total of 131 adult patients with Crohn's disease receiving thiopurine treatment were included." | 1.56 | Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease. ( Baek, SY; Choi, R; Hong, SN; Kim, K; Kim, TJ; Kim, YH; Lee, MN; Lee, SY, 2020) |
| " The routine clinical use of thiopurines has, however, been questioned due to a number of potential adverse effects." | 1.56 | Safety of Thiopurine Use in Paediatric Gastrointestinal Disease. ( Benninga, MA; Broekaert, I; Dolinsek, J; Mas, E; Miele, E; Orel, R; Pienar, C; Ribes-Koninckx, C; Thapar, N; Thomassen, RA; Thomson, M; Tzivinikos, C, 2020) |
| "Incident cases of non-melanoma skin cancers and non-Hodgkin lymphoma diagnosed after prescription of thiopurine and/or anti-tumor necrosis factor-α were identified between April 2008 and January 2018." | 1.56 | Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. ( Hibi, T; Kobayashi, T; Uda, A; Udagawa, E, 2020) |
| "Among those cases, isolated gastric Crohn's disease is even rarer." | 1.51 | Pyloric stenosis as a manifestation of isolated gastric Crohn's disease responding to intralesional steroid injection and balloon dilation: a case report. ( Balendran, K; Nawaraththne, NMM; Udumalagala, S, 2019) |
| "Thiopurines are classically used in Crohn's disease (CD)." | 1.51 | Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience. ( Abreu Garcia, L; Arevalo Serrano, J; Calvo Moya, M; González-Lama, Y; González-Partida, I; Matallana Royo, V; Suárez Ferrer, C; Vera Mendoza, I, 2019) |
| "Two sisters, initially managed for Crohn's disease based upon clinical, imaging and pathological findings, were later found to have MNGIE." | 1.51 | Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease. ( Chinnery, PF; Coulter, LL; Parkes, M; Patel, R; Rimmer, J; Swift, O, 2019) |
| " Continuing standard dosing regimens after primary non-response was rarely helpful; only 14 (12·4% [95% CI 6·9-19·9]) of 113 patients entered remission by week 54." | 1.51 | Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. ( Ahmad, T; Bewshea, C; Bouri, S; Chanchlani, N; Cummings, JRF; Gaya, DR; Goodhand, JR; Green, HD; Hamilton, B; Hart, AL; Heap, GA; Heerasing, NM; Hendy, P; Irving, PM; Kennedy, NA; Lees, CW; Lin, S; Lindsay, J; Mansfield, JC; McDonald, TJ; McGovern, D; Nice, R; Parkes, M; Perry, MH; Russell, RK; Sebastian, S; Selinger, CP; Thomas, A; Walker, GJ, 2019) |
| "We present the case of a patient with Crohn's disease and treated azathioprine that develops lymphomatoid granulomatosis, as well as its diagnostic process and the chosen treatment." | 1.51 | A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn's disease. ( Curieses Luengo, M; López Fernández, E; Varela Trastoy, P, 2019) |
| "The included patients had either Crohn's disease (54; 65." | 1.51 | Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine. ( Akiyama, S; Arai, M; Fujii, T; Fukuda, K; Hamada, S; Hashiguchi, M; Hisamatsu, T; Iwao, Y; Kanai, T; Kiyohara, H; Matsuoka, K; Mizuno, S; Mochizuki, M; Motobayashi, M; Nagahori, M; Naganuma, M; Nanki, K; Ogata, H; Ohtsuka, K; Saito, E; Shimizu, M; Sugimoto, S; Suzuki, K; Takenaka, K; Watanabe, M, 2019) |
| "Azathioprine is commonly used in Crohn's disease." | 1.48 | A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. ( Audrain, M; Caldari, D; Dert, C; Hémont, C; Joyau, C; Léger, A; Mirallié, S; Monteil-Ganiere, C; Thomas, C, 2018) |
| "There was the assumption that Crohn's disease (CD) patients with perianal lesions might have different clinical courses compared to those without." | 1.48 | Effects of Perianal Involvement on Clinical Outcomes in Crohn's Disease over 10 Years. ( Cheon, JH; Kim, TI; Kim, WH; Park, SJ; Yoon, JY, 2018) |
| "We report three cases of pediatric Crohn's disease presenting with vulvar swelling." | 1.48 | Vulvar swelling as the first presentation of Crohn's disease in children-A report of three cases. ( Ahad, T; Martindale, E; Owen, C; Riley, A; von Bremen, B, 2018) |
| "Vitamin D deficiency is common in patients with IBD." | 1.48 | Clinical factors are associated with vitamin D levels in IBD patients: A retrospective analysis. ( Glass, Ä; Huth, A; Lamprecht, G; Reiner, J; Schäffler, H; Schmidt, M, 2018) |
| "Patients with endoscopic recurrence detected by either ileocolonoscopy or CE received pharmacologic therapy with azathioprine or infliximab." | 1.48 | Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease. ( Ai, XY; Bai, Y; Chen, ZY; Feng, XC; Han, ZM; Li, AM; Li, MS; Liu, SD; Qiao, WG; Wan, TM; Xu, ZM; Zhang, J; Zhi, FC, 2018) |
| "Azathioprine can prevent postoperative recurrences in Crohn's disease." | 1.48 | Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn's disease. ( Cai, X; Cao, L; Gong, J; Guo, Z; Li, Y; Liu, R; Wang, Z; Zhu, W, 2018) |
| "There is a reported association with Crohn's disease." | 1.46 | Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema. ( Alexakis, C; Chong, H; Gordon, K; Mellor, R; Mortimer, P; Pollok, R, 2017) |
| "Mercaptopurine was effective in 39% of cases (95% CI 31-48%)." | 1.46 | Mercaptopurine and inflammatory bowel disease: the other thiopurine. ( Aicart, M; Algaba, A; Bermejo San José, F; Bonillo, D; de Lucas, M; Garrido, E; Guerra, I; Hernández-Tejero, M; López Durán, S; López Sanromán, A, 2017) |
| "Twenty-three patients (21 Crohn's disease, and 2 ulcerative colitis) developed AAA with subsequent LOR and were thereafter prescribed an immunomodulator as salvage therapy (thiopurine n = 14, methotrexate n = 9)." | 1.46 | Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. ( Bar-Gil Shitrit, A; Ben-Horin, S; Chowers, Y; Eliakim, R; Engel, T; Fudim, E; Kopylov, U; Lang, A; Paul, S; Picard, O; Roblin, X; Ungar, B; Williet, N; Yavzori, M, 2017) |
| "Prednisone use was associated with higher mortality [HR = 3." | 1.46 | Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. ( Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017) |
| "Ulcerative colitis (UC) and Crohn's disease (CD) were analyzed separately." | 1.46 | Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study. ( Alexakis, C; Cecil, E; Chhaya, V; Curcin, V; Pollok, R; Saxena, S, 2017) |
| "The treatment with azathioprine could be responsible for this anti-inflammatory profile of monocytes." | 1.46 | CSF-1 regulates the function of monocytes in Crohn's disease patients in remission. ( Cantó, E; Garcia-Planella, E; Gordillo, J; Juárez, C; Nieto, JC; Ortiz, MA; Vidal, S; Zamora, C, 2017) |
| "Vitamin D deficiency was seen in 86." | 1.46 | Bone density in pediatric Crohn's disease: A cross-sectional observation from South India. ( Khan, SS; Patil, SS, 2017) |
| "Postoperative recurrence of Crohn's disease is common." | 1.46 | Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease. ( Candia, R; Naimark, D; Nguyen, GC; Sander, B, 2017) |
| "Thiopurine-induced severe hair loss causes cosmetic problems, and it takes a long time to recover." | 1.43 | NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. ( Endo, K; Kakuta, Y; Kimura, T; Kinouchi, Y; Kuroha, M; Naito, T; Negoro, K; Onodera, M; Shiga, H; Shimosegawa, T, 2016) |
| "Clinical remission was defined as Crohn's Disease Activity Index (CDAI) < 150 and endoscopic remission as CDAI < 150 + absence of mucosal lesions + no signs of active inflammation on ileocolonoscopy." | 1.43 | Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. ( Ampuero, J; Castro-Fernández, M; Guerrero-Jiménez, P; Millán-Lorenzo, M; Rojas-Feria, M; Romero-Gómez, M, 2016) |
| "AZA-induced acute pancreatitis is a common adverse event in IBD patients, but in this study had a mild course in all patients." | 1.43 | Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. ( Bokemeyer, B; Bündgens, B; Büning, J; Drabik, A; Helwig, U; Hüppe, D; Klugmann, T; Kruis, W; Maaser, C; Miehlke, S; Mohl, W; Siegmund, B; Stallmach, A; Teich, N; Weismüller, J, 2016) |
| "Early stages of Crohn's disease [CD] are predominantly inflammatory and early treatment could be useful to change the natural history of CD." | 1.43 | Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. ( Abreu, L; Agudo, B; Arévalo, J; Bernardo, C; Calvo, M; de la Revilla, J; González-Lama, Y; González-Partida, I; Ibarrola, P; Magaz, M; Matallana, V; Relea, L; Suárez, C; Vera, MI, 2016) |
| "Thiopurine-induced leukopenia is a relatively common adverse event related to thiopurine medication in Korean pediatric Crohn's disease." | 1.43 | NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease. ( Hwang, EH; Kang, B; Kim, SY; Lee, YJ; Park, JH; Shin, JH, 2016) |
| "A total of 350 adult patients with Crohn's disease received either infliximab [n = 178, 51%] or adalimumab [n = 172, 49%] monotherapy." | 1.43 | Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. ( Antunes, O; Filipe, V; Filippi, J; Hébuterne, X; Louis, E; Peyrin-Biroulet, L; Reenaers, C; Roblin, X; Salleron, J, 2016) |
| "Data of 678 incident IBD patients (Crohn's disease/ulcerative colitis(CD/UC): 331/347) diagnosed from 1st January 2000 to 31st December 2012 were analyzed (CD: m/f: 176/155, median age at diagnosis: 28, IQR: 21-40 years, disease duration: 6, IQR: 2-9 years; UC: m/f: 200/147, median age at diagnosis: 36, IQR: 26-50 years, duration: 7, IQR: 4-10 years)." | 1.43 | Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. ( Balogh, M; Golovics, PA; Gonczi, L; Kurti, Z; Lakatos, L; Lakatos, PL; Lovasz, BD; Pandur, T; Rogler, G; Szita, I; Vavricka, SR; Vegh, Z, 2016) |
| "Overall, 113/164 (69%) patients with Crohn's disease and 83/136 (61%) patients with ulcerative/unclassified colitis had a clinical response by the end of follow-up (median 19 months), while 85 (52%) patients with Crohn's disease and 74 (54%) patients with ulcerative/unclassified colitis were in clinical remission." | 1.43 | Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study. ( Abdulrehman, A; Ansari, A; Bull, C; Duley, J; Kerr, P; Pavlidis, P; Stamoulos, P, 2016) |
| "The disease is rarely associated with Crohn's disease (CRD)." | 1.43 | Coexistence of Celiac and Crohn's Disease in a Patient Presenting with Chronic Diarrhea. ( Abbas, Z; Butt, MO; Laeq, SM; Lail, G; Luck, NH; Mubarak, M; Tasneem, AA, 2016) |
| " Thiopurines are used in the treatment of Crohn's disease (CD) and thiopurine S-methyltransferase (TPMT) activity can guide thiopurine dosing to avoid adverse events." | 1.43 | Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study. ( Afif, W; AlYafi, M; Benmassaoud, A; Bessissow, T; Bitton, A; Theoret, Y; Xie, X, 2016) |
| "No significant risk for other intestinal cancers was found, especially for small bowel carcinoma." | 1.43 | Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016) |
| "She developed an encephalopathy which resolved after discontinuation of ganciclovir." | 1.43 | Ganciclovir-induced ataxia and encephalopathy. ( Kramer, MH; Möhlmann, MC; Stiksma, J, 2016) |
| "Although leukopenia is a well-recognized side effect of AZA/6-MP treatment, its association with therapeutic effects has yet to be determined." | 1.42 | Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. ( Cheon, JH; Hong, SP; Kim, DH; Kim, TI; Kim, WH; Park, MS; Park, SJ, 2015) |
| "Azathioprine was the most commonly used oral immunosuppressive agent, with an efficacy of 57%." | 1.42 | Vulval Crohn's disease: a clinical study of 22 patients. ( Bailey, C; Fuller, LC; Laftah, Z; Lewis, F; Setterfield, J; Zaheri, S, 2015) |
| "A total of 500 patients (404 with Crohn's disease, 96 with ulcerative colitis) who received anti-TNF agents between June 2002 and July 2013 were identified and retrospectively investigated." | 1.42 | Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. ( Byeon, JS; Kim, JH; Kim, KJ; Myung, SJ; Park, SH; Soh, JS; Won, CH; Yang, DH; Yang, SK; Ye, BD; Yun, WJ, 2015) |
| "Of 132 observations, 77 [58%] had Crohn's disease and 55 [42%] ulcerative colitis." | 1.42 | Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. ( Asher, R; Collins, P; Dibb, M; Jackson, R; Kneebone, A; Poon, SS; Probert, C; Subramanian, S, 2015) |
| "Progressive multifocal leukoencephalopathy is a rare but fatal brain infection caused by John Cunningham (JC) virus and has been associated with natalizumab use." | 1.42 | Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. ( Bellaguarda, E; Cohen, RD; Keyashian, K; Pekow, J; Rubin, DT; Sakuraba, A, 2015) |
| "Treatment with azathioprine appears to be a risk factor for early EBV seropositivity in children with IBD, and the infliximab dose was associated with a higher EBV viral load." | 1.42 | Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. ( Bronsky, J; Copova, I; Durilova, M; Hradsky, O; Hubacek, P; Maminak, M; Nevoral, J; Zarubova, K, 2015) |
| "To determine the incidence and predictors of thiopurine-related adverse events." | 1.42 | Clinical predictors of thiopurine-related adverse events in Crohn's disease. ( Dubeau, MF; Eksteen, B; Ghosh, S; Kaplan, GG; Moran, GW; Panaccione, R; Yang, H, 2015) |
| "Here, we report a rare case of Sweet's syndrome induced by azathioprine in a patient with Crohn's disease." | 1.42 | A Rare Case of Azathioprine-Induced Sweet's Syndrome in a Patient with Crohn's Disease. ( Aounallah, A; Ben Salem, C; Fathallah, N; Hmouda, H; Larif, S; Sakhri, J; Salem, CB; Slim, R, 2015) |
| "When treating Crohn disease (CD) with thiopurines, achievement of an objective response is essential." | 1.42 | Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease. ( Chen, BL; Chen, MH; He, Y; Mao, R; Qiu, Y; Zeng, ZR; Zhang, SH, 2015) |
| "Inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are chronic diseases characterized by an inappropriate immune response, which may also increase the risk of infections." | 1.42 | Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977-2013. ( Hoffmann, S; Jess, T; Kantsø, B; Petersen, AM; Simonsen, J; Valentiner-Branth, P, 2015) |
| "Extraintestinal manifestations in Crohn's disease (CD) are frequent and well recognized." | 1.42 | Histologically confirmed case of cerebral vasculitis associated with Crohn's disease--a case report. ( Asaoka, K; Gekka, M; Kato, Y; Nishihara, H; Nomura, M; Sugiyama, T, 2015) |
| " Unfortunately, the high rate of adverse events (AEs) leading to drug withdrawal represents a major limitation in the use of these drugs." | 1.42 | Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort. ( Chen, BL; Chen, MH; Guo, J; He, Y; Li, MY; Mao, R; Qiu, Y; Zeng, ZR; Zhang, SH, 2015) |
| "Azathioprine (AZA) treatment appeared to decrease the risk for initial surgery in patients with non-penetrating and non-stricturing CD (HR = 0." | 1.42 | Risk factors for initial surgery in patients with Crohn's disease in Central China. ( Chen, M; Huang, M; Li, J; Li, L; Xia, B; Yan, W; Yi, F; Zhou, F, 2015) |
| "Preventing a recurrence of Crohn's disease is a problem that remains to be solved." | 1.40 | Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: a single-center paired case-control study. ( Araki, T; Fujikawa, H; Inoue, M; Inoue, Y; Kusunoki, M; Mohri, Y; Ohi, M; Okita, Y; Tanaka, K; Uchida, K, 2014) |
| "In this study in Crohn's disease patients no pharmacokinetic interaction was shown between adalimumab and the conventional thiopurines, azathioprine and mercaptopurine." | 1.40 | The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients. ( Bakker, JA; Bus, P; Engels, LG; Gilissen, LP; Hooymans, PM; Masclee, AA; Neef, C; Pierik, M; Seinen, ML; van Bodegraven, AA; Wong, DR, 2014) |
| "Sera of 110 CD patients, 82 ulcerative colitis (UC), and 150 healthy controls were collected and the presence of antibodies against the mycobacterial protein tyrosine phosphatase PtpA was assayed using ELISA." | 1.40 | Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins. ( Bach, H; Bressler, B; Grist, J; Silverberg, MS; Stempak, JM; Xia, A, 2014) |
| " The occurrence of adverse effects is a major drawback in the use of these drugs, and short- and long-term toxicity represent a major limitation to their use." | 1.40 | Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects. ( Avallone, EV; Cassieri, C; Paoluzi, P; Pica, R; Vernia, P; Zippi, M, 2014) |
| "187 (10." | 1.40 | Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011. ( Balogh, M; Erdelyi, Z; Golovics, PA; Horvath, A; Kiss, LS; Lakatos, L; Lakatos, PL; Lovasz, BD; Mandel, MD; Müller, KE; Pandur, T; Szipocs, I; Vegh, Z; Veres, G, 2014) |
| "Thiopurines prevent Crohn's disease (CD) endoscopic recurrence (ER) at least in 50% of patients 1 year after surgery." | 1.40 | Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study. ( Bernal, I; Boix, J; Cabré, E; Domènech, E; Lorenzo-Zúñiga, V; Mañosa, M; Marín, L; Moreno, V; Zabana, Y, 2014) |
| "She was diagnosed with Crohn's disease after undergoing colonoscopy and CT enterography." | 1.40 | [A case of IgG4-related sclerosing mesenteritis associated with Crohn's disease]. ( Bae, GH; Kim, EJ; Kim, EY; Lee, HC; Lee, TS; Oh, HK; Song, JE, 2014) |
| "Perianal fistulas are the most common and frequently encountered types of fistulas in Crohn's disease (CD)." | 1.40 | [Combination biological therapy for fistular Crohn's disease: clinical demonstration]. ( Knyazev, OV; Konoplyannikov, AG; Lischchinskaya, AA; Parfenov, AI; Ruchkina, IN; Shcherbakov, PL, 2014) |
| "Azathioprine was started within the first month in 33/52 patients; 26/52 received a second EEN course." | 1.40 | Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome. ( Bufler, P; Frivolt, K; Koletzko, S; Schatz, SB; Schwarzer, A; Schwerd, T; Werkstetter, KJ, 2014) |
| "The hazard ratio (HR) for disease progression was lower for both monotherapy with azathioprine (HR: 0." | 1.40 | Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. ( Andrade, P; Camila-Dias, C; Coelho, R; Lopes, S; Macedo, G; Magro, F; Rodrigues-Pinto, E; Santos-Antunes, J, 2014) |
| "Patients with Crohn's disease were able to avoid new prescriptions for corticosteroids at a statistically higher rate when treated with an anti-TNF agent." | 1.40 | Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease. ( Bedenbaugh, AV; Jaganathan, S; Kane, SV; Palmer, L; Schwartz, DA, 2014) |
| "The natural course of Crohn's disease (CD), with continuing relapses and remissions, leads to irreversible intestinal damage." | 1.40 | Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. ( Cheon, JH; Hong, SP; Kim, DH; Kim, TI; Kim, WH; Kwak, MS; Park, SJ, 2014) |
| "Infliximab withdrawal in patients with Crohn's disease on concomitant antimetabolite therapy is considered to be superior if obtained after a maintenance therapy period compared to induction alone." | 1.40 | Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. ( Amiot, A; Bastuji-Garin, S; Belhassan, M; Chauvin, A; Delchier, JC; Le Baleur, Y; Le Thuaut, A; Mesli, F, 2014) |
| "Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients." | 1.40 | Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. ( Amil Dias, J; Barabino, A; Braegger, CP; Bronsky, J; Buderus, S; De Ridder, L; Dignass, A; Eliakim, A; Escher, JC; Fagerberg, UL; Griffiths, A; Hugot, JP; Kierkus, J; Kolacek, S; Koletzko, S; Kolho, KL; Levine, A; Lionetti, P; Martín-de-Carpi, J; Miele, E; Navas López, VM; Paerregaard, A; Ruemmele, FM; Russell, RK; Serban, DE; Shaoul, R; Turner, D; Van Rheenen, P; Veereman, G; Veres, G; Weiss, B; Wilson, D; Winter, H, 2014) |
| " We investigated the effects of GMAA combined with thiopurines on patients with early-diagnosed CD." | 1.40 | Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease. ( Ashida, K; Fukuchi, T; Ito, D; Koga, H; Matsuura, M; Nakase, H; Shimazu, K; Toyonaga, T; Ubukata, S; Yamashita, H; Yoshino, T, 2014) |
| " Variation in thiopurine dosing and metabolite measurement was found among practitioners." | 1.40 | Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. ( Baldassano, RN; Boyle, BM; Colletti, RB; Crandall, WV; Kappelman, MD; Milov, DE, 2014) |
| "Capsule endoscopy Crohn's disease activity (CECDAI) index was used to assess ileitis severity." | 1.40 | A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. ( Chin, JL; Hall, B; Holleran, G; Mahmud, N; McNamara, D; Ryan, B; Smith, S, 2014) |
| "While clinical relapse is noted frequently following drug withdrawal, there are few published data on predictive factors." | 1.40 | Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. ( Ahmad, T; Al-Hilou, H; Arnott, ID; Cummings, JR; Dattani, R; Felwick, R; Gambles, CJ; Gaya, DR; Harris, R; Irving, PM; Kalla, R; Kennedy, NA; Lamb, CA; Lees, CW; Lindsay, JO; Lobo, AJ; Mansfield, J; Marriott, S; Musy, R; Nayee, H; Parkes, M; Reynolds, S; Satsangi, J; Senanayake, SM; Smith, M; Warner, B, 2014) |
| " To identify predictive factors associated with the development of thiopurine-induced adverse events." | 1.39 | Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. ( Aldeguer, X; Barreiro-de Acosta, M; Barrio, J; Bastida, G; Cabré, E; Cabriada, JL; Ceña, G; Chaparro, M; Esteve, M; García-Planella, E; Garcia-Sanchez, V; Garcia-Sepulcre, M; Gisbert, JP; Gomollón, F; Gutiérrez, A; Hinojosa, J; Márquez, L; Maté, J; Mendoza, JL; Merino, O; Montoro, MA; Muñoz, F; Ordás, I; Peñalva, M; Saro, C; Vera, I, 2013) |
| "The baseline mean Crohn's disease activity index (CDAI) and C-reactive protein were 177." | 1.39 | Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients. ( Abe, Y; Fujiwara, K; Higuchi, K; Inoue, T; Ishida, K; Kakimoto, K; Kawakami, K; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Okada, T; Sakanaka, T; Takeuchi, T; Tokioka, S; Umegaki, E, 2013) |
| "Crohn's disease is a chronic, inflammatory disease of the gastrointestinal tract, affecting both children and adults." | 1.39 | Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn's Disease. ( Bertolone, S; Cheerva, A; Dillard, R, 2013) |
| "Although general guidelines have suggested weight-based dosing of azathioprine (AZA, 2." | 1.39 | [How should azathioprine be dosed in Crohn's disease? a novel strategy of maximum dose-titration based on the lower limit of leukocyte count and tolerability]. ( Choi, JM; Kim, JB; Lee, JS; Lim, CS; Moon, W; Park, MI; Park, SJ; Yoo, JH, 2013) |
| "Azathioprine was associated with seropositivity (P = 0." | 1.39 | Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. ( Dieleman, L; Fedorak, D; Fedorak, RN; Kroeker, K; Linton, MS, 2013) |
| "He was diagnosed with Crohn's disease 3 years ago after suffering from abdominal pain and hematochezia for 12 years." | 1.39 | [A case of pleomorphic liposarcoma in a patient with Crohn's disease taking azathioprine]. ( Ahn, SM; Bae, JY; Oh, YM; Park, CA; Sim, HH; Song, CM; Suh, SO; Yun, CY, 2013) |
| "Cases of Crohn's disease (CD) and ulcerative colitis (UC) were identified from medical record review." | 1.39 | Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. ( Ananthakrishnan, AN; de Silva, P; Desai, A; Korzenik, J; Nguyen, DD; Yajnik, V; Zator, ZA, 2013) |
| "To assess the levels of red blood cell thiopurine methyltransferase (TPMT) in subjects with inflammatory bowel disease (IBD) and to determine how these levels impacted thiopurine dosing and leukopenia over the first six months of therapy." | 1.39 | The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease. ( Bernstein, CN; Chisick, L; Oleschuk, C, 2013) |
| " The major drawback of these drugs are their serious adverse effects (SAE), highlighting the importance of preemptive identification of patients at risk." | 1.39 | Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. ( Chowers, Y; Efrati, E; Elkin, H; Karban, A; Koifman, E; Krivoy, N; Mazor, Y, 2013) |
| "Crohn's disease is rare in South African black people and primary sclerosing cholangitis (PSC) is also rare in black patients with IBD, from South Africa." | 1.38 | Primary sclerosing cholangitis, Crohn's disease and HLA-B27 in black South African women. ( Bezuidenhout, E; Bosch, FJ; Buchel, OC; de K Grundling, H; de Vries, CS; Fevery, J; Janse van Rensburg, J; Middlecote, BD; van Zyl, JH, 2012) |
| "He was diagnosed as Crohn's disease (CD) based on clinical, laboratory and histological findings and, corticosteroid therapy was started." | 1.38 | An infant with severe refractory Crohn's disease and homozygous MEFV mutation who dramatically responded to colchicine. ( Birsin Özçakar, Z; Ekim, M; Ensari, A; Kansu, A; Kuloğlu, Z; Ustündağ, G, 2012) |
| " Numbers and types of adverse events were roughly equivalent among groups, although enrollment was limited, so it was not clear how rare adverse events might affect overall outcomes in practice." | 1.38 | Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. ( Finlayson, SR; Sands, BE; Siegel, CA; Tosteson, AN, 2012) |
| "A total of 82 Crohn's disease patients who received their first course of azathioprine or 6-mercaptopurine treatment at Severance Hospital between June 1996 and July 2007 were recruited to the study." | 1.38 | Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease. ( Cheon, JH; Hong, SP; Kim, TI; Kim, WH; Park, JJ, 2012) |
| "Medical therapy for Crohn's disease (CD) has changed significantly over the past 20 years with increasing use of immunosuppressives." | 1.38 | Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. ( Balogh, M; David, G; Erdelyi, Z; Golovics, PA; Horvath, A; Kiss, LS; Komaromi, E; Lakatos, L; Lakatos, PL; Lovasz, BD; Mester, G; Molnar, C; Pandur, T; Szathmari, M; Szipocs, I; Veres, G, 2012) |
| "A case of IgA nephropathy (IgAN) associated with Crohn's disease (CD) and preceded Helicobacter pylori (Hp) infection is described." | 1.38 | Is there any association between IgA nephropathy, Crohn's disease and Helicobacter pylori infection? ( Grapsa, E; Michopoulos, S; Mpakirtzi, T; Pipili, C; Sotiropoulou, M, 2012) |
| "Eleven cases occurred in patients with Crohn's disease." | 1.38 | Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. ( Allez, M; Beaugerie, L; Brousse, N; Carrat, F; Dupas, JL; Flourié, B; Laharie, D; Lerebours, E; Maynadié, M; Peyrin-Biroulet, L; Simon, T; Sokol, H, 2012) |
| "Infliximab is licenced for use in Crohn's disease (CD)." | 1.38 | Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. ( Ford, AC; Greer, D; Hamlin, J; Sprakes, MB; Warren, L, 2012) |
| " There is heterogeneous thiopurine methyltransferase metabolism among patients, which has implications for clinical dosing and risk for adverse events." | 1.38 | Initiating azathioprine for Crohn's disease. ( Levesque, BG; Loftus, EV, 2012) |
| "The sTREM-1 was detectable in 87 Crohn's disease patients (46%)." | 1.38 | Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease. ( Bigard, MA; Billioud, V; Bronowicki, JP; Chevaux, JB; Gibot, S; Guéant, JL; Massin, F; Oussalah, A; Peyrin-Biroulet, L; Williet, N, 2012) |
| " 13 adverse events occurred, including 6 specific to co-therapy (3 rash, 2 abnormal liver function tests, 1 dosing error)." | 1.38 | Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. ( Anderson, SH; Blaker, P; Irving, PM; Marinaki, AM; Sanderson, JD; Smith, MA, 2012) |
| "Appropriate treatment of perianal fistulas in Crohn's disease (CD) involves accurate anatomic evaluation." | 1.38 | Endoscopic ultrasound for perianal Crohn's disease: disease and fistula characteristics, and impact on therapy. ( Assulin, Y; Beer-Gabel, M; Chowers, Y; Lahat, A, 2012) |
| "Medical therapy for Crohn's disease has changed significantly over the past 20 years with the increasing use of immunosuppressants." | 1.38 | [The effect of early immunosuppressive therapy on the rate of resections performed in patients with Chron's disease, in Veszprém county, Hungary, a population-based cohort study]. ( Balogh, M; Dávid, G; Erdélyi, Z; Golovics, PA; Horváth, A; Kiss, LS; Komáromi, E; Lakatos, L; Lakatos, PL; Lovász, BD; Mester, G; Molnár, C; Pandur, T; Szathmári, M; Szipocs, I, 2012) |
| "Azathioprine (AZA) treatment in transplant or autoimmune patients and subsequent appearance squamous cell carcinomas at various sites, particularly skin and cervix, has shown a close relationship." | 1.38 | [A case of squamous cell carcinoma of the breast in a patient with Crohn's disease taking azathioprine]. ( Cho, JY; Heo, SW; Ju, DU; Kim, EJ; Kim, EY; Oh, HK; Park, KC; Ryu, JI, 2012) |
| "The orofacial manifestation of Crohn's disease, which is rare, can develop irrespective of intestinal involvement." | 1.38 | [Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation]. ( Cho, HD; Chung, IK; Chung, SK; Jung, BY; Kim, SJ; Lee, CK; Lee, SH; Lee, TH, 2012) |
| "The cumulative incidence of the first Crohn's disease-related major abdominal surgery was estimated using the Kaplan-Meier method, and independent predictors of surgery were identified using Cox proportional hazards regression with propensity scores adjustment." | 1.37 | Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. ( Bigard, MA; Bresler, L; Oussalah, A; Peyrin-Biroulet, L; Pillot, C; Williet, N, 2011) |
| "She was diagnosed with Crohn's disease and right internal iliac vein thrombosis." | 1.37 | Internal iliac vein thrombosis in pediatric Crohn's disease. ( Baysoy, G; Besbas, N; Daar, G; Demir, H; Elmas, SA; Haliloğlu, M, 2011) |
| "Characteristics of childhood-onset Crohn's disease in Hungary are similar to those obtained in other European countries." | 1.37 | [To grow up with Crohn's disease]. ( Kovács, J; Lorincz, M; Nagy, A; Szabó, A, 2011) |
| "We present the case of a woman with Crohn's disease who developed psoriasis after treatment with two anti-TNF- α drugs (infliximab and adalimumab)." | 1.37 | [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]. ( Bosque López, MJ; Rocamora Durán, V; Royo Escosa, V; Sansó Sureda, A; Sapiña Camaró, A, 2011) |
| "Common characteristics include: Crohn's disease (CD), thiopurine administration, fever lasting more than 5 days, lymphadenopathy, splenomegaly, anemia, lymphopenia, and elevated serum triglycerides and ferritin." | 1.37 | Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. ( Biank, VF; Kugathasan, S; Margolis, D; Sheth, MK; Simpson, P; Stephens, M; Talano, J, 2011) |
| "Physicians must be followed up Crohn's disease patients in order to rapidly detect and treat the clinical relapses of the disease." | 1.37 | [Long term evolution of corticodependant and corticoresistant Crohn's disease patients treated by azzathioprine]. ( Bibani, N; Boubaker, J; Filali, A; Hamrouni, A; Karoui, S; Serghini, M, 2011) |
| "Nearly 70% of patients with Crohn's disease (CD) undergo surgical resection, with one-quarter subsequently developing clinical recurrence within 12 months." | 1.37 | Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. ( Ananthakrishnan, AN; Hur, C; Juillerat, P; Korzenik, JR, 2011) |
| "Here we report two cases of Crohn's disease refractory to weekly GMA who responded to intensive GMA." | 1.37 | Treatment of refractory Crohn's disease by intensive granulocyte and monocyte adsorption apheresis: a report on two drug refractory cases. ( Kani, K; Kato, S; Matsuda, A; Ogawa, T; Takabayashi, H; Yakabi, K; Yamamoto, R, 2011) |
| " Dose intensification to weekly dosing was needed in 16." | 1.37 | [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary]. ( Banai, J; Bartha, Z; Farkas, K; Gasztonyi, B; Golovics, PA; Horváth, G; Kiss, LS; Lakatos, L; Lakatos, PL; Lovász, BD; Miheller, P; Molnár, T; Nagy, F; Palatka, K; Papp, M; Salamon, A; Szamosi, T; Szathmári, M; Szenes, M; Tóth, GT; Tulassay, Z; Végh, Z; Veres, G; Vincze, A, 2011) |
| "Erythema nodosum is the most common form of septal panniculitis and the most frequent skin manifestation associated with inflammatory bowel disease, affecting up to 15% of Crohn's disease patients." | 1.37 | [Crohn's disease presenting with erythema nodosum as an early sign: a case report]. ( Chang, HK; Kang, SJ; Kim, JB; Kim, KJ; Moon, W; Park, MI; Park, MJ; Park, SJ, 2011) |
| "The development of hepatocellular carcinoma (HCC) is attributed to several factors, including chronic viral infection, alcohol consumption, exposure to aflatoxin B1 and metabolic disorders." | 1.37 | Gut-liver axis plays a role in hepatocarcinogenesis of patients with Crohn's disease. ( Cui, DJ; Ouyang, Q; Zheng, SM, 2011) |
| "A 57-year old woman with perianal Crohn's disease receiving azathioprine and infliximab developed this type of lymphoma after a short period of time on the treatment." | 1.37 | Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection. ( Aldeguer, M; Arevalo, N; Benito, DM; de Fuenmayor, ML; Foncillas, MA; Plaza, R; Ponferrada, A, 2011) |
| "The birth outcomes in women with ulcerative colitis are examined in a nationwide, Danish, cohort of women based on data from the Danish National Hospital Discharge Registry and the Danish Medical Birth Registry, and within a Hungarian case-control data set." | 1.37 | Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. ( Nørgård, BM, 2011) |
| "Neutropenia was ameliorated with use of granulocyte colony-stimulating factor." | 1.37 | Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn's disease. ( Alkim, C; Alkim, H; Altinkaya, E; Boğa, S; Buğdaci, MS; Köksal, AR; Özdoğan, O; Sökmen, M, 2011) |
| "Kwashiorkor is one of the severe forms of protein-energy malnutrition." | 1.36 | Cutaneous presentation of kwashiorkor due to infantile Crohn's disease. ( Al Goufi, T; Al-Khenaizan, S; Al-Mubarak, L, 2010) |
| "In contrast, in ulcerative colitis (UC), smoking might improve the disease course." | 1.36 | Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colit ( Banai, J; Czegledi, Z; David, G; Erdelyi, Z; Gemela, O; Lakatos, L; Lakatos, PL; Pandur, T; Papp, J; Papp, M; Szamosi, T; Zsigmond, F, 2010) |
| "A total of 20 IBD (14 Crohn's disease, 6 ulcerative colitis) HIV infected patients and 40 matched control seronegative IBD patients (2 controls per case) were compared regarding relapse of their disease." | 1.36 | Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. ( Baraboutis, IG; Georgiadis, D; Georgiou, O; Karamanolis, DG; Papastamopoulos, V; Rodias, M; Skoutelis, A; Viazis, N; Vlachogiannakos, J, 2010) |
| "Surgical recurrence occurred in 151/326 (46." | 1.36 | The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. ( Dejaco, C; Gratzer, C; Herkner, H; Ho, E; Lissner, D; Miehsler, W; Novacek, G; Papay, P; Reinisch, W; Riss, S; Vogelsang, H, 2010) |
| " Infliximab failure was defined by: (i) disease flare requiring shortening of the dosing interval or increasing the infliximab dose to 10 mg/kg, or switching to adalimumab; (ii) acute or delayed hypersensitivity reactions leading to infliximab discontinuation; or (iii) CD-related surgery." | 1.36 | Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. ( Bigard, MA; Chevaux, JB; Fay, R; Oussalah, A; Peyrin-Biroulet, L; Sandborn, WJ, 2010) |
| "Azathioprine was the most frequent causative factor (three cases in two patients); all the other causative drugs were documented only in single cases: mesalazine, dexamethasone, ramipril, mycophenolate mofetil, cytarabine, and valproate." | 1.36 | Incidence, severity, and etiology of drug-induced acute pancreatitis. ( Procházka, M; Procházka, V; Urbánek, K; Vinklerová, I, 2010) |
| "We report a case of hepatocellular carcinoma (HCC) occurring in a patient with Crohn's disease (CD) without chronic hepatitis or liver cirrhosis, and review the clinicopathological features of HCC in CD patients." | 1.36 | Hepatocellular carcinoma occurring in a Crohn's disease patient. ( Andoh, A; Fujiyama, Y; Hotta, M; Ishida, M; Kojima, F; Kurumi, Y; Naka, S; Nakahara, T; Okabe, H; Saito, Y; Shiomi, H; Takikita-Suzuki, M; Tani, T; Tsujikawa, T, 2010) |
| "Case notes from Crohn's disease incidence studies in Cardiff were reviewed retrospectively for disease characteristics and follow-up information on drug therapy, and the need for surgery for Crohn's disease." | 1.36 | Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. ( Gunesh, S; Hawthorne, AB; Ramadas, AV; Thomas, GA; Williams, GT, 2010) |
| "This retrospective review examines 32 ulcerative colitis (UC) patients and 19 Crohn's disease (CD) patients (12." | 1.36 | Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. ( Aoyagi, Y; Arai, K; Baba, Y; Fujii, T; Ikuse, T; Inage, E; Kudo, T; Nagata, S; Ohtani, K; Ohtsuka, Y; Shimizu, T; Suzuki, R; Yamakawa, Y, 2010) |
| "Allopurinol has been presented as a safe and effective adjunct to thiopurine therapy in inflammatory bowel disease (IBD)." | 1.36 | Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. ( Govani, SM; Higgins, PD, 2010) |
| "Azathioprine was stopped and antibiotics started." | 1.36 | Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease. ( Lal, S; Ormerod, C; Sarkar, S; White, D; Woodcock, B, 2010) |
| "Azathioprine was stopped after 4 months of combination therapy, without loss of efficacy or adverse reactions attributable to immunogenicity." | 1.36 | Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies. ( Martín-de-Carpi, J; Pociello, N; Varea, V, 2010) |
| "paratuberculosis; isolates from Crohn's disease patients tended to be more susceptible than were bovine-origin isolates." | 1.35 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. ( Collins, MT; Shin, SJ, 2008) |
| "Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous (AZA) hypersensitivity reaction were studied prospectively." | 1.35 | Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. ( Farkas, K; Lonovics, J; Molnar, T; Nagy, F; Nyari, T; Szepes, Z, 2008) |
| "Sweet syndrome is a reactive, sterile, pustular dermatosis that occurs in association with infection, malignancy, or connective tissue disease or in response to the use of certain medications." | 1.35 | Sweet syndrome as a manifestation of azathioprine hypersensitivity. ( Brunner, KL; El-Azhary, RA; Gibson, LE, 2008) |
| "Treating Crohn's disease may lead to improvement in steroid-resistant myositis where the two are associated." | 1.35 | Association of idiopathic inflammatory myopathy and Crohn's disease. ( Danko, K; Dezso, B; Gunasekera, W; Kulcsar, I; Lukacs, S; Nagy-Toldi, A; Szabo, N, 2009) |
| "Perianal fistulizing Crohn's disease (PFCD) treatment is based on fistula drainage, antibiotics, immunosuppressant (IS) drugs, and infliximab." | 1.35 | Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. ( Koning, E; Lerebours, E; Michot, F; Savoye, G; Savoye-Collet, C; Tougeron, D, 2009) |
| "Immunocompromised adults without varicella history are at high risk to develop life-threatening complications of varicella." | 1.35 | Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus. ( Encke, J; Filusch, A; Hartschuh, W; Konstandin, M; Sauer, P; Sauerbrei, A; Schnitzler, P; Springfeld, C; Stremmel, W, 2009) |
| "The renal biopsy was performed and IgA nephropathy (type IV) was diagnosed." | 1.35 | [Crohn's disease in association with IgA nephropathy]. ( Choi, YJ; Chung, WC; Kim, HW; Lee, JM; Lee, JR; Lee, KM; Paik, CN; Yang, JM, 2008) |
| " The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia." | 1.35 | Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine. ( de Boer, NK; Kanis, BM; van Asseldonk, DP; van Bodegraven, AA, 2009) |
| "Azathioprine dosage was adjusted according to clinical response and occurrence of adverse events." | 1.35 | Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. ( Chebli, JM; Chebli, LA; do Amaral, FJ; Gaburri, PD; Meirelles de Souza, AF; Moraes, JP; Pace, FH; Pinto, AL; Ribeiro, MS, 2009) |
| "Extraintestinal manifestations of Crohn's disease such as erythema nodosum and pyoderma gangrenosum are well recognized and appreciated." | 1.35 | Clinical spectrum of vulva metastatic Crohn's disease. ( Buchman, AL; Collyer, J; Leu, S; Mirowski, GW; Schlosser, B; Smidt, A; Stika, CS; Sun, PK; Vanagunas, A, 2009) |
| "We sought to determine whether treatment with steroids, immunosuppressives (ISs), and anti-tumor necrosis factor (TNF) agents is associated with an increased risk of adverse events in patients with Crohn's disease (CD)." | 1.35 | Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. ( Arrighi, HM; Hass, S; Marehbian, J; Sandborn, WJ; Tian, H, 2009) |
| "We identified outpatients with ulcerative colitis (UC) or Crohn's disease (CD) evaluated at the University of Maryland and the Baltimore Veterans Affairs Medical Center from 1997-2005." | 1.35 | Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. ( Cross, RK; Flasar, MH; Johnson, T; Roghmann, MC, 2008) |
| "Azathioprine intolerance is a common clinical problem, requiring drug withdrawal in up to 30% of patients." | 1.35 | Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. ( Arnott, ID; Hansoti, B; Lees, CW; Maan, AK; Satsangi, J, 2008) |
| " Although general guidelines have been suggested for weight-based dosing of thiopurines, no standard of care has been established." | 1.35 | How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. ( Abreu, MT; Sparrow, MP; Woodward, M; Yip, JS, 2008) |
| "In addition, acute pancreatitis is one of the extra-intestinal manifestations of acute exacerbation of CD without the previous use of azathioprine." | 1.35 | [Acute pancreatitis following azathioprine therapy of crohn's disease--a case report and the overview of the literature]. ( Koren, M; Potrc, S; Sinkovic, A; Skok, P, 2008) |
| "Eighteen patients (11 ulcerative colitis, 6 Crohn's disease, 1 indeterminate colitis), mean age 28." | 1.35 | Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. ( Kane, SV; Kornbluth, AA; Murphy, SJ; Present, DH; Reddy, D, 2008) |
| "Recto-urethral fistulas due to Crohn's disease are very uncommon." | 1.35 | [Urethral fistula due to Crohn's disease: case report of successful conservative management]. ( Borovicka, J; Engeler, DS; Hetzer, FH; Meyer, D; Schmid, HP; Schwab, C, 2008) |
| " Bioavailability of thiopurines may be competitively inhibited by dietary purines." | 1.35 | Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. ( Ansari, A; Aslam, Z; De Sica, A; Duley, J; Fairbanks, L; Gilshenan, K; Marinaki, A; Sanderson, J; Smith, M, 2008) |
| "Patients with longstanding quiescent Crohn's disease on azathioprine usually maintain an excellent quality of life but are also concerned about long-term safety." | 1.34 | How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? ( Kalantzis, C; Kalantzis, N; Koilakou, S; Mantzaris, GJ; Raptis, N; Roussos, A, 2007) |
| "Azathioprine is an immunosuppressant prescribed for the treatment of inflammatory conditions and after organ transplantation." | 1.34 | Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. ( Bruce, I; Elliott, R; Fargher, EA; Newman, W; Payne, K; Roberts, SA; Shaffer, JL; Tricker, K, 2007) |
| "Crohn's disease is a chronic inflammatory bowel disease that can involve any portion of the gastrointestinal tract." | 1.34 | [Azathioprine for prevention of postoperative recurrence in Crohn's disease]. ( Abdelli, MN; Ben Abdallah, H; Bouali, MR; Houissa, F; Khediri, MF, 2007) |
| "The azathioprine dose was adapted to reach a 6-tioguanine level of >250 pmol/8 x 10(8) red blood cells." | 1.33 | 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. ( Bessard, G; Bonaz, B; Chartier, A; Faucheron, JL; Hardy, G; Helluwaert, F; Phelip, JM; Roblin, X; Serre-Debeauvais, F, 2005) |
| " AZA dose selection based on pharmacogenetic testing of TPMT and metabolite monitoring (MM) may offer a safety and efficacy advantage over traditional dosing strategies." | 1.33 | A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. ( Chiou, CF; Dubinsky, MC; Ofman, J; Reyes, E; Sandborn, WJ; Wade, S, 2005) |
| "Azathioprine is an important steroid sparing agent in the management of patients with inflammatory bowel disease." | 1.33 | Re-introduction of azathioprine in previously intolerant patients. ( Green, CJ; Mee, AS, 2006) |
| "Data on newly diagnosed Crohn's disease patients were prospectively collected within 3 weeks of diagnosis, 6 months after diagnosis, and 1 year after diagnosis." | 1.33 | Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. ( Baldassano, RN; Jacobstein, DA; Leonard, M; Mamula, P; Markowitz, JE, 2006) |
| "Azathioprine is a frequently used immunosuppressant for managing inflammatory bowel disease (IBD)." | 1.33 | Myelotoxicity and hepatotoxicity during azathioprine therapy. ( de Boer, NK; Mulder, CJ; van Bodegraven, AA, 2005) |
| "Diagnostic criteria for CD, ulcerative colitis (UC), and indeterminate colitis (IC) were defined." | 1.33 | Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease. ( Bonova, O; Dedek, P; Frühauf, P; Havlickova, A; Janatova, T; Jimramovsky, F; Klimova, L; Klusacek, D; Kocourkova, D; Kolek, A; Kotalova, R; Maly, J; Marx, D; Nevoral, J; Petro, R; Petru, O; Plasilova, I; Pozler, O; Schreierova, I; Seidl, Z; Sekyrova, I; Semendak, N; Stanek, J; Sulakova, A; Sykora, J; Toukalkova, L; Travnickova, R; Volf, V; Zahradnicek, L; Zenisková, I, 2006) |
| "To evaluate pharmacokinetics and tolerance after initiation of thiopurine treatment with a fixed dosing schedule in patients with IBD." | 1.33 | Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. ( Almer, S; Hindorf, U; Hjortswang, H; Lindqvist, M; Peterson, C; Pousette, A; Söderkvist, P; Ström, M, 2006) |
| "Long-term tacrolimus therapy appears safe and effective in refractory IBD." | 1.33 | Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. ( Baumgart, DC; Dignass, AU; Pintoffl, JP; Sturm, A; Wiedenmann, B, 2006) |
| "Hepatocellular carcinoma is known to be associated with underlying liver diseases, such as cirrhosis, hemochromatosis, and chronic viral hepatitis." | 1.33 | Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. ( Chen, SC; Cho, WK; Cummings, OW; Filomena, CA; Hartley, MP, 2006) |
| "We report a case of Crohn's disease which was refractory to the conventional treatment." | 1.33 | Infliximab treatment of pediatric refractory Crohn's disease: a case report. ( Akman, SA; Arikan, C; Oztürk, C; Sözen, G; Yağci, RV, 2006) |
| "In patients with steroid-refractory Crohn's disease, the therapeutic goal is to achieve both rapid remission and maintenance of clinical response." | 1.33 | Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. ( Moser, C; Schmidt, C; Stallmach, A; Wittig, BM; Zeitz, M, 2006) |
| " These observations suggest that the development of muscular weakness in patients on azathioprine should be considered as an adverse effect of the drug." | 1.33 | Severe muscular weakness: an unusual adverse effect of azathioprine therapy. ( Arora, M; Dutta, SK; Karhadkar, AS; Schwartz, HJ, 2006) |
| "Active disease was defined as Pediatric Crohn's Disease Activity Index (PCDAI) greater than 10 or systemic corticosteroid use." | 1.33 | Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. ( de Ridder, L; Escher, JC; Jaspers, GJ; Rings, EH; Taminiau, JA; Verkade, HJ, 2006) |
| "Recurrence of Crohn's disease (CD) after surgery is common." | 1.33 | Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease. ( Almer, S; Andersson, P; Bodemar, G; Myrelid, P; Olaison, G; Svärm, S, 2006) |
| "Crohn disease is a chronic inflammatory disease characterized by sharply demarcated segments of gastrointestinal involvement from mouth to anus." | 1.33 | Perianal Crohn disease. ( Asma, SD; Kahena, J; Nejib, D; Raouf, DM; Soumaya, Y, 2006) |
| "We report for the first time that Crohn's disease patients with TPMT deficiency can be successfully treated with AZA." | 1.32 | Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. ( Deflandre, J; Eichelbaum, M; Graepler, F; Gregor, M; Hindorf, U; Kaskas, BA; Louis, E; Schaeffeler, E; Schmiegelow, K; Schwab, M; Zanger, UM, 2003) |
| "Two patients presented cutaneous varicella complicated by pneumonia and esophagitis respectively, one patient had cutaneous herpes zoster and the other had fatal pneumonia possibly caused by the Herpesvirus." | 1.32 | [Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy]. ( Bernal, I; Cabré, E; Domènech, E; García-Planella, E; Gassull, MA, 2003) |
| "The morphological substrate of Crohn's disease in the Hydro-MRI images is reliably detected." | 1.32 | [Follow up of Crohn's disease under therapy with hydro-MRI]. ( Encke, J; Erb, G; Flosdorff, P; Ganten, M; Grüber-Hoffmann, B; Hansmann, J, 2003) |
| "Prednisone dosage was reduced from a mean of 19." | 1.32 | Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. ( France, R; Kinney, T; Kozarek, R; Patterson, D; Rawlins, M, 2003) |
| "The purine analogues 6-mercaptopurine (6-MP) and azathioprine have been found to be safe and efficacious in both inducing remission of Crohn's disease in adults and maintaining remission in adults and children." | 1.32 | Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. ( Markowitz, JF, 2003) |
| "We present the case of a patient with Crohn's disease under immunosuppressive therapy who developed a spontaneous covered spleen rupture in the course of a septic shock with DIG due to a Varizella zoster infection." | 1.32 | [Functional asplenia after severe varicella zoster-infection diagnosis by colour Doppler ultrasound]. ( Arnold, R; Diedrich, J; Eissele, R; Görg, C, 2003) |
| "6-mercaptopurine/azathioprine was used by 24% of patients with Crohn's disease and 12% of patients with ulcerative colitis (95% CI for the difference: 8." | 1.32 | A national survey on the patterns of treatment of inflammatory bowel disease in Canada. ( Best, A; Hilsden, RJ; Pocobelli, G; Verhoef, MJ, 2003) |
| "An open prospective study was made on Crohn's disease patients treated with TG." | 1.32 | Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. ( Belaiche, J; Boitard, J; Bonaz, B; Cadiot, G; Coffin, B; Colombel, JF; Cortot, A; Flourié, B; Lémann, M; Marteau, P; Metman, EH, 2003) |
| "The subgroups with ulcerative colitis and Crohn's disease and the effect of taking azathioprine were compared." | 1.32 | Bone density improves with disease remission in patients with inflammatory bowel disease. ( Jugdaohsingh, R; Meenan, J; Powell, JJ; Reffitt, DM; Sanderson, JD; Thompson, RP, 2003) |
| "Azathioprine has demonstrable benefits after induction therapy with prednisone." | 1.32 | Clinical features and management of Crohn's disease in Chinese patients. ( Chu, XQ; Jia, LM; Shi, XH; Wang, FM; Zheng, JJ, 2004) |
| "The risk of colorectal cancer was not increased, either in the total group of patients or in patients with colonic Crohn's disease exclusively (standardized morbidity ratio, 1." | 1.32 | Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. ( Binder, V; Jess, T; Langholz, E; Munkholm, P; Winther, KV, 2004) |
| "Azathioprine has been reported to heal fistulas in 30-40% of cases." | 1.32 | Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. ( Blumenstein, I; Schröder, O; Schulte-Bockholt, A; Stein, J, 2004) |
| "Potential biomarkers for Crohn's disease (CD) and ulcerative colitis (UC) were identified from two sets of full thickness pathologic samples utilizing DermArray and PharmArray DNA microarrays relative to uninvolved (Un) colon or normal colon." | 1.32 | Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. ( Curto, EV; Davis, RL; Dooley, TP; Elson, CO; Lambert, GW; Reddy, SP; Wilborn, TW, 2004) |
| "A retrospective cohort analysis of clinical data regarding adverse events of azathioprine in Crohn's disease." | 1.32 | Side effects of azathioprine in patients with Crohn's disease. ( de Jong, DJ; Goullet, M; Naber, TH, 2004) |
| "Forty-one patients (32 with Crohn's disease [CD] and 9 with ulcerative colitis [UC]) were enrolled in a 4-month prospective nonrandomized study with AZA, and 101 (65 with CD and 36 with UC) were on either maintenance AZA or 6-mercaptopurine (6-MP)." | 1.32 | Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. ( Bayless, TM; Cuffari, C; Dassopoulos, T; Thompson, RE; Turnbough, L, 2004) |
| "A 48 year old patient with active Crohn's disease presented with bilateral nodules over his lungs resembling malignant metastasis." | 1.32 | Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease. ( Majoor, CJ; Schreurs, AJ; Weers-Pothoff, G, 2004) |
| "Forty patients (27 male; 24 Crohn's, 16 ulcerative colitis) with chronic active disease or recurrent flares despite standard dose azathioprine for a median 8 months (range 3-114) increased their dose from a median 2." | 1.32 | Azathioprine dose escalation in inflammatory bowel disease. ( Emmanuel, AV; Hart, AL; Hayward, CM; Kamm, MA; Rayner, CK, 2004) |
| "Seventy-two patients were studied (66 Crohn's disease and six ulcerative colitis)." | 1.32 | Experience with the use of low-dose methotrexate for inflammatory bowel disease. ( Ansari, A; Hirst, J; Raoof, S; Sanderson, JD; Soon, SY; Yaneza, M, 2004) |
| " Optimal dosage for AZA is around 2." | 1.32 | [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD]. ( Dejaco, C; Knoflach, P; Petritsch, W; Reinisch, W; Tilg, H; Vogelsang, H, 2004) |
| "Clinical recurrence rate at 3 years was significantly lower in the IS group than in the control group (3/12, 25% vs 6/10, 60%; P < 0." | 1.32 | Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? ( Alves, A; Bouhnik, Y; Joly, F; Lavergne-Slove, A; Panis, Y; Pocard, M; Valleur, P, 2004) |
| "Azathioprine was discontinued, and the patient improved after initiating treatment with steroids and trimethoprim-sulfamethoxazole." | 1.32 | Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. ( Sandborn, WJ; Velayos, FS, 2004) |
| "Acute pancreatitis is rarely seen when azathioprine is used for other diseases than Crohn's disease." | 1.32 | Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. ( Homan van der Heide, JJ; Jansen, PL; Oostenbrug, LE; Peters, FT; Ploeg, RJ; Posthumus, MD; van den Berg, AP; van Dullemen, HM; van Haastert, M; Weersma, RK, 2004) |
| "Data from all patients with Crohn's disease whose diagnosis had been performed before 1st January 1978 were analyzed." | 1.32 | Crohn's disease over 20 years after diagnosis in a referral population. ( Beaugerie, L; Bouhnik, Y; Cosnes, J; Etienney, I; Gendre, JP; Lémann, M; Matuchansky, C; Modigliani, R; Rambaud, JC, 2004) |
| "In patients with Crohn's disease on long term azathioprine therapy, it is clear that myelosuppression, particularly leucopenia, is caused by other factors in addition to variable TPMT activity and therefore monitoring of blood cell counts throughout treatment is essential." | 1.31 | TPMT in the treatment of Crohn's disease with azathioprine. ( Lennard, L, 2002) |
| "The rise of fistulae in Crohn's disease has been classed with the disorder complications, although it is a possible component of natural development of the so-called A type (De Dombal classification) or aggressive-perforating type (Greenstein's classification) of this idiopathic intestinal inflammation." | 1.31 | Immunosuppressive treatment of Crohn's disease with fistulae. ( Dastych, M; Dite, P; Pazourkova, M; Pokorny, A; Prokopova, L; Zboril, V, 2002) |
| " The long-term use of immunodulating agents in patients with CD is not without risks, and early therapy related myelodysplasia might not be easily detected by blood count and morphology assessment alone." | 1.31 | Clonal marrow abnormalities after azathioprine and sulfasalazine exposure in Crohn's disease: a cautionary tale. ( Au, WY; Lai, KC; Ma, SK; Wan, TS; Yuen, MF, 2002) |
| "Azathioprine is a useful agent for the treatment of Crohn's disease but side effects occur in 10% of patients." | 1.31 | Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury. ( Arnott, ID; Ghosh, S, 2000) |
| "Azathioprine is a commonly used and effective treatment for maintenance of remission for patients with steroid-dependent Crohn's disease (CD)." | 1.31 | Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. ( Lewis, JD; Lichtenstein, GR; Schwartz, JS, 2000) |
| " Patients treated with either branded azathioprine or 6-mercaptopurine achieved significantly higher erythrocyte 6-thioguanine levels than patients treated with generic azathioprine, thereby suggesting that branded azathioprine has improved oral bioavailability compared to generic azathioprine." | 1.31 | Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. ( Bayless, TM; Cuffari, C; Hunt, S, 2000) |
| "Azathioprine is an immunosuppressor drug widely used in the treatment of autoimmune diseases." | 1.31 | [Aplasia after azathioprine administration: role of the thiopurine methyltransferase genetic polymorphism]. ( Baiget, M; Corominas, H; Díaz, C; Domènech, M; González-Juan, D; González-Suárez, B; Pujol, J; Vázquez, G, 2000) |
| "Azathioprine is a useful therapy in patients with inflammatory bowel disease that is difficult to control." | 1.31 | The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. ( Boulton-Jones, JR; Mahmoud, AA; Pritchard, K, 2000) |
| "Recurrence of Crohn's disease (CD) lesions in the neo-ileum after apparently curative resection frequently occurs after surgery." | 1.31 | [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease]. ( Aguilera, V; Berenguer, J; Hinojosa, J; Molés, JR; Nos, P; Pastor, M; Ponce, J, 2000) |
| "Up to 50% of patients with Crohn's disease (CD) develop steroid-dependent or refractory disease requiring immunosuppression." | 1.31 | Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? ( Gangl, A; Miehsler, W; Moser, G; Reinisch, W; Vogelsang, H, 2001) |
| "Probabilities of clinical recurrence according to the Kaplan-Meier method were 9, 16 and 28% at 1, 2 and 3 years, respectively." | 1.31 | Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. ( Allez, M; Bouhnik, Y; Cuillerier, E; Lémann, M; Modigliani, R; Rambaud, JC, 2001) |
| "Azathioprine is effective treatment for ulcerative colitis and Crohn's disease." | 1.31 | The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. ( Fraser, AG; Jewell, DP; Orchard, TR, 2002) |
| "Pancreatitis was significantly more frequent in girls as compared to boys (P = 0." | 1.31 | [Pancreatic involvement in inflammatory bowel diseases in children]. ( Cézard, JP; Faure, C; Hugot, JP; Le Large-Guiheneuf, C; Mougenot, JF; Munck, A; Navarro, J, 2002) |
| "Azathioprine was discontinued early for side-effect in 8 (26." | 1.31 | [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease]. ( Beau, P; Kull, E, 2002) |
| "Age of onset, surgical past history of Crohn's disease, colonic or ileal involvement, or Harvey-Bradshaw score were not different between groups." | 1.30 | Anal lesions: any significant prognosis in Crohn's disease? ( Bretagne, JF; Gosselin, M; Juguet, F; Mary, JY; Mortaji, A; Siproudhis, L, 1997) |
| " Three patients were treated with intravenous acyclovir with concomitant reduction of steroid dosage and recovered completely." | 1.30 | Management of varicella infection during the course of inflammatory bowel disease. ( Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997) |
| "To ascertain whether patients with Crohn's disease treated with azathioprine maintained bone mineral mass better than patients treated with steroids alone." | 1.30 | Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. ( Ahrén, B; Bartosik, J; Bengtsson, M; Florén, CH; Obrant, K, 1998) |
| "Twenty-eight patients (13 ulcerative colitis and 15 Crohn's disease) received oral cyclosporin for a mean of nine months (range 0." | 1.30 | Oral cyclosporin in refractory inflammatory bowel disease. ( Connell, WR; d'Apice, AJ; Elliott, R; Taylor, AC, 1998) |
| "In contrast with Crohn's disease of any other localization, the formation of fistulas is exceptional." | 1.30 | [Duodenal Crohn's disease: diagnostic and therapeutic complexity]. ( Cabrera Chaves, T; Gomollón García, F; Sanjuán Portugal, F; Yus Gotor, C, 1998) |
| "In this study 7 patients with severe ulcerative colitis and 4 patients with active Crohn's disease unresponsive to prednisone were treated with high dose intravenous cyclosporine." | 1.30 | [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases]. ( Dejaco, C; Gangl, A; Gasché, C; Moser, G; Novacek, G; Reinisch, W; Tillinger, W; Vogelsang, H, 1998) |
| "Thirty children operated on for Crohn's disease (CD) were reviewed (1975-1994)." | 1.30 | Postoperative outcome of Crohn's disease in 30 children. ( Aigrain, Y; Besnard, M; Cézard, JP; Debrun, A; Delagausie, P; Faure, C; Ferkdadji, L; Jaby, O; Mougenot, JF; Navarro, J; Peuchmaur, M, 1998) |
| "Azathioprine was also introduced earlier (20." | 1.30 | [Diffuse jejuno-ileitis of Crohn's disease: a separate form of the disease?]. ( Colombel, JF; Cortot, A; Gower-Rousseau, C; Grandbastien, B; Paris, JC; Quandalle, P; Touze, I, 1999) |
| "Discontinuation of 6MP, while Crohn's disease is in remission, leads to higher relapse rates and continuation of 6MP reduces the likelihood of relapse." | 1.30 | Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. ( Gleim, GW; Kim, PS; Korelitz, BI; Zlatanic, J, 1999) |
| "A patient with Crohn's disease (CD) subsequently developed the clinical and histological features of hidradenitis suppurative (HS)." | 1.29 | Hidradenitis suppurativa in Crohn's disease. A further support to this association. ( Dalekos, GN; Hatzis, J; Merkouropoulos, M; Tsianos, EV; Tzermias, C, 1995) |
| "A 19 year old man with a history of Crohn's disease treated with azathioprine and prednisone, died after a primary infection with Epstein-Barr virus." | 1.29 | Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. ( Kluin, PM; Kluin-Nelemans, JC; Lamers, CB; Posthuma, EF; van der Sluys Veer, A; Westendorp, RG, 1995) |
| "Among patients with extensive chronic ulcerative colitis there was no difference in cancer frequency between 86 who had received azathioprine and 180 matched patients who had never received it." | 1.29 | Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. ( Balkwill, AM; Connell, WR; Dickson, M; Kamm, MA; Lennard-Jones, JE; Ritchie, JK, 1994) |
| "Two patients with recurrent Crohn's disease in the reservoir after ileoanal anastomosis were treated with azathioprine for 18 and 24 months, respectively." | 1.29 | Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine. ( Berrebi, W; Bruhl, AL; Chaussade, S; Couturier, D; Hautefeuille, P; Pariente, A; Valleur, P, 1993) |
| "Eighty-one percent had Crohn's disease, 8% ulcerative colitis, and 11% indeterminant colitis." | 1.29 | Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. ( Daum, F; Grancher, K; Mandel, F; Markowitz, J, 1993) |
| "The outcome of treatment of perianal Crohn's disease was assessed in 127 patients." | 1.29 | Perianal Crohn's disease--is it all bad news? ( Keenan, RA; McKee, RF, 1996) |
| "Both alopecia and polymyositis are rarely associated with inflammatory bowel disease; thus, they have to be discussed as extraintestinal manifestations." | 1.29 | Polymyositis, alopecia universalis, and primary sclerosing cholangitis in a patient with Crohn's disease. ( Jakob, F; Klein, R; Seibold, F, 1996) |
| "In the second patient, Crohn's disease was less severe and remission occurred without treatment." | 1.29 | [Crohn's disease and pregnancy. Two case reports]. ( Abboud, P; Messing, B; Napoléone, C; Quéreux, C; Wahl, P; Zeitoun, P, 1996) |
| "About 20% of patients with active Crohn's disease do not respond to acute-phase-therapy with glucocorticoids at an initial dose of 60 mg prednisolone-equivalent and stepwise dose reduction every week." | 1.28 | [Internistic therapy possibilities in therapy-resistant Crohn disease]. ( Hoffmann, R, 1992) |
| "The surgical treatment of Crohn's disease consists of resection of the lesions with anastomosis or ileostomy in case of total proctocolectomy." | 1.28 | [Treatment of Crohn disease]. ( Modigliani, R, 1991) |
| "Sixteen patients with Crohn's disease who had symptoms uncontrolled by high-dose steroids (n = 11) or symptoms invariably appearing on reduction or withdrawal of immunosuppressive therapy (n = 5) were treated with elemental diet." | 1.28 | Elemental diet in steroid-dependent and steroid-refractory Crohn's disease. ( Cann, PA; Giaffer, MH; Holdsworth, CD; O'Brien, CJ, 1991) |
| "Nine patients had ulcerative colitis and 12 patients had Crohn disease; the patients' ages ranged from 3 to 17 years." | 1.28 | Azathioprine in the treatment of children with inflammatory bowel disease. ( Grand, RJ; Verhave, M; Winter, HS, 1990) |
| "A patient with Crohn's disease and alopecia totalis is described." | 1.28 | Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine. ( August, PJ; Goddard, CJ; Whorwell, PJ, 1989) |
| "The diagnosis of Crohn's disease with extensive involvement of small intestine and colon was first made in a 12 3/4-year-old girl, now 15 1/2 years old." | 1.27 | [Crohn disease: initial experiences with cyclosporin A in an adolescent girl]. ( Dannecker, G; Malchow, H; Niessen, KH; Ranke, MB, 1985) |
| "Increasing incidence of Crohn's disease particularly in childhood and adolescence has made inflammatory bowel disease one of the most important aspects of paediatric gastroenterology." | 1.27 | [Crohn disease in childhood]. ( Bender, SW; Kirchmann, H; Posselt, HG, 1986) |
| "Etiology and pathogenesis of Crohn's disease, the incidence of which seems to be increasing lately, are still unknown." | 1.26 | [Clinical features of inflammatory bowel disease (author's transl)]. ( Classen, M; Leuschner, U; Strohm, WD, 1982) |
| "The diagnostic possibility of Crohn's disease in unusual sites should be considered in any child with unexplained failure to thrive." | 1.26 | Isolated gastroduodenal Crohn's disease in a ten-year-old girl. ( Malleson, P, 1980) |
| "In a high percentage of patients with ulcerative colitis good results are obtained with conservative therapy, using salazopyridine alone or in combination with cortisone." | 1.26 | [Inflammatory intestinal diseases: ulcerative colitis and Crohn's disease. Early diagnosis and treatment]. ( Belohlavek, D; Koch, H; Morl, M, 1976) |
| "Sulfasalazine alone was used in 24 patients, steroids alone were used in four patients, both drugs were used together in 29 patients and azathioprine was added to the drug regimen of five patients." | 1.26 | Anti-inflammatory drug treatment in Crohn's disease. ( Abramson, J; Goldstein, F; Thornton, JJ, 1976) |
| "Recurrent Crohn's disease and that characterized by small bowel obstruction each displayed a characteristic appearance." | 1.26 | Radiographic findings of the National Cooperative Crohn's Disease Study. ( Caruthers, SB; Goldberg, HI; Nelson, JA; Singleton, JW, 1979) |
| "The remission period of patients with ulcerative colitis was extended by long term treatment with 2-3 g sulphasalazine daily." | 1.26 | [Long-term therapy in ulcerative colitis and Crohn's disease]. ( Malchow, H, 1979) |
| "Curative therapy of regional enteritis does not exist." | 1.26 | [Surgical and medical treatment of Crohn's disease (author's transl)]. ( Brünner, H; Eckhardt, R; Ewe, K; Krieg, H, 1977) |
| "Metastatic Crohn's disease is a term used to describe a granulomatous reaction occurring in flexures, and separated from the affected areas of the gastro-intestinal tract by normal skin." | 1.26 | Metastatic Crohn's disease. ( Gray, WM; McCallum, DI, 1976) |
| "Thirty-nine patients with Crohn's disease and 17 normal people were tested for hypersensitivity to sarcoid and normal spleen suspensions using the leucocyte migration test." | 1.25 | Leucocyte migration studies with spleen preparations in Crohn's disease. ( Gough, KR; Richens, ER; Williams, MJ, 1973) |
| "Granulomatous inflammation typifying Crohn's disease was centred within or confined to appendices in six patients, two of whom developed lesions attributable to Crohn's disease elsewhere in the gut." | 1.25 | Crohn's disease of the appendix. ( Campbell, JS; Liepa, E; Sirois, J; Tolnai, G; Wang, TK, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 188 (14.70) | 18.7374 |
| 1990's | 109 (8.52) | 18.2507 |
| 2000's | 360 (28.15) | 29.6817 |
| 2010's | 535 (41.83) | 24.3611 |
| 2020's | 87 (6.80) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SJ | 2 |
| Collins, MT | 1 |
| Chao, K | 2 |
| Huang, Y | 1 |
| Zhu, X | 1 |
| Tang, J | 2 |
| Wang, X | 3 |
| Lin, L | 1 |
| Guo, H | 1 |
| Zhang, C | 1 |
| Li, M | 3 |
| Yang, Q | 1 |
| Huang, J | 1 |
| Ye, L | 1 |
| Hu, P | 2 |
| Huang, M | 2 |
| Cao, Q | 2 |
| Gao, X | 2 |
| Singh, S | 1 |
| Murad, MH | 1 |
| Fumery, M | 7 |
| Sedano, R | 1 |
| Jairath, V | 3 |
| Panaccione, R | 11 |
| Sandborn, WJ | 31 |
| Ma, C | 3 |
| Classen, JM | 1 |
| Muzalyova, A | 1 |
| Nagl, S | 1 |
| Fleischmann, C | 1 |
| Ebigbo, A | 1 |
| Römmele, C | 1 |
| Messmann, H | 1 |
| Schnoy, E | 2 |
| Jeong, TJ | 1 |
| Kim, ES | 2 |
| Kwon, Y | 1 |
| Kim, S | 3 |
| Seo, SW | 1 |
| Choe, YH | 8 |
| Kim, MJ | 6 |
| Choi, S | 2 |
| Choi, SY | 6 |
| Park, JH | 4 |
| Choe, BH | 2 |
| Lee, SY | 3 |
| Kang, B | 8 |
| Gökbulut, V | 1 |
| Özin, Y | 1 |
| Kalkan, İH | 1 |
| Arı, D | 1 |
| Yüksel, M | 1 |
| Kılıç, ZMY | 1 |
| Kayaçetin, E | 1 |
| Ås, J | 1 |
| Bertulyte, I | 1 |
| Eriksson, N | 1 |
| Magnusson, PKE | 1 |
| Wadelius, M | 1 |
| Hallberg, P | 1 |
| Banerjee, R | 1 |
| Raghunathan, N | 1 |
| Ben-Hammamia, S | 1 |
| Charfi, O | 1 |
| Belhadj, A | 1 |
| Bouchrika, A | 1 |
| Chebbi, F | 1 |
| Lakhoua, G | 1 |
| El Aidli, S | 1 |
| Ranjan, MK | 3 |
| Kante, B | 3 |
| Vuyyuru, SK | 3 |
| Kumar, P | 4 |
| Mundhra, SK | 2 |
| Golla, R | 2 |
| Sharma, R | 3 |
| Sahni, P | 2 |
| Das, P | 3 |
| Makharia, G | 3 |
| Kedia, S | 3 |
| Ahuja, V | 5 |
| Zhang, Z | 1 |
| Yu, X | 1 |
| Fang, N | 1 |
| Long, X | 1 |
| Ruan, X | 1 |
| Qiu, J | 1 |
| Tao, S | 1 |
| Gong, P | 1 |
| Nie, K | 1 |
| Li, A | 1 |
| Tian, L | 1 |
| Jongsma, MME | 3 |
| Vuijk, SA | 1 |
| Cozijnsen, MA | 3 |
| van Pieterson, M | 3 |
| Norbruis, OF | 2 |
| Groeneweg, M | 2 |
| Wolters, VM | 2 |
| van Wering, HM | 2 |
| Hojsak, I | 3 |
| Kolho, KL | 4 |
| van Wijk, MP | 3 |
| Teklenburg-Roord, STA | 2 |
| de Meij, TGJ | 2 |
| Escher, JC | 6 |
| de Ridder, L | 7 |
| Zaimi, Y | 1 |
| Bouksir, C | 1 |
| Ayadi, S | 1 |
| Ayari, M | 1 |
| Ksontini, FL | 1 |
| Renoux, MC | 1 |
| Dutronc, S | 1 |
| Kollen, L | 1 |
| Theret, S | 1 |
| Moreau, J | 3 |
| Sahu, P | 1 |
| Virmani, S | 1 |
| Madhusudhan, KS | 1 |
| Panwar, R | 1 |
| Lerchova, T | 2 |
| Hradsky, O | 5 |
| Kulich, M | 1 |
| Veres, G | 5 |
| Dias, JA | 1 |
| Sładek, M | 2 |
| Kolacek, S | 3 |
| Van Biervliet, S | 1 |
| Melek, J | 2 |
| Serban, DE | 2 |
| Winther, K | 1 |
| de Meij, T | 2 |
| Schwarz, J | 1 |
| Bronsky, J | 6 |
| Lee, YJ | 2 |
| Kim, YB | 1 |
| Kim, JY | 1 |
| Lee, K | 1 |
| Lee, KJ | 1 |
| Kang, KS | 1 |
| Lee, YM | 2 |
| Kim, HJ | 4 |
| Kang, Y | 1 |
| Jang, HJ | 1 |
| Yi, DY | 1 |
| Hong, SJ | 1 |
| Choi, YJ | 2 |
| Hong, J | 1 |
| Kim, SC | 2 |
| Syal, G | 2 |
| Melmed, GY | 2 |
| Almario, CV | 2 |
| Spiegel, BMR | 2 |
| Chung, A | 1 |
| Carroll, M | 1 |
| Almeida, P | 1 |
| Petrova, A | 1 |
| Isaac, D | 1 |
| Mould, D | 1 |
| Wine, E | 1 |
| Huynh, H | 1 |
| Louis, E | 10 |
| Resche-Rigon, M | 1 |
| Laharie, D | 10 |
| Satsangi, J | 10 |
| Ding, N | 1 |
| Siegmund, B | 4 |
| D'Haens, G | 22 |
| Picon, L | 3 |
| Bossuyt, P | 5 |
| Vuitton, L | 2 |
| Irving, P | 2 |
| Viennot, S | 1 |
| Lamb, CA | 2 |
| Pollok, R | 4 |
| Baert, F | 13 |
| Nachury, M | 2 |
| Gilletta, C | 1 |
| Almer, S | 3 |
| Ben-Horin, S | 9 |
| Bouhnik, Y | 10 |
| Colombel, JF | 33 |
| Hertervig, E | 2 |
| Schineis, C | 1 |
| Warschkow, R | 1 |
| Bruder, L | 1 |
| Lauscher, JC | 1 |
| Kamphues, C | 1 |
| Kreis, M | 1 |
| Weixler, B | 1 |
| Costes, LMM | 1 |
| Tindemans, I | 1 |
| Raatgreep, RHC | 1 |
| Li, Y | 3 |
| Samsom, JN | 2 |
| Nouha, T | 1 |
| Asma, M | 1 |
| Nadia, B | 1 |
| Emna, BM | 1 |
| Yosra, Z | 1 |
| Yosra, S | 1 |
| Al Yacoub, R | 1 |
| Brown, K | 1 |
| Ladna, M | 1 |
| Díaz-Villamarín, X | 1 |
| Fernández-Varón, E | 1 |
| Rojas Romero, MC | 1 |
| Callejas-Rubio, JL | 1 |
| Cabeza-Barrera, J | 1 |
| Rodríguez-Nogales, A | 1 |
| Gálvez, J | 1 |
| Morón, R | 1 |
| Cardinaels, N | 1 |
| Van Rompaey, W | 1 |
| Bos, S | 1 |
| Bode, H | 1 |
| Tousseyn, T | 1 |
| Van Bleyenbergh, P | 1 |
| Gjuladin-Hellon, T | 1 |
| Iheozor-Ejiofor, Z | 1 |
| Gordon, M | 2 |
| Akobeng, AK | 3 |
| Abdallah, M | 1 |
| Saleh, M | 1 |
| Elgouhari, H | 1 |
| Huntington, MK | 1 |
| Bommelaer, G | 4 |
| Nancey, S | 5 |
| Hebuterne, X | 7 |
| Roblin, X | 11 |
| Peyrin-Biroulet, L | 20 |
| Richard, D | 1 |
| Pereira, B | 3 |
| Goutte, M | 1 |
| Buisson, A | 6 |
| Gueutier, A | 1 |
| Leducq, S | 1 |
| Joly, A | 1 |
| Vaillant, L | 1 |
| Samimi, M | 1 |
| Booth, AT | 1 |
| Forster, E | 1 |
| Curran, T | 1 |
| George, V | 1 |
| Martins, R | 1 |
| Carmona, C | 1 |
| George, B | 1 |
| Epstein, J | 1 |
| Ribaldone, DG | 3 |
| Caviglia, GP | 1 |
| Pellicano, R | 5 |
| Vernero, M | 1 |
| Italia, A | 1 |
| Morino, M | 1 |
| Saracco, GM | 2 |
| Astegiano, M | 3 |
| Balendran, K | 1 |
| Udumalagala, S | 1 |
| Nawaraththne, NMM | 1 |
| Siegel, CA | 2 |
| Thompson, KD | 1 |
| Walls, D | 1 |
| Gollins, J | 1 |
| Olympie, A | 1 |
| Beaugerie, L | 12 |
| Hazlewood, GS | 1 |
| Pokharel, G | 1 |
| Deardon, R | 1 |
| Marshall, DA | 1 |
| Bombardier, C | 1 |
| Tomlinson, G | 1 |
| Seow, CH | 4 |
| Kaplan, GG | 5 |
| Williet, N | 5 |
| Boschetti, G | 2 |
| Phelip, JM | 4 |
| Del Tedesco, E | 2 |
| Berger, AE | 1 |
| Vedrines, P | 1 |
| Duru, G | 2 |
| Flourie, B | 4 |
| Paul, S | 3 |
| Samarani, S | 1 |
| Sagala, P | 1 |
| Jantchou, P | 1 |
| Grimard, G | 1 |
| Faure, C | 3 |
| Deslandres, C | 3 |
| Amre, DK | 1 |
| Ahmad, A | 1 |
| Schnell, A | 1 |
| Schwarz, B | 1 |
| Wahlbuhl, M | 1 |
| Allabauer, I | 1 |
| Hess, M | 1 |
| Weber, S | 1 |
| Werner, F | 1 |
| Schmidt, H | 1 |
| Rechenauer, T | 1 |
| Siebenlist, G | 1 |
| Kaspar, S | 1 |
| Ehrsam, C | 1 |
| Rieger, D | 1 |
| Rückel, A | 1 |
| Metzler, M | 1 |
| Christoph, J | 1 |
| Woelfle, J | 1 |
| Rascher, W | 1 |
| Hoerning, A | 1 |
| Thomsen, SB | 1 |
| Allin, KH | 1 |
| Burisch, J | 1 |
| Jensen, CB | 1 |
| Hansen, S | 1 |
| Gluud, LL | 2 |
| Theede, K | 2 |
| Kiszka-Kanowitz, M | 2 |
| Nielsen, AM | 1 |
| Jess, T | 4 |
| Ungaro, RC | 1 |
| Yzet, C | 1 |
| Baert, FJ | 3 |
| Vanasek, T | 2 |
| D'Haens, GR | 7 |
| Joustra, VW | 1 |
| Novacek, G | 7 |
| Reinisch, W | 24 |
| Armuzzi, A | 5 |
| Golovchenko, O | 1 |
| Prymak, O | 1 |
| Goldis, A | 1 |
| Travis, SP | 1 |
| Ferrante, M | 6 |
| Rogler, G | 9 |
| Danese, S | 4 |
| Rydzewska, G | 1 |
| Pariente, B | 5 |
| Stanciu, C | 1 |
| Serrero, M | 1 |
| Diculescu, M | 2 |
| Wright, JP | 1 |
| Gomollón, F | 3 |
| Gubonina, I | 1 |
| Schreiber, S | 8 |
| Motoya, S | 6 |
| Hellström, PM | 1 |
| Halfvarson, J | 2 |
| Butler, JW | 1 |
| Petersson, J | 3 |
| Petralia, F | 1 |
| Sosa Solís, AM | 1 |
| Fernández Antuña, L | 1 |
| Royo Cuadra, Y | 1 |
| Castellarnau Figueras, E | 1 |
| Rastogi, P | 1 |
| Nada, R | 2 |
| Choi, R | 1 |
| Lee, MN | 2 |
| Kim, K | 3 |
| Baek, SY | 1 |
| Kim, TJ | 1 |
| Hong, SN | 1 |
| Kim, YH | 3 |
| Erzin, Y | 2 |
| Şişman, G | 2 |
| Hatemi, İ | 1 |
| Baca, B | 1 |
| Hamzaoglu, İ | 1 |
| Dirican, A | 1 |
| Korman, U | 1 |
| Çelik, AF | 1 |
| Townsend, CM | 2 |
| Nguyen, TM | 3 |
| Cepek, J | 1 |
| Abbass, M | 1 |
| Parker, CE | 4 |
| MacDonald, JK | 9 |
| Khanna, R | 4 |
| Feagan, BG | 9 |
| Biancardi, AL | 1 |
| Costa, JB | 1 |
| de Azevedo, LGB | 1 |
| de Moraes, HV | 1 |
| Barroso, PF | 1 |
| Zaltman, C | 1 |
| Pascual Pérez, AI | 1 |
| Pujol Muncunill, G | 1 |
| Domínguez Sánchez, P | 1 |
| Feo Ortega, S | 1 |
| Martín de Carpi, J | 3 |
| Lauterbach, R | 1 |
| Linder, R | 1 |
| Vitner, D | 1 |
| Solt, I | 1 |
| Boube, M | 1 |
| Minet-Quinard, R | 1 |
| Fasoulas, K | 1 |
| Kafalis, N | 1 |
| Soufleris, K | 1 |
| Canard, C | 1 |
| Diaz, E | 1 |
| Gusdorf, L | 1 |
| Loget, J | 1 |
| Durlach, A | 1 |
| Graesslin, O | 1 |
| Cadiot, G | 3 |
| Viguier, M | 1 |
| Miele, E | 2 |
| Benninga, MA | 5 |
| Broekaert, I | 1 |
| Dolinsek, J | 1 |
| Mas, E | 1 |
| Orel, R | 1 |
| Pienar, C | 1 |
| Ribes-Koninckx, C | 1 |
| Thomassen, RA | 1 |
| Thomson, M | 1 |
| Tzivinikos, C | 1 |
| Thapar, N | 1 |
| Balram, B | 1 |
| Lubov, J | 1 |
| Theoret, Y | 3 |
| Afif, W | 3 |
| Bitton, A | 4 |
| Wild, G | 1 |
| Lakatos, PL | 16 |
| Bessissow, T | 2 |
| Harris, RE | 1 |
| Aloi, M | 1 |
| Croft, NM | 1 |
| Koletzko, S | 3 |
| Levine, A | 5 |
| Turner, D | 4 |
| Veereman, G | 2 |
| Neyt, M | 1 |
| Bigot, L | 1 |
| Ruemmele, FM | 6 |
| Russell, RK | 7 |
| Crouwel, F | 2 |
| Buiter, HJC | 3 |
| de Boer, NK | 10 |
| Targownik, LE | 2 |
| Benchimol, EI | 2 |
| Bernstein, CN | 7 |
| Singh, H | 2 |
| Tennakoon, A | 2 |
| Zubieta, AA | 1 |
| Coward, S | 3 |
| Jones, J | 3 |
| Kuenzig, ME | 1 |
| Murthy, SK | 2 |
| Nguyen, GC | 4 |
| Peña-Sánchez, JN | 2 |
| Ran, Z | 2 |
| Wu, K | 1 |
| Matsuoka, K | 2 |
| Jeen, YT | 1 |
| Wei, SC | 1 |
| Chen, M | 2 |
| Hu, PJ | 2 |
| Andoh, A | 5 |
| Yang, SK | 7 |
| Watanabe, M | 9 |
| Ng, SC | 3 |
| Hibi, T | 10 |
| Hilmi, IN | 1 |
| Suzuki, Y | 6 |
| Han, DS | 3 |
| Leung, WK | 1 |
| Sollano, J | 1 |
| Ooi, CJ | 2 |
| Qian, J | 1 |
| Effenberger, M | 1 |
| Reider, S | 1 |
| Waschina, S | 1 |
| Bronowski, C | 1 |
| Enrich, B | 1 |
| Adolph, TE | 1 |
| Koch, R | 1 |
| Moschen, AR | 1 |
| Rosenstiel, P | 1 |
| Aden, K | 1 |
| Tilg, H | 3 |
| Snijders, RJALM | 1 |
| Pape, S | 1 |
| Gevers, TJG | 1 |
| Drenth, JPH | 1 |
| Candia, R | 2 |
| Bravo-Soto, GA | 1 |
| Monrroy, H | 1 |
| Hernandez, C | 1 |
| Štanclová, M | 1 |
| Dědek, P | 2 |
| Malý, J | 2 |
| Bayer, M | 1 |
| Pozler, O | 2 |
| Bureš, J | 1 |
| Séverine, W | 1 |
| Xavier, K | 1 |
| Jean-Charles, C | 1 |
| Luber, RP | 1 |
| Dawson, L | 1 |
| Munari, S | 1 |
| Kariyawasam, VC | 2 |
| Martin, C | 1 |
| Gibson, PR | 4 |
| Sparrow, MP | 5 |
| Ward, MG | 1 |
| Zeze, K | 1 |
| Hirano, A | 1 |
| Torisu, T | 1 |
| Esaki, M | 6 |
| Moriyama, T | 1 |
| Umeno, J | 1 |
| Kawasaki, K | 1 |
| Fujioka, S | 1 |
| Fuyuno, Y | 1 |
| Matsuno, Y | 1 |
| Kitazono, T | 1 |
| Lund, K | 1 |
| Larsen, MD | 1 |
| Knudsen, T | 1 |
| Kjeldsen, J | 2 |
| Nielsen, RG | 1 |
| Mertz Nørgård, B | 1 |
| Verstockt, B | 1 |
| Boets, L | 1 |
| Sabino, J | 1 |
| Vermeire, S | 16 |
| Stournaras, E | 1 |
| Qian, W | 1 |
| Pappas, A | 1 |
| Hong, YY | 1 |
| Shawky, R | 1 |
| Raine, T | 1 |
| Parkes, M | 4 |
| Appleton, L | 1 |
| Day, AS | 4 |
| Szczeklik, K | 1 |
| Darczuk, D | 1 |
| Krok-Ziółkowska, J | 1 |
| Ligara, J | 1 |
| Kuszaj, M | 1 |
| Cibor, D | 1 |
| Pytko-Polończyk, J | 1 |
| Owczarek, D | 1 |
| Rivière, P | 2 |
| Lambrecht, G | 1 |
| Oldenburg, B | 1 |
| de Sousa Magalhães, R | 1 |
| Xavier, S | 1 |
| Cúrdia Gonçalves, T | 1 |
| Dias de Castro, F | 1 |
| Rosa, B | 1 |
| Moreira, MJ | 2 |
| Cotter, J | 2 |
| Orlando, A | 2 |
| Mocciaro, F | 1 |
| Ventimiglia, M | 1 |
| Renna, S | 2 |
| Rispo, A | 3 |
| Scribano, ML | 1 |
| Testa, A | 1 |
| Aratari, A | 1 |
| Bossa, F | 1 |
| Angelucci, E | 5 |
| Onali, S | 1 |
| Cappello, M | 2 |
| Giunta, M | 1 |
| Scimeca, D | 1 |
| Macaluso, FS | 1 |
| Castiglione, F | 3 |
| Papi, C | 2 |
| Annese, V | 1 |
| Biancone, L | 2 |
| Kohn, A | 2 |
| Di Mitri, R | 1 |
| Cottone, M | 3 |
| Mahadevan, U | 1 |
| Long, MD | 2 |
| Kane, SV | 4 |
| Roy, A | 2 |
| Dubinsky, MC | 7 |
| Sands, BE | 3 |
| Cohen, RD | 4 |
| Chambers, CD | 1 |
| de Boer, NKH | 2 |
| Aardoom, MA | 1 |
| Hummel, T | 1 |
| Stapelbroek, J | 1 |
| van der Feen, C | 1 |
| van Rheenen, PF | 1 |
| Schreurs, MWJ | 1 |
| Rizopoulos, D | 1 |
| Doukas, M | 1 |
| Jagt, JZ | 1 |
| Pothof, CD | 1 |
| van Limbergen, JE | 2 |
| Céruti, H | 1 |
| Kayem, G | 1 |
| Guilbaud, L | 1 |
| Dussaux, C | 1 |
| Gervais, A | 1 |
| Beaufrère, A | 1 |
| Coffin, B | 2 |
| Mandelbrot, L | 1 |
| Maisonneuve, E | 1 |
| Montenegro, ML | 1 |
| Corral, JE | 1 |
| Lukens, FJ | 1 |
| Ji, B | 1 |
| Kröner, PT | 1 |
| Farraye, FA | 1 |
| Bi, Y | 1 |
| Kyriakos, N | 1 |
| Papaefthymiou, A | 1 |
| Giakoumis, M | 2 |
| Galanopoulos, M | 1 |
| Galanis, P | 1 |
| Mylonas, I | 1 |
| Karatzas, P | 2 |
| Mantzaris, G | 3 |
| Liatsos, C | 1 |
| Narula, N | 1 |
| Wong, ECL | 1 |
| Dulai, PS | 1 |
| Marshall, JK | 4 |
| Pospisilova, K | 1 |
| Siroka, J | 1 |
| Karaskova, E | 1 |
| Zarubova, K | 4 |
| Copova, I | 4 |
| Gonsorcikova, L | 1 |
| Velganova-Veghova, M | 1 |
| Francova, I | 1 |
| Urbanek, L | 1 |
| Geryk, M | 1 |
| Mihal, V | 1 |
| Tavassolifar, MJ | 1 |
| Changaei, M | 1 |
| Salehi, Z | 1 |
| Ghasemi, F | 1 |
| Javidan, M | 1 |
| Nicknam, MH | 1 |
| Pourmand, MR | 1 |
| Hawthorne, TZ | 1 |
| Shellien, R | 1 |
| Chambers, L | 1 |
| Devereux, G | 1 |
| Wu, Y | 1 |
| Tan, Y | 1 |
| Ou, D | 1 |
| Wang, Y | 3 |
| Manlay, L | 1 |
| Rubin, DT | 4 |
| Kirchgesner, J | 2 |
| Desai, RJ | 1 |
| Schneeweiss, S | 1 |
| Cassinotti, A | 1 |
| Corona, A | 1 |
| Duca, P | 1 |
| Nebuloni, M | 1 |
| Maconi, G | 3 |
| Fociani, P | 1 |
| Ardizzone, S | 4 |
| Ribeiro, AC | 1 |
| Barroso, LHF | 1 |
| Mourao-Junior, CA | 1 |
| Chebli, JMF | 1 |
| Nascimento, JWL | 1 |
| Mederacke, I | 1 |
| Wiestler, M | 1 |
| Wedemeyer, H | 1 |
| Won, YB | 1 |
| Seo, SK | 1 |
| Cho, S | 1 |
| Choi, YS | 1 |
| Lee, BS | 1 |
| Yun, BH | 1 |
| López-Sanromán, A | 6 |
| Vera-Mendoza, I | 2 |
| Domènech, E | 11 |
| Taxonera, C | 5 |
| Vega Ruiz, V | 1 |
| Marín-Jiménez, I | 2 |
| Guardiola, J | 3 |
| Castro, L | 2 |
| Esteve, M | 5 |
| Iglesias, E | 2 |
| Ceballos, D | 2 |
| Martínez-Montiel, P | 2 |
| Gisbert, JP | 13 |
| Mínguez, M | 3 |
| Echarri, A | 4 |
| Calvet, X | 4 |
| Barrio, J | 3 |
| Hinojosa, J | 5 |
| Martín-Arranz, MD | 2 |
| Márquez-Mosquera, L | 2 |
| Bermejo, F | 6 |
| Rimola, J | 2 |
| Pons, V | 2 |
| Nos, P | 7 |
| Dillman, JR | 1 |
| Dehkordy, SF | 1 |
| Smith, EA | 1 |
| DiPietro, MA | 1 |
| Sanchez, R | 1 |
| DeMatos-Maillard, V | 1 |
| Adler, J | 2 |
| Zhang, B | 1 |
| Trout, AT | 1 |
| Tavares Dos Santos, H | 1 |
| Augusto Benevenuto de Andrade, B | 1 |
| Fernandes, D | 1 |
| Caxias Travassos, D | 1 |
| Bufalino, A | 1 |
| Magister, MJ | 1 |
| Ghaffari, G | 1 |
| Patwala, K | 1 |
| Crump, N | 1 |
| De Cruz, P | 3 |
| Yarur, AJ | 1 |
| Gondal, B | 1 |
| Hirsch, A | 1 |
| Christensen, B | 1 |
| Grover, Z | 2 |
| Guo, J | 3 |
| Chen, BL | 6 |
| Chen, ZH | 1 |
| Luo, XP | 1 |
| Qiu, Y | 5 |
| Zhang, SH | 5 |
| Feng, R | 2 |
| He, Y | 6 |
| Zeng, ZR | 6 |
| Song, XM | 1 |
| Mao, R | 6 |
| Chen, MH | 6 |
| Grove, EL | 1 |
| Nandy, N | 1 |
| Gavin, M | 1 |
| Martin, D | 1 |
| McCarthy, D | 1 |
| Sousa, M | 1 |
| Proença, L | 1 |
| Carvalho, J | 1 |
| Thomas, C | 1 |
| Monteil-Ganiere, C | 1 |
| Mirallié, S | 1 |
| Hémont, C | 1 |
| Dert, C | 1 |
| Léger, A | 1 |
| Joyau, C | 1 |
| Caldari, D | 2 |
| Audrain, M | 1 |
| Valdés Delgado, T | 1 |
| Cordero Ruiz, P | 2 |
| Bellido Muñoz, F | 1 |
| Senilă, S | 1 |
| Seicean, A | 1 |
| Fechete, O | 1 |
| Grad, A | 1 |
| Ungureanu, L | 1 |
| Lukas, M | 4 |
| Danalioglu, A | 1 |
| Travis, S | 4 |
| Rutgeerts, P | 25 |
| Hommes, D | 4 |
| Neimark, E | 1 |
| Huang, B | 1 |
| Zhou, Q | 1 |
| Mendez, P | 1 |
| Wallace, K | 1 |
| Robinson, AM | 1 |
| Thakkar, RB | 1 |
| Watanabe, K | 6 |
| Matsumoto, T | 7 |
| Hisamatsu, T | 6 |
| Nakase, H | 6 |
| Yoshimura, N | 4 |
| Ishida, T | 4 |
| Kato, S | 6 |
| Nakagawa, T | 4 |
| Nagahori, M | 6 |
| Matsui, T | 6 |
| Naito, Y | 4 |
| Kanai, T | 7 |
| Nojima, M | 5 |
| Yoon, JY | 1 |
| Cheon, JH | 7 |
| Park, SJ | 5 |
| Kim, TI | 4 |
| Kim, WH | 5 |
| Manetta, T | 1 |
| Mengozzi, G | 1 |
| Guerra Romero, A | 1 |
| Pérez Calle, JL | 1 |
| López Serrano, P | 1 |
| Ahad, T | 1 |
| Riley, A | 1 |
| Martindale, E | 1 |
| von Bremen, B | 1 |
| Owen, C | 1 |
| Jørgensen, KK | 1 |
| Lundin, KE | 1 |
| Olsen, IC | 1 |
| Kvien, TK | 1 |
| Jahnsen, J | 1 |
| Schäffler, H | 1 |
| Schmidt, M | 1 |
| Huth, A | 1 |
| Reiner, J | 1 |
| Glass, Ä | 1 |
| Lamprecht, G | 1 |
| Choi, J | 1 |
| Sohn, I | 1 |
| Lee, HJ | 4 |
| Blackwell, J | 1 |
| Saxena, S | 6 |
| Pollok, RC | 4 |
| Djurić, Z | 1 |
| Šaranac, L | 1 |
| Budić, I | 1 |
| Pavlović, V | 1 |
| Djordjević, J | 1 |
| Primas, C | 2 |
| Reinisch, S | 1 |
| Han, ZM | 1 |
| Qiao, WG | 1 |
| Ai, XY | 1 |
| Li, AM | 1 |
| Chen, ZY | 1 |
| Feng, XC | 1 |
| Zhang, J | 1 |
| Wan, TM | 1 |
| Xu, ZM | 1 |
| Bai, Y | 1 |
| Li, MS | 1 |
| Liu, SD | 1 |
| Zhi, FC | 1 |
| Monasterio, C | 1 |
| Kreisel, W | 1 |
| Hasselblatt, P | 1 |
| Aguas, M | 1 |
| Chaparro, M | 5 |
| García-Planella, E | 9 |
| Guerra, I | 3 |
| Kurti, Z | 2 |
| Ilias, A | 1 |
| Gonczi, L | 2 |
| Vegh, Z | 5 |
| Fadgyas-Freyler, P | 1 |
| Korponay, G | 1 |
| Golovics, PA | 7 |
| Lovasz, BD | 7 |
| Hoekman, DR | 2 |
| Stibbe, JA | 1 |
| Caenepeel, P | 4 |
| Vergauwe, P | 3 |
| De Vos, M | 3 |
| Hommes, DW | 9 |
| Vermeire, SA | 1 |
| Choi, YO | 1 |
| Lee, JH | 3 |
| Winn, RT | 1 |
| Brass, D | 1 |
| Meggitt, SJ | 1 |
| Brunet, E | 1 |
| Martínez de Sola, M | 1 |
| Garcia-Iglesias, P | 1 |
| Miechowiecki, J | 1 |
| Stainer, W | 1 |
| Wallner, G | 1 |
| Tuppy, H | 1 |
| Aichinger, W | 1 |
| Prammer, W | 1 |
| Kirchgatterer, A | 1 |
| Zhou, Z | 1 |
| Jing, Y | 1 |
| Ran, Y | 1 |
| Zhao, J | 1 |
| Zhou, L | 1 |
| Wang, BM | 1 |
| Papamichael, K | 5 |
| Cheifetz, AS | 3 |
| Boyapati, RK | 1 |
| Torres, J | 2 |
| Palmela, C | 1 |
| Silverberg, OM | 1 |
| Upadhyaya, SD | 1 |
| Luber, R | 1 |
| Dige, A | 1 |
| Magnusson, MK | 1 |
| Uhrenholt, C | 1 |
| Rasmussen, TK | 1 |
| Kragstrup, T | 1 |
| Öhman, L | 1 |
| Dahlerup, J | 1 |
| Agnholt, J | 2 |
| Mizuno, S | 2 |
| Naganuma, M | 3 |
| Teich, N | 4 |
| Klugmann, T | 2 |
| Shi, HY | 1 |
| Guo, Z | 2 |
| Cai, X | 1 |
| Liu, R | 1 |
| Gong, J | 2 |
| Cao, L | 2 |
| Wang, Z | 1 |
| Zhu, W | 2 |
| Qian, X | 1 |
| Wang, T | 1 |
| Shen, J | 1 |
| Begun, J | 2 |
| Sparrow, M | 2 |
| Hanauer, SB | 14 |
| Lichtenstein, GR | 5 |
| Essmann, J | 1 |
| Keil, C | 1 |
| Unruh, O | 1 |
| Otte, A | 1 |
| Manns, MP | 1 |
| Bachmann, O | 1 |
| Adedokun, OJ | 2 |
| Gasink, C | 1 |
| Gao, LL | 1 |
| Cornillie, FJ | 3 |
| Rutgeerts, PJ | 4 |
| Whittaker, K | 1 |
| Guggenberger, K | 1 |
| Venhoff, N | 1 |
| Doostkam, S | 1 |
| Schaefer, HE | 1 |
| Fritsch, B | 1 |
| Pallotta, N | 1 |
| Vincoli, G | 1 |
| Pezzotti, P | 1 |
| Giovannone, M | 1 |
| Gigliozzi, A | 1 |
| Badiali, D | 1 |
| Vernia, P | 5 |
| Corazziari, ES | 1 |
| Ziade, F | 1 |
| Rungoe, C | 2 |
| Kallemose, T | 1 |
| Paerregaard, A | 3 |
| Wewer, AV | 1 |
| Jakobsen, C | 2 |
| Lix, L | 1 |
| Leung, S | 1 |
| Aviña, A | 1 |
| Kaplan, G | 2 |
| Stokkeland, K | 1 |
| Höijer, J | 1 |
| Bottai, M | 1 |
| Söderberg-Löfdal, K | 1 |
| Bergquist, A | 1 |
| Ong, C | 1 |
| Lim, PT | 1 |
| Logarajah, V | 1 |
| Liwanag, MJ | 1 |
| Ang, BX | 1 |
| Cher, Y | 1 |
| Chiou, FK | 1 |
| Kader, A | 1 |
| Suárez Ferrer, C | 1 |
| González-Lama, Y | 2 |
| González-Partida, I | 2 |
| Calvo Moya, M | 1 |
| Vera Mendoza, I | 1 |
| Matallana Royo, V | 1 |
| Arevalo Serrano, J | 1 |
| Abreu Garcia, L | 1 |
| Iborra, M | 1 |
| Herreras, J | 1 |
| Boscá-Watts, MM | 1 |
| Cortés, X | 2 |
| Trejo, G | 1 |
| Cerrillo, E | 1 |
| Hervás, D | 1 |
| Beltrán, B | 1 |
| Patel, R | 1 |
| Coulter, LL | 1 |
| Rimmer, J | 1 |
| Chinnery, PF | 1 |
| Swift, O | 1 |
| Bishnoi, A | 2 |
| Kaushik, A | 1 |
| Banerjee, N | 2 |
| Parsad, D | 2 |
| Kochhar, R | 2 |
| Saikia, UN | 1 |
| Knyazev, OV | 4 |
| Kagramanova, AV | 1 |
| Fadeeva, NA | 1 |
| Lishchinskaya, AA | 1 |
| Boldyreva, ON | 2 |
| Noskova, KK | 1 |
| Gudkova, RB | 1 |
| Konoplyannikov, AG | 4 |
| Parfenov, AI | 4 |
| Ruiz, VV | 1 |
| Alba, C | 1 |
| Kandavel, P | 1 |
| Eder, SJ | 1 |
| Newman, NE | 1 |
| Waljee, AK | 1 |
| Whitfield, EP | 1 |
| Kennedy, NA | 5 |
| Heap, GA | 1 |
| Green, HD | 1 |
| Hamilton, B | 1 |
| Bewshea, C | 1 |
| Walker, GJ | 1 |
| Thomas, A | 3 |
| Nice, R | 1 |
| Perry, MH | 1 |
| Bouri, S | 1 |
| Chanchlani, N | 1 |
| Heerasing, NM | 1 |
| Hendy, P | 1 |
| Lin, S | 1 |
| Gaya, DR | 2 |
| Cummings, JRF | 1 |
| Selinger, CP | 2 |
| Lees, CW | 6 |
| Hart, AL | 2 |
| Sebastian, S | 1 |
| Mansfield, JC | 1 |
| Irving, PM | 6 |
| Lindsay, J | 1 |
| McDonald, TJ | 1 |
| McGovern, D | 1 |
| Goodhand, JR | 1 |
| Ahmad, T | 2 |
| Silva, J | 1 |
| Brito, BS | 1 |
| Silva, INN | 1 |
| Nóbrega, VG | 1 |
| da Silva, MCSM | 1 |
| Gomes, HDN | 1 |
| Fortes, FM | 1 |
| Pimentel, AM | 1 |
| Mota, J | 1 |
| Almeida, N | 1 |
| Surlo, VC | 1 |
| Lyra, A | 1 |
| Rocha, R | 1 |
| Santana, GO | 1 |
| Steinhart, AH | 4 |
| Bressler, B | 3 |
| Targownik, L | 1 |
| Borgaonkar, M | 2 |
| Chauhan, U | 1 |
| Halloran, B | 1 |
| Kennedy, E | 1 |
| Leontiadis, GI | 1 |
| Loftus, EV | 2 |
| Meddings, J | 1 |
| Moayyedi, P | 2 |
| Murthy, S | 1 |
| Plamondon, S | 2 |
| Rosenfeld, G | 1 |
| Schwartz, D | 1 |
| Williams, C | 1 |
| Neubauer, K | 1 |
| Kempinski, R | 1 |
| Matusiewicz, M | 1 |
| Bednarz-Misa, I | 1 |
| Krzystek-Korpacka, M | 1 |
| López Fernández, E | 1 |
| Curieses Luengo, M | 1 |
| Varela Trastoy, P | 1 |
| Kunisaki, R | 2 |
| Matsuura, M | 2 |
| Fukata, N | 1 |
| Inoue, S | 1 |
| Sugaya, T | 1 |
| Sakuraba, H | 1 |
| Hirai, F | 2 |
| Akiyama, S | 1 |
| Fukuda, K | 1 |
| Hamada, S | 1 |
| Shimizu, M | 1 |
| Nanki, K | 1 |
| Kiyohara, H | 1 |
| Arai, M | 1 |
| Sugimoto, S | 1 |
| Iwao, Y | 2 |
| Ogata, H | 1 |
| Motobayashi, M | 1 |
| Suzuki, K | 1 |
| Takenaka, K | 1 |
| Fujii, T | 2 |
| Saito, E | 1 |
| Ohtsuka, K | 1 |
| Mochizuki, M | 1 |
| Hashiguchi, M | 1 |
| Yuksel, I | 4 |
| Kilincalp, S | 2 |
| Coskun, Y | 4 |
| Akinci, H | 4 |
| Hamamci, M | 3 |
| Alkan, A | 1 |
| Chang, JY | 1 |
| Sato, K | 1 |
| Suga, T | 1 |
| Hirayama, A | 1 |
| Daikuhara, S | 1 |
| Uehara, T | 1 |
| Tanaka, E | 1 |
| Sánchez Melgarejo, JF | 1 |
| Navarro, B | 1 |
| Rubio, JM | 1 |
| Bastida, G | 2 |
| Buchel, OC | 1 |
| Bosch, FJ | 1 |
| Janse van Rensburg, J | 1 |
| Bezuidenhout, E | 1 |
| de Vries, CS | 1 |
| van Zyl, JH | 1 |
| Middlecote, BD | 1 |
| de K Grundling, H | 1 |
| Fevery, J | 1 |
| Nielsen, OH | 2 |
| Bjerrum, JT | 1 |
| Herfarth, H | 9 |
| Bouma, G | 3 |
| Baggen, JM | 1 |
| van Bodegraven, AA | 11 |
| Mulder, CJ | 5 |
| Kraal, G | 1 |
| Zwiers, A | 1 |
| Horrevoets, AJ | 1 |
| van der Pouw Kraan, CT | 1 |
| Araki, T | 1 |
| Uchida, K | 1 |
| Okita, Y | 1 |
| Fujikawa, H | 1 |
| Inoue, M | 1 |
| Ohi, M | 1 |
| Tanaka, K | 1 |
| Inoue, Y | 1 |
| Mohri, Y | 1 |
| Kusunoki, M | 1 |
| Yarur, A | 1 |
| Ben Salah, L | 1 |
| Belkhiria el Haj Amor, M | 1 |
| Chbili, C | 1 |
| Khlifi, S | 1 |
| Fathallah, N | 2 |
| Bougmiza, I | 1 |
| Ben Jazia, E | 1 |
| Houdret, N | 1 |
| Ben Salem, C | 2 |
| Saguem, S | 1 |
| Bär, F | 1 |
| Sina, C | 2 |
| Fellermann, K | 5 |
| Bal, K | 1 |
| Nys, K | 1 |
| Agostinis, P | 1 |
| Karaahmet, F | 2 |
| Ayte, R | 1 |
| Chande, N | 4 |
| Tsoulis, DJ | 4 |
| Cosnes, J | 14 |
| Bourrier, A | 2 |
| Nahon, S | 1 |
| Carbonnel, F | 3 |
| Allez, M | 3 |
| Dupas, JL | 4 |
| Reimund, JM | 1 |
| Savoye, G | 4 |
| Jouet, P | 1 |
| Mary, JY | 6 |
| Ordás, I | 1 |
| Cabré, E | 7 |
| Garcia-Sanchez, V | 3 |
| Peñalva, M | 2 |
| Merino, O | 1 |
| Gutiérrez, A | 3 |
| Márquez, L | 1 |
| Garcia-Sepulcre, M | 1 |
| Vera, I | 1 |
| Muñoz, F | 1 |
| Mendoza, JL | 2 |
| Cabriada, JL | 1 |
| Montoro, MA | 1 |
| Barreiro-de Acosta, M | 1 |
| Ceña, G | 1 |
| Saro, C | 1 |
| Aldeguer, X | 1 |
| Maté, J | 1 |
| Koifman, E | 3 |
| Karban, A | 4 |
| Mazor, Y | 2 |
| Chermesh, I | 1 |
| Waterman, M | 2 |
| Almog, R | 2 |
| Eliakim, R | 2 |
| Krivoy, N | 2 |
| Efrati, E | 3 |
| Chowers, Y | 7 |
| Karoui, S | 3 |
| Serghini, M | 2 |
| Dachraoui, A | 1 |
| Boubaker, J | 4 |
| Filali, A | 4 |
| Ishida, K | 1 |
| Inoue, T | 1 |
| Fujiwara, K | 1 |
| Sakanaka, T | 1 |
| Narabayashi, K | 1 |
| Nouda, S | 1 |
| Okada, T | 1 |
| Kakimoto, K | 1 |
| Kuramoto, T | 1 |
| Kawakami, K | 1 |
| Abe, Y | 1 |
| Takeuchi, T | 1 |
| Murano, M | 1 |
| Tokioka, S | 1 |
| Umegaki, E | 1 |
| Higuchi, K | 1 |
| Cyrus, N | 1 |
| Stavert, R | 1 |
| Mason, AR | 1 |
| Ko, CJ | 1 |
| Choi, JN | 1 |
| Dongarrà, ML | 1 |
| Belvedere, A | 2 |
| Ferlazzo, G | 1 |
| Fries, W | 2 |
| Mañosa, M | 4 |
| Bernal, I | 5 |
| Ricart, E | 1 |
| Boix, J | 4 |
| Piñol, M | 3 |
| Gassull, MA | 5 |
| Miller, CP | 1 |
| Stedman, J | 1 |
| Nagaratnam, K | 1 |
| Gray, R | 1 |
| Cheerva, A | 1 |
| Dillard, R | 1 |
| Bertolone, S | 1 |
| Abou Zahr, A | 1 |
| Saad Aldin, E | 1 |
| Yunyongying, P | 1 |
| Panés, J | 4 |
| Torres, Y | 1 |
| Piqueras, M | 1 |
| Gomez-García, M | 1 |
| Sans, M | 3 |
| Ledder, OD | 1 |
| Lemberg, DA | 2 |
| Ooi, CY | 1 |
| Yamamoto, T | 3 |
| Watanabe, T | 2 |
| Felice, C | 2 |
| Papa, A | 1 |
| Marzo, M | 1 |
| Pugliese, D | 1 |
| Andrisani, G | 1 |
| Federico, F | 1 |
| De Vitis, I | 1 |
| Rapaccini, GL | 1 |
| Guidi, L | 1 |
| Macdonagh, E | 1 |
| Pugh, S | 1 |
| Fox, R | 1 |
| Kotze, PG | 2 |
| de Barcelos, IF | 1 |
| da Silva Kotze, LM | 1 |
| Wong, DR | 2 |
| Pierik, M | 2 |
| Seinen, ML | 3 |
| Gilissen, LP | 1 |
| Bus, P | 1 |
| Bakker, JA | 1 |
| Masclee, AA | 2 |
| Neef, C | 1 |
| Engels, LG | 1 |
| Hooymans, PM | 2 |
| Mantzaris, GJ | 11 |
| Kornbluth, A | 8 |
| Rachmilewitz, D | 3 |
| Lichtiger, S | 3 |
| van der Woude, CJ | 3 |
| Diamond, RH | 2 |
| Oortwijn, AF | 1 |
| Tang, KL | 5 |
| Miller, M | 2 |
| Cornillie, F | 4 |
| Diamond, R | 1 |
| Tang, LK | 1 |
| Moran, GW | 2 |
| Dubeau, MF | 2 |
| Yang, H | 2 |
| Fedorak, RN | 5 |
| Dieleman, LA | 2 |
| Barkema, HW | 2 |
| Ghosh, S | 7 |
| Lowe, AW | 1 |
| Moseley, RH | 1 |
| Lim, CS | 1 |
| Moon, W | 2 |
| Park, MI | 2 |
| Choi, JM | 1 |
| Yoo, JH | 1 |
| Kim, JB | 2 |
| Lee, JS | 2 |
| de Souza, GS | 2 |
| Vidigal, FM | 2 |
| Chebli, LA | 5 |
| da Rocha Ribeiro, TC | 2 |
| Furtado, MC | 2 |
| de Lima Pace, FH | 2 |
| de Miranda Chaves, LD | 1 |
| de Oliveira Zanini, KA | 2 |
| Gaburri, PD | 4 |
| de Azevedo Lucca, F | 1 |
| Zanini, A | 2 |
| Ribeiro, LC | 2 |
| Chebli, JM | 5 |
| Mudter, J | 2 |
| Neurath, MF | 6 |
| Ruiz-Clavijo, D | 1 |
| Arín, A | 2 |
| Vila, JJ | 1 |
| Albéniz, E | 1 |
| Picazo, R | 1 |
| Casi, M | 1 |
| Hagihara, Y | 1 |
| Ohfuji, S | 1 |
| Yamagami, H | 1 |
| Fukushima, W | 1 |
| Maeda, K | 1 |
| Kamata, N | 1 |
| Sogawa, M | 1 |
| Shiba, M | 1 |
| Tanigawa, T | 1 |
| Tominaga, K | 1 |
| Fujiwara, Y | 1 |
| Hirota, Y | 1 |
| Arakawa, T | 1 |
| Nguyen, TV | 1 |
| Vu, DH | 1 |
| Lachaux, A | 1 |
| Boulieu, R | 1 |
| Savarino, E | 3 |
| Bodini, G | 2 |
| Dulbecco, P | 2 |
| Assandri, L | 1 |
| Bruzzone, L | 1 |
| Mazza, F | 1 |
| Frigo, AC | 1 |
| Fazio, V | 1 |
| Marabotto, E | 2 |
| Savarino, V | 2 |
| Rodríguez-Grau, Mdel C | 1 |
| Díaz, R | 1 |
| Linton, MS | 1 |
| Kroeker, K | 1 |
| Fedorak, D | 1 |
| Dieleman, L | 1 |
| Langholz, E | 2 |
| Andersson, M | 2 |
| Basit, S | 1 |
| Nielsen, NM | 1 |
| Wohlfahrt, J | 1 |
| Wu, J | 1 |
| Gao, Y | 2 |
| Yang, C | 1 |
| Yang, X | 1 |
| Li, X | 1 |
| Xiao, S | 1 |
| González-Artacho, C | 1 |
| Rodríguez Sicilia, MJ | 1 |
| Alegría-Motte, C | 1 |
| Gómez García, M | 2 |
| Musumba, CO | 1 |
| Bouguen, G | 3 |
| Evans, E | 1 |
| Rhatigan, E | 1 |
| Arnott, ID | 8 |
| Noble, CL | 2 |
| Shand, AG | 2 |
| Seo, GS | 1 |
| Walters, TD | 1 |
| Kim, MO | 1 |
| Denson, LA | 1 |
| Griffiths, AM | 4 |
| Dubinsky, M | 3 |
| Markowitz, J | 6 |
| Baldassano, R | 2 |
| Crandall, W | 2 |
| Rosh, J | 3 |
| Pfefferkorn, M | 2 |
| Otley, A | 2 |
| Heyman, MB | 1 |
| LeLeiko, N | 2 |
| Baker, S | 1 |
| Guthery, SL | 1 |
| Evans, J | 2 |
| Ziring, D | 1 |
| Kellermayer, R | 1 |
| Stephens, M | 2 |
| Mack, D | 2 |
| Oliva-Hemker, M | 2 |
| Patel, AS | 1 |
| Kirschner, B | 1 |
| Moulton, D | 1 |
| Cohen, S | 1 |
| Liu, C | 1 |
| Essers, J | 1 |
| Kugathasan, S | 4 |
| Hyams, JS | 3 |
| Ahn, SM | 1 |
| Suh, SO | 1 |
| Oh, YM | 1 |
| Yun, CY | 1 |
| Sim, HH | 1 |
| Park, CA | 1 |
| Song, CM | 1 |
| Bae, JY | 1 |
| van Loo, ES | 2 |
| Vosseberg, NW | 1 |
| van der Heide, F | 1 |
| Pierie, JP | 1 |
| van der Linde, K | 1 |
| Ploeg, RJ | 3 |
| Dijkstra, G | 2 |
| Nieuwenhuijs, VB | 2 |
| Dassopoulos, T | 4 |
| Bentsen, JL | 1 |
| Martin, CF | 1 |
| Galanko, JA | 1 |
| Seidman, EG | 5 |
| Sandler, RS | 1 |
| Xia, A | 1 |
| Stempak, JM | 1 |
| Grist, J | 1 |
| Silverberg, MS | 1 |
| Bach, H | 1 |
| Santos-Antunes, J | 4 |
| Abreu, C | 2 |
| Magro, F | 5 |
| Coelho, R | 3 |
| Vilas-Boas, F | 3 |
| Andrade, P | 3 |
| Lopes, S | 5 |
| Macedo, G | 5 |
| Terdiman, JP | 1 |
| Gruss, CB | 1 |
| Heidelbaugh, JJ | 1 |
| Sultan, S | 2 |
| Falck-Ytter, YT | 2 |
| Inadomi, JM | 1 |
| Fernandez Salazar, L | 1 |
| Rojo, S | 1 |
| De Lejarazu, RO | 1 |
| Castro, E | 1 |
| Higuera, E | 1 |
| González, JM | 2 |
| Shcherbakov, PL | 3 |
| Ruchkina, IN | 3 |
| Chatu, S | 3 |
| Subramanian, V | 5 |
| Rodrigues-Pinto, E | 2 |
| Ribeiro, OS | 1 |
| Herrlinger, KR | 6 |
| Stange, EF | 13 |
| Hernández-Camba, A | 1 |
| Lakhwani, S | 1 |
| Ramos, L | 1 |
| Raya, JM | 1 |
| Quintero, E | 1 |
| Yu, LF | 1 |
| Zhong, J | 2 |
| Cheng, SD | 1 |
| Tang, YH | 2 |
| Miao, F | 1 |
| Brown, CJ | 1 |
| Achkar, JP | 1 |
| Bressler, BL | 1 |
| Maclean, AR | 1 |
| Remzi, FH | 1 |
| Park, SH | 3 |
| Park, SK | 3 |
| Kim, JW | 3 |
| Yang, DH | 3 |
| Jung, KW | 1 |
| Kim, KJ | 6 |
| Ye, BD | 6 |
| Byeon, JS | 4 |
| Myung, SJ | 4 |
| Yoon, YS | 1 |
| Yu, CS | 1 |
| Kim, JH | 5 |
| Fraser, AG | 3 |
| Korelitz, BI | 11 |
| Present, DH | 7 |
| Rammohan, H | 1 |
| Pai, CG | 1 |
| Hawthorne, AB | 2 |
| Probert, CS | 1 |
| Sanderson, JD | 7 |
| Curcin, V | 3 |
| Yadegarfar, G | 1 |
| Gunn, L | 1 |
| Majeed, A | 2 |
| Avallone, EV | 1 |
| Pica, R | 1 |
| Cassieri, C | 1 |
| Zippi, M | 1 |
| Paoluzi, P | 1 |
| García-Martín, P | 1 |
| Sánchez-Pérez, J | 1 |
| Fraga, J | 1 |
| García-Diez, A | 1 |
| Lakatos, L | 10 |
| Horvath, A | 4 |
| Pandur, T | 7 |
| Erdelyi, Z | 6 |
| Balogh, M | 5 |
| Szipocs, I | 4 |
| Müller, KE | 1 |
| Kiss, LS | 6 |
| Mandel, MD | 1 |
| Vavricka, SR | 4 |
| Schoepfer, AM | 2 |
| Scharl, M | 1 |
| González Lama, Y | 1 |
| Zabana, Y | 1 |
| Marín, L | 1 |
| Lorenzo-Zúñiga, V | 2 |
| Moreno, V | 1 |
| Duncan, H | 1 |
| Buchanan, E | 1 |
| Cardigan, T | 1 |
| Garrick, V | 2 |
| Curtis, L | 1 |
| McGrogan, P | 2 |
| Barclay, A | 1 |
| Kim, EJ | 2 |
| Kim, EY | 2 |
| Song, JE | 1 |
| Lee, HC | 1 |
| Bae, GH | 1 |
| Oh, HK | 2 |
| Lee, TS | 1 |
| Carvalho, AT | 1 |
| Esberard, BC | 1 |
| Fróes, RS | 1 |
| Rapozo, DC | 1 |
| Grinman, AB | 1 |
| Simão, TA | 1 |
| Santos, JC | 1 |
| Carneiro, AJ | 1 |
| Ribeiro-Pinto, LF | 1 |
| de Souza, HS | 1 |
| Jones, GR | 1 |
| Nordstrom, E | 1 |
| Fischer, M | 1 |
| Hofmann-Aßmus, M | 1 |
| Sagynbaeva, VE | 1 |
| Khomeriki, SG | 1 |
| Lazebnik, LB | 1 |
| Lischchinskaya, AA | 1 |
| Frivolt, K | 1 |
| Schwerd, T | 1 |
| Werkstetter, KJ | 1 |
| Schwarzer, A | 1 |
| Schatz, SB | 1 |
| Bufler, P | 1 |
| Camila-Dias, C | 1 |
| Mostafa, NM | 1 |
| Chao, J | 1 |
| Arora, V | 1 |
| Camez, A | 1 |
| Thakkar, R | 1 |
| Jaganathan, S | 1 |
| Bedenbaugh, AV | 1 |
| Palmer, L | 1 |
| Schwartz, DA | 2 |
| Kwak, MS | 1 |
| Kim, DH | 3 |
| Hong, SP | 3 |
| Chauvin, A | 1 |
| Le Thuaut, A | 1 |
| Belhassan, M | 1 |
| Le Baleur, Y | 1 |
| Mesli, F | 1 |
| Bastuji-Garin, S | 1 |
| Delchier, JC | 2 |
| Amiot, A | 1 |
| Griffiths, A | 2 |
| Amil Dias, J | 2 |
| Barabino, A | 1 |
| Braegger, CP | 1 |
| Buderus, S | 1 |
| Martín-de-Carpi, J | 2 |
| Fagerberg, UL | 1 |
| Hugot, JP | 2 |
| Kierkus, J | 2 |
| Lionetti, P | 2 |
| Navas López, VM | 1 |
| Shaoul, R | 2 |
| Van Rheenen, P | 1 |
| Weiss, B | 3 |
| Wilson, D | 2 |
| Dignass, A | 2 |
| Eliakim, A | 1 |
| Winter, H | 1 |
| Kopylov, U | 3 |
| Amre, D | 1 |
| Waluga, M | 1 |
| Hartleb, M | 1 |
| Boryczka, G | 1 |
| Kukla, M | 1 |
| Zwirska-Korczala, K | 1 |
| Huang, V | 2 |
| Fedorak, DK | 1 |
| Kroeker, KI | 1 |
| Halloran, BP | 1 |
| Katelaris, PH | 1 |
| Jones, DB | 1 |
| McDonald, C | 1 |
| Barr, G | 1 |
| Chapman, G | 1 |
| Colliwshaw, J | 1 |
| Lunney, PC | 1 |
| Middleton, K | 1 |
| Wang, RR | 1 |
| Huang, T | 1 |
| Andrews, J | 1 |
| Leong, RW | 5 |
| Fukuchi, T | 1 |
| Ubukata, S | 1 |
| Yoshino, T | 1 |
| Toyonaga, T | 1 |
| Shimazu, K | 1 |
| Koga, H | 1 |
| Yamashita, H | 1 |
| Ito, D | 1 |
| Ashida, K | 1 |
| Connors, W | 1 |
| Griffiths, C | 1 |
| Patel, J | 1 |
| Belletrutti, PJ | 1 |
| De Cassan, C | 1 |
| Cinotti, E | 1 |
| Taylor, K | 1 |
| Thomas, AG | 1 |
| Boyle, BM | 1 |
| Kappelman, MD | 2 |
| Colletti, RB | 4 |
| Baldassano, RN | 6 |
| Milov, DE | 1 |
| Crandall, WV | 2 |
| McDonald, JW | 3 |
| Scott, FI | 1 |
| Vajravelu, RK | 1 |
| Bewtra, M | 1 |
| Mamtani, R | 1 |
| Lee, D | 1 |
| Goldberg, DS | 1 |
| Lewis, JD | 2 |
| Robb, PM | 1 |
| Sorrentino, D | 3 |
| Ott, C | 3 |
| Takses, A | 1 |
| Obermeier, F | 2 |
| Salzberger, B | 1 |
| Müller, M | 1 |
| Fujita, T | 1 |
| Matnani, R | 1 |
| Peker, D | 1 |
| Ejeil, AL | 1 |
| Mercier, S | 1 |
| Moreau, N | 1 |
| Battat, R | 1 |
| Benmassaoud, A | 2 |
| Paradis-Surprenant, L | 1 |
| Park, MS | 1 |
| Hall, B | 1 |
| Holleran, G | 1 |
| Chin, JL | 1 |
| Smith, S | 1 |
| Ryan, B | 1 |
| Mahmud, N | 1 |
| McNamara, D | 1 |
| Kalla, R | 1 |
| Warner, B | 1 |
| Gambles, CJ | 1 |
| Musy, R | 1 |
| Reynolds, S | 1 |
| Dattani, R | 1 |
| Nayee, H | 1 |
| Felwick, R | 1 |
| Harris, R | 1 |
| Marriott, S | 1 |
| Senanayake, SM | 1 |
| Al-Hilou, H | 1 |
| Mansfield, J | 1 |
| Cummings, JR | 1 |
| Lobo, AJ | 3 |
| Smith, M | 2 |
| Lindsay, JO | 2 |
| Abbey, A | 1 |
| Elsmore, AC | 1 |
| Fan, R | 1 |
| Wang, ZT | 1 |
| Li, SY | 1 |
| Zhou, J | 1 |
| Heitman, SJ | 1 |
| Clement, F | 1 |
| Negron, M | 1 |
| Seow, C | 1 |
| Leung, YP | 1 |
| Castro, AC | 1 |
| Pinto, AL | 3 |
| do Valle Pinheiro, B | 1 |
| Machado de Oliveira, J | 1 |
| Wenzl, HH | 2 |
| Teml, A | 4 |
| Öfferlbauer-Ernst, A | 1 |
| Högenauer, C | 1 |
| Vogelsang, H | 7 |
| Petritsch, W | 6 |
| Schmutz, JL | 1 |
| Zuo, L | 1 |
| Zhang, W | 1 |
| Gu, L | 1 |
| Li, N | 1 |
| Li, J | 2 |
| Trigo Salado, C | 1 |
| Leo Carnerero, E | 1 |
| Pizarro Moreno, Á | 1 |
| de la Cruz Ramírez, MD | 1 |
| Araujo Miguez, Á | 1 |
| Herrera Justiniano, JM | 1 |
| Márquez Galán, JL | 1 |
| Saibeni, S | 2 |
| Meucci, G | 2 |
| Schmidt, C | 4 |
| Herrlinger, K | 4 |
| Bokemeyer, B | 4 |
| Stallmach, A | 9 |
| Ledder, O | 2 |
| Fraser, A | 1 |
| Kamm, MA | 7 |
| Hamilton, AL | 2 |
| Ritchie, KJ | 2 |
| Krejany, EO | 2 |
| Gorelik, A | 2 |
| Liew, D | 2 |
| Prideaux, L | 2 |
| Lawrance, IC | 2 |
| Andrews, JM | 2 |
| Bampton, PA | 2 |
| Florin, TH | 2 |
| Gearry, RB | 4 |
| Radford-Smith, G | 2 |
| Macrae, FA | 4 |
| Debinski, H | 2 |
| Selby, W | 2 |
| Kronborg, I | 2 |
| Johnston, MJ | 2 |
| Woods, R | 2 |
| Elliott, PR | 2 |
| Bell, SJ | 2 |
| Brown, SJ | 2 |
| Connell, WR | 4 |
| Desmond, PV | 2 |
| Stiefelhagen, P | 3 |
| Iwańczak, B | 1 |
| Wegner, A | 1 |
| Dadalski, M | 1 |
| Grzybowska-Chlebowczyk, U | 1 |
| Łazowska, I | 1 |
| Maślana, J | 1 |
| Toporowska-Kowalska, E | 1 |
| Czaja-Bulsa, G | 1 |
| Mierzwa, G | 1 |
| Korczowski, B | 1 |
| Czkwianianc, E | 1 |
| Żabka, A | 1 |
| Szymańska, E | 1 |
| Krzesiek, E | 1 |
| Więcek, S | 1 |
| Chhaya, V | 2 |
| Cecil, E | 2 |
| Sninsky, C | 1 |
| DʼHaens, G | 1 |
| Molenda, M | 1 |
| Jannekevan der Woude, C | 1 |
| Benítez, JM | 1 |
| Henderson, P | 1 |
| Cameron, FL | 1 |
| Wilson, DC | 1 |
| Laftah, Z | 1 |
| Bailey, C | 1 |
| Zaheri, S | 1 |
| Setterfield, J | 1 |
| Fuller, LC | 1 |
| Lewis, F | 1 |
| Demirtas, AM | 1 |
| Maignant, S | 1 |
| Pélatan, C | 1 |
| Breton, E | 1 |
| Cagnard, B | 2 |
| Chaillou, E | 1 |
| Giniès, JL | 1 |
| Le Hénaff, G | 1 |
| Ségura, JF | 1 |
| Willot, S | 1 |
| Bridoux, L | 1 |
| Jobert, A | 1 |
| Darviot, E | 1 |
| Delaperrière, N | 2 |
| Lapeyre, D | 1 |
| Carré, E | 1 |
| Grimal, I | 1 |
| Hankard, R | 1 |
| Wagner, AC | 1 |
| Balençon, M | 1 |
| Tourtelier, Y | 1 |
| Dabadie, A | 2 |
| Oortwijn, A | 1 |
| Bevelander, GS | 1 |
| Karmiris, K | 1 |
| Moreels, T | 2 |
| Scarcelli, A | 1 |
| Legido, J | 1 |
| Dotan, I | 2 |
| Naismith, GD | 1 |
| Jussila, A | 2 |
| Preiss, JC | 2 |
| Kruis, W | 8 |
| Li, AC | 2 |
| Yanai, H | 2 |
| Steinwurz, F | 1 |
| Katsanos, KH | 2 |
| Subramaniam, K | 2 |
| Tarabar, D | 1 |
| Zaganas, IV | 1 |
| Chua, EW | 1 |
| Cree, S | 1 |
| Barclay, ML | 3 |
| Doudney, K | 1 |
| Lehnert, K | 1 |
| Aitchison, A | 1 |
| Kennedy, MA | 1 |
| Ramakrishna, BS | 1 |
| Makharia, GK | 1 |
| Ghoshal, UC | 1 |
| Jayanthi, V | 1 |
| Perakath, B | 1 |
| Abraham, P | 1 |
| Bhasin, DK | 1 |
| Bhatia, SJ | 1 |
| Choudhuri, G | 1 |
| Dadhich, S | 1 |
| Desai, D | 1 |
| Goswami, BD | 1 |
| Issar, SK | 1 |
| Jain, AK | 1 |
| Loganathan, G | 1 |
| Misra, SP | 1 |
| Ganesh Pai, C | 1 |
| Pal, S | 1 |
| Philip, M | 1 |
| Pulimood, A | 1 |
| Puri, AS | 1 |
| Ray, G | 1 |
| Singh, SP | 1 |
| Sood, A | 2 |
| Soh, JS | 1 |
| Yun, WJ | 1 |
| Won, CH | 1 |
| Machado, JF | 1 |
| Oya, V | 1 |
| Coy, CS | 1 |
| Morcillo, AM | 1 |
| Severino, SD | 1 |
| Wu, C | 1 |
| Sgarbieri, VC | 1 |
| Vilela, MM | 1 |
| Massa, AF | 1 |
| Campos, MA | 1 |
| Baptista, A | 1 |
| Costa, C | 1 |
| Lima, O | 1 |
| Osório Ferreira, E | 1 |
| Stocco, G | 1 |
| Cuzzoni, E | 1 |
| De Iudicibus, S | 1 |
| Favretto, D | 1 |
| Malusà, N | 1 |
| Martelossi, S | 1 |
| Pozzi, E | 1 |
| Ventura, A | 2 |
| Decorti, G | 1 |
| Ruiz Hernández, C | 1 |
| Sánchez Hernández, D | 1 |
| Vila Miravet, V | 1 |
| Pinillos Pisón, S | 1 |
| Kreijne, JE | 1 |
| Wilhelm, AJ | 1 |
| Viazis, N | 4 |
| Koukouratos, T | 1 |
| Anastasiou, J | 1 |
| Triantos, C | 1 |
| Tsolias, C | 1 |
| Theocharis, G | 1 |
| Karamanolis, DG | 4 |
| Mišak, Z | 1 |
| Jadrešin, O | 1 |
| Močić Pavić, A | 1 |
| Lev-Tzion, R | 1 |
| Renbaum, P | 1 |
| Beeri, R | 1 |
| Mevorach, R | 1 |
| Muise, AM | 1 |
| Cintolo, M | 1 |
| Guarneri, C | 1 |
| Lentini, M | 1 |
| Goldberg, R | 1 |
| Schröder, T | 1 |
| Schmidt, KJ | 1 |
| Olsen, V | 1 |
| Möller, S | 1 |
| Mackenroth, T | 1 |
| Lehnert, H | 1 |
| Büning, J | 2 |
| Duricova, D | 1 |
| Archavlis, E | 2 |
| Bortlik, M | 1 |
| Van Assche, G | 9 |
| Bevelander, G | 1 |
| Rodrigues, S | 1 |
| Gallego-Gutiérrez, S | 1 |
| Navas-López, VM | 1 |
| Kolorz, M | 1 |
| Bartosova, L | 1 |
| Lukac, K | 1 |
| Luque-Pérez, S | 1 |
| Núñez-Caro, L | 1 |
| García-Galán, P | 1 |
| Fernández-Crehuet, FG | 1 |
| Blasco-Alonso, J | 1 |
| Serrano-Nieto, MJ | 1 |
| Sierra-Salinas, C | 1 |
| Poon, SS | 1 |
| Asher, R | 1 |
| Jackson, R | 1 |
| Kneebone, A | 1 |
| Collins, P | 1 |
| Probert, C | 2 |
| Dibb, M | 1 |
| Subramanian, S | 1 |
| de Abreu, NC | 1 |
| Reboredo, MM | 1 |
| Pinheiro, HS | 1 |
| Bellaguarda, E | 1 |
| Keyashian, K | 1 |
| Pekow, J | 1 |
| Sakuraba, A | 1 |
| Roberts, RL | 2 |
| Coenen, MJ | 1 |
| de Jong, DJ | 2 |
| van Marrewijk, CJ | 1 |
| Derijks, LJ | 1 |
| Vermeulen, SH | 1 |
| Klungel, OH | 1 |
| Verbeek, AL | 1 |
| Peters, WH | 1 |
| te Morsche, RH | 1 |
| Newman, WG | 2 |
| Scheffer, H | 1 |
| Guchelaar, HJ | 1 |
| Franke, B | 1 |
| Kakuta, Y | 1 |
| Naito, T | 1 |
| Onodera, M | 1 |
| Kuroha, M | 1 |
| Kimura, T | 1 |
| Shiga, H | 1 |
| Endo, K | 1 |
| Negoro, K | 1 |
| Kinouchi, Y | 1 |
| Shimosegawa, T | 1 |
| Durilova, M | 1 |
| Nevoral, J | 3 |
| Maminak, M | 1 |
| Hubacek, P | 1 |
| Garavagno, M | 1 |
| Bresso, F | 1 |
| Fagoonee, S | 1 |
| David, E | 1 |
| Sapone, N | 1 |
| Bonagura, AG | 1 |
| Resegotti, A | 1 |
| Eksteen, B | 1 |
| McCarthy, NE | 1 |
| Hedin, CR | 1 |
| Sanders, TJ | 1 |
| Amon, P | 1 |
| Hoti, I | 1 |
| Ayada, I | 1 |
| Baji, V | 1 |
| Giles, EM | 1 |
| Wildemann, M | 1 |
| Bashir, Z | 1 |
| Whelan, K | 1 |
| Sanderson, I | 1 |
| Stagg, AJ | 1 |
| Ampuero, J | 2 |
| Rojas-Feria, M | 1 |
| Castro-Fernández, M | 2 |
| Millán-Lorenzo, M | 1 |
| Guerrero-Jiménez, P | 1 |
| Romero-Gómez, M | 2 |
| Salem, CB | 1 |
| Larif, S | 1 |
| Slim, R | 1 |
| Aounallah, A | 1 |
| Sakhri, J | 1 |
| Hmouda, H | 1 |
| Jakobovits, S | 1 |
| Woo, SY | 1 |
| Levesque, BG | 2 |
| Zou, G | 1 |
| Stitt, LW | 1 |
| Greenberg, GR | 1 |
| Paré, P | 2 |
| MacIntosh, D | 1 |
| Donner, A | 2 |
| Vandervoort, MK | 1 |
| Morris, JC | 1 |
| Kantsø, B | 1 |
| Simonsen, J | 1 |
| Hoffmann, S | 1 |
| Valentiner-Branth, P | 1 |
| Petersen, AM | 1 |
| Santos, L | 1 |
| Gekka, M | 1 |
| Sugiyama, T | 1 |
| Nomura, M | 1 |
| Kato, Y | 1 |
| Nishihara, H | 1 |
| Asaoka, K | 1 |
| Hawthrone, AB | 1 |
| Fedorak, R | 1 |
| Mohl, W | 2 |
| Bündgens, B | 1 |
| Miehlke, S | 1 |
| Hüppe, D | 1 |
| Maaser, C | 1 |
| Helwig, U | 1 |
| Weismüller, J | 1 |
| Drabik, A | 1 |
| Li, MY | 1 |
| Gerdin, L | 1 |
| Eriksson, AS | 1 |
| Olaison, G | 2 |
| Sjödahl, R | 1 |
| Ström, M | 2 |
| Söderholm, JD | 1 |
| Myrelid, P | 2 |
| Antunes, H | 1 |
| Patraquim, C | 1 |
| Baptista, V | 1 |
| Silva Monteiro, L | 1 |
| Bollen, L | 1 |
| Vande Casteele, N | 1 |
| Ballet, V | 1 |
| Gils, A | 1 |
| Patton, PH | 1 |
| Thomas, BS | 1 |
| Suárez, C | 1 |
| Calvo, M | 1 |
| Matallana, V | 1 |
| de la Revilla, J | 1 |
| Magaz, M | 1 |
| Bernardo, C | 1 |
| Agudo, B | 1 |
| Ibarrola, P | 1 |
| Relea, L | 1 |
| Arévalo, J | 1 |
| Vera, MI | 1 |
| Abreu, L | 1 |
| Nelson, S | 1 |
| Mentzer, A | 1 |
| Goel, R | 1 |
| Elliott, T | 1 |
| Campbell, H | 2 |
| Hullah, E | 1 |
| Patel, P | 1 |
| Challacombe, S | 1 |
| Escudier, M | 1 |
| Carvalho, MA | 1 |
| Dias, JT | 1 |
| Satrapa, DA | 1 |
| Silva, RG | 1 |
| Machado, NC | 1 |
| Vandenbulcke, H | 1 |
| Borgies, P | 1 |
| Dubois, A | 1 |
| Patris, A | 1 |
| Gallez, JF | 1 |
| El Nawar, A | 1 |
| Rahier, JF | 2 |
| Tennstedt, D | 1 |
| Nakad, A | 1 |
| Actis, GC | 1 |
| Rosina, F | 1 |
| Hwang, EH | 1 |
| Shin, JH | 1 |
| Kim, SY | 1 |
| Salleron, J | 1 |
| Filippi, J | 2 |
| Reenaers, C | 3 |
| Antunes, O | 2 |
| Filipe, V | 1 |
| Chen, G | 1 |
| Crispin, P | 1 |
| Cherian, M | 1 |
| Dahlstrom, JE | 1 |
| Sethna, FF | 1 |
| Kaye, G | 1 |
| Pavli, P | 1 |
| Szita, I | 1 |
| Eun, CS | 1 |
| Kwak, MJ | 1 |
| Lee, AR | 1 |
| Park, DI | 1 |
| Kim, YS | 2 |
| Kim, JF | 1 |
| Burgess, C | 1 |
| Muir, R | 1 |
| Reilly, C | 1 |
| Lewindon, PJ | 1 |
| Roelofs, JJ | 1 |
| van Schuppen, J | 1 |
| Schonenberg-Meinema, D | 1 |
| Chi, S | 1 |
| Lim, Y | 1 |
| Jeon, TY | 1 |
| Afzali, A | 1 |
| Park, CJ | 1 |
| Zhu, K | 1 |
| Hu, JK | 1 |
| Sharma, P | 1 |
| Sinanan, MN | 1 |
| Lee, SD | 1 |
| Kim, HS | 1 |
| Liu, Q | 1 |
| Mei, Q | 1 |
| Han, W | 1 |
| Hu, J | 1 |
| Hu, N | 1 |
| Schlak, A | 1 |
| Greenfield, K | 1 |
| Crewe, S | 1 |
| Lee, CC | 1 |
| Austin, J | 1 |
| Vaccaro, A | 1 |
| Carrat, F | 3 |
| Sokol, H | 6 |
| Schwarzinger, M | 1 |
| Pavlidis, P | 1 |
| Stamoulos, P | 1 |
| Abdulrehman, A | 1 |
| Kerr, P | 1 |
| Bull, C | 1 |
| Duley, J | 2 |
| Ansari, A | 4 |
| Lail, G | 1 |
| Tasneem, AA | 1 |
| Butt, MO | 1 |
| Luck, NH | 1 |
| Laeq, SM | 1 |
| Abbas, Z | 1 |
| Mubarak, M | 1 |
| Maxwell, EC | 1 |
| Grossman, AB | 2 |
| Fiorino, G | 1 |
| Elliott, TR | 1 |
| Miller, C | 1 |
| Xie, X | 1 |
| AlYafi, M | 1 |
| Cheddani, H | 1 |
| Dauchet, L | 1 |
| Charpentier, C | 1 |
| Marie Bouvier, A | 1 |
| Gower-Rousseau, C | 3 |
| Cheraghi, N | 1 |
| Yasuda, M | 1 |
| Deng, A | 1 |
| Mailhot, J | 1 |
| Jossen, J | 1 |
| Barnes, EL | 1 |
| Goldin, A | 1 |
| Winter, RW | 1 |
| Collins, E | 1 |
| Cao, B | 1 |
| Carrellas, M | 1 |
| Crowell, AM | 1 |
| Korzenik, JR | 2 |
| Zhang, Y | 1 |
| Xia, JJ | 1 |
| Xiao, P | 1 |
| Zhao, Y | 1 |
| Ye, LN | 1 |
| Li, XL | 1 |
| Lin, ZW | 1 |
| Xu, ZJ | 1 |
| Huang, YB | 1 |
| Wang, MY | 1 |
| Qian, JM | 1 |
| Alexakis, C | 2 |
| Gordon, K | 1 |
| Mellor, R | 1 |
| Chong, H | 1 |
| Mortimer, P | 1 |
| Coelho, T | 1 |
| Andreoletti, G | 1 |
| Ashton, JJ | 1 |
| Batra, A | 1 |
| Afzal, NA | 1 |
| Williams, AP | 1 |
| Beattie, RM | 2 |
| Ennis, S | 1 |
| Mottet, C | 1 |
| Juillerat, P | 2 |
| Froehlich, F | 1 |
| Kessler-Brondolo, V | 1 |
| Seibold, F | 2 |
| Michetti, P | 2 |
| Bermejo San José, F | 1 |
| Algaba, A | 3 |
| López Durán, S | 1 |
| Aicart, M | 1 |
| Hernández-Tejero, M | 1 |
| Garrido, E | 2 |
| de Lucas, M | 1 |
| Bonillo, D | 1 |
| López Sanromán, A | 1 |
| Walldorf, J | 1 |
| Bruns, T | 1 |
| Ungar, B | 2 |
| Engel, T | 1 |
| Yavzori, M | 1 |
| Fudim, E | 1 |
| Picard, O | 1 |
| Lang, A | 1 |
| Bar-Gil Shitrit, A | 1 |
| Giannini, EG | 1 |
| De Maria, C | 1 |
| Furnari, M | 1 |
| Ferreira, C | 1 |
| Soares, J | 1 |
| Maia, T | 1 |
| Pardal, J | 1 |
| Nogueira, A | 1 |
| Tavares, M | 1 |
| Trindade, E | 1 |
| Fraser, D | 1 |
| Boyle, S | 1 |
| Amft, N | 1 |
| Jeuring, SF | 1 |
| van den Heuvel, TR | 1 |
| Liu, LY | 1 |
| Zeegers, MP | 1 |
| Hameeteman, WH | 1 |
| Romberg-Camps, MJ | 1 |
| Oostenbrug, LE | 2 |
| Jonkers, DM | 1 |
| Pierik, MJ | 1 |
| Möhlmann, MC | 1 |
| Stiksma, J | 1 |
| Kramer, MH | 1 |
| Cuilleron, M | 1 |
| Jarlot, C | 1 |
| Prantera, C | 2 |
| Lindgren, S | 1 |
| Huang, Z | 2 |
| Boice, J | 1 |
| Huyck, S | 1 |
| Axelrad, JE | 1 |
| Lawlor, G | 1 |
| Korelitz, B | 1 |
| van de Meeberg, MM | 1 |
| Derikx, LA | 1 |
| Sinnige, HA | 1 |
| Nooijen, P | 1 |
| Schipper, DL | 1 |
| Nissen, LH | 1 |
| Monteiro, S | 1 |
| Ribeiro, JM | 1 |
| Zhi, M | 1 |
| Rouskova, B | 1 |
| Pos, L | 1 |
| Skaba, R | 1 |
| Hwang, SW | 1 |
| Im, JP | 1 |
| Koo, HS | 1 |
| Huh, KC | 1 |
| Kim, JS | 1 |
| Nieto, JC | 1 |
| Zamora, C | 1 |
| Cantó, E | 1 |
| Gordillo, J | 2 |
| Ortiz, MA | 1 |
| Juárez, C | 1 |
| Vidal, S | 1 |
| de Graaf, P | 2 |
| van der Hulst, RW | 1 |
| Zoetekouw, L | 1 |
| van Kuilenburg, AB | 1 |
| Efthymiou, A | 1 |
| Papadimitriou, N | 1 |
| Tzourmakliotis, D | 1 |
| Raptis, S | 1 |
| Olaiwan, A | 1 |
| Wendling, J | 1 |
| Pouzoulet, J | 1 |
| Gaulier, A | 1 |
| Ingen-Housz-Oro, S | 1 |
| Sigal, M | 1 |
| Badina, L | 1 |
| Taddio, A | 1 |
| Miller, V | 1 |
| Whorwell, PJ | 2 |
| Yoshizawa, S | 1 |
| Treton, X | 2 |
| Joly, F | 2 |
| Alves, A | 2 |
| Panis, Y | 2 |
| Desilva, S | 1 |
| Tsujikawa, T | 4 |
| Ban, H | 3 |
| Hashimoto, T | 1 |
| Bamba, S | 2 |
| Ogawa, A | 1 |
| Sasaki, M | 4 |
| Saito, Y | 4 |
| Fujiyama, Y | 5 |
| Mossop, H | 1 |
| Davies, P | 1 |
| Murphy, MS | 1 |
| Francolla, KA | 1 |
| Altman, A | 1 |
| Sylvester, FA | 1 |
| Nagy, F | 3 |
| Molnar, T | 2 |
| Szepes, Z | 1 |
| Farkas, K | 2 |
| Nyari, T | 1 |
| Lonovics, J | 1 |
| Lémann, M | 13 |
| Feagan, B | 2 |
| Schmidt, S | 1 |
| Sturniolo, GC | 1 |
| Mikhailova, T | 1 |
| Alexeeva, O | 1 |
| Sanna, L | 1 |
| Haas, T | 1 |
| Korom, S | 1 |
| Mayer, H | 1 |
| Noman, M | 3 |
| Aerden, I | 1 |
| Van Olmen, G | 1 |
| El-Azhary, RA | 1 |
| Brunner, KL | 1 |
| Gibson, LE | 1 |
| Wong, A | 1 |
| Bass, D | 1 |
| Schumann, M | 1 |
| Loddenkemper, C | 1 |
| Günther, U | 1 |
| Somasundaram, R | 1 |
| Zeitz, M | 3 |
| Diamanti, A | 1 |
| Basso, MS | 1 |
| Gambarara, M | 1 |
| Papadatou, B | 2 |
| Bracci, F | 1 |
| Noto, C | 1 |
| Castro, M | 2 |
| Almer, SH | 1 |
| Hjortswang, H | 2 |
| Hindorf, U | 3 |
| Etchevers, MJ | 1 |
| Aceituno, M | 1 |
| Burakoff, R | 1 |
| Tanaka, A | 1 |
| Duclos, B | 3 |
| Soule, JC | 4 |
| Lerebours, E | 5 |
| Kiefer, K | 1 |
| El-Matary, W | 3 |
| Szabo, N | 1 |
| Lukacs, S | 1 |
| Kulcsar, I | 1 |
| Gunasekera, W | 1 |
| Nagy-Toldi, A | 1 |
| Dezso, B | 1 |
| Danko, K | 1 |
| Tougeron, D | 1 |
| Savoye-Collet, C | 1 |
| Koning, E | 1 |
| Michot, F | 1 |
| Christidou, A | 1 |
| Sfakianakis, M | 1 |
| Roussos, A | 3 |
| Koilakou, S | 3 |
| Petraki, K | 2 |
| Polyzou, P | 1 |
| Springfeld, C | 1 |
| Sauerbrei, A | 1 |
| Filusch, A | 1 |
| Konstandin, M | 1 |
| Hartschuh, W | 1 |
| Sauer, P | 1 |
| Encke, J | 2 |
| Stremmel, W | 1 |
| Schnitzler, P | 1 |
| Moran, G | 1 |
| Dillon, J | 1 |
| Green, J | 1 |
| Lee, JM | 1 |
| Lee, KM | 2 |
| Kim, HW | 1 |
| Chung, WC | 1 |
| Paik, CN | 1 |
| Lee, JR | 1 |
| Yang, JM | 1 |
| Kappen, JH | 1 |
| Mensink, PB | 1 |
| Lesterhuis, W | 1 |
| Lachman, S | 1 |
| van Daele, PL | 1 |
| van Hagen, PM | 1 |
| van Laar, JA | 1 |
| Hizawa, K | 1 |
| Nagata, Y | 1 |
| Taniguchi, M | 1 |
| Nakamori, M | 1 |
| Iida, M | 1 |
| Prefontaine, E | 3 |
| Sutherland, LR | 7 |
| Cepoiu, M | 1 |
| Zamvar, V | 1 |
| Sugarman, ID | 2 |
| Tawfik, RF | 1 |
| Macmullen-Price, J | 1 |
| Puntis, JW | 2 |
| Serrate, C | 1 |
| Silva-Moreno, M | 1 |
| Dartigues, P | 1 |
| Poujol-Robert, A | 1 |
| Gorin, NC | 1 |
| Coppo, P | 1 |
| N'guyen, Y | 2 |
| Andreoletti, L | 2 |
| Patey, M | 1 |
| Lecoq-Lafon, C | 1 |
| Cornillet, P | 1 |
| Léon, A | 1 |
| Jaussaud, R | 2 |
| Fieschi, C | 1 |
| Strady, C | 2 |
| Meier, J | 1 |
| Sturm, A | 5 |
| Uchiyama, K | 1 |
| Nakamura, M | 1 |
| Kubota, T | 1 |
| Yamane, T | 1 |
| Fujise, K | 1 |
| Tajiri, H | 1 |
| Beigel, F | 1 |
| Jürgens, M | 1 |
| Filik, L | 2 |
| Bader, L | 1 |
| Lück, C | 1 |
| Göke, B | 5 |
| Ochsenkühn, T | 5 |
| Brand, S | 2 |
| Seiderer, J | 2 |
| Kaser, A | 1 |
| Umegae, S | 1 |
| Matsumoto, K | 1 |
| García López, S | 1 |
| Al-Mubarak, L | 1 |
| Al-Khenaizan, S | 1 |
| Al Goufi, T | 1 |
| Leung, M | 1 |
| Piatkov, I | 1 |
| Rochester, C | 1 |
| Boyages, SC | 1 |
| Iesalnieks, I | 2 |
| Glass, H | 1 |
| Kilger, A | 1 |
| Klebl, F | 2 |
| Agha, A | 1 |
| Schlitt, HJ | 1 |
| Strauch, U | 3 |
| Villafruela Cives, M | 1 |
| Moya Valverde, E | 1 |
| de Manuel Moreno, J | 1 |
| Sandoval Martínez, A | 1 |
| Beceiro Pedreño, I | 1 |
| van Asseldonk, DP | 1 |
| Kanis, BM | 1 |
| Ribeiro, MS | 1 |
| Pace, FH | 1 |
| Moraes, JP | 1 |
| do Amaral, FJ | 1 |
| Meirelles de Souza, AF | 1 |
| Varea, V | 2 |
| Lerner, A | 1 |
| Shapiro, R | 1 |
| Broide, E | 1 |
| Fradkin, A | 1 |
| Bujanover, Y | 2 |
| Leu, S | 1 |
| Sun, PK | 1 |
| Collyer, J | 1 |
| Smidt, A | 1 |
| Stika, CS | 1 |
| Schlosser, B | 1 |
| Mirowski, GW | 1 |
| Vanagunas, A | 1 |
| Buchman, AL | 1 |
| von Roon, AC | 1 |
| Reese, GE | 1 |
| Orchard, TR | 2 |
| Tekkis, PP | 1 |
| Lam, MY | 1 |
| Feller, ER | 1 |
| Lonks, JR | 1 |
| Shah, SA | 2 |
| Seksik, P | 3 |
| Nion-Larmurier, I | 4 |
| Vienne, A | 2 |
| Paviotti, A | 1 |
| McLeod, RS | 3 |
| Wolff, BG | 1 |
| Ross, S | 2 |
| Parkes, R | 1 |
| McKenzie, M | 1 |
| Holtmann, MH | 2 |
| Krummenauer, F | 3 |
| Claas, C | 2 |
| Kremeyer, K | 2 |
| Lorenz, D | 2 |
| Rainer, O | 2 |
| Vogel, I | 2 |
| Böcker, U | 2 |
| Böhm, S | 2 |
| Büning, C | 3 |
| Duchmann, R | 2 |
| Gerken, G | 2 |
| Lügering, N | 2 |
| Reinshagen, M | 4 |
| Schmidt, J | 2 |
| Stein, J | 6 |
| Galle, PR | 4 |
| Marehbian, J | 1 |
| Arrighi, HM | 1 |
| Hass, S | 1 |
| Tian, H | 1 |
| Moss, AC | 2 |
| Fernandez-Becker, N | 1 |
| Cury, D | 1 |
| Kübler, I | 1 |
| Koslowski, MJ | 1 |
| Gersemann, M | 1 |
| Beisner, J | 1 |
| Becker, S | 1 |
| Rothfuss, K | 1 |
| Wehkamp, J | 2 |
| Cesarini, M | 3 |
| Persad, R | 1 |
| Murakami, A | 1 |
| Tanaka, Y | 1 |
| Ueda, M | 1 |
| Nagano, Y | 1 |
| Morimoto, M | 1 |
| Enaka, M | 1 |
| Tanabe, M | 1 |
| Kawachi, K | 1 |
| Sasaki, T | 1 |
| Nozawa, A | 1 |
| Zelinkova, Z | 1 |
| De Boer, IP | 1 |
| Van Dijke, MJ | 1 |
| Kuipers, EJ | 1 |
| Deltenre, P | 1 |
| Czegledi, Z | 2 |
| Szamosi, T | 3 |
| Banai, J | 3 |
| David, G | 5 |
| Zsigmond, F | 2 |
| Gemela, O | 2 |
| Papp, J | 2 |
| Papp, M | 2 |
| Velayos, FS | 2 |
| Lebowitz, O | 1 |
| Fidder, HH | 1 |
| Maza, I | 1 |
| Reif, S | 1 |
| Nguyen, T | 1 |
| Vacek, PM | 1 |
| O'Neill, P | 1 |
| Finette, BA | 1 |
| Van-Domselaar, M | 1 |
| García-Garzón, S | 1 |
| Piqueras, B | 1 |
| De La Poza, G | 1 |
| Vlachogiannakos, J | 1 |
| Georgiou, O | 1 |
| Rodias, M | 1 |
| Georgiadis, D | 1 |
| Papastamopoulos, V | 1 |
| Baraboutis, IG | 1 |
| Skoutelis, A | 1 |
| García-Olmo, D | 1 |
| Moreira, T | 1 |
| Lago, P | 1 |
| Salgado, M | 1 |
| Pimentel, R | 1 |
| Bar-Meir, S | 3 |
| Trapero-Marugán, M | 1 |
| Moreno-Otero, R | 1 |
| Moortgat, L | 1 |
| Stokkers, P | 1 |
| Courby, S | 1 |
| Fabre, B | 1 |
| Salameire, D | 1 |
| Gaulard, P | 1 |
| Hincky-Vitrat, V | 1 |
| Gressin, R | 1 |
| Bonaz, B | 5 |
| Epaulard, O | 1 |
| Papay, P | 1 |
| Ho, E | 1 |
| Gratzer, C | 1 |
| Lissner, D | 1 |
| Herkner, H | 1 |
| Riss, S | 1 |
| Dejaco, C | 5 |
| Miehsler, W | 4 |
| Belaiche, J | 5 |
| Jolobe, O | 1 |
| Kuloğlu, Z | 1 |
| Kansu, A | 1 |
| Ustündağ, G | 1 |
| Birsin Özçakar, Z | 1 |
| Ensari, A | 1 |
| Ekim, M | 1 |
| Robineau, O | 1 |
| Enrico, J | 1 |
| Lemaire, X | 1 |
| Poissy, J | 1 |
| Legout, L | 1 |
| Senneville, E | 1 |
| Yazdanpanah, Y | 1 |
| Da-Silva, N | 1 |
| Arasaradnam, R | 1 |
| Getliffe, K | 1 |
| Sung, E | 1 |
| Oo, Y | 1 |
| Nwokolo, C | 1 |
| Reichel, C | 1 |
| Streit, J | 1 |
| Wunsch, S | 1 |
| Murakami, Y | 1 |
| Takatsu, N | 1 |
| Takaki, Y | 1 |
| Nagahama, T | 1 |
| Hisabe, T | 1 |
| Beppu, T | 1 |
| Miyaoka, M | 1 |
| Maki, S | 1 |
| Takeichi, M | 1 |
| Nishimura, T | 1 |
| Ueki, T | 1 |
| Yao, K | 1 |
| Pitchumoni, CS | 1 |
| Rubin, A | 1 |
| Das, K | 1 |
| Chi, HS | 1 |
| Theodoropoulos, I | 1 |
| Karakoidas, C | 1 |
| Raptis, N | 2 |
| Smyrnidis, A | 1 |
| Agalos, G | 1 |
| Leung, VK | 1 |
| Lee, CK | 3 |
| Chau, TN | 1 |
| Cheung, WI | 1 |
| Lo, FH | 1 |
| Lai, KB | 1 |
| Lin, CK | 1 |
| Ben Hriz, F | 1 |
| Habbessi, H | 1 |
| Maamouri, N | 1 |
| Belkahla, N | 1 |
| Ouerdiane, S | 1 |
| Chouaib, S | 1 |
| Ouerghi, H | 1 |
| Chaabouni, H | 1 |
| Ben Mami, N | 1 |
| Cortot, A | 7 |
| Tremblay, L | 1 |
| Jouet, JP | 1 |
| Allorge, D | 2 |
| Broly, F | 3 |
| Pushpakom, SP | 1 |
| Gambhir, N | 1 |
| Latif, A | 1 |
| Hadfield, KD | 1 |
| Campbell, S | 2 |
| Kallel, L | 2 |
| Naijaa, N | 1 |
| Fekih, M | 1 |
| Frikha, I | 1 |
| Bellaaj, H | 1 |
| Romdhane, NB | 1 |
| van Geenen, EJ | 1 |
| Stassen, P | 1 |
| Linskens, RK | 1 |
| Bruno, MJ | 1 |
| Stegeman, CA | 1 |
| Ford, L | 1 |
| Berg, J | 1 |
| Bischoff, A | 1 |
| Fogo, AJ | 1 |
| Hunt, JB | 1 |
| Clement, M | 1 |
| Calderón, R | 1 |
| Estrada, S | 1 |
| Ramírez de la Piscina, P | 1 |
| Salvador, M | 1 |
| Zabaleta, S | 1 |
| Enciso, C | 1 |
| Delgado, E | 1 |
| García-Campos, F | 1 |
| Ochenrider, MG | 1 |
| Patterson, DJ | 1 |
| Aboulafia, DM | 1 |
| Nugent, Z | 1 |
| Blanchard, JF | 1 |
| Oussalah, A | 4 |
| Chevaux, JB | 3 |
| Fay, R | 1 |
| Bigard, MA | 3 |
| Broussard, DL | 1 |
| Imaeda, H | 1 |
| Kobori, A | 1 |
| Vinklerová, I | 1 |
| Procházka, M | 1 |
| Procházka, V | 1 |
| Urbánek, K | 1 |
| Rajwal, SK | 1 |
| Sugarman, I | 1 |
| Picton, S | 1 |
| Devlin, J | 1 |
| Davison, S | 1 |
| McClean, P | 1 |
| Rosien, U | 1 |
| Weiss, S | 1 |
| Layer, P | 1 |
| Angelberger, S | 4 |
| Shonova, O | 2 |
| Schaeffeler, E | 6 |
| Schwab, M | 8 |
| Dilger, K | 3 |
| Greinwald, R | 2 |
| Mueller, R | 2 |
| Bryant, DL | 1 |
| Miles, CJ | 1 |
| Ishida, M | 1 |
| Naka, S | 1 |
| Shiomi, H | 1 |
| Nakahara, T | 1 |
| Kurumi, Y | 1 |
| Takikita-Suzuki, M | 1 |
| Kojima, F | 1 |
| Hotta, M | 1 |
| Tani, T | 1 |
| Okabe, H | 1 |
| Thia, KT | 1 |
| Ling, KL | 1 |
| Kong, SC | 1 |
| Ramadas, AV | 1 |
| Gunesh, S | 1 |
| Thomas, GA | 1 |
| Williams, GT | 1 |
| Fölsch, UR | 1 |
| Nitschmann, S | 1 |
| Barber, CE | 1 |
| Lee, P | 1 |
| Lazarou, J | 1 |
| Błogowski, W | 1 |
| Marlicz, W | 1 |
| Smereczyński, A | 1 |
| Lawniczak, M | 1 |
| Lewosiuk, A | 1 |
| Starzyńska, T | 1 |
| Ford, AC | 5 |
| Haines, ML | 1 |
| Ajlouni, Y | 1 |
| Rose, R | 1 |
| Carrión, S | 1 |
| Concepción, M | 1 |
| Guarner, C | 1 |
| Caturelli, E | 1 |
| Gelber, AC | 1 |
| Ruffolo, C | 1 |
| Scarpa, M | 1 |
| Bassi, N | 1 |
| Ohtsuka, Y | 1 |
| Arai, K | 1 |
| Aoyagi, Y | 1 |
| Yamakawa, Y | 1 |
| Ohtani, K | 1 |
| Ikuse, T | 1 |
| Baba, Y | 1 |
| Inage, E | 1 |
| Kudo, T | 1 |
| Suzuki, R | 1 |
| Nagata, S | 1 |
| Shimizu, T | 1 |
| Gidrewicz, D | 1 |
| Lehman, D | 1 |
| Rabizadeh, S | 1 |
| Majlessipour, F | 1 |
| Miheller, P | 2 |
| Loganathan, S | 1 |
| Zaitoun, A | 1 |
| Charlton, CP | 1 |
| Canedo, J | 1 |
| Lee, SH | 2 |
| Pinto, R | 1 |
| Murad-Regadas, S | 1 |
| Rosen, L | 1 |
| Wexner, SD | 1 |
| Ramos, JM | 1 |
| García-Sepulcre, MF | 1 |
| Masiá, M | 1 |
| Brotons, A | 1 |
| Grau, MC | 1 |
| Gutiérrez, F | 1 |
| Higgins, PD | 3 |
| Gassull, M | 1 |
| Kamm, M | 1 |
| Löfberg, R | 1 |
| Quary, A | 1 |
| Sands, B | 1 |
| Watermeyer, G | 2 |
| Watermayer, G | 1 |
| Lashner, B | 1 |
| Plevy, S | 1 |
| Siegel, C | 1 |
| Targan, S | 1 |
| Williams, JV | 1 |
| Revington, PJ | 1 |
| Govani, SM | 1 |
| Haveran, LA | 1 |
| Sehgal, R | 1 |
| Poritz, LS | 1 |
| McKenna, KJ | 1 |
| Stewart, DB | 1 |
| Koltun, WA | 1 |
| López-Martín, C | 1 |
| de la Fuente-Fernández, E | 1 |
| Corbatón, P | 1 |
| Sánchez, MC | 1 |
| Pillot, C | 1 |
| Bresler, L | 1 |
| Reffet, A | 1 |
| Belleannée, G | 1 |
| Chabrun, E | 1 |
| Subtil, C | 1 |
| Razaire, S | 1 |
| Capdepont, M | 1 |
| de Lédinghen, V | 1 |
| Calabrese, E | 1 |
| Baysoy, G | 1 |
| Daar, G | 1 |
| Demir, H | 1 |
| Elmas, SA | 1 |
| Haliloğlu, M | 1 |
| Besbas, N | 1 |
| Khan, KJ | 1 |
| Ullman, TA | 1 |
| Talley, NJ | 1 |
| Kovács, J | 1 |
| Nagy, A | 1 |
| Szabó, A | 1 |
| Lorincz, M | 1 |
| Messerschmidt, A | 1 |
| French, H | 1 |
| Mark Dalzell, A | 1 |
| Srinivasan, R | 1 |
| Borowiec, AM | 1 |
| Blumenstein, I | 2 |
| Herrmann, E | 1 |
| Filmann, N | 1 |
| Zosel, C | 1 |
| Tacke, W | 1 |
| Bock, H | 1 |
| Hartmann, F | 1 |
| Zeuzem, S | 1 |
| Schröder, O | 2 |
| Zelante, A | 1 |
| Borgoni, R | 1 |
| Galuppi, C | 1 |
| Cifalà, V | 1 |
| Melchiorri, L | 1 |
| Gullini, S | 1 |
| Baricordi, O | 1 |
| Rizzo, R | 1 |
| Girlich, C | 1 |
| Plentz, A | 1 |
| Schölmerich, J | 5 |
| Sansó Sureda, A | 1 |
| Rocamora Durán, V | 1 |
| Sapiña Camaró, A | 1 |
| Royo Escosa, V | 1 |
| Bosque López, MJ | 1 |
| Baumard, S | 1 |
| Salmon, JH | 1 |
| Lemoine, L | 1 |
| Lévêque, N | 1 |
| Servettaz, A | 1 |
| Biank, VF | 1 |
| Sheth, MK | 1 |
| Talano, J | 1 |
| Margolis, D | 1 |
| Simpson, P | 1 |
| Castro Márquez, C | 1 |
| Méndez Rufián, V | 1 |
| Castro Laria, L | 1 |
| Caunedo Álvarez, A | 1 |
| Romero Vázquez, J | 1 |
| Herrerías Gutiérrez, JM | 1 |
| Munkholm, P | 3 |
| Wewer, V | 1 |
| Sagüés, M | 1 |
| Navarro, JT | 2 |
| Ribera, JM | 2 |
| Millá, F | 2 |
| Hamrouni, A | 1 |
| Bibani, N | 1 |
| Ananthakrishnan, AN | 3 |
| Hur, C | 1 |
| Nguyen, MC | 1 |
| Kaeser, P | 1 |
| Kani, K | 1 |
| Takabayashi, H | 1 |
| Yamamoto, R | 1 |
| Ogawa, T | 1 |
| Matsuda, A | 1 |
| Yakabi, K | 1 |
| Presti, MA | 1 |
| Costantino, G | 1 |
| Della Torre, A | 1 |
| Cascio, A | 1 |
| Vincze, A | 1 |
| Palatka, K | 1 |
| Bartha, Z | 1 |
| Gasztonyi, B | 1 |
| Salamon, A | 1 |
| Horváth, G | 1 |
| Tóth, GT | 1 |
| Tulassay, Z | 1 |
| Szenes, M | 1 |
| Szathmári, M | 4 |
| Kang, SJ | 1 |
| Park, MJ | 1 |
| Chang, HK | 1 |
| Doherty, GA | 1 |
| Miksad, RA | 1 |
| Riello, L | 1 |
| Talbotec, C | 1 |
| Garnier-Lengliné, H | 1 |
| Pigneur, B | 1 |
| Svahn, J | 1 |
| Canioni, D | 1 |
| Goulet, O | 2 |
| Schmitz, J | 3 |
| Zheng, SM | 1 |
| Cui, DJ | 1 |
| Ouyang, Q | 1 |
| Vos, AC | 1 |
| Wildenberg, ME | 1 |
| Arijs, I | 1 |
| Duijvestein, M | 1 |
| Verhaar, AP | 1 |
| de Hertogh, G | 1 |
| van den Brink, GR | 1 |
| Finlayson, SR | 1 |
| Tosteson, AN | 1 |
| Bravatà, I | 1 |
| Cocorullo, G | 1 |
| Cacciatore, M | 1 |
| Florena, AM | 1 |
| Paroli, MP | 1 |
| Spinucci, G | 1 |
| Bruscolini, A | 1 |
| La Cava, M | 1 |
| Abicca, I | 1 |
| Park, JJ | 1 |
| Alvarez, JA | 1 |
| Hernandez, MP | 1 |
| Grau, M | 1 |
| Plaza, R | 1 |
| Ponferrada, A | 1 |
| Benito, DM | 1 |
| Arevalo, N | 1 |
| Foncillas, MA | 1 |
| de Fuenmayor, ML | 1 |
| Aldeguer, M | 1 |
| Nørgård, BM | 1 |
| Schöffel, N | 1 |
| Sahm, M | 1 |
| Groneberg, DA | 1 |
| Pross, M | 1 |
| Hofmann, U | 2 |
| Heinkele, G | 1 |
| Lichtenberger, C | 1 |
| Jaeger, S | 1 |
| Mester, G | 3 |
| Molnar, C | 3 |
| Komaromi, E | 3 |
| Köksal, AR | 1 |
| Alkim, C | 1 |
| Altinkaya, E | 1 |
| Buğdaci, MS | 1 |
| Özdoğan, O | 1 |
| Boğa, S | 1 |
| Alkim, H | 1 |
| Sökmen, M | 1 |
| Sultan, K | 1 |
| Present, D | 1 |
| Katz, S | 1 |
| Sunday, S | 1 |
| Shapira, I | 1 |
| Pipili, C | 1 |
| Michopoulos, S | 1 |
| Sotiropoulou, M | 1 |
| Mpakirtzi, T | 1 |
| Grapsa, E | 1 |
| Maynadié, M | 1 |
| Simon, T | 1 |
| Brousse, N | 1 |
| Wedekind, S | 1 |
| Sprakes, MB | 1 |
| Warren, L | 1 |
| Greer, D | 2 |
| Hamlin, J | 1 |
| Billioud, V | 1 |
| Gibot, S | 1 |
| Massin, F | 1 |
| Bronowicki, JP | 1 |
| Guéant, JL | 1 |
| Smith, MA | 1 |
| Blaker, P | 1 |
| Marinaki, AM | 2 |
| Anderson, SH | 1 |
| Desales, AL | 1 |
| Mendez-Navarro, J | 1 |
| Méndez-Tovar, LJ | 1 |
| Ortiz-Olvera, NX | 1 |
| Cullen, G | 1 |
| Ocampo, J | 1 |
| Lemus, W | 1 |
| Tun, AE | 1 |
| Mayoral-Zavala, A | 1 |
| Dehesa-Violante, M | 1 |
| López San Román, A | 2 |
| Wonders, J | 1 |
| Van Weyenberg, SJ | 1 |
| Lahat, A | 1 |
| Assulin, Y | 1 |
| Beer-Gabel, M | 1 |
| Rieder, F | 1 |
| Karrasch, T | 1 |
| Schirbel, A | 1 |
| Ehehalt, R | 1 |
| de Haar, C | 1 |
| Velin, D | 1 |
| Latella, G | 1 |
| Scaldaferri, F | 1 |
| Higgins, P | 1 |
| Lariou, C | 1 |
| Balhau, R | 1 |
| Lopes, JM | 1 |
| Beça, F | 1 |
| Eloy, C | 1 |
| Han, BJ | 1 |
| Na, SY | 1 |
| Boo, SJ | 1 |
| Jeong, KW | 1 |
| McCabe, RP | 1 |
| Chow, CJ | 1 |
| Rothenberger, DA | 1 |
| Glorieus, E | 1 |
| Peeters, H | 1 |
| Franchimont, D | 1 |
| Dewit, O | 3 |
| Mullier, F | 1 |
| Maignen, F | 1 |
| Cornet, Y | 1 |
| Graux, C | 1 |
| Chatelain, C | 1 |
| Chatelain, B | 1 |
| Dogne, JM | 1 |
| Cabezuelo, JB | 1 |
| Egea, JP | 1 |
| Ramos, F | 1 |
| Torrella, E | 1 |
| Muray, S | 1 |
| Alcázar, C | 1 |
| Hoentjen, F | 1 |
| Harrell, LE | 1 |
| Desai, A | 1 |
| Zator, ZA | 1 |
| de Silva, P | 1 |
| Nguyen, DD | 1 |
| Korzenik, J | 1 |
| Yajnik, V | 1 |
| Saito, S | 1 |
| Shimizu, U | 1 |
| Nan, Z | 1 |
| Mandai, N | 1 |
| Yokoyama, J | 1 |
| Terajima, K | 1 |
| Akazawa, K | 1 |
| Fitzgerald, MP | 1 |
| Armstrong, L | 1 |
| Hague, R | 1 |
| Fraison, JB | 1 |
| Guilpain, P | 1 |
| Schiffmann, A | 1 |
| Veyrac, M | 2 |
| Le Moing, V | 1 |
| Rispail, P | 1 |
| Le Quellec, A | 1 |
| Bollegala, N | 1 |
| Brill, H | 1 |
| Walker, G | 1 |
| Venkatachalam, P | 1 |
| Bird, J | 1 |
| Malik, S | 1 |
| Mason, A | 1 |
| Bakhshi, A | 1 |
| Young, D | 1 |
| Bishop, J | 1 |
| Ahmed, SF | 1 |
| Le Guenno, G | 1 |
| Galicier, L | 1 |
| Uro-Coste, E | 1 |
| Petitcolin, V | 1 |
| Rieu, V | 1 |
| Ruivard, M | 1 |
| Lee, GJ | 1 |
| Boyle, B | 1 |
| King, E | 1 |
| Pratt, JM | 1 |
| Mandel, M | 1 |
| Ormerod, C | 1 |
| Sarkar, S | 1 |
| Woodcock, B | 1 |
| White, D | 1 |
| Lal, S | 1 |
| Sokumbi, O | 1 |
| Wetter, DA | 1 |
| Makol, A | 1 |
| Warrington, KJ | 1 |
| de Bie, C | 1 |
| Kindermann, A | 1 |
| Escher, J | 1 |
| Cossu, A | 1 |
| Ascolani, M | 1 |
| Pallone, F | 1 |
| Boirivant, M | 1 |
| Dasari, BV | 1 |
| McBrearty, A | 1 |
| Gardiner, K | 1 |
| Marchetti, M | 1 |
| Liberato, NL | 1 |
| Di Sabatino, A | 1 |
| Corazza, GR | 1 |
| You, E | 1 |
| Yang, JJ | 1 |
| Cho, SY | 1 |
| Lee, WI | 1 |
| Yoon, HJ | 1 |
| Park, TS | 1 |
| Weinkove, R | 1 |
| Dickson, M | 2 |
| Eliadou, E | 1 |
| Stace, NH | 1 |
| Goossens, L | 1 |
| Ferguson, P | 1 |
| Hartmann, H | 1 |
| Howaldt, S | 1 |
| Nikolov, R | 1 |
| Petrov, A | 1 |
| Reindl, W | 1 |
| Otte, JM | 1 |
| Stoynov, S | 1 |
| Voiosu, R | 1 |
| Ammendola, A | 1 |
| Dietrich, B | 1 |
| Hentsch, B | 1 |
| Bašić Kinda, S | 1 |
| Duraković, N | 1 |
| Dotlić, S | 1 |
| Serventi Seiwerth, R | 1 |
| Davidović Mrsić, S | 1 |
| Dubravčić, K | 1 |
| Aurer, I | 1 |
| Yajima, T | 1 |
| Camus, M | 1 |
| Baumer, P | 1 |
| Mayberry, JF | 1 |
| Lobo, A | 1 |
| Gustavsson, A | 1 |
| Magnuson, A | 1 |
| Blomberg, B | 1 |
| Tysk, C | 1 |
| Strobel, S | 1 |
| Abreu, MT | 4 |
| Park, KC | 1 |
| Ju, DU | 1 |
| Heo, SW | 1 |
| Ryu, JI | 1 |
| Cho, JY | 1 |
| Millán, M | 1 |
| Duchateau, NC | 1 |
| Aerts, O | 1 |
| Lambert, J | 1 |
| Herfarth, HH | 1 |
| Isaacs, KL | 2 |
| Kinnucan, JA | 1 |
| Chisick, L | 1 |
| Oleschuk, C | 1 |
| Flynn, AD | 1 |
| Azar, JM | 1 |
| Chiorean, MV | 1 |
| Niemelä, S | 1 |
| Färkkilä, M | 1 |
| Järvinen, HJ | 1 |
| Lennard, L | 2 |
| Menor, C | 1 |
| Fueyo, J | 1 |
| Escribano, O | 1 |
| Piña, MJ | 1 |
| Redondo, P | 1 |
| Cara, C | 1 |
| Román, ID | 1 |
| Fernández-Moreno, MD | 1 |
| Guijarro, LG | 2 |
| Evans, WE | 1 |
| Schäffeler, E | 1 |
| Marx, C | 1 |
| Fischer, C | 3 |
| Lang, T | 1 |
| Behrens, C | 3 |
| Gregor, M | 2 |
| Eichelbaum, M | 3 |
| Zanger, UM | 2 |
| Kaskas, BA | 2 |
| Zboril, V | 1 |
| Prokopova, L | 1 |
| Dite, P | 1 |
| Pokorny, A | 1 |
| Dastych, M | 1 |
| Pazourkova, M | 1 |
| Sackmann, M | 2 |
| Regueiro, M | 1 |
| Mardini, H | 1 |
| Aguilera, V | 2 |
| Calvo, F | 1 |
| Molla, A | 1 |
| Esteban, R | 1 |
| Ponce, J | 2 |
| Au, WY | 1 |
| Yuen, MF | 1 |
| Lai, KC | 1 |
| Wan, TS | 1 |
| Ma, SK | 1 |
| Daperno, M | 1 |
| Rosen, R | 1 |
| Integlia, MJ | 1 |
| Bousvaros, A | 3 |
| Deflandre, J | 1 |
| Graepler, F | 1 |
| Schmiegelow, K | 3 |
| Ulker, A | 1 |
| Dagli, U | 1 |
| Parlak, E | 1 |
| Tunc, B | 1 |
| Disibeyaz, S | 1 |
| Alstead, EM | 1 |
| Nelson-Piercy, C | 1 |
| Alvarez Delgado, A | 1 |
| Pérez García, ML | 1 |
| Fradejas Salazar, PM | 1 |
| de la Coba Ortíz, C | 1 |
| Rodríguez Pérez, A | 1 |
| Watts, D | 1 |
| Fleig, WE | 1 |
| Hoffmann, J | 1 |
| Buhr, HJ | 1 |
| Kroesen, AJ | 1 |
| Ganten, M | 1 |
| Flosdorff, P | 1 |
| Grüber-Hoffmann, B | 1 |
| Erb, G | 1 |
| Hansmann, J | 1 |
| Warnakulasuriya, S | 1 |
| Thompson, RP | 2 |
| Kinney, T | 1 |
| Rawlins, M | 1 |
| Kozarek, R | 1 |
| France, R | 1 |
| Patterson, D | 1 |
| Milo, T | 1 |
| Buller, H | 1 |
| Markowitz, JF | 3 |
| Mate, JL | 1 |
| Granada, I | 1 |
| Juncà, J | 1 |
| Batlle, M | 1 |
| Feliu, E | 1 |
| Qasim, A | 1 |
| Seery, J | 1 |
| Buckley, M | 1 |
| Morain, CO | 1 |
| Beglinger, Ch | 1 |
| Diedrich, J | 1 |
| Görg, C | 1 |
| Eissele, R | 1 |
| Arnold, R | 1 |
| Verkasalo, M | 1 |
| Hilsden, RJ | 1 |
| Verhoef, MJ | 1 |
| Best, A | 1 |
| Pocobelli, G | 1 |
| Christodoulou, DK | 1 |
| Zioga, A | 1 |
| Tsianos, EV | 2 |
| Holtmann, M | 1 |
| Schreiner, O | 1 |
| Köhler, H | 1 |
| Denzer, U | 1 |
| Neurath, M | 1 |
| Höhler, T | 1 |
| Boitard, J | 1 |
| Marteau, P | 4 |
| Metman, EH | 1 |
| Knutson, D | 1 |
| Greenberg, G | 1 |
| Cronau, H | 1 |
| Reuther, LO | 1 |
| Sonne, J | 1 |
| Larsen, NE | 1 |
| Larsen, B | 1 |
| Christensen, S | 1 |
| Rasmussen, SN | 1 |
| Tofteng, F | 1 |
| Haaber, A | 1 |
| Johansen, N | 1 |
| Bollani, S | 1 |
| Manzionna, G | 1 |
| Imbesi, V | 2 |
| Colombo, E | 3 |
| Bianchi Porro, G | 2 |
| Lecomte, T | 1 |
| Contou, JF | 1 |
| Cattan, S | 3 |
| Gendre, JP | 7 |
| Giese, T | 1 |
| Ludwig, B | 1 |
| Mueller-Molaian, I | 1 |
| Meuer, SC | 1 |
| Roussomoustakaki, M | 1 |
| Dimoulios, P | 1 |
| Chatzicostas, C | 1 |
| Kritikos, HD | 1 |
| Romanos, J | 1 |
| Panayiotides, JG | 1 |
| Kouroumalis, EA | 1 |
| Serre-Debeauvais, F | 2 |
| Bessard, G | 2 |
| Reffitt, DM | 1 |
| Meenan, J | 1 |
| Jugdaohsingh, R | 1 |
| Powell, JJ | 1 |
| Lemyze, M | 1 |
| Tavernier, JY | 1 |
| Chevalon, B | 1 |
| Lamblin, C | 1 |
| Harrer, M | 1 |
| Waldhoer, T | 1 |
| Zheng, JJ | 2 |
| Shi, XH | 2 |
| Chu, XQ | 2 |
| Jia, LM | 1 |
| Wang, FM | 1 |
| Winther, KV | 1 |
| Binder, V | 2 |
| Schulte-Bockholt, A | 1 |
| Cuffari, C | 4 |
| Li, DY | 1 |
| Mahoney, J | 1 |
| Barnes, Y | 1 |
| Bayless, TM | 4 |
| Dooley, TP | 1 |
| Curto, EV | 1 |
| Reddy, SP | 1 |
| Davis, RL | 1 |
| Lambert, GW | 1 |
| Wilborn, TW | 1 |
| Elson, CO | 1 |
| Goullet, M | 1 |
| Naber, TH | 1 |
| Turnbough, L | 1 |
| Thompson, RE | 2 |
| Richeldi, L | 1 |
| Ewer, K | 1 |
| Losi, M | 1 |
| Hansell, DM | 1 |
| Roversi, P | 1 |
| Fabbri, LM | 1 |
| Lalvani, A | 1 |
| Vilien, M | 2 |
| Dahlerup, JF | 1 |
| Munck, LK | 1 |
| Nørregaard, P | 1 |
| Grønbaek, K | 1 |
| Fallingborg, J | 1 |
| Duley, JA | 1 |
| Arenas, M | 1 |
| Sumi, S | 1 |
| Lewis, CM | 1 |
| Shobowale-Bakre, el-M | 1 |
| Escuredo, E | 1 |
| Fairbanks, LD | 1 |
| Borrelli, O | 1 |
| Bascietto, C | 1 |
| Viola, F | 1 |
| Bueno de Mesquita, M | 1 |
| Barbato, M | 1 |
| Mancini, V | 1 |
| Bosco, S | 1 |
| Cucchiara, S | 1 |
| Majoor, CJ | 1 |
| Schreurs, AJ | 1 |
| Weers-Pothoff, G | 1 |
| Rayner, CK | 1 |
| Hayward, CM | 1 |
| Emmanuel, AV | 1 |
| Bebb, JR | 1 |
| Scott, BB | 1 |
| Wright, S | 1 |
| Sanders, DS | 1 |
| Soon, SY | 1 |
| Yaneza, M | 1 |
| Raoof, S | 1 |
| Hirst, J | 1 |
| Goldenberg, BA | 1 |
| Rawsthorne, P | 1 |
| Sampietro, GM | 1 |
| Russo, A | 1 |
| Radice, E | 1 |
| Molteni, M | 1 |
| Danelli, PG | 1 |
| Taschieri, AM | 1 |
| Babu, TG | 1 |
| Boctor, D | 1 |
| Davey, A | 1 |
| Bond, MC | 1 |
| Jacobson, K | 1 |
| Knoflach, P | 1 |
| Pocard, M | 1 |
| Lavergne-Slove, A | 1 |
| Valleur, P | 2 |
| Losco, A | 1 |
| Gianelli, U | 1 |
| Cassani, B | 1 |
| Baldini, L | 1 |
| Conte, D | 1 |
| Basilisco, G | 1 |
| Seddik, M | 2 |
| Meliez, H | 1 |
| Seguy, D | 2 |
| Viget, N | 2 |
| Weersma, RK | 3 |
| Peters, FT | 2 |
| van den Berg, AP | 1 |
| van Haastert, M | 1 |
| Posthumus, MD | 1 |
| Homan van der Heide, JJ | 1 |
| Jansen, PL | 1 |
| van Dullemen, HM | 3 |
| Akbulut, S | 1 |
| Yavuz, B | 1 |
| Köseoğlu, T | 1 |
| Gököz, A | 1 |
| Saritaş, U | 1 |
| Hlavaty, T | 1 |
| Scala, L | 1 |
| Casalots, A | 1 |
| Esteve-Comas, M | 1 |
| Reyes, J | 1 |
| Moitinho, E | 1 |
| Ginard, D | 1 |
| Obrador, A | 1 |
| Mardini, HE | 2 |
| Afchain, P | 1 |
| Tiret, E | 1 |
| Kennedy, ED | 2 |
| Urbach, DR | 1 |
| Krahn, MD | 1 |
| Cohen, Z | 1 |
| Etienney, I | 1 |
| Matuchansky, C | 3 |
| Modigliani, R | 12 |
| Rambaud, JC | 6 |
| Homann, N | 1 |
| Klarmann, U | 1 |
| Brüning, A | 1 |
| Klingenberg-Noftz, R | 1 |
| Witthöft, T | 1 |
| Ludwig, D | 2 |
| Jacobstein, DA | 2 |
| Vogt, W | 1 |
| Hamdan, R | 1 |
| Libersa, C | 2 |
| Faucheron, JL | 1 |
| Hardy, G | 1 |
| Chartier, A | 1 |
| Helluwaert, F | 1 |
| Papo, M | 1 |
| López-San Román, A | 1 |
| Bajaj, JS | 1 |
| Saeian, K | 1 |
| Varma, RR | 1 |
| Franco, J | 1 |
| Knox, JF | 1 |
| Podoll, J | 1 |
| Emmons, J | 1 |
| Levy, M | 1 |
| Binion, DG | 2 |
| Melliez, H | 1 |
| Belloni Fortina, A | 1 |
| Piaserico, S | 1 |
| Zattra, E | 1 |
| Alaibac, M | 1 |
| Thisted, RA | 1 |
| Roberts-Thomson, IC | 1 |
| Butler, WJ | 1 |
| Helpman, L | 1 |
| Pauzner, D | 1 |
| Lessing, JB | 1 |
| Kupferminc, MJ | 1 |
| Gutman, G | 1 |
| Mascheretti, S | 1 |
| Barthel, HR | 1 |
| Gille, T | 1 |
| Halbsguth, A | 1 |
| Kramer, M | 1 |
| Alexander, S | 1 |
| Dowling, D | 1 |
| Juffermans, NP | 1 |
| Jager, A | 1 |
| Kersten, MJ | 1 |
| van Oers, MH | 1 |
| Sauk, J | 1 |
| Kane, S | 1 |
| Reyes, E | 1 |
| Ofman, J | 1 |
| Chiou, CF | 1 |
| Wade, S | 1 |
| von Ahsen, N | 2 |
| Armstrong, VW | 2 |
| von Tirpitz, C | 2 |
| Bias, P | 2 |
| Adler, G | 3 |
| Shipkova, M | 2 |
| Oellerich, M | 2 |
| Schütz, E | 2 |
| Kiesslich, R | 1 |
| Teichgräber, U | 1 |
| Chaudhary, R | 1 |
| Carpani, M | 1 |
| Playford, RJ | 1 |
| Glas, J | 2 |
| Török, HP | 2 |
| Daczo, J | 1 |
| Tonenchi, L | 1 |
| Folwaczny, M | 1 |
| Folwaczny, C | 2 |
| Green, CJ | 1 |
| Mee, AS | 1 |
| Mamula, P | 1 |
| Markowitz, JE | 1 |
| Leonard, M | 1 |
| Bonova, O | 1 |
| Frühauf, P | 1 |
| Havlickova, A | 1 |
| Janatova, T | 1 |
| Jimramovsky, F | 1 |
| Klimova, L | 1 |
| Klusacek, D | 1 |
| Kocourkova, D | 1 |
| Kolek, A | 1 |
| Kotalova, R | 1 |
| Marx, D | 1 |
| Petro, R | 1 |
| Petru, O | 1 |
| Plasilova, I | 1 |
| Seidl, Z | 1 |
| Sekyrova, I | 1 |
| Semendak, N | 1 |
| Schreierova, I | 1 |
| Stanek, J | 1 |
| Sykora, J | 1 |
| Sulakova, A | 1 |
| Toukalkova, L | 1 |
| Travnickova, R | 1 |
| Volf, V | 1 |
| Zahradnicek, L | 1 |
| Zenisková, I | 1 |
| D'Halluin, PN | 1 |
| Tribut, O | 2 |
| Branger, B | 1 |
| Lebreton, C | 1 |
| Bretagne, JF | 3 |
| Bentue-Ferrer, D | 2 |
| Heresbach, D | 1 |
| Barta, Z | 1 |
| Tóth, L | 1 |
| Zeher, M | 1 |
| Kronberger, IE | 1 |
| Graziadei, IW | 1 |
| Vogel, W | 1 |
| Lindqvist, M | 1 |
| Peterson, C | 1 |
| Söderkvist, P | 1 |
| Pousette, A | 1 |
| Baumgart, DC | 1 |
| Pintoffl, JP | 1 |
| Wiedenmann, B | 1 |
| Dignass, AU | 1 |
| Zech, CJ | 1 |
| Diebold, J | 1 |
| Schoenberg, SO | 1 |
| Tillack, C | 1 |
| González Carro, P | 1 |
| Pérez Roldán, F | 1 |
| Roncero García Escribano, O | 1 |
| Lafuente, R | 1 |
| Legaz Huidobro, ML | 1 |
| Amigo Echenagusía, A | 1 |
| Bourreille, A | 1 |
| Sobahni, I | 1 |
| Chen, SC | 1 |
| Cummings, OW | 1 |
| Hartley, MP | 1 |
| Filomena, CA | 1 |
| Cho, WK | 1 |
| Soto-Fernández, S | 1 |
| González-Carro, P | 1 |
| De Pedro-Esteban, A | 1 |
| Legaz-Huidobro, ML | 1 |
| Pérez-Roldán, F | 1 |
| Roncero García-Escribano, O | 1 |
| Valbuena-González, M | 1 |
| Ruiz-Carrillo, F | 1 |
| Jarbandhan, SV | 1 |
| van Elburg, RM | 1 |
| Vlietinck, R | 1 |
| Akman, SA | 1 |
| Arikan, C | 1 |
| Sözen, G | 1 |
| Oztürk, C | 1 |
| Yağci, RV | 1 |
| Wittig, BM | 1 |
| Moser, C | 1 |
| Löwenberg, M | 1 |
| Peppelenbosch, M | 1 |
| Karhadkar, AS | 1 |
| Schwartz, HJ | 1 |
| Arora, M | 1 |
| Dutta, SK | 1 |
| Lochs, H | 1 |
| Jaspers, GJ | 1 |
| Verkade, HJ | 1 |
| Taminiau, JA | 2 |
| Rings, EH | 1 |
| Banerjee, S | 1 |
| Bishop, WP | 1 |
| Svärm, S | 1 |
| Andersson, P | 1 |
| Bodemar, G | 1 |
| van den Brande, JM | 1 |
| Peppelenbosch, MP | 1 |
| Uhlen, S | 1 |
| Belbouab, R | 1 |
| Narebski, K | 1 |
| Cézard, JP | 3 |
| Turck, D | 1 |
| Kalantzis, C | 1 |
| Kalantzis, N | 1 |
| Halkerston, KM | 1 |
| Farrant, T | 1 |
| Linehan, JD | 1 |
| Oliva-Hemker, MM | 1 |
| Abadom, V | 1 |
| Urcelay, E | 1 |
| Lana, R | 1 |
| Martín, MC | 1 |
| López, N | 1 |
| Mayol, JA | 1 |
| de la Concha, EG | 1 |
| Peña, AS | 1 |
| Díaz-Rubio, M | 1 |
| De Souza, AF | 1 |
| Felga, GE | 1 |
| Forn, CG | 1 |
| Pimentel, CF | 1 |
| Müller, R | 1 |
| Storr, M | 1 |
| Wagner, A | 1 |
| Tosoni-Verlingue, D | 1 |
| Moizard, C | 1 |
| Bridoux-Henno, L | 1 |
| Kristinsson, JO | 1 |
| Hopman, WP | 1 |
| Oyen, WJ | 1 |
| Drenth, JP | 1 |
| Fargher, EA | 1 |
| Tricker, K | 1 |
| Newman, W | 1 |
| Elliott, R | 2 |
| Roberts, SA | 1 |
| Shaffer, JL | 1 |
| Bruce, I | 1 |
| Payne, K | 1 |
| Samarasena, J | 1 |
| Itaba, S | 1 |
| Iwasa, T | 1 |
| Sadamoto, Y | 1 |
| Nasu, T | 1 |
| Misawa, T | 1 |
| Inoue, K | 1 |
| Shimokawa, H | 1 |
| Nakamura, K | 1 |
| Takayanagi, R | 1 |
| Rivero Fernández, M | 1 |
| Garrido Gómez, E | 1 |
| Rodríguez Gandía, MA | 1 |
| Ruiz Del Arbol Olmos, L | 1 |
| Milicua Salamero, JM | 1 |
| Asma, SD | 1 |
| Soumaya, Y | 1 |
| Kahena, J | 1 |
| Raouf, DM | 1 |
| Nejib, D | 1 |
| Csillag, C | 1 |
| Borup, R | 1 |
| Olsen, J | 1 |
| Nielsen, FC | 1 |
| Casellas, F | 1 |
| Rodrigo, L | 1 |
| Niño, P | 1 |
| Pantiga, C | 1 |
| Riestra, S | 1 |
| Malagelada, JR | 1 |
| Heuschkel, RB | 1 |
| Colbert, C | 1 |
| Chavarria, A | 1 |
| Berkelhammer, C | 1 |
| Attila, T | 1 |
| Otterson, MF | 1 |
| Lipchik, RJ | 1 |
| Massey, BT | 1 |
| Komorowski, RA | 1 |
| Yenson, PR | 1 |
| Forrest, D | 1 |
| Dalal, BI | 1 |
| Elsing, C | 1 |
| Placke, J | 1 |
| Herrmann, T | 1 |
| Caprilli, R | 1 |
| Navarro, FA | 1 |
| Kirschner, BS | 2 |
| Palaniappan, S | 1 |
| Everett, SM | 1 |
| Chalmers, DM | 1 |
| Axon, AT | 1 |
| Hamlin, PJ | 1 |
| To, T | 1 |
| Detsky, A | 1 |
| Llewellyn-Thomas, HA | 1 |
| Din, S | 2 |
| Cochrane, CJ | 1 |
| Flasar, MH | 1 |
| Johnson, T | 1 |
| Roghmann, MC | 1 |
| Cross, RK | 1 |
| Bastida Paz, G | 1 |
| Nos Mateu, P | 1 |
| Aguas Peris, M | 1 |
| Beltrán Niclós, B | 1 |
| Rodríguez Soler, M | 1 |
| Ponce García, J | 1 |
| Maan, AK | 1 |
| Hansoti, B | 1 |
| Rodríguez-Moranta, F | 1 |
| Soriano-Izquierdo, A | 1 |
| Mahgoub, LE | 1 |
| Chetcuti, PA | 1 |
| Abdelli, MN | 1 |
| Ben Abdallah, H | 1 |
| Houissa, F | 1 |
| Bouali, MR | 1 |
| Khediri, MF | 1 |
| Yip, JS | 1 |
| Woodward, M | 1 |
| Dahele, A | 1 |
| Fennel, J | 1 |
| Aitken, S | 1 |
| Bosques-Padilla, F | 1 |
| Tuynman, H | 1 |
| van Deventer, S | 2 |
| Stitt, L | 1 |
| Van De Mierop, FJ | 1 |
| Coche, JR | 1 |
| van der Woude, J | 1 |
| Van Hootegem, PP | 1 |
| Lambrecht, GL | 1 |
| Mana, F | 1 |
| Punati, J | 1 |
| Lerer, T | 1 |
| Hyams, J | 1 |
| Moyer, MS | 1 |
| Wyllie, R | 1 |
| Mezoff, A | 1 |
| Keljo, D | 1 |
| Hommel, KA | 1 |
| Davis, CM | 1 |
| Sinkovic, A | 1 |
| Koren, M | 1 |
| Skok, P | 1 |
| Potrc, S | 1 |
| Swaminath, A | 1 |
| Haller, CA | 1 |
| Epstein, D | 1 |
| Hlatshwayo, S | 1 |
| George, D | 1 |
| Locketz, M | 1 |
| Omar, H | 1 |
| Spiller, R | 1 |
| Zhou, CL | 1 |
| Seng, BW | 1 |
| Reddy, D | 1 |
| Murphy, SJ | 1 |
| Kornbluth, AA | 1 |
| Ehmsen, L | 1 |
| Marko, C | 1 |
| Breidert, M | 1 |
| Magdelaine-Beuzelin, C | 1 |
| Ternant, D | 1 |
| Watier, H | 1 |
| Paintaud, G | 1 |
| Batstra, MR | 1 |
| Kleibeuker, JH | 1 |
| Virgilio, T | 1 |
| D'Incà, R | 1 |
| Spina, L | 1 |
| Bortoli, A | 1 |
| Paccagnella, M | 1 |
| Peli, M | 1 |
| Sablich, R | 1 |
| Benedetti, G | 1 |
| Girelli, CM | 1 |
| Casella, G | 1 |
| Grasso, G | 1 |
| de Franchis, R | 1 |
| Vecchi, M | 1 |
| Schwab, C | 1 |
| Meyer, D | 1 |
| Hetzer, FH | 1 |
| Borovicka, J | 1 |
| Schmid, HP | 1 |
| Engeler, DS | 1 |
| MacLean, LD | 1 |
| Sleisenger, MH | 1 |
| Goldstein, F | 7 |
| Singleton, JW | 7 |
| Bläker, F | 1 |
| Harms, HK | 1 |
| Bertele, RM | 1 |
| Willoughby, JM | 5 |
| Bartnik, W | 1 |
| Shorter, RG | 2 |
| Morettini, A | 1 |
| Scartabelli, S | 1 |
| Bechi, P | 1 |
| Bartolozzi, C | 1 |
| Taddei, GL | 1 |
| Bartoletti, L | 1 |
| D'Albasio, G | 1 |
| Allamani, A | 1 |
| Ewe, K | 4 |
| Karbach, U | 1 |
| Wuchter, J | 1 |
| Vuoristo, M | 1 |
| Leuschner, U | 1 |
| Strohm, WD | 1 |
| Classen, M | 1 |
| MacKechnie, HL | 1 |
| Menduke, H | 1 |
| Thornton, JJ | 2 |
| Abramson, J | 2 |
| Bender, SW | 2 |
| Posselt, HG | 2 |
| Waag, KL | 1 |
| McCarthy, CF | 1 |
| Stave, R | 1 |
| Farthing, MJ | 3 |
| Dawson, AM | 4 |
| Kirsner, JB | 2 |
| Deutsch, S | 1 |
| Akovbiantz, A | 1 |
| Fahrländer, H | 4 |
| Fruhmorgen, P | 1 |
| Kasper, H | 4 |
| Malchow, H | 4 |
| Schreiber, HW | 1 |
| Lee, FL | 1 |
| Murray, SM | 1 |
| Prior, J | 1 |
| Shreeve, DR | 1 |
| Ten Berge, RJ | 1 |
| Schellekens, PT | 1 |
| Krowka, MJ | 1 |
| Breuer, RI | 1 |
| Kehoe, TJ | 1 |
| Arthurs, Y | 1 |
| Fielding, JF | 1 |
| Lennard-Jones, JE | 7 |
| Ahmed, AR | 1 |
| Moy, R | 1 |
| Pattison, CP | 1 |
| Moeller, DD | 1 |
| Ginsberg, AL | 1 |
| Coxon, AY | 1 |
| Sheaff, PC | 1 |
| Malleson, P | 1 |
| Van O, EC | 1 |
| Zins, BJ | 1 |
| Tremaine, WJ | 5 |
| Mays, DC | 2 |
| Lipsky, JJ | 2 |
| Gross, V | 1 |
| Andus, T | 1 |
| Burrows, NP | 1 |
| Stephens, J | 1 |
| Goldstein, R | 1 |
| Crippin, J | 1 |
| Husberg, B | 1 |
| Holman, M | 1 |
| Gonwa, TA | 1 |
| Klintmalm, G | 1 |
| Kirkin, BV | 1 |
| Mikhaĭlova, TL | 1 |
| Maiat, KE | 1 |
| Dalekos, GN | 1 |
| Tzermias, C | 1 |
| Merkouropoulos, M | 1 |
| Hatzis, J | 1 |
| Pearson, DC | 2 |
| May, GR | 2 |
| Fick, GH | 1 |
| Posthuma, EF | 1 |
| Westendorp, RG | 1 |
| van der Sluys Veer, A | 1 |
| Kluin-Nelemans, JC | 1 |
| Kluin, PM | 1 |
| Lamers, CB | 1 |
| Stark, ME | 1 |
| Balkwill, AM | 1 |
| Ritchie, JK | 3 |
| van Hogezand, RA | 1 |
| George, J | 1 |
| Sachar, DB | 5 |
| Larvol, L | 1 |
| Le Tourneau, A | 1 |
| Derkx, B | 1 |
| Taminiau, J | 1 |
| Radema, S | 1 |
| Stronkhorst, A | 1 |
| Wortel, C | 1 |
| Tytgat, G | 1 |
| Wilson, BE | 1 |
| Parsonnet, J | 1 |
| Grancher, K | 2 |
| Rosa, J | 1 |
| Aiges, H | 1 |
| Daum, F | 3 |
| Press, AG | 1 |
| Singe, CC | 1 |
| Stufler, M | 1 |
| Ueberschaer, B | 1 |
| Hommel, G | 1 |
| Meyer zum Büschenfelde, KH | 3 |
| Berrebi, W | 1 |
| Chaussade, S | 1 |
| Bruhl, AL | 1 |
| Pariente, A | 1 |
| Hautefeuille, P | 1 |
| Couturier, D | 1 |
| Mandel, F | 1 |
| Hoffmann, R | 2 |
| Candy, S | 1 |
| Wright, J | 1 |
| Gerber, M | 1 |
| Adams, G | 1 |
| Gerig, M | 1 |
| Goodman, R | 1 |
| Scemama, G | 1 |
| Taï, R | 1 |
| McKee, RF | 1 |
| Keenan, RA | 1 |
| Greenfield, S | 1 |
| Robinson, M | 1 |
| Ramakrishna, J | 1 |
| Langhans, N | 1 |
| Calenda, K | 1 |
| Grand, RJ | 2 |
| Verhave, M | 2 |
| Veldman, W | 1 |
| van Beek, M | 1 |
| Keuning, JJ | 1 |
| Driessen, WM | 1 |
| Rosselli, M | 1 |
| Casà, A | 1 |
| Klein, R | 1 |
| Jakob, F | 1 |
| Stotland, BR | 1 |
| Rosati, P | 1 |
| Lucidi, V | 1 |
| Scotta, MS | 1 |
| Hadorn, HB | 1 |
| Shanahan, F | 1 |
| Bourgaux, JF | 1 |
| Bondu, F | 1 |
| Raffanel, C | 1 |
| Balmes, JL | 1 |
| Borda, F | 1 |
| Jiménez, FJ | 1 |
| Martín-Granizo, I | 1 |
| Aznarez, R | 1 |
| Abboud, P | 1 |
| Messing, B | 3 |
| Quéreux, C | 1 |
| Napoléone, C | 1 |
| Zeitoun, P | 1 |
| Wahl, P | 1 |
| Aissaoui, M | 1 |
| Mounedji, N | 1 |
| Mathelier-Fusade, P | 1 |
| Leynadier, F | 1 |
| Druschky, A | 1 |
| Heckmann, J | 1 |
| Engelhardt, A | 1 |
| Kullmann, F | 1 |
| Kullmann, M | 1 |
| Leser, HG | 1 |
| Krämer, BK | 1 |
| Riegger, AJ | 1 |
| Siproudhis, L | 2 |
| Mortaji, A | 1 |
| Juguet, F | 1 |
| Gosselin, M | 2 |
| Koop, I | 1 |
| Lavaud, F | 1 |
| Abdelli, N | 1 |
| Thiefin, G | 1 |
| Geboes, K | 3 |
| Ponette, E | 1 |
| Penninckx, F | 1 |
| Hinterleitner, TA | 2 |
| Aichbichler, B | 1 |
| Fickert, P | 2 |
| Ranner, G | 1 |
| Krejs, GJ | 1 |
| Mouzas, IA | 1 |
| Greenstein, AJ | 1 |
| Giannadaki, E | 1 |
| Balasubramanian, S | 1 |
| Manousos, ON | 1 |
| Pohl, C | 1 |
| Egan, LJ | 1 |
| Florén, CH | 1 |
| Ahrén, B | 1 |
| Bengtsson, M | 1 |
| Bartosik, J | 1 |
| Obrant, K | 1 |
| Taylor, AC | 1 |
| d'Apice, AJ | 1 |
| van Deventer, SJ | 1 |
| Tytgat, GN | 1 |
| Sanjuán Portugal, F | 1 |
| Cabrera Chaves, T | 1 |
| Yus Gotor, C | 1 |
| Gomollón García, F | 1 |
| Breslin, NP | 1 |
| Thuillier, F | 1 |
| Bengoufa, D | 1 |
| Rabian, C | 1 |
| Ngo, Y | 1 |
| Gasché, C | 1 |
| Moser, G | 2 |
| Tillinger, W | 1 |
| Gangl, A | 2 |
| Romagnuolo, J | 1 |
| Sadowski, DC | 1 |
| Lalor, E | 1 |
| Jewell, L | 1 |
| Thomson, AB | 1 |
| Besnard, M | 1 |
| Jaby, O | 1 |
| Mougenot, JF | 2 |
| Ferkdadji, L | 1 |
| Debrun, A | 1 |
| Delagausie, P | 1 |
| Peuchmaur, M | 1 |
| Aigrain, Y | 1 |
| Navarro, J | 2 |
| Casella, P | 1 |
| Alves, F | 1 |
| Cabral, J | 1 |
| Aichbichler, BW | 1 |
| Vandeputte, L | 1 |
| Lehrnbecher, T | 1 |
| Kontny, HU | 1 |
| Jeschke, R | 1 |
| Wanitschke, R | 1 |
| Peters, M | 1 |
| Schlaak, JF | 1 |
| Lowry, PW | 2 |
| Velicia, MR | 1 |
| Fernández, P | 1 |
| Remacha, B | 1 |
| Martín, MA | 1 |
| Sánchez, G | 1 |
| Goyeneche, ML | 1 |
| Caro-Paton, A | 1 |
| Casson, DH | 1 |
| Davies, SE | 1 |
| Thomson, MA | 1 |
| Lewis, A | 1 |
| Walker-Smith, JA | 1 |
| Murch, SH | 1 |
| Touze, I | 1 |
| Grandbastien, B | 1 |
| Paris, JC | 2 |
| Quandalle, P | 1 |
| Bellaiche, G | 1 |
| Nouts, A | 1 |
| Ley, G | 1 |
| Slama, JL | 1 |
| Glasbrenner, B | 1 |
| Güthner, C | 1 |
| Röcken, C | 1 |
| Mattfeld, T | 1 |
| Hetzel, W | 1 |
| Rondeau, M | 1 |
| Escalin, G | 1 |
| Nodot, I | 1 |
| Storck, D | 1 |
| Weber, JC | 1 |
| Tennenbaum, R | 1 |
| Elefant, E | 1 |
| Wolf, DC | 1 |
| Targan, SR | 3 |
| Sninsky, CA | 1 |
| Pike, MG | 1 |
| Gordon, S | 1 |
| Kleoudis, CS | 1 |
| Murdock, RH | 1 |
| Cissoko, H | 1 |
| Jonville-Béra, AP | 1 |
| Lenain, H | 1 |
| Rivière, MF | 1 |
| Saugier, J | 1 |
| Casanova, JL | 1 |
| Autret-Leca, E | 1 |
| Kim, PS | 1 |
| Zlatanic, J | 1 |
| Gleim, GW | 1 |
| Weaver, AL | 1 |
| Kougo, Y | 1 |
| Desreumaux, P | 1 |
| Jouret, A | 1 |
| Ectors, N | 1 |
| Patriquin, H | 1 |
| Thomsen, MK | 1 |
| Gerner, CU | 1 |
| Hassard, PV | 2 |
| Vasiliauskas, EA | 2 |
| Kam, LY | 2 |
| Hiwatashi, N | 1 |
| Garrido Serrano, A | 1 |
| Pérez Martín, F | 1 |
| Guerrero Igea, FJ | 1 |
| Galbarro Muñoz, J | 1 |
| Palomo Gil, S | 1 |
| Jeshion, WC | 1 |
| Larsen, KL | 1 |
| Jawad, AF | 1 |
| Piccoli, DA | 1 |
| Verma, R | 1 |
| Maller, ES | 2 |
| Fick, G | 1 |
| Sandborn, W | 1 |
| Sutherland, L | 1 |
| Pearson, D | 1 |
| May, G | 1 |
| Schwartz, JS | 1 |
| Ferrari, N | 1 |
| Debuysere, H | 1 |
| Touze, Y | 1 |
| Catala, P | 1 |
| Kader, HA | 1 |
| Wenner, WJ | 1 |
| Telega, GW | 1 |
| Wendum, D | 1 |
| Chazouilleres, O | 1 |
| Hunt, S | 1 |
| Glintborg, B | 1 |
| Del Vecchio Blanco, G | 2 |
| Mazzacca, G | 2 |
| Constantinescu, CS | 1 |
| Whiteley, A | 1 |
| Blumhardt, LD | 1 |
| Faubion, WA | 1 |
| Corominas, H | 1 |
| Domènech, M | 1 |
| González-Juan, D | 1 |
| González-Suárez, B | 1 |
| Díaz, C | 1 |
| Pujol, J | 1 |
| Vázquez, G | 1 |
| Baiget, M | 1 |
| Werlin, SL | 1 |
| Parker-Hartigan, L | 1 |
| Freeman, KB | 1 |
| Balint, JP | 1 |
| Zurakowski, D | 1 |
| Ferry, GD | 1 |
| Leichtner, AM | 1 |
| Boulton-Jones, JR | 1 |
| Pritchard, K | 1 |
| Mahmoud, AA | 1 |
| Cozzolino, A | 1 |
| Di Girolamo, E | 1 |
| Cappuccio, D | 1 |
| Tsang, JF | 1 |
| Farrell, RJ | 1 |
| Lodhavia, PJ | 1 |
| Alsahli, M | 1 |
| Falchuk, KR | 1 |
| Peppercorn, MA | 2 |
| Carter, MJ | 1 |
| Van Gossum, A | 1 |
| Desager, JP | 2 |
| Horsmans, Y | 2 |
| Vergara, M | 1 |
| Brullet, E | 1 |
| Campo, R | 1 |
| Blanch, L | 1 |
| Molés, JR | 1 |
| Pastor, M | 1 |
| Berenguer, J | 1 |
| Marbet, U | 1 |
| Schmid, I | 1 |
| López-Cepero Andrada, JM | 1 |
| Ferré Alamo, A | 1 |
| López Silva, M | 1 |
| Salado Fuentes, M | 1 |
| Benítez Roldán, A | 1 |
| Martínez Tirado, P | 1 |
| Redondo Cerezo, E | 1 |
| Gónzalez Aranda, Y | 1 |
| J Cabello Tapia, M | 1 |
| Nogueras López, F | 1 |
| Lankarani, KB | 1 |
| van Wijngaarden, P | 1 |
| Meijssen, MA | 1 |
| Corbett, M | 1 |
| Schlup, M | 1 |
| Cuillerier, E | 1 |
| Aithal, GP | 1 |
| Hoffman, BJ | 1 |
| Vanheuverzwyn, R | 1 |
| Jewell, DP | 1 |
| Hafraoui, S | 1 |
| Le Large-Guiheneuf, C | 1 |
| Munck, A | 1 |
| Kull, E | 1 |
| Beau, P | 1 |
| Dunning, AJ | 1 |
| Belohlavek, D | 1 |
| Koch, H | 1 |
| Morl, M | 2 |
| Gardner, RC | 1 |
| Cavell, B | 1 |
| Hildebrand, H | 1 |
| Meeuwisse, GW | 1 |
| Lindquist, B | 1 |
| Fuchigami, T | 1 |
| Yao, T | 1 |
| Allan, R | 1 |
| Steinberg, DM | 1 |
| Williams, JA | 2 |
| Cooke, WT | 2 |
| Dubois, RS | 1 |
| Rothschild, J | 1 |
| Silverman, A | 1 |
| Sabra, A | 1 |
| Hoexter, B | 1 |
| Labow, S | 1 |
| Powell-Tuck, J | 2 |
| Müller-Schoop, J | 1 |
| Winship, DH | 1 |
| Summers, RW | 2 |
| Best, WR | 2 |
| Becktel, JM | 2 |
| Lenk, LF | 1 |
| Kern, F | 2 |
| Switz, DM | 1 |
| Sessions, JT | 2 |
| Law, DH | 2 |
| Kelley, ML | 1 |
| Mekhjian, HS | 1 |
| Sturdevant, RA | 2 |
| Deren, JL | 1 |
| McCleery, JL | 1 |
| Beeken, WL | 1 |
| Bozymski, EM | 1 |
| Goldberg, HI | 1 |
| Caruthers, SB | 1 |
| Nelson, JA | 1 |
| Hansen, R | 1 |
| Brooke, BN | 3 |
| Cave, DR | 1 |
| King, DW | 1 |
| Dölle, W | 1 |
| Herfarth, C | 1 |
| O'Donoghue, DP | 1 |
| Bown, RL | 1 |
| Kitis, G | 1 |
| Hilmer, R | 1 |
| Goulston, K | 1 |
| Farmer, RG | 1 |
| Demling, L | 1 |
| Ament, ME | 1 |
| Rothmund, M | 1 |
| Hofmann, S | 1 |
| Baumann, W | 1 |
| Knolle, J | 1 |
| Gyte, GM | 2 |
| Clifton, JA | 1 |
| Westaby, S | 1 |
| Everett, WG | 1 |
| Dick, AP | 1 |
| Radbil', OS | 1 |
| Deltz, E | 1 |
| Hantschmann, N | 1 |
| Bonardi, R | 1 |
| Krieg, H | 2 |
| Brünner, H | 1 |
| Eckhardt, R | 2 |
| Paloyan, D | 1 |
| Levin, B | 2 |
| Simonowitz, D | 1 |
| Zanghì, M | 1 |
| McCallum, DI | 1 |
| Gray, WM | 1 |
| Wallis, SM | 1 |
| Walker-Smith, J | 1 |
| Auer, I | 1 |
| Taub, RN | 1 |
| Ramachandar, K | 1 |
| Meyers, S | 1 |
| Forman, SP | 1 |
| Douglas, SD | 1 |
| Janowitz, HD | 2 |
| Rosenberg, JL | 1 |
| Wall, AJ | 1 |
| Shephard, DA | 1 |
| Shalev, E | 2 |
| Stojan, B | 1 |
| Fischbach, W | 1 |
| Delwaide, J | 2 |
| Gast, P | 2 |
| Zelig, MP | 1 |
| Choi, PM | 1 |
| Mesnard, B | 1 |
| Chiche, A | 1 |
| Masamune, O | 1 |
| Shah, MD | 1 |
| Berman, WF | 1 |
| McCarthy, DA | 1 |
| Rampton, DS | 1 |
| Liu, YC | 1 |
| Kopeĭkin, VN | 1 |
| Bogdanovich, NE | 1 |
| Lukoianova, GM | 1 |
| Kopylov, MV | 1 |
| Sheliakhina, NE | 1 |
| Li, V | 1 |
| Steinberg, H | 1 |
| Raoul, JL | 1 |
| Cado, JP | 1 |
| O'Brien, CJ | 1 |
| Giaffer, MH | 1 |
| Cann, PA | 1 |
| Holdsworth, CD | 1 |
| Puy-Montbrun, T | 1 |
| Pigot, F | 1 |
| Vuong, PN | 1 |
| Ganansia, R | 1 |
| Denis, J | 1 |
| O'Brien, JJ | 1 |
| Bayless, JA | 1 |
| Yamazaki, Y | 1 |
| Fukushima, T | 1 |
| Sugita, A | 1 |
| Takemura, H | 1 |
| Tsuchiya, S | 1 |
| Purrmann, J | 1 |
| Hengels, KJ | 1 |
| Cleveland, S | 1 |
| Gemsa, R | 1 |
| Koldehoff, M | 1 |
| Strohmeyer, G | 1 |
| Lloyd-Still, JD | 1 |
| Winter, HS | 1 |
| Bonhomme, P | 1 |
| Bitoun, A | 1 |
| Riemann, JF | 1 |
| Goddard, CJ | 1 |
| August, PJ | 1 |
| Nagy, G | 2 |
| Prónay, G | 2 |
| Ujszászy, L | 2 |
| Dannecker, G | 1 |
| Niessen, KH | 1 |
| Ranke, MB | 1 |
| Greenberger, N | 1 |
| Donaldson, RM | 1 |
| Miller, JP | 1 |
| Kirchmann, H | 1 |
| Gerok, W | 1 |
| Steinhoff, J | 1 |
| Schulz, E | 1 |
| Herbst, EW | 1 |
| Fricke, L | 1 |
| Sack, K | 1 |
| Cox, J | 1 |
| Daneshmend, TK | 1 |
| Hawkey, CJ | 1 |
| Logan, RF | 1 |
| Walt, RP | 1 |
| Nyman, M | 1 |
| Hansson, I | 1 |
| Eriksson, S | 1 |
| Kinlen, LJ | 1 |
| Rhodes, J | 3 |
| Bainton, D | 2 |
| Beck, P | 2 |
| Javett, SL | 3 |
| Davison, OW | 1 |
| Kane, SP | 1 |
| Nye, FJ | 1 |
| Beckett, J | 2 |
| Kumar, PJ | 1 |
| Jones, RA | 2 |
| Gray, GM | 1 |
| Phlippen, R | 1 |
| Tumen, HJ | 1 |
| Fehr, HF | 1 |
| Delespesse, G | 1 |
| Kennes, B | 1 |
| Duchateau, J | 1 |
| Miller, B | 1 |
| Martini, GA | 1 |
| Hoffmann, DC | 1 |
| Swarbrick, ET | 1 |
| Brown, P | 1 |
| Mallinson, CN | 1 |
| Candy, JC | 1 |
| Cowan, R | 1 |
| Prior, A | 1 |
| Zimmermann, HD | 1 |
| Nägele, E | 1 |
| Moeschlin, S | 1 |
| Clarke, JR | 1 |
| Richens, ER | 2 |
| Williams, MJ | 2 |
| Gough, KR | 2 |
| Ancill, RJ | 1 |
| Campbell, AC | 1 |
| Skinner, JM | 1 |
| Hersey, P | 1 |
| Roberts-Thomson, P | 1 |
| MacLennan, IC | 1 |
| Truelove, SC | 1 |
| Cassano, C | 1 |
| Torsoli, A | 1 |
| Perlmann, P | 1 |
| Skinner, MD | 1 |
| Schwartz, RS | 2 |
| Fausa, O | 3 |
| Jensen, KB | 1 |
| Papp, JP | 1 |
| Watson, DW | 1 |
| Bull, FE | 2 |
| Klein, M | 1 |
| Binder, HJ | 1 |
| Mitchell, M | 1 |
| Aaronson, R | 1 |
| Spiro, H | 1 |
| Goligher, JC | 1 |
| de Dombal, FT | 1 |
| Burton, I | 1 |
| Vachon, MA | 1 |
| Barthe, TJ | 1 |
| Kressmann, P | 1 |
| Piante, M | 1 |
| Hoffmann, VJ | 1 |
| Brys, R | 1 |
| Ringoir, S | 1 |
| Elewaut, A | 1 |
| Barbier, F | 1 |
| Meuwissen, SG | 1 |
| Roseau, E | 1 |
| Lockhart-Mummery, HE | 1 |
| Thiele, KG | 1 |
| Kawanishi, H | 1 |
| Rudolph, E | 1 |
| Kavin, H | 1 |
| Bremner, CG | 1 |
| Schneider, J | 1 |
| Levine, E | 1 |
| Hinder, RA | 1 |
| Reitzig, P | 1 |
| Apostoloff, E | 1 |
| Lisewski, G | 1 |
| Spranger, GD | 1 |
| Winkelstein, A | 1 |
| Segel, D | 1 |
| Stolzer, BL | 1 |
| Fogel, M | 1 |
| Shadduck, RK | 1 |
| Lewis, M | 1 |
| Chevrel, B | 1 |
| Davis, R | 1 |
| Schmaman, A | 1 |
| Cosman, B | 1 |
| Bouchier, IA | 1 |
| Chantar Barrios, C | 1 |
| Yamagata, S | 1 |
| Watanabe, H | 1 |
| Nogueira, JR | 1 |
| Freedman, MA | 1 |
| Hamer, DB | 1 |
| Northfield, TC | 1 |
| Roberts, CI | 1 |
| Wisch, N | 1 |
| Kettner, W | 1 |
| Wallensten, S | 3 |
| Persson, S | 3 |
| Wang, TK | 1 |
| Tolnai, G | 1 |
| Campbell, JS | 1 |
| Sirois, J | 1 |
| Liepa, E | 1 |
| Karayannopoulos, S | 1 |
| Chazan, BI | 1 |
| Hancock, DM | 1 |
| Kempsey, EP | 1 |
| Gjone, E | 1 |
| Grewe, HE | 1 |
| Lampe, K | 1 |
| Berndt, V | 1 |
| Olbermann, M | 1 |
| Bolte, JP | 1 |
| Lambermont, J | 1 |
| Drucker, WR | 1 |
| Jeejeebhoy, KN | 1 |
| Brown, CH | 1 |
| Achkar, E | 1 |
| Patterson, JF | 1 |
| Norton, RA | 1 |
| Harries, JT | 1 |
| Lloyd, JK | 1 |
| Kobayashi, T | 1 |
| Uda, A | 1 |
| Udagawa, E | 1 |
| Khan, SS | 1 |
| Patil, SS | 1 |
| Naimark, D | 1 |
| Sander, B | 1 |
| Bohn Thomsen, S | 1 |
| Mertz Nielsen, A | 1 |
| Ong, DE | 1 |
| Hartono, JL | 1 |
| Lust, M | 1 |
| Elkin, H | 1 |
| Rinawi, F | 1 |
| Rosenbach, Y | 1 |
| Assa, A | 1 |
| Shamir, R | 1 |
| Yi, F | 1 |
| Zhou, F | 1 |
| Yan, W | 1 |
| Li, L | 1 |
| Xia, B | 1 |
| Byun, JM | 1 |
| Rhee, SY | 1 |
| Shim, JJ | 1 |
| Jang, JY | 1 |
| Bar-Yoseph, H | 1 |
| Billiet, T | 1 |
| Aslam, Z | 1 |
| De Sica, A | 1 |
| Gilshenan, K | 1 |
| Fairbanks, L | 1 |
| Marinaki, A | 1 |
| Sanderson, J | 1 |
| Pociello, N | 1 |
| Tozer, P | 1 |
| Siddiqui, MR | 1 |
| Burling, D | 1 |
| Gupta, A | 1 |
| Swatton, A | 1 |
| Tripoli, S | 1 |
| Vaizey, CJ | 1 |
| Phillips, R | 1 |
| Hart, A | 1 |
| Jang, BI | 1 |
| Choi, CH | 1 |
| Lee, H | 1 |
| Jung, BY | 1 |
| Chung, SK | 1 |
| Lee, TH | 1 |
| Chung, IK | 1 |
| Kim, SJ | 1 |
| Cho, HD | 1 |
| Lohse, P | 1 |
| Roggel, C | 1 |
| Hartmann, P | 1 |
| Gilman, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Thiopurine Dose Optimization by NUDT 15 R139C on Reducing Thiopurine-induced Leucopenia in Inflammatory Bowel Disease[NCT02929706] | 400 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | |||
| An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease[NCT01235689] | Phase 3 | 252 participants (Actual) | Interventional | 2011-02-11 | Completed | ||
| Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy[NCT02852694] | Phase 4 | 312 participants (Anticipated) | Interventional | 2017-02-28 | Recruiting | ||
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)[NCT03046056] | Phase 2 | 78 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease[NCT00904878] | 1,500 participants (Anticipated) | Observational | 2007-08-31 | Recruiting | |||
| Pregnancy in Greek Female Patients With Inflammatory Bowel Disease - Panhellenic Recording[NCT05562726] | 100 participants (Anticipated) | Observational [Patient Registry] | 2020-01-01 | Recruiting | |||
| Top-down Infliximab Study in Kids With Crohn's Disease[NCT02517684] | Phase 4 | 100 participants (Anticipated) | Interventional | 2015-04-30 | Active, not recruiting | ||
| Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease[NCT01564823] | Phase 3 | 86 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Prospective Longitudinal Study on the Effect of Tight Control Management on Perianal Crohn's Disease[NCT03861689] | 40 participants (Anticipated) | Interventional | 2019-07-01 | Enrolling by invitation | |||
| Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy[NCT00094458] | Phase 3 | 508 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.[NCT04731831] | 120 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease[NCT00546546] | Phase 4 | 120 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis[NCT02549976] | 54 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Early MRI Prediction of Response to Medical Therapy and Mucosal Healing in Small Bowel Crohn's Disease[NCT03340519] | 35 participants (Anticipated) | Observational | 2018-12-17 | Active, not recruiting | |||
| Impact of a Shared Decision Making Intervention in Paediatric Inflammatory Bowel Disease Therapeutic Decision-making[NCT05689892] | 150 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| A Multi-site Trial of Azathioprine Dosing in Crohn's Disease[NCT00113503] | Phase 2 | 50 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Insufficient enrollment) | ||
| The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives[NCT03291743] | 38 participants (Actual) | Interventional | 2017-02-10 | Terminated (stopped due to Death of Principal Investigator) | |||
| A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease[NCT00445432] | Phase 2/Phase 3 | 82 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation[NCT02994836] | Phase 4 | 139 participants (Actual) | Interventional | 2017-04-21 | Completed | ||
| Randomized Trial for Unstable Pediatric Crohn's Disease Patients Comparing the Use of Crohn's Disease Exclusion Diet (CDED) on Top of Standard Therapy Versus Standard Therapy Alone.[NCT04777656] | Phase 3 | 120 participants (Anticipated) | Interventional | 2022-09-26 | Recruiting | ||
| Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomography[NCT04650867] | 23 participants (Actual) | Observational | 2021-03-22 | Completed | |||
| Study of Compliance, Practice Patterns, and Barriers REgarding Established National Screening Programs for Barrett's Esophagus: SCREEN-BE[NCT04408105] | 725 participants (Actual) | Observational | 2020-02-19 | Active, not recruiting | |||
| "Post-Operative Crohn's Disease Endoscopic Recurrence POCER Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause"[NCT00989560] | Phase 3 | 175 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.[NCT02247258] | Phase 2 | 63 participants (Actual) | Interventional | 2005-10-31 | Terminated (stopped due to Slow recruitment) | ||
| Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.[NCT00521950] | 853 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| Post-Operative Crohn's Disease Outcome in Children (The POPCORN Trial): a Prospective Comparative Non-interventional Open Study[NCT03681652] | 100 participants (Anticipated) | Observational | 2019-02-11 | Recruiting | |||
| A Cluster Randomized Controlled Trial of a Treatment Algorithm for the Management of Crohn's Disease[NCT01030809] | Phase 4 | 1,999 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy[NCT00705614] | 2,662 participants (Actual) | Observational | 2003-07-31 | Completed | |||
| A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection[NCT01015391] | 100 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)[NCT04578392] | 181 participants (Anticipated) | Interventional | 2020-07-28 | Recruiting | |||
| A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease[NCT01540942] | 91 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Crohn's Disease. Endoscopic Treatment (Self-expanding Metal Prosthesis/Ballon Dilation) vc Surgical Resection (ENDOCIR STUDY)[NCT04330846] | 40 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | |||
| Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission: Functional MRI Study[NCT02874495] | 44 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease[NCT01442025] | Phase 4 | 121 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649] | 388 participants (Actual) | Observational | 2002-03-01 | Completed | |||
| A Cluster Randomized Controlled Trial of a Care-Path for the Management of Ulcerative Colitis[NCT01882426] | Phase 4 | 192 participants (Actual) | Interventional | 2014-05-31 | Terminated | ||
| Early Serum Infliximab Levels in Severe Ulcerative Colitis[NCT01971814] | Phase 1 | 11 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease[NCT02193802] | 42 participants (Anticipated) | Interventional | 2014-05-31 | Active, not recruiting | |||
| Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches[NCT03885713] | Phase 4 | 180 participants (Anticipated) | Interventional | 2019-09-10 | Recruiting | ||
| A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease[NCT02904590] | 1,204 participants (Actual) | Observational [Patient Registry] | 2016-10-31 | Completed | |||
| "Prospective and Multicenter Study About the Epidemiology and the Characteristics Omics in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain"[NCT03689257] | 376 participants (Actual) | Observational | 2017-10-01 | Completed | |||
| A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease[NCT01698307] | Phase 4 | 1,095 participants (Actual) | Interventional | 2014-03-28 | Completed | ||
| Efficacy of Infliximab Treatment Based on TDM (Therapeutic Drug Monitoring) in Adult Patients With Active Perianal Fistulizing Crohn's Disease[NCT06051253] | Phase 4 | 86 participants (Anticipated) | Interventional | 2023-10-02 | Not yet recruiting | ||
| Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study on the Efficacy and Safety of Azathioprine Versus Mesalazine for Prevention of Clinical Relapses in Crohn's Disease Patients With Postoperative Moderate or Severe Endoscopic Recurrence[NCT00946946] | Phase 3 | 78 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease[NCT02085083] | 150 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Exploratory, Open-label Study to Demonstrate Efficacy, Safety and Tolerability of SC12267 (35 mg) in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)[NCT00820365] | Phase 2 | 34 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Impact of Anti-TNF Antibodies on the T-lymphocyte and Macrophage Cooperation in the Crohn Disease[NCT00561548] | 20 participants (Anticipated) | Interventional | 2007-05-31 | Terminated | |||
| Multicenter Study Evaluating the Persistence, Efficacy and Tolerability of Methotrexate in Inflammatory Bowel Disease Patients[NCT05927064] | 1,000 participants (Anticipated) | Observational | 2023-07-21 | Recruiting | |||
| Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue[NCT01157650] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Early Surgery Versus Conservative Treatment in Patients With Ileocaecal Crohn's Disease - Prospective Randomized Study[NCT02716454] | 200 participants (Anticipated) | Interventional | 2016-05-31 | Not yet recruiting | |||
| Mesenteric Bacterial Translocation in Evolved Crohn's Disease[NCT05891756] | 40 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux[NCT00554710] | Phase 4 | 129 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (Stage I)[NCT04893928] | 351 participants (Anticipated) | Observational | 2021-05-03 | Recruiting | |||
| Counseling to Optimize Medication Adherence in Expectant Mothers With Inflammatory Bowel Disease (COACH-IBD)[NCT03091309] | 220 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | |||
| Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial[NCT00723047] | Phase 3 | 77 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Nutritional Status and Body Composition in Children With Inflammatory Bowel Disease: A Prospective Cohort Study[NCT02704026] | 72 participants (Actual) | Observational | 2015-07-31 | Completed | |||
| Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas[NCT01635543] | 0 participants (Actual) | Observational | 2011-10-31 | Withdrawn (stopped due to This study was terminated due to some challenges in recruitment process) | |||
| Chronotherapy in Inflammatory Bowel Disease[NCT04304950] | Phase 4 | 28 participants (Actual) | Interventional | 2016-04-25 | Completed | ||
| Screening of Nutritional Status and Sarcopenia Among Inflammatory Bowel Disease Patients in Assuit University Hospital[NCT05877209] | 100 participants (Anticipated) | Observational | 2023-06-15 | Not yet recruiting | |||
| Stopping Biological Therapy in Perianal Crohn's Disease Patients With Radiologically Healed Fistulas: a Prospective Cohort Study[NCT04129723] | 0 participants (Actual) | Interventional | 2022-01-01 | Withdrawn (stopped due to No suitable case identified) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. A negative change from Baseline indicates improvement. (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | -6.4 |
| Tight Control Management | -7.7 |
"The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, from 0 (not at all) to 4 (very much). The FACIT-Fatigue score ranges from 0 to 52, with higher scores denoting lower levels of fatigue.~A positive change from Baseline score indicates an improvement.~." (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | 7.6 |
| Tight Control Management | 13.0 |
The PHQ-9 is a 9-item questionnaire for assessing the severity of depression. Each question is answered on a scale from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, where higher scores indicate more severe depression. A negative change from Baseline score indicates improvement. (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | -3.6 |
| Tight Control Management | -5.6 |
The IBDQ measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease, feeling in general, and mood. Each question is answered on a scale from 1 (all of the time) to 7 ( none of the time); the total score ranges from 7 (worst) to 224 (best). A positive change from baseline indicates improvement. (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | 31.2 |
| Tight Control Management | 41.9 |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | hospitalizations (Number) |
|---|---|
| Clinically Driven Management | 37 |
| Tight Control Management | 25 |
Any hospitalization with an overnight stay in hospital/clinic related to Crohn's disease. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | hospitalizations (Number) |
|---|---|
| Clinically Driven Management | 29 |
| Tight Control Management | 14 |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | emergency hospitalizations (Number) |
|---|---|
| Clinically Driven Management | 11 |
| Tight Control Management | 4 |
The total number of CD-related surgical procedures included major CD-related surgery, debridement, perineal related surgery - abscess drainage, seton placement, fistulotomy, and TPN. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | surgical procedures (Number) |
|---|---|
| Clinically Driven Management | 9 |
| Tight Control Management | 7 |
"Major Crohn's disease-related intra-abdominal surgery included:~bowel resection~ostomy~by-pass~strictureplasty~drainage of abdominal or pelvic abscess (surgical drainage or percutaneous drainage by interventional radiology).~The following were excluded:~debridement~exploration laparotomy~abdominal surgery for other reason~perineal related surgery~abscess drainage~placement of setons~fistulotomy~Total parental nutrition (TPN) use" (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | surgeries (Number) |
|---|---|
| Clinically Driven Management | 3 |
| Tight Control Management | 6 |
"Biologic remission was defined as high sensitivity C-reactive protein (hs-CRP) < 5 mg/L, fecal Calprotectin < 250 μg/g, and CDEIS < 4 at 48 weeks after randomization.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 15.6 |
| Tight Control Management | 29.5 |
"Deep remission was defined as CDAI < 150, discontinuation from steroids for at least 8 weeks, absence of draining fistula, CDEIS < 4 and no deep ulcerations.~CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing data 48 weeks after randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 23.0 |
| Tight Control Management | 36.9 |
"Complete mucosal healing was defined as CDEIS = 0. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 16.4 |
| Tight Control Management | 18.0 |
"Endoscopic response was defined as a decrease CDEIS > 5 points. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 40.2 |
| Tight Control Management | 50.8 |
"Percentage of participants with mucosal healing (defined as a CDEIS < 4) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 30.3 |
| Tight Control Management | 45.9 |
"Percentage of participants with mucosal healing (defined as CDEIS < 4) and CDEIS < 4 in every segment on ileocolonoscopy at 48 weeks after randomization. The ileocolonoscopies were evaluated by the site.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 23.8 |
| Tight Control Management | 29.5 |
"Percentage of participants with mucosal healing (defined as Crohn's disease endoscopy Index of severity [CDEIS] < 4) and no deep ulcerations on ileocolonoscopy (defined as the absence of all deep ulcerations in all segments explored in CDEIS) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing data 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 30.3 |
| Tight Control Management | 45.9 |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Clinical remission was defined as CDAI < 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI scores generally range from 0 to 600 where higher scores indicate more severe disease. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | 78 |
| Tight Control Management | 43 |
Time to Crohn's disease flare, where flare is defined as an increase in CDAI ≥ 70 points compared to Week 8 or Early Randomization CDAI, and a CDAI > 220. (NCT01235689)
Timeframe: From Randomization to 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Crohn's disease-related hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic for reasons related to Crohn's disease (CD). Hospitalization for adverse events relating to study medication, i.e., prednisone, azathioprine or adalimumab, were according to Investigator's clinical judgment. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Steroid-free remission was defined as CDAI < 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | 162 |
| Tight Control Management | 159 |
The total dose of prednisone each participant received during both the run-in phase and post-randomization treatment phase. (NCT01235689)
Timeframe: From Baseline through 48 weeks after Randomization
| Intervention | mg (Mean) |
|---|---|
| Clinically Driven Management | 1505.7 |
| Tight Control Management | 1369.8 |
(NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Mean) |
|---|---|
| Clinically Driven Management | 40.2 |
| Tight Control Management | 50.1 |
(NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Mean) |
|---|---|
| Clinically Driven Management | 9.8 |
| Tight Control Management | 15.8 |
The Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. Participants were asked to record the frequency of stools, abdominal pain and general well-being on a daily basis. In addition to the diary data, the investigator assessed the following for the calculation of CDAI: presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. The CDAI is the sum of the products of each item multiplied by a weighting factor and generally ranges from 0 up to 600, where remission of Crohn's disease is defined as CDAI < 150, and severe disease is defined as CDAI > 450. A negative change from Baseline indicates improvement. (NCT01235689)
Timeframe: Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 of Prednisone Run-in | Week 8 of Prednisone Run-in | 2 Weeks After Randomization | 6 Weeks After Randomization | 11 Weeks After Randomization | 14 Weeks After Randomization | 18 Weeks After Randomization | 23 Weeks After Randomization | 26 Weeks After Randomization | 30 Weeks After Randomization | 35 Weeks After Randomization | 38 Weeks After Randomization | 42 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | -78.3 | -64.2 | -80.2 | -93.1 | -103.5 | -71.1 | -69.9 | -143.3 | -71.8 | -47.9 | -140.4 | -60.8 | -76.8 | -146.2 |
| Tight Control Management | -90.9 | -105.5 | -110.1 | -130.8 | -141.0 | -101.2 | -112.0 | -154.1 | -135.7 | -143.8 | -166.4 | -132.8 | -107.4 | -175.8 |
High sensitivity C-reactive protein was analyzed by a central laboratory. (NCT01235689)
Timeframe: Baseline and 8 weeks during the prednisone run-in, and 11, 23, 35, and 48 weeks after Randomization.
| Intervention | mg/L (Mean) | ||||
|---|---|---|---|---|---|
| Week 8 of Prednisone Run-in | 11 Weeks After Randomization | 23 Weeks After Randomization | 35 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | -10.3 | -14.6 | -15.1 | -11.0 | -12.3 |
| Tight Control Management | -9.2 | -15.9 | -14.7 | -14.0 | -13.2 |
"The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).~The physical component summary (PCS) score summarizes the subscales physical functioning, role-physical, bodily pain, and general health. The mental component summary (MCS) score summarizes the subscales vitality, social functioning, role-emotional, and mental health. Each score ranges from 0 to 100 where higher scores indicate a better quality of life. A positive change from Baseline score indicates an improvement." (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physical Component Summary Score | Mental Component Summary Score | |
| Clinically Driven Management | 6.3 | 5.8 |
| Tight Control Management | 9.2 | 9.3 |
"The WPAI:CD questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease. The self-administered questionnaire consisted of 6 questions.~Work time missed was defined as the percentage of time absent from work due to Crohn's disease in the past week.~Impairment while working is the participant's assessment of the degree to which Crohn's disease affected productivity while working in the past 7 days.~Total work productivity impairment takes into account both hours missed due to Crohn's disease symptoms and the patient's assessment of the degree to which Crohn's disease affected their productivity while working.~Total activity impairment is the percent impairment of non-work related activities due to Crohn's disease.~WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. A negative change from Baseline indicates improvement." (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | percent impairment (Mean) | |||
|---|---|---|---|---|
| Work time missed | Impairment while working | Overall work impairment | Activity impairment | |
| Clinically Driven Management | -12.8 | -17.5 | -21.7 | -19.2 |
| Tight Control Management | -17.6 | -25.8 | -29.2 | -27.7 |
"Clinical remission was defined as CDAI < 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.~Participants with missing data at each time point were counted as non-responders." (NCT01235689)
Timeframe: Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 of Prednisone Run-in | Week 8 of Prednisone Run-in | 2 Weeks After Randomization | 6 Weeks After Randomization | 11 Weeks After Randomization | 14 Weeks After Randomization | 18 Weeks After Randomization | 23 Weeks After Randomization | 26 Weeks After Randomization | 30 Weeks After Randomization | 35 Weeks After Randomization | 38 Weeks After Randomization | 42 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | 24.6 | 14.8 | 23.8 | 32.8 | 41.8 | 8.2 | 9.0 | 50.8 | 4.1 | 3.3 | 45.1 | 4.1 | 4.1 | 43.4 |
| Tight Control Management | 30.3 | 22.1 | 41.0 | 47.5 | 62.3 | 6.6 | 8.2 | 65.6 | 20.5 | 23.0 | 59.8 | 9.0 | 7.4 | 59.8 |
"Steroid-free remission was defined as CDAI < 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.~Participants with missing data at each time point were counted as non-responders." (NCT01235689)
Timeframe: 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Weeks After Randomization | 14 Weeks After Randomization | 18 Weeks After Randomization | 23 Weeks After Randomization | 26 Weeks After Randomization | 30 Weeks After Randomization | 35 Weeks After Randomization | 38 Weeks After Randomization | 42 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | 23.8 | 4.1 | 3.3 | 45.1 | 2.5 | 0.8 | 42.6 | 4.1 | 4.1 | 39.3 |
| Tight Control Management | 39.3 | 4.9 | 7.4 | 63.1 | 18.9 | 21.3 | 59.0 | 9.0 | 7.4 | 59.8 |
The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. A score of < 150 indicates remission. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement. (NCT03046056)
Timeframe: Baseline; Week 10
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Filgotinib 200 mg | -105 |
| Filgotinib 100 mg | -88 |
| Placebo | -57 |
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. The score ranges from 0 to 600. A score of < 150 indicates remission. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement. (NCT03046056)
Timeframe: Baseline; Week 24
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Filgotinib 200 mg | -86 |
| Filgotinib 100 mg | -71 |
| Placebo | -66 |
MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening. (NCT03046056)
Timeframe: Baseline; Week 24
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Filgotinib 200 mg | -1.1 |
| Filgotinib 100 mg | -0.5 |
| Placebo | 0.5 |
MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system.The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A positive change from baseline indicates disease worsening. (NCT03046056)
Timeframe: Baseline; Week 24
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Filgotinib 200 mg | 0.4 |
| Filgotinib 100 mg | 0.6 |
| Placebo | 0.5 |
Magnetic resonance enterography (MRE) is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and relative contrast enhancement (RCE). A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these components for the terminal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening. (NCT03046056)
Timeframe: Baseline; Week 24
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Filgotinib 200 mg | -1.8 |
| Filgotinib 100 mg | 0.7 |
| Placebo | 0.5 |
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease (CD). The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of < 150. A higher score indicates more severe disease. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 25.0 |
| Filgotinib 100 mg | 25.0 |
| Placebo | 16.7 |
The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of < 150. A higher score indicates more severe disease. (NCT03046056)
Timeframe: Week 10
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 39.3 |
| Filgotinib 100 mg | 25.0 |
| Placebo | 22.2 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score < 7 in distal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 10.0 |
| Filgotinib 100 mg | 0 |
| Placebo | 16.7 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score < 7 in jejunum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 33.3 |
| Filgotinib 100 mg | 0 |
| Placebo | 0 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score < 7 in terminal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 4.5 |
| Filgotinib 100 mg | 6.7 |
| Placebo | 6.3 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score < 11 with baseline score ≥ 11, or a segmental MaRIA score < 7 with baseline score < 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score≥ 7 in the distal ileum. For segments with baseline MaRIA score ≥ 15, the minimum detectable difference (MDD) is 6.5 units and for baseline MaRIA score < 15, the MDD is 4.0 units. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 20.0 |
| Filgotinib 100 mg | 12.5 |
| Placebo | 16.7 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score < 11 with baseline score ≥ 11, or a segmental MaRIA score < 7 with baseline score < 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the jejunum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score < 15, the MDD is 4.0 units. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 50.0 |
| Filgotinib 100 mg | 12.5 |
| Placebo | 0 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score < 11 with baseline score ≥ 11, or a segmental MaRIA score < 7 with baseline score < 11, or ≥ minimum detectable difference (MDD) units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the terminal ileum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score < 15, the MDD is 4.0 units. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 22.7 |
| Filgotinib 100 mg | 10.0 |
| Placebo | 25.0 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Small bowel MaRIA remission was defined as MaRIA score < 7 at Week 24 in each of the 3 small bowel segments, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 8.0 |
| Filgotinib 100 mg | 6.3 |
| Placebo | 0 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Participant level small bowel MaRIA response was defined as all small bowel segments with baseline MaRIA score ≥7 achieve segment level MaRIA response, with no segment level disease worsening in any other segment(s) at Week 24, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline. (NCT03046056)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Filgotinib 200 mg | 20.0 |
| Filgotinib 100 mg | 12.5 |
| Placebo | 16.7 |
Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than (<) 150 in participants who have not received any dose of systemic corticosteroids (prednisone or equivalent) for greater than or equal to (>=) 3 weeks and have not received budesonide at a dose > 6 milligram per day (mg/day) for >= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse). (NCT00094458)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Azathioprine + Placebo | 30.0 |
| Infliximab + Placebo | 44.4 |
| Infliximab + Azathioprine | 56.8 |
Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) < 150 who have not received any dose of systemic corticosteroids (prednisone or equivalent) for >= 3 weeks and have not received budesonide at a dose > 6 milligram per day (mg/day) for >= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse). (NCT00094458)
Timeframe: Week 50
| Intervention | percentage of participants (Number) |
|---|---|
| Azathioprine + Placebo | 54.7 |
| Infliximab + Placebo | 60.8 |
| Infliximab + Azathioprine | 72.2 |
Complete absence of mucosal ulcerations in the colon and terminal ileum as assessed by video endoscopy. (NCT00094458)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Azathioprine + Placebo | 16.5 |
| Infliximab + Placebo | 30.1 |
| Infliximab + Azathioprine | 43.9 |
Average daily dose of systemic corticosteroid concomitant medications(prednisone or equivalent) (NCT00094458)
Timeframe: Weeks 2, 6, 10, 18 and 26
| Intervention | milligram per day (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 (n=48, 50, 49) | Week 6 (n=53, 52, 51) | Week 10 (n=56, 56, 52) | Week 18 (n=59, 57, 56) | Week 26 (n=60, 60, 58) | |
| Azathioprine + Placebo | 22.92 | 18.56 | 16.19 | 13.49 | 11.57 |
| Infliximab + Azathioprine | 22.75 | 18.26 | 15.01 | 11.64 | 9.35 |
| Infliximab + Placebo | 21.20 | 17.68 | 15.68 | 13.23 | 10.96 |
Quality of life as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ). The IBDQ is a 32- item questionnaire and the total IBDQ score can range from 32 (very poor) to 224 (perfect). (NCT00094458)
Timeframe: Baseline and Weeks 2, 6, 10, 18, 26
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 (n= 160, 160, 163) | Week 6 (n= 162, 161, 165) | Week 10 (n= 162, 161, 165) | Week 18 (n= 162, 161, 165) | Week 26 (n= 162, 161, 165) | |
| Azathioprine + Placebo | 20.1 | 28.3 | 31.0 | 30.3 | 31.4 |
| Infliximab + Azathioprine | 31.4 | 39.9 | 42.4 | 43.7 | 45.2 |
| Infliximab + Placebo | 27.7 | 34.8 | 37.8 | 39.9 | 39.9 |
Clinical remission is defined as a CDAI < 150, compared to baseline (Week 0) (NCT00094458)
Timeframe: Weeks 2, 6, 10, 18 and 26
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 6 | Week 10 | Week 18 | Week 26 | |
| Azathioprine + Placebo | 17.6 | 27.6 | 34.1 | 33.5 | 31.8 |
| Infliximab + Azathioprine | 36.7 | 52.1 | 59.8 | 60.4 | 60.4 |
| Infliximab + Placebo | 32.5 | 49.1 | 47.3 | 49.7 | 47.9 |
Clinical remission is defined as a CDAI < 150, compared to baseline (Week 0) (NCT00094458)
Timeframe: Weeks 34, 42 and 50
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 34 | Week 42 | Week 50 | |
| Azathioprine + Placebo | 61.3 | 58.7 | 54.7 |
| Infliximab + Azathioprine | 69.4 | 73.1 | 74.1 |
| Infliximab + Placebo | 66.0 | 72.2 | 66.0 |
Clinical response, defined as a >=100-point decrease in CDAI from Baseline. (NCT00094458)
Timeframe: Weeks 2, 6, 10, 18, 26
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 6 | Week 10 | Week 18 | Week 26 | |
| Azathioprine + Placebo | 22.4 | 37.6 | 39.4 | 38.8 | 37.6 |
| Infliximab + Azathioprine | 47.3 | 63.3 | 69.2 | 62.7 | 62.1 |
| Infliximab + Placebo | 42.6 | 54.4 | 55.6 | 55.0 | 54.4 |
Clinical response, defined as a >=100-point decrease in CDAI from Baseline. (NCT00094458)
Timeframe: Weeks 34, 42, 50
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 34 | Week 42 | Week 50 | |
| Azathioprine + Placebo | 66.7 | 65.3 | 62.7 |
| Infliximab + Azathioprine | 76.9 | 77.8 | 78.7 |
| Infliximab + Placebo | 76.3 | 74.2 | 72.2 |
Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/apthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score >=0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | units on a scale (Mean) |
|---|---|
| Any Adalimumab | -143.0 |
Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
| Intervention | units on a scale (Mean) |
|---|---|
| DB Adalimumab 40 mg Eow | -83.7 |
| Placebo Eow | -9.1 |
"IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period with 32 questions about bowel function and related symptoms & their social/emotional impact. Per item, participants select 1 of 7 responses (1=poor quality of life [e.g., feeling of fatigue all of the time]; 7=good quality [e.g., feeling of fatigue none of the time]). Scoring range=32 to 224. Higher scores indicate better quality of life; increases in IBDQ=improved overall quality of life." (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | units on a scale (Mean) |
|---|---|
| Any Adalimumab | 27.2 |
"IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each item, participants select 1 of 7 responses. 1=poor quality of life (e.g., feeling of fatigue all of the time) and 7=good quality (e.g., feeling of fatigue none of the time). Scoring range = 32 to 224. Higher scores indicate better quality of life; increases in IBDQ = improved overall quality of life." (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
| Intervention | units on a scale (Mean) |
|---|---|
| DB Adalimumab 40 mg Eow | 27.8 |
| Placebo Eow | 1.8 |
The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease. (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | units on a scale (Mean) |
|---|---|
| Any Adalimumab | -1.7 |
The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease. (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
| Intervention | units on a scale (Mean) |
|---|---|
| DB Adalimumab 40 mg Eow | -0.8 |
| Placebo Eow | -0.2 |
The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score). (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | units on a scale (Mean) |
|---|---|
| Any Adalimumab | 6.44 |
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score). (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
| Intervention | units on a scale (Mean) |
|---|---|
| DB Adalimumab 40 mg Eow | 9.6 |
| Placebo Eow | 0.3 |
The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 to 100, with 0=Poorest Health and 100=Best Health. (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | units on a scale (Mean) |
|---|---|
| Any Adalimumab | 5.44 |
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 (Poorest Health) to 100 (Best Health). (NCT00445432)
Timeframe: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
| Intervention | units on a scale (Mean) |
|---|---|
| DB Adalimumab 40 mg Eow | 4.4 |
| Placebo Eow | 0.2 |
Clinical remission = Crohn's Disease (CD) Activity Index (CDAI) <150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is >= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement. (NCT00445432)
Timeframe: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | participants (Number) |
|---|---|
| Any Adalimumab | 21 |
Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) <150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is >= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement. (NCT00445432)
Timeframe: Week 52 of double-blind treatment
| Intervention | Participants (Number) |
|---|---|
| DB Adalimumab 40 mg Eow | 8 |
| Placebo Eow | 2 |
Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) <150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Week 52 of open-label treatment
| Intervention | Participants (Number) |
|---|---|
| OL Adalimumab 40 mg Eow | 5 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | participants (Number) |
|---|---|
| Any Adalimumab | 26 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Week 52 of double-blind treatment
| Intervention | Participants (Number) |
|---|---|
| DB Adalimumab 40 mg Eow | 8 |
| Placebo Eow | 2 |
| OL Adalimumab 40 mg Eow | 8 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Intervention | participants (Number) |
|---|---|
| Any Adalimumab | 28 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement. (NCT00445432)
Timeframe: Week 52 of double-blind treatment
| Intervention | Participants (Number) |
|---|---|
| DB Adalimumab 40 mg Eow | 9 |
| Placebo Eow | 2 |
| OL Adalimumab 40 mg Eow | 10 |
The number of participant fatalities was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 30 |
| Standard Therapy | 14 |
| Switched to Remicade | 4 |
The number of participants with demyelinating neurological disorders was evaluated. Demyelinating neurological disorders were defined as multiple sclerosis, optic neuritis, peripheral syndromes such as peripheral neuropathy, mononeuropathy multipex, cranial neuropathies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and transverse myelitis. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 4 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants wtih hematologic conditions was evaluated. A hematologic condition was defined as thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, or aplastic anemia. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 50 |
| Standard Therapy | 11 |
| Switched to Remicade | 7 |
The number of participants with infusion-related reactions and/or hypersensitivity was evaluated. An infuson-related reaction/hypersensitivity was defined as as an acute reaction, including anaphylactic shock that occurs after the onset of the infusion or within the 1- to 2-hour observation period following the end of the infusion. Delayed hypersensitivity reactions (myalgia and/or arthralgia with fever and rash within 14 days of the infusion) were included. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 173 |
| Standard Therapy | 1 |
| Switched to Remicade | 28 |
The number of participants wtih lymphoproliferative disorders and/or malignancies was evaluated. A lymphoproliferative disorder and /or malignancy included, but was not limited to, lymphoma, gastrointestinal cancer, skin cancer (including basocellular and squamous carcinoma, melanoma) and in situ cervical carcinoma. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 49 |
| Standard Therapy | 21 |
| Switched to Remicade | 8 |
The number of participants with new or worsening congestive heart failure was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 1 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants experiencing serious infections was evaluated. Serious infections included, but were not limited to, tuberculosis, opportunistic infections (such as Pneumocystis carinii [PCP] pneumonia, listeriosis, atypical mycobacteria, and histoplasmosis), salmonellosis,and serious viral infections. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 132 |
| Standard Therapy | 47 |
| Switched to Remicade | 18 |
The duration of hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Days (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=657,418 ,0) | Visit 2 (n=304,126, 33) | Visit 3 (n=216, 58, 35) | Visit 4 (n=151, 60, 24) | Visit 5 (n=105, 35, 34) | Visit 6 (n=107, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=80, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 12.2 | 14.4 | 14.2 | 12.6 | 11.7 | 10.8 | 10.6 | 9.5 | 12.4 | 10.1 | 11.4 |
| Standard Therapy | 10.8 | 12.0 | 9.4 | 8.5 | 9.8 | 13.7 | 10.2 | 16.3 | 6.9 | 8.0 | 8.7 |
| Switched to Remicade | NA | 13.0 | 13.5 | 9.1 | 7.1 | 18.3 | 10.0 | 14.7 | 10.7 | 9.0 | 18.1 |
The number of participant hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Hospital Stays (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1539, 1121, 0) | Visit 2 (n=1418, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1170, 665, 208) | Visit 7 (n=1111, 615, 219) | Visit 8 (n=1099, 589, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1031, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 0.7 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Standard Therapy | 0.5 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Switched to Remicade | NA | 0.5 | 0.4 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
The number of participants undergoing surgical procedures for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Surgical Procedures (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Basline; n=660, 419, 0) | Visit 2 (n=304, 126, 33) | Visit 3 (n=217, 57, 36) | Visit 4 (n=153, 60, 24) | Visit 5 (n=106, 36, 34) | Visit 6 (n=108, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=82, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 171 | 135 | 121 | 68 | 50 | 49 | 48 | 43 | 38 | 38 | 34 |
| Standard Therapy | 81 | 51 | 23 | 16 | 14 | 21 | 20 | 12 | 13 | 13 | 6 |
| Switched to Remicade | NA | 7 | 12 | 8 | 14 | 11 | 6 | 7 | 8 | 8 | 8 |
The number of participants with a draining fistula was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1541, 1120, 0) | Visit 2 (n=1420, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1169, 666, 208) | Visit 7 (n=1110, 615, 219) | Visit 8 (n=1097, 588, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1030, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 349 | 211 | 170 | 146 | 125 | 114 | 97 | 105 | 98 | 85 | 87 |
| Standard Therapy | 96 | 51 | 41 | 31 | 29 | 26 | 31 | 23 | 32 | 15 | 16 |
| Switched to Remicade | NA | 16 | 19 | 12 | 15 | 15 | 15 | 16 | 15 | 20 | 20 |
The participant assessment of overall health status was evaluated at baseline and each study visit. The overall health status questionnaire asked participants to rate their current health status over the prior 24 hours as 1=best possible, 2=much better than average, 3=better than average, 4=average, 5=worse than average, 6=much worse than average, or 7=worst possible. Scores ranged from 1 to 7 with lower scores indicating better health status. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1526, 1116, 0) | Visit 2 (n=1344, 903, 95) | Visit 3 (n=1280, 809, 146) | Visit 4 (n=1217, 755, 162) | Visit 5 (n=1160, 704, 184) | Visit 6 (n=1110, 649, 202) | Visit 7 (n=1046, 606, 212) | Visit 8 (n=1044, 573, 221) | Visit 9 (n=999, 544, 223) | Visit 10 (n=963, 520, 227) | Visit 11 (n=956, 527, 235) | |
| Remicade | 4.3 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.0 | 3.0 |
| Standard Therapy | 3.9 | 3.3 | 3.1 | 3.0 | 3.1 | 3.0 | 3.0 | 3.0 | 2.9 | 2.8 | 2.8 |
| Switched to Remicade | NA | 3.9 | 3.6 | 3.5 | 3.2 | 3.4 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 |
The Harvey-Bradshaw Index of Crohn's Disease Acitivity was evaluated at each study visit. The Harvey-Bradshaw Index evaluates participants' general health in the day prior in the domains of well being, abdominal pain, number of liquid stools per day, and abdominal mass and complications and was evaluated on the day of the study visit. The score is derived from a 0-4 score for general well being, 0-3 for abdmonial pain, raw score for number of liquid stools per day, 0-3 for abdominal mass, and raw score for complications. The total score is from 0 to infinity, with lower scores indicating better outcomes. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1505, 1106, 0) | Visit 2 (n=1320, 876, 91) | Visit 3 (n=1250, 785, 143) | Visit 4 (n=1196, 742, 159) | Visit 5 (n=1127, 692, 181) | Visit 6 (n=1070, 647, 199) | Visit 7 (n=1023, 592, 209) | Visit 8 (n=1015, 562, 224) | Visit 9 (n=953, 546, 219) | Visit 10 (n=936, 526, 225) | Visit 11 (n=918, 525, 238) | |
| Remicade | 8.2 | 4.1 | 3.7 | 3.8 | 3.7 | 3.6 | 3.6 | 3.6 | 3.6 | 3.4 | 3.4 |
| Standard Therapy | 6.2 | 3.8 | 3.5 | 3.2 | 3.4 | 3.1 | 3.0 | 3.2 | 2.9 | 2.7 | 2.7 |
| Switched to Remicade | NA | 6.0 | 4.4 | 4.8 | 4.9 | 4.5 | 4.1 | 4.1 | 4.4 | 4.3 | 4.2 |
The participant work/daily activity status score was evaluated at each study visit. The work/daily activity questionnaire asked participants to rate their level of daily functioning on a scale of 1 to 10 with a lower score indicating less of an impact of Crohn's disease on work or daily life functioning. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1496, 1108, 0) | Visit 2 (n=1316, 895, 94) | Visit 3 (n=1235, 797, 143) | Visit 4 (n=1192, 738, 159) | Visit 5 (n=1128, 694, 179) | Visit 6 (n=1077, 638, 201) | Visit 7 (n=1030, 601, 207) | Visit 8 (n=1025, 571, 221) | Visit 9 (n=982, 542, 222) | Visit 10 (n=934, 514, 225) | Visit 11 (n=925, 521, 235) | |
| Remicade | 5.9 | 4.2 | 3.8 | 3.6 | 3.4 | 3.3 | 3.2 | 3.3 | 3.3 | 3.1 | 3.2 |
| Standard Therapy | 4.9 | 3.7 | 3.2 | 2.9 | 3.0 | 2.7 | 2.8 | 2.7 | 2.6 | 2.4 | 2.4 |
| Switched to Remicade | NA | 5.5 | 4.8 | 4.3 | 4.0 | 3.9 | 3.6 | 3.5 | 3.5 | 3.6 | 3.6 |
This is to examine if the intervention results in a lower level of 6-Methylmercaptopurine in the participants. If so, the participants are expected to have less symptom severity. Comparing baseline taken at visit one to visit two levels 10 weeks after intervention start. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | pmol/8 x 10 ^8 RBC (Mean) |
|---|---|
| Evening Group Medication Administration | 2395.27 |
| Morning Group Medication Administration | 825.15 |
Harvey Bradshaw Activity Index has 5 questions. The final score is totaled and will fall into the following categories, which are used to define the severity of the disease: >16 severe diseases, 8-16 moderate disease, 5-7 mild disease, <5 remission. Scores range from 0 ( lowest possible score) to 17. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Evening Group Medication Administration | 2.15 |
| Morning Group Medication Administration | 3.09 |
This questionnaire is used to collect primary sleep times, such as bed- and rise-times, including the time a person is fully awake, sleep latency and inertia, in addition to other time points. The MCTQ uses the midpoint of sleep between sleep onset and offset to assess chronotype. Chronotype is your body's natural time to be awake or asleep at certain times. Total scores can range from 16 to 86, with the lowest values representing extreme-late chronotype. For this study corrected midpoint of sleep (MSFc) was calculated. This information is combined to determine the mean time of day at which respondents were more likely to feel most alert. The numbers provided in the outcome measure data table represent time (hour and minute). The hour has been converted to military time and the minutes were converted to decimals. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | hours (Mean) |
|---|---|
| Evening Group Medication Administration | 3.70 |
| Morning Group Medication Administraion | 2.57 |
Quality of Life Measure Score:1-7 (The higher the number the greater the quality of life) (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Evening Group Medication Administration | 5.83 |
| Morning Group Medication Administration | 5.91 |
This is to examine if the intervention results in a greater level of thioguanine in the participants. If so, the participants are expected to have less symptom severity. Comparing baseline taken at visit one to visit two levels 10 weeks after intervention start. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | pmol/8 x 10^8 RBC (Mean) |
|---|---|
| Evening Group Medication Administration | 175.04 |
| Morning Group Medication Administration | 225.65 |
194 reviews available for azathioprine and Crohn Disease
| Article | Year |
|---|---|
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Benzene | 2021 |
Imputability of Azathioprine in the Occurrence of Chronic Myeloid Leukemia in Crohn's Disease: An Exceptional Case Report.
Topics: Azathioprine; Chronic Disease; Crohn Disease; Female; Humans; Immunosuppressive Agents; Leukemia, My | 2023 |
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Mercaptopur | 2019 |
Adalimumab for maintenance of remission in Crohn's disease.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Adm | 2020 |
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Asia; Azathioprine; Colitis, Ulcerative; Crohn Disease | 2021 |
Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
Topics: Adalimumab; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Dise | 2020 |
Pancreatic Disorders in Patients with Inflammatory Bowel Disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Pancreatitis; Azathioprin | 2022 |
The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs.
Topics: Adrenal Cortex Hormones; Algorithms; Azathioprine; Crohn Disease; Gastrointestinal Agents; Humans; I | 2017 |
Therapeutic role of methotrexate in pediatric Crohn's disease.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Drug Administration Schedule; Humans; Immunosuppress | 2018 |
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Mercaptopurin | 2018 |
Immune thrombocytopenic purpura associated with Crohn's disease with complete response to infliximab.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Azathioprine; Benzoates; Crohn Disease; Humans; Hydra | 2019 |
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Topics: Adult; Azathioprine; Combined Modality Therapy; Crohn Disease; Feasibility Studies; Gastrointestinal | 2018 |
[Inflammatory Bowel Diseases - Diagnosis and Therapy in Practice].
Topics: Adrenal Cortex Hormones; Azathioprine; Capsule Endoscopy; Colitis, Ulcerative; Colonoscopy; Crohn Di | 2018 |
The state of the art on treatment of Crohn's disease.
Topics: Adrenal Cortex Hormones; Asia; Azathioprine; Crohn Disease; Drug Monitoring; Humans; Immunomodulatio | 2018 |
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Topics: Anti-Inflammatory Agents; Azathioprine; Biological Products; Clinical Decision-Making; Colitis, Ulce | 2019 |
Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Azathioprine; Colitis, Ulcerative; Crohn Disease; Dru | 2019 |
Recent advances using immunomodulators for inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; | 2013 |
Update on pregnancy and breastfeeding in the era of biologics.
Topics: Adalimumab; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Inflammatory | 2013 |
Thiopurines in inflammatory bowel disease revisited.
Topics: Animals; Anti-Infective Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Gastrointestinal A | 2013 |
Autophagy: a new target or an old strategy for the treatment of Crohn's disease?
Topics: Autophagy; Azathioprine; Crohn Disease; Curcumin; Disease Management; Humans; Tumor Necrosis Factor- | 2013 |
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Induction Chemotherapy; Mercaptopurin | 2013 |
Prognostic factors in Crohn's disease: a systematic review.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Intestines; Prognosis | 2013 |
Strategies for the prevention of postoperative recurrence of Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Colectomy; Colon; Col | 2013 |
[Treatment of chronic inflammatory bowel disease based on evidence and according to stage: top down].
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Biological Products; Colitis, Ulcerat | 2013 |
Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Focal Nodular Hyperplasia; Humans; Immunos | 2013 |
A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Agents; I | 2013 |
Comparing medical treatments for Crohn's disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Azathioprine; Biological Facto | 2013 |
Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under azathioprine and steroids: First case report and literature review.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Herpes Simp | 2014 |
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Topics: Azathioprine; Crohn Disease; Gastroenterology; Humans; Mercaptopurine; Methotrexate; Remission Induc | 2013 |
The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis.
Topics: Azathioprine; Confidence Intervals; Crohn Disease; Digestive System Surgical Procedures; Disease Man | 2014 |
Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery - colorectal surgery.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine | 2014 |
Steroid use in Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Budesonide; Clinical Trials as Topic; Crohn Disease; Humans; | 2014 |
Positioning therapy for Crohn's disease.
Topics: Azathioprine; Crohn Disease; Drug Monitoring; Gastrointestinal Agents; Humans; Mercaptopurine; Metho | 2014 |
Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance--progress and prospects.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; | 2014 |
Can we get more from our current treatments?
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Methotrexate | 2014 |
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2014 |
Methotrexate for induction of remission in refractory Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Induction Che | 2014 |
[Role of thiopurine agents in ulcerative colitis].
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Disease Susceptibility; | 2011 |
[Azathioprine in Crohn's disease therapy--guidance against the background of recent studies].
Topics: Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Immu | 2014 |
Thiopurine-induced pancreatitis in inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Gastrointestina | 2015 |
Toxicity and response to thiopurines in patients with inflammatory bowel disease.
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Crohn Disease; Humans; Im | 2015 |
Update on thiopurine pharmacogenetics in inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Hypersensitivity; Drug-Related Side Effects a | 2015 |
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Mercaptopur | 2015 |
New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
Topics: Anti-Inflammatory Agents; Azathioprine; Budesonide; Colitis, Ulcerative; Congresses as Topic; Crohn | 2015 |
Crohn's Disease treated with azathioprine and basal cell carcinoma : three cases and literature review.
Topics: Adult; Azathioprine; Carcinoma, Basal Cell; Crohn Disease; Female; Humans; Immunosuppressive Agents; | 2015 |
6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.
Topics: Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Substi | 2015 |
Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azathioprine; Colitis, Ulcerative; Crohn Dise | 2016 |
PREGNANCY, CROHN'S DISEASE AND AZATHIOPRINE: A CASE STUDY AND LITERATURE REVIEW.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Middle Aged; Pregnancy | 2016 |
Advances in Pediatric Inflammatory Bowel Disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal, Huma | 2016 |
Therapeutic drug monitoring in inflammatory bowel disease.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Child; Colitis, Ulcerati | 2016 |
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Topics: Adult; Antimetabolites; Azathioprine; Crohn Disease; Glucocorticoids; Humans; Immunosuppressive Agen | 2016 |
Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents | 2016 |
[New therapy in inflammatory bowel disease (infliximab)].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Humans; Immunosuppres | 2008 |
Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aza | 2008 |
Laboratory evaluation of inflammatory bowel disease.
Topics: Adolescent; Azathioprine; Biomarkers; Child; Child, Preschool; Clinical Laboratory Techniques; Colit | 2008 |
Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.
Topics: Azathioprine; Colectomy; Colitis, Ulcerative; Crohn Disease; Disease Progression; Drug Administratio | 2008 |
[Treatment of Crohn's disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Biological Products; Colectomy; Combined Modality Therapy; Cr | 2009 |
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Prodrugs; Randomized | 2009 |
[From research to clinic: The case of Crohn's disease and Tumor Necrosis Factor].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Human | 2000 |
Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Azathioprine; Biological Products; Colitis, Ulcerati | 2009 |
Crohn's disease.
Topics: Administration, Oral; Adrenal Cortex Hormones; Azathioprine; Colectomy; Crohn Disease; Enteral Nutri | 2007 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Emerging treatments for complex perianal fistula in Crohn's disease.
Topics: Anti-Bacterial Agents; Azathioprine; Crohn Disease; Humans; Immunologic Factors; Mercaptopurine; Rec | 2009 |
Mild to moderate Crohn's disease: still room for step-up therapies?
Topics: Antibodies, Monoclonal; Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Infliximab; M | 2009 |
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Mercaptopu | 2009 |
[For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroi | 2009 |
Pancreatitis in inflammatory bowel diseases.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Dis | 2010 |
Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
Topics: Adalimumab; Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Ag | 2010 |
[Postoperative recurrence of Crohn's disease, and its prevention].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Dis | 2010 |
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Mer | 2010 |
Thiopurines in Crohn's disease, is there something new?
Topics: Azathioprine; Crohn Disease; Drug Monitoring; Humans; Immunosuppressive Agents; Mercaptopurine; Meth | 2010 |
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aza | 2011 |
Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
Topics: Azathioprine; Crohn Disease; Humans; Hypertension, Portal; Immunosuppressive Agents; Liver; Male; Me | 2011 |
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Humans; Immunosuppressive Agents; In | 2011 |
Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Randomized Controlled Trials as Topic | 2011 |
Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field.
Topics: Anti-Bacterial Agents; Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans; Palliative Ca | 2011 |
Current status of thiopurine analogues in the treatment in Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Immunosuppressive Agents; Methyltrans | 2011 |
[Small intestinal signet-ring cell carcinoma in Crohn's disease: case report and review of the literature].
Topics: Adult; Anastomosis, Surgical; Azathioprine; Carcinoma, Signet Ring Cell; Cell Transformation, Neopla | 2013 |
Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence.
Topics: Adalimumab; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; | 2012 |
Prevention of postoperative recurrence of Crohn's disease.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, M | 2012 |
Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2012 |
Oral squamous cell carcinoma in a Crohn's disease patient taking azathioprine: case report and review of the literature.
Topics: Adult; Azathioprine; Carcinoma, Squamous Cell; Crohn Disease; Female; Humans; Immunosuppressive Agen | 2012 |
A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine.
Topics: Aged; Antineoplastic Agents; Azathioprine; Bone Marrow; Chromosome Aberrations; Crohn Disease; Human | 2012 |
Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Biotransformation; Crohn Disease; Drug Hypersensitivity; Drug | 2012 |
Update on idiopathic colitides.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2013 |
Methotrexate for induction of remission in refractory Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Induction Che | 2012 |
Methotrexate: underused and ignored?
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Methotrexate; Patient Preference; Treatmen | 2012 |
[Drug therapy of Crohn disease].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr | 2001 |
[Can the postoperative relapse of Crohn disease be influenced?].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Clinical Trials as Top | 2001 |
[Sciatica secondary to a presacral abscess as the first manifestation of Crohn's disease].
Topics: Abscess; Adult; Azathioprine; Combined Modality Therapy; Crohn Disease; Drug Therapy, Combination; E | 2002 |
Advances in medical therapy for Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Age | 2002 |
Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.
Topics: Animals; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Humans; Infliximab; Mercaptopurine; Tu | 2003 |
[Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Bude | 2003 |
[Conservative therapy of inflammatory bowel diseases].
Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro | 2002 |
[Treatment of Crohn's disease].
Topics: Acute Disease; Adjuvants, Immunologic; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; An | 2003 |
[Drug therapy and nutrition therapy of a young patient with Crohn disease].
Topics: Adjuvants, Immunologic; Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal | 2003 |
Management of Crohn's disease--a practical approach.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; | 2003 |
How effective are the usual treatments for Crohn's disease?
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathi | 2004 |
Review article: chronic active disease and maintaining remission in Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Chronic Disease; Croh | 2004 |
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Agents; Mercapto | 2004 |
Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy.
Topics: Antimetabolites; Azathioprine; Crohn Disease; Hematologic Tests; Humans; Leukocyte Count; Mercaptopu | 2004 |
Advances in medical therapy for Crohn's disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; Humans; Immu | 2004 |
[Chronic inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Can we alter the natural history of Crohn disease in children?
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Child; Crohn Disease; Disease-Free Su | 2005 |
[Inflammatory bowel disease--diagnosis and therapy].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathioprine; Colitis, Ul | 2005 |
[Azathioprine].
Topics: Apoptosis; Azathioprine; CD28 Antigens; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combinatio | 2005 |
[New therapies for inflammatory bowel disease].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Colitis, Ulcera | 2005 |
Genetic testing in Crohn disease: utility in individualizing patient management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disea | 2005 |
The use of medications for inflammatory bowel disease during pregnancy and nursing.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; B | 2005 |
[Crohn's disease--standards of treatment 2004].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Algorithms; Aminosalicylic Acids; Anti-Inflammatory A | 2005 |
Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Evidence-Ba | 2006 |
Small bowel adenocarcinoma in Crohn's disease: a case report and review of literature.
Topics: Adenocarcinoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Humans; | 2006 |
What's new: innovative concepts in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; | 2006 |
Infliximab and azathioprine: bridge or parachute?
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Age | 2006 |
Pharmacogenetics in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; | 2006 |
Biological therapy in the management of recent-onset Crohn's disease: why, when and how?
Topics: Algorithms; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Gastroin | 2006 |
Conventional therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2006 |
Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Azathioprine; Cell Survival; Crohn Disease; Huma | 2007 |
[Cytokine targetting therapy for inflammatory bowel diseases].
Topics: Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cytokines; Drug Therapy, C | 2006 |
[Postoperative recurrence in Crohn's disease. Risk factors and methods of prevention].
Topics: Algorithms; Anastomosis, Surgical; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2006 |
[Medical therapy of inflammatory bowel diseases: Crohn's disease].
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ster | 2007 |
Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.
Topics: Adult; Aged; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Lung Diseases; M | 2007 |
Review article: the evidence base for interventions used to maintain remission in Crohn's disease.
Topics: Adalimumab; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azat | 2008 |
[Current status of treatment of inflammatory bowel disease].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2007 |
[Current medical treatment of inflammatory bowel disease].
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2007 |
Optimizing drug therapy in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
IBD in children: lessons for adults.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; An | 2007 |
[Immunomodulator therapy for maintenance of remission in Crohn's disease].
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Drug Administration Schedule; Evidence-Based | 2008 |
[Therapy of Crohn's disease in childhood].
Topics: Azathioprine; Child; Crohn Disease; Doxycycline; Drug Therapy, Combination; Humans; Metronidazole; P | 1981 |
The immunology of inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Complement System Proteins; Crohn Disease; Humans; Hypersensitivi | 1982 |
Azathioprine.
Topics: Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Colitis, Ulcerative; Crohn Diseas | 1981 |
[Crohn disease: prevention and drug therapy].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 1995 |
Immunosuppressive therapy of inflammatory bowel disease: a historical perspective.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Female; History, 20th Century; Human | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Intestinal Fistula; Mercaptopurin | 1995 |
[Cryptogenetic inflammatory diseases of the intestine and pregnancy. Reality and prejudices].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Postopera | 1993 |
Maintenance of symptomatic remission in patients with Crohn's disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Clinical Trials as Topic; Crohn Disease | 1993 |
Medical management of patients with difficult-to-treat inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine | 1994 |
Immunosuppressive drugs in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Cyclosporins; Humans; Immunosuppressive Agents; Mercaptopurine; Methotr | 1994 |
Newer treatments for inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Azathioprine; Colitis, Ulcerat | 1996 |
[Myositis--a rare complication of Crohn disease].
Topics: Azathioprine; Biopsy; Crohn Disease; Drug Therapy, Combination; Humans; Male; Methylprednisolone; Mi | 1996 |
[Drug treatment of Crohn's disease].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Clinical | 1998 |
The case against routine post-operative therapy for prevention of recurrence in Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Digestive System S | 1998 |
Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity.
Topics: Azathioprine; Cholestasis, Intrahepatic; Crohn Disease; Drug Hypersensitivity; Humans; Immunosuppres | 1998 |
Immunosuppressive drugs in the treatment of Crohn's disease.
Topics: Azathioprine; Crohn Disease; Cyclosporine; Humans; Immunosuppressive Agents; Methotrexate; Treatment | 1998 |
[Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease].
Topics: Acute Disease; Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Pancrea | 1999 |
New strategies in the management of inflammatory bowel disease.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprin | 1999 |
[Recent progress in therapy of inflammatory bowel diseases].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative | 1999 |
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; Colitis, Ulc | 1999 |
[Azathioprine treatment of Crohn disease].
Topics: Antimetabolites; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents | 2000 |
[Medical treatment of Crohn's disease].
Topics: Antibodies, Monoclonal; Azathioprine; CD4 Antigens; Crohn Disease; Enteral Nutrition; Heparin; Human | 2000 |
[Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease].
Topics: Adult; Azathioprine; Crohn Disease; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Immunosuppre | 2000 |
Azathioprine for maintaining remission of Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Prodrugs | 2000 |
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.
Topics: Antimetabolites; Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans; Mercaptopurine; Rem | 2000 |
[Azathioprine in chronic inflammatory bowel diseases. Evidence base].
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Evidence-Based Medicine; | 2000 |
Clinical pharmacology of inflammatory bowel disease therapies.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Colitis, | 2000 |
Medical therapies for ulcerative colitis and Crohn's disease.
Topics: Adjuvants, Immunologic; Aminosalicylic Acids; Antimetabolites; Appendectomy; Azathioprine; Colitis, | 2000 |
Conventional treatment of Crohn's disease: objectives and outcomes.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 2001 |
Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr | 2001 |
[Ki-1 lymphoma of the skin in a patient with Crohn's disease undergoing treatment with azathioprine].
Topics: Adult; Autoimmune Diseases; Azathioprine; Candidiasis; Crohn Disease; Humans; Hydronephrosis; Immuno | 2001 |
[Therapeutic principles for chronic inflammatory bowel disease].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colectomy; Colitis; C | 2001 |
Management of fistulas in patients with Crohn's disease: antibiotic to antibody.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Colonic Diseases; Crohn Disease; Cyclos | 2001 |
Maintenance drugs for inflammatory bowel disease.
Topics: Aminosalicylic Acids; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Crohn Disease; Gast | 2001 |
Drug treatment of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Bacterial Agents; Antidiarrheals; Azathio | 1979 |
The protean manifestations of Crohn's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arthritis; Azathioprine; Child; Colectomy; Colitis, | 1975 |
Inflammatory disease of the colon: ulcerative colitis and Crohn's colitis.
Topics: Adrenal Cortex Hormones; Adult; Anus Diseases; Arthritis; Azathioprine; Child, Preschool; Colectomy; | 1975 |
Immunotherapy in inflammatory bowel disease.
Topics: Adult; Alkylating Agents; Antimetabolites; Azathioprine; Child; Clinical Trials as Topic; Colitis, U | 1978 |
[Immunodepressants in the treatment of Crohn's disease and non-specific ulcerative colitis].
Topics: Alkylating Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Folic Acid Antagonists; Humans; | 1976 |
[Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Colitis, Ulcerative; Crohn Disease; Hum | 1992 |
Maintenance treatment for Crohn's disease: has the time arrived?
Topics: Aminosalicylic Acids; Azathioprine; Crohn Disease; Drug Administration Schedule; Drug Therapy, Combi | 1992 |
[Therapeutic alternatives in Crohn disease and in ulcero-hemorrhagic rectocolitis: current findings].
Topics: Antineoplastic Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Humans; Merca | 1992 |
[Immunosuppressive treatment and Crohn's disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Cyclosporins; Humans; Immunosuppressive Agents | 1991 |
The medical, nutritional and surgical treatment of fistulae in Crohn's disease.
Topics: Adult; Azathioprine; Colonic Diseases; Combined Modality Therapy; Crohn Disease; Enteral Nutrition; | 1990 |
[Azathioprine, 6-mercaptopurine, and inflammatory diseases of the intestine].
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Mercaptopurine; | 1990 |
6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine | 1989 |
Regional enteritis.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Diagnosis, Differential; Humans; Intestinal Absorpti | 1985 |
Management of medical problems in pregnancy--inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Delivery, Obstetric; Fema | 1985 |
Current status of drug therapy for inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Administration Sched | 1985 |
Inflammatory bowel disease in pregnancy: a review.
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Fe | 1986 |
Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects.
Topics: Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Mer | 1987 |
Inflammatory bowel disease.
Topics: Adrenocorticotropic Hormone; Anti-Bacterial Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease | 1974 |
[Auto-immune diseases and immunodepressive therapy. II. Current clinical indications].
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Arteritis; Autoimmune | 1974 |
[What is secured in the therapy of chronic inflammatory colonic diseases?].
Topics: Administration, Topical; Amebiasis; Azathioprine; Chronic Disease; Colitis; Colitis, Ulcerative; Col | 1974 |
Cytotoxic drugs in treatment of nonmalignant diseases.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlor | 1972 |
Clinical progress in Crohn's disease.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia, Hypochromic; Anti-Bacterial Agents; Az | 1974 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid | 1972 |
[Treatment of Crohn's disease and the sequelae of small intestinal resection].
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Diet Therapy; Humans; Intestine, Small; Malabs | 1972 |
IgM turnover in man.
Topics: Abscess; Adult; Azathioprine; Celiac Disease; Chronic Disease; Clone Cells; Crohn Disease; Feces; Ga | 1972 |
Crohn's disease, with special reference to surgical management.
Topics: Abdomen; Anus Diseases; Azathioprine; Barium Sulfate; Colitis, Ulcerative; Crohn Disease; Diagnosis, | 1972 |
Crohn's disease.
Topics: Adult; Azathioprine; Colon; Crohn Disease; Female; Humans; Intestine, Small; Male; Pregnancy; Progno | 1971 |
[Treatment of granulomatous colitis. Crohn's disease of the colon].
Topics: Anti-Bacterial Agents; Azathioprine; Colonic Diseases; Crohn Disease; Diet Therapy; Gastrointestinal | 1970 |
The place of surgery in Crohn's disease.
Topics: Abscess; Acute Disease; Anemia; Appendectomy; Azathioprine; Colectomy; Colonic Diseases; Crohn Disea | 1971 |
[Ulcerative colitis].
Topics: Aminocaproates; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; Humans; M | 1971 |
Treatment algorithms in Crohn's - up, down or something else?
Topics: Adalimumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pego | 2014 |
Genetic variants and the risk of Crohn's disease: what does it mean for future disease management?
Topics: Adaptor Proteins, Signal Transducing; Animals; Clinical Trials as Topic; Crohn Disease; Genetic Pred | 2006 |
130 trials available for azathioprine and Crohn Disease
| Article | Year |
|---|---|
Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
Topics: Anemia; Azathioprine; Crohn Disease; Genotype; Humans; Leukopenia; Mercaptopurine; Pyrophosphatases | 2021 |
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Infliximab; Recurrence; Tumor | 2023 |
Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.
Topics: Azathioprine; C-Reactive Protein; Child; Crohn Disease; Gastrointestinal Agents; Humans; Infliximab; | 2023 |
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.
Topics: Azathioprine; Crohn Disease; Curcumin; Humans; Quality of Life; Recurrence; Treatment Outcome | 2020 |
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Therapy, Combination; | 2020 |
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Disease Progression; Drug | 2020 |
Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Colectomy; Crohn Disease; | 2020 |
Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Azathioprine; Child; Crohn Disease; Female; Humans | 2020 |
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
Topics: Adult; Azathioprine; Colon; Colonoscopy; Crohn Disease; Drug Therapy, Combination; Female; Gastroint | 2021 |
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial.
Topics: Azathioprine; Crohn Disease; Double-Blind Method; Humans; Mesalamine; Recurrence | 2020 |
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Topics: Adolescent; Anti-Inflammatory Agents; Azathioprine; Child; Child, Preschool; Crohn Disease; Female; | 2022 |
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
Topics: Adalimumab; Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Post | 2017 |
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Topics: Adalimumab; Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; C-Reactive Protein; Crohn D | 2017 |
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Topics: Adalimumab; Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; C-Reactive Protein; Crohn D | 2017 |
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Topics: Adalimumab; Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; C-Reactive Protein; Crohn D | 2017 |
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Topics: Adalimumab; Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; C-Reactive Protein; Crohn D | 2017 |
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug The | 2018 |
Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biological Products; Colonoscopy; Crohn Disease; Drug | 2018 |
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Topics: Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Gastrointestinal Agents; Huma | 2019 |
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial.
Topics: Adalimumab; Adult; Azathioprine; Crohn Disease; Endoscopes, Gastrointestinal; Female; Humans; Immuno | 2019 |
Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug The | 2019 |
Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Topics: Adalimumab; Adolescent; Adult; Aged; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Dr | 2019 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Young Adult | 2013 |
Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Anti-Infective Agents; Azathioprine; Crohn Disease; Double-Blind Method; Drug The | 2013 |
Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Double-Blind Method; Female; Humans; Immunosuppressive Agents; M | 2013 |
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopri | 2013 |
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Cohort Studies; Crohn Disease; Disease Progression; Dru | 2013 |
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biomarkers; C-Reactive Protei | 2014 |
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biomarkers; C-Reactive Protei | 2014 |
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biomarkers; C-Reactive Protei | 2014 |
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biomarkers; C-Reactive Protei | 2014 |
Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Incidence; Kaplan-Meier Estimate; Mesalamine; Middle Age | 2013 |
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; | 2013 |
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Body Weight; Child; Crohn Disease; Double-Blind Method; Female; Hum | 2014 |
Cell therapy of refractory Crohn's disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopri | 2013 |
Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Double-Balloon Enteroscopy; Drug Administration Sche | 2014 |
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn | 2014 |
Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Demography; Female; Humans; Ileocecal Valve; Intestinal Obstruct | 2014 |
Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Austria; Azathioprine; Crohn Disease; Double-Blind Method; Drug Adm | 2015 |
Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Phytotherapy; Po | 2015 |
Crohn's disease management after intestinal resection: a randomised trial.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Colonoscopy; Crohn Disease; Fema | 2015 |
Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Drug Therapy, Combination; Female; Gastrointestinal | 2015 |
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
Topics: Adult; Azathioprine; Biomarkers; Crohn Disease; Double-Blind Method; Drug Therapy, Combination; Eryt | 2015 |
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; C-Reactive Protein; Crohn Disease; Drug Therapy, Combin | 2015 |
Whey and soy protein supplements changes body composition in patients with Crohn's disease undergoing azathioprine and anti-TNF-alpha therapy.
Topics: Adult; Azathioprine; Body Composition; Crohn Disease; Dietary Supplements; Female; Humans; Immunosup | 2015 |
Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Dose-Response Relationship | 2015 |
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence.
Topics: Adult; Anastomosis, Surgical; Azathioprine; Clinical Decision-Making; Colon; Colonoscopy; Crohn Dise | 2015 |
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Dosage Calcu | 2015 |
Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Crohn Disease; Female; Humans; Immun | 2015 |
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.
Topics: Adalimumab; Adult; Aged; Azathioprine; Colonoscopy; Crohn Disease; Drug Therapy, Combination; Female | 2015 |
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Topics: Adalimumab; Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; | 2015 |
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Topics: Adalimumab; Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; | 2015 |
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Topics: Adalimumab; Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; | 2015 |
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Topics: Adalimumab; Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; | 2015 |
The Swedish Crohn Trial: A Prematurely Terminated Randomized Controlled Trial of Thiopurines or Open Surgery for Primary Treatment of Ileocaecal Crohn's Disease.
Topics: Adult; Age Factors; Anastomosis, Surgical; Area Under Curve; Azathioprine; Budesonide; Cecum; Colect | 2016 |
Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
Topics: Azathioprine; Child; Combined Modality Therapy; Crohn Disease; Enteral Nutrition; Female; Follow-Up | 2016 |
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug The | 2016 |
Standard-dose versus low-dose azathioprine in the treatment of Crohn's disease: A prospective randomized study.
Topics: Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Age | 2016 |
Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Exome; Female | 2016 |
Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Azathioprine; Cecum; Child; Child, Preschool; Colo | 2017 |
Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Topics: Administration, Oral; Azathioprine; Biomarkers, Pharmacological; Chromatography, High Pressure Liqui | 2008 |
A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Crohn Disease; Double-Blind Method; Everolimus; Female; Human | 2008 |
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial.
Topics: Adult; Aged; Anti-Infective Agents; Azathioprine; Combined Modality Therapy; Crohn Disease; Drug The | 2008 |
6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azathioprine; Crohn Disease; Drug Resistance; Female; | 2009 |
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse.
Topics: Adult; Azathioprine; C-Reactive Protein; Cohort Studies; Crohn Disease; Female; Follow-Up Studies; H | 2009 |
Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
Topics: Adult; Azathioprine; Budesonide; Crohn Disease; Dose-Response Relationship, Drug; Drug Resistance; E | 2009 |
Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodi | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Cr | 2009 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Disease; Double-Bli | 2010 |
[New therapeutic option for M. Crohn : SONIC study (study of biologic and immunomodulator naive patients in Crohn's disease)].
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, | 2010 |
Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Azathioprine; Colonoscopy; Crohn Disease; Ep | 2011 |
Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Topics: Abdominal Abscess; Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anti | 2012 |
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Topics: Adolescent; Adult; Allopurinol; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Administratio | 2013 |
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Biphenyl Compounds; Blood Sedimentation; C-Reac | 2013 |
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Crohn Disease; Double-Blind Method; Female; Follow-Up St | 2003 |
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Crohn Disease; Double-Blind Method; Female; Follow-Up St | 2003 |
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Crohn Disease; Double-Blind Method; Female; Follow-Up St | 2003 |
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Crohn Disease; Double-Blind Method; Female; Follow-Up St | 2003 |
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anus Diseases; Azathioprine; | 2003 |
Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year.
Topics: Adult; Aged; Azathioprine; Crohn Disease; Disease-Free Survival; Dose-Response Relationship, Drug; H | 2004 |
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Topics: Adolescent; Antibodies, Monoclonal; Azathioprine; Blood Sedimentation; Body Height; Body Weight; C-R | 2004 |
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Diges | 2004 |
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.
Topics: Adult; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Double-Blind Method; Female; Hum | 2005 |
Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.
Topics: Adult; Alanine; Azathioprine; Crohn Disease; Cysteine; Female; Humans; Inosine Triphosphatase; Male; | 2005 |
The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Granulocytes; Humans; Immunosuppres | 2005 |
Pulse cyclophosphamide therapy for inflammatory bowel disease.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclophosphamide; Female; Humans; Imm | 2006 |
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Colonoscopy; Crohn Disease; Double-B | 2006 |
Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppr | 2007 |
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; D | 2007 |
Medical therapy for Crohn's disease: top-down or step-up?
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biomarkers; | 2007 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Belgium; Chi-Square Distribution; Cro | 2008 |
Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China.
Topics: Adolescent; Adult; Aged; Azathioprine; China; Crohn Disease; Dose-Response Relationship, Drug; Femal | 2008 |
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Belgium; C-Reactive Protein; | 2008 |
The National Cooperative Crohn's Disease Study.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Placebos; Prednisone; Prognosis; Sulf | 1980 |
How should we treat Crohn's disease?
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind | 1980 |
Azathioprine has a very limited role in the treatment of Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Humans; Prednisone; Rand | 1981 |
Pharmacotherapy of inflammatory bowel disease. Part 3. 6-Mercaptopurine.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Humans; Mercaptopurine | 1983 |
Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease.
Topics: Adjuvants, Pharmaceutic; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; | 1981 |
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.
Topics: Adult; Aged; Azathioprine; Crohn Disease; Erythrocytes; Female; Guanine Nucleotides; Humans; Immunos | 1995 |
[Diagnosis and treatment of inflammatory infiltrates of the abdominal cavity in Crohn disease].
Topics: Abdomen; Anti-Inflammatory Agents; Azathioprine; Combined Modality Therapy; Crohn Disease; Drug Ther | 1994 |
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans; Middle Aged; Pred | 1993 |
A controlled double blind study of azathioprine in the management of Crohn's disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Double-Blind Method; | 1995 |
Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Cyclosporine; | 1996 |
Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Crohn Disease; Cyclosporine; Drug Therapy, Co | 1998 |
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Drug | 1999 |
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Topics: Administration, Oral; Adult; Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Double-B | 1999 |
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.
Topics: Adult; Azathioprine; Biopsy; Colitis; Colon; Crohn Disease; Drug Therapy, Combination; Endoscopy, Ga | 1999 |
Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Fem | 1999 |
Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. German Imurek Study Group.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Follow-Up Studies | 1999 |
Oral tacrolimus treatment of severe colitis in children.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Drug T | 2000 |
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.
Topics: Adult; Antimetabolites; Azathioprine; Child; Crohn Disease; Drug Resistance; Female; Humans; Male; M | 2001 |
Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Crohn Disease; Drug | 2002 |
[Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate].
Topics: Adult; Azathioprine; Cohort Studies; Crohn Disease; Female; Humans; Male; Methotrexate; Middle Aged; | 2002 |
Drug treatment of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Bacterial Agents; Antidiarrheals; Azathio | 1979 |
National Cooperative Crohn's Disease Study: study design and conduct of the study.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Drug Therapy, Combinatio | 1979 |
National Cooperative Crohn's Disease Study: results of drug treatment.
Topics: Adult; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Female; Follow-Up | 1979 |
National Cooperative Crohn's Disease Study: adverse reactions to study drugs.
Topics: Adult; Azathioprine; Blood Cell Count; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; | 1979 |
Azathioprine-related pancreatitis in patients with Crohn's disease.
Topics: Adult; Amylases; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Female; | 1979 |
Correlations between clinical, blood leukocyte, and skin test data in the National Cooperative Crohn's Disease Study.
Topics: Adult; Azathioprine; Crohn Disease; Female; Granulocytes; Humans; Immunity, Cellular; Intradermal Te | 1979 |
[Indications for surgical and conservative therapy of Crohn's disease].
Topics: Acute Disease; Azathioprine; Chronic Disease; Clinical Trials as Topic; Crohn Disease; Humans; Intes | 1977 |
Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.
Topics: Adult; Aged; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Drug Evalua | 1978 |
Maintenance azathioprine in Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans | 1978 |
Immunotherapy in inflammatory bowel disease.
Topics: Adult; Alkylating Agents; Antimetabolites; Azathioprine; Child; Clinical Trials as Topic; Colitis, U | 1978 |
A controlled trial of azathioprine in Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Clinical Trials as Topic; Crohn Disease; Female; Humans; Male; Midd | 1975 |
[Methotrexate treatment in Crohn disease].
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Hum | 1992 |
[Azathioprine, 6-mercaptopurine, and inflammatory diseases of the intestine].
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Mercaptopurine; | 1990 |
Azathioprine and the treatment of chronic inflammatory bowel disease.
Topics: Adolescent; Adult; Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Double-Blind Method; Hum | 1990 |
[Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Clinical Trials as Topic; Colitis, Ulce | 1986 |
Long-term immunosuppressive treatment in Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Clinical Trials as Topic; Crohn Disease; Female; Follow-Up Studies; | 1985 |
Azathioprine in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Time Factors | 1970 |
Controlled trial of azathioprine in Crohn's disease.
Topics: Azathioprine; Blood Cell Count; Blood Platelets; Blood Sedimentation; Clinical Trials as Topic; Croh | 1971 |
Controlled trial of azathioprine in Crohn's disease.
Topics: Adolescent; Adult; Aged; Arthritis; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Bl | 1971 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid | 1972 |
Azathioprine in the treatment of Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Colic; Crohn Disease; Humans; Leukopenia; Lymphoma; Placebos | 1972 |
Azathioprine treatment in Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Body Weight; Clinical Trials as Topic; Crohn Disease; Diarrhea; Fem | 1974 |
Treatment of Crohn's disease with azathioprine: a controlled evaluation.
Topics: Administration, Oral; Adolescent; Adult; Antibody Formation; Antigens; Azathioprine; Clinical Trials | 1974 |
A double-blind trial of azathioprine in Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Placebos; Prednisolone; Recurrence | 1971 |
Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies; Crohn Disease; Drug Therapy, Combination; Female; | 2017 |
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Crohn Disease; Dose-Response Relati | 2007 |
959 other studies available for azathioprine and Crohn Disease
| Article | Year |
|---|---|
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
Topics: Animals; Azathioprine; Bacteriological Techniques; Cattle; Cattle Diseases; Colony Count, Microbial; | 2008 |
Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Topics: Aged; Antibody Formation; Azathioprine; Cohort Studies; COVID-19; COVID-19 Vaccines; Crohn Disease; | 2022 |
Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; | 2022 |
NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
Topics: Azathioprine; Child; Crohn Disease; Gastrointestinal Agents; Humans; Infliximab; Treatment Outcome | 2022 |
Parenteral Methotrexate Is Efficient in the Treatment of Azathioprine Refractory Crohn's Disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Remission I | 2022 |
HLA variants associated with azathioprine-induced pancreatitis in patients with Crohn's disease.
Topics: Acute Disease; Azathioprine; Crohn Disease; HLA-DQ alpha-Chains; HLA-DRB1 Chains; Humans; Inflammato | 2022 |
Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
Topics: Azathioprine; Crohn Disease; Humans; Leukopenia; Precision Medicine | 2022 |
Azathioprine and Acenocoumarol Drug Interaction in Patients with Crohn's Disease: A Case Report.
Topics: Acenocoumarol; Adult; Anticoagulants; Azathioprine; Crohn Disease; Drug Interactions; Female; Humans | 2023 |
Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Topics: Azathioprine; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Humans; India; Inflammatory Bowel | 2022 |
Can visceral adipose tissue and skeletal muscle predict recurrence of newly diagnosed Crohn's disease in different treatments.
Topics: Adipose Tissue; Azathioprine; Biological Products; Crohn Disease; Humans; Intra-Abdominal Fat; Muscl | 2022 |
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Child; Crohn Disease; Enteral Nutrition; Humans; Remission In | 2022 |
A Case of Disseminated Tuberculosis in a Child with Crohn's Disease After Treatment with Azathioprine, Adalimumab and Ustekinumab.
Topics: Adalimumab; Azathioprine; Child; Crohn Disease; Granuloma; Humans; Immunosuppressive Agents; Treatme | 2021 |
Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Immunosuppressive Age | 2022 |
Monotherapy with thiopurines in stricturing Crohn's disease: A real-life experience from low- and middle-income countries.
Topics: Adult; Azathioprine; Constriction, Pathologic; Crohn Disease; Developing Countries; Female; Humans; | 2022 |
Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN.
Topics: Azathioprine; Child; Crohn Disease; Humans; Immunosuppressive Agents; Prospective Studies; Recurrenc | 2023 |
Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era.
Topics: Azathioprine; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Diseases; Inf | 2022 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Early Infliximab Clearance Predicts Remission in Children with Crohn's Disease.
Topics: Adult; Azathioprine; Child; Crohn Disease; Gastrointestinal Agents; Humans; Immunosuppressive Agents | 2023 |
[Effectiveness of Mucosal Advancement Flaps in Surgery of Perianal Fistulas from Crohn´s Disease and Cryptoglandular Fistulas - a Long-term Follow-up Study].
Topics: Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Rectal Fistula; Retrospective Studies; Treat | 2023 |
Acute myeloid leukemia after 10 years of azathioprine treatment for Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Leukemia | 2023 |
Successful multidisciplinary treatment of the rare pathology of vulvar Crohn's disease.
Topics: Azathioprine; Crohn Disease; Dermatitis; Erythema; Female; Granuloma; Humans; Infliximab; Ulcer; Vul | 2023 |
Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation.
Topics: Azathioprine; Crohn Disease; Genotype; Humans; Immunosuppressive Agents; Methyltransferases; Pharmac | 2023 |
An atypical case of a pulmonary mass in an immunocompromised patient.
Topics: Aged; Azathioprine; Biopsy; Bronchoscopy; Chest Pain; Crohn Disease; Dyspnea; Endosonography; Female | 2020 |
Development of Leiomyosarcoma in a Patient Treated with Azathioprine.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Agents; Leiomyosarcoma | 2019 |
Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; Drug Resistance; Female; Humans; Inf | 2019 |
Gastrocolic Fistula Involving the Pancreas in a Patient With Crohn's Disease.
Topics: Adalimumab; Azathioprine; Budesonide; Colectomy; Colitis; Crohn Disease; Gastric Fistula; Humans; Il | 2019 |
Management of Crohn's disease: summary of updated NICE guidance.
Topics: Azathioprine; Colectomy; Crohn Disease; Disease Management; Humans; Immunosuppressive Agents; Metron | 2019 |
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Disease | 2019 |
Pyloric stenosis as a manifestation of isolated gastric Crohn's disease responding to intralesional steroid injection and balloon dilation: a case report.
Topics: Abdominal Pain; Adult; Azathioprine; Crohn Disease; Dilatation; Endoscopy, Digestive System; Female; | 2019 |
Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease.
Topics: Azathioprine; Crohn Disease; Gastroenterologists; Humans; Immunosuppressive Agents; Infliximab; Merc | 2021 |
Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.
Topics: Adalimumab; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; Femal | 2020 |
Phenotypic and Functional Changes in Peripheral Blood Natural Killer Cells in Crohn Disease Patients.
Topics: Adalimumab; Adolescent; Azathioprine; Child; Crohn Disease; Female; Flow Cytometry; Humans; Inflixim | 2020 |
Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy.
Topics: Azathioprine; B-Lymphocyte Subsets; Child; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Agen | 2021 |
Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Topics: Adult; Allopurinol; Azathioprine; Colitis, Ulcerative; Crohn Disease; Denmark; Drug Therapy, Combina | 2020 |
Perianal disease as the first manifestation in paediatric Crohn's disease.
Topics: Abscess; Adalimumab; Anemia, Hypochromic; Azathioprine; Child; Crohn Disease; Fissure in Ano; Gastro | 2020 |
How Does It Look in an Autopsy? Hepatosplenic T-Cell Lymphoma in a Patient with Crohn’s Disease on Azathioprine
Topics: Adult; Antimetabolites, Antineoplastic; Azathioprine; Crohn Disease; Humans; Lymphoma, T-Cell; Male | 2020 |
Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Genotype; Humans; Leukopenia; Methyltransferases; Polymorphism, | 2020 |
Predictors of endoscopic recurrence in resected patients with Crohn's disease in a long-term follow-up cohort: History of multiple previous resections and residual synchronous disease in the remnant intestine.
Topics: Adult; Azathioprine; Colectomy; Colon; Colonoscopy; Crohn Disease; Female; Follow-Up Studies; Humans | 2020 |
Severe Necrotising Toxoplasmic Retinochoroiditis in a Patient With Crohn's Disease in Use of Adalimumab and Azathioprine.
Topics: Adalimumab; Adult; Azathioprine; Chorioretinitis; Choroid; Crohn Disease; Female; Humans; Immunosupp | 2020 |
[Duration of sustained remission after treatment by induction with exclusive enteral nutrition and azathioprine in patients with Crohn's disease].
Topics: Azathioprine; Causality; Crohn Disease; Enteral Nutrition; Humans; Remission Induction | 2021 |
Azathioprine-induced cholestasis of pregnancy-A new insight on azathioprine safety in pregnancy.
Topics: Adult; Azathioprine; Bile Acids and Salts; Cholestasis; Crohn Disease; Female; Humans; Immunosuppres | 2020 |
Azathioprine-Induced Tremor: A Rare, Dose-Dependent Side Effect of Azathioprine in a Patient With Active Crohn Disease.
Topics: Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Age | 2020 |
[Isolated Crohn's disease of the vulva with rapid clinical response to infliximab and azathioprine].
Topics: Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; In | 2020 |
Safety of Thiopurine Use in Paediatric Gastrointestinal Disease.
Topics: Azathioprine; Child; Crohn Disease; Gastrointestinal Agents; Humans; Immunologic Factors; Immunosupp | 2020 |
Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Gastroint | 2021 |
Discontinuation rate of azathioprine.
Topics: Azathioprine; Crohn Disease; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents | 2020 |
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Topics: Adalimumab; Adult; Azathioprine; Biological Products; Canada; Colitis, Ulcerative; Crohn Disease; Dr | 2020 |
Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients.
Topics: Adult; Antimetabolites; Azathioprine; Bacteroidetes; Biosynthetic Pathways; Butyrates; Colitis, Ulce | 2021 |
Discontinuation rate of azathioprine.
Topics: Azathioprine; Crohn Disease; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents | 2020 |
Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease.
Topics: Azathioprine; Child; Crohn Disease; Drug Synergism; Humans; Immunosuppressive Agents; Infliximab; Pe | 2020 |
A rare case of Azathioprine-induced leukopenia in an European woman.
Topics: Adult; Asian People; Azathioprine; Crohn Disease; Female; Humans; Leukopenia; Pyrophosphatases | 2022 |
Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
Topics: Azathioprine; Biomarkers; Crohn Disease; Drug Therapy, Combination; Female; Guanine Nucleotides; Hum | 2021 |
Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.
Topics: Adult; Antimetabolites; Azathioprine; Biological Products; Crohn Disease; Drug Monitoring; Drug Syne | 2021 |
Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study.
Topics: Adalimumab; Adolescent; Azathioprine; Child; Crohn Disease; Denmark; Drug Therapy, Combination; Fema | 2021 |
Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunologic Factors; Immunosuppressive Agents | 2021 |
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Gastrointestinal Agents; Humans; Ma | 2021 |
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Topics: Azathioprine; Crohn Disease; Gastrointestinal Agents; Humans; Infliximab; Oncostatin M | 2020 |
Oral non-specific lesions in patient with Crohn's disease - a case report.
Topics: Adalimumab; Adult; Azathioprine; Crohn Disease; Drug-Related Side Effects and Adverse Reactions; Fem | 2020 |
Does Perianal Disease Influence the Efficacy of Combination Therapy in Crohn's Disease?
Topics: Adult; Anal Canal; Anus Diseases; Azathioprine; Crohn Disease; Drug Therapy, Combination; Endoscopy, | 2021 |
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biological Products; Colitis, Ulcerative; Crohn Disea | 2021 |
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biological Products; Colitis, Ulcerative; Crohn Disea | 2021 |
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biological Products; Colitis, Ulcerative; Crohn Disea | 2021 |
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biological Products; Colitis, Ulcerative; Crohn Disea | 2021 |
There is still a place for optimised thiopurine therapy in IBD.
Topics: Azathioprine; Crohn Disease; Humans; Mercaptopurine | 2021 |
Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Topics: Adolescent; Antimetabolites; Azathioprine; Biomarkers, Pharmacological; Child; Cohort Studies; Colit | 2022 |
Intrahepatic cholestasis of pregnancy associated with azathioprine: A case series.
Topics: Adult; Azathioprine; Bile Acids and Salts; Cholagogues and Choleretics; Cholestasis, Intrahepatic; C | 2021 |
Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
Topics: Adolescent; Adult; Azathioprine; Biological Products; Chronic Disease; Colitis, Ulcerative; Crohn Di | 2022 |
Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
Topics: Adult; Azathioprine; Clinical Trials as Topic; Constriction, Pathologic; Crohn Disease; Endoscopy, G | 2021 |
Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.
Topics: Adolescent; Azathioprine; Biomarkers; Child; Crohn Disease; Drug Therapy, Combination; Female; Human | 2021 |
Redox imbalance in Crohn's disease patients is modulated by Azathioprine.
Topics: Antioxidants; Azathioprine; Crohn Disease; Humans; Oxidation-Reduction; Oxidative Stress | 2021 |
CMV pneumonitis in a patient with Crohn's disease taking azathioprine.
Topics: Antiviral Agents; Azathioprine; Crohn Disease; Cytomegalovirus Infections; Female; Ganciclovir; Huma | 2021 |
Azathioprine-induced toxoplasma gondii infection in a patient with Crohn's disease with NUDT15 variation: A case report.
Topics: Azathioprine; Crohn Disease; DNA Mutational Analysis; Humans; Male; Middle Aged; Mutation; Pharmacog | 2021 |
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Control Groups; Crohn Disease; Female; Gastr | 2021 |
Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.
Topics: Adult; Azathioprine; Cohort Studies; Crohn Disease; Datasets as Topic; Female; France; Gastrointesti | 2022 |
Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Feces; Humans; Inflammatory Bowel Diseases; Leukoc | 2021 |
Simultaneous Monitoring of Azathioprine Metabolites in Erythrocytes of Crohn's Disease Patients by HPLC-UV.
Topics: Azathioprine; Chromatography, High Pressure Liquid; Crohn Disease; Erythrocytes; Humans; Immunosuppr | 2022 |
An Unusual Cause of Erythema on Both Lower Legs in a Patient With Crohn's Disease.
Topics: Arthralgia; Azathioprine; C-Reactive Protein; Cough; Crohn Disease; Drug Hypersensitivity Syndrome; | 2022 |
Vulvar Crohn's disease in an adolescent diagnosed after unsuccessful surgical treatment.
Topics: Adolescent; Azathioprine; Crohn Disease; Female; Humans; Recurrence; Vulvar Diseases | 2021 |
Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy.
Topics: Adolescent; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Gastrointestinal Agents; | 2017 |
Beyond remission and mucosal healing in Crohn's disease. Exploring the deep with cross sectional imaging.
Topics: Azathioprine; Crohn Disease; Humans; Intestinal Mucosa; Remission Induction; Treatment Outcome; Woun | 2017 |
Chronic paracoccidioidmycosis in a woman with Crohn Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chronic Disease; Crohn Disease; Female; Gingi | 2017 |
Granulomatous cheilitis mimicking angioedema.
Topics: Adolescent; Angioedema; Azathioprine; Crohn Disease; Diagnosis, Differential; Gastrointestinal Agent | 2017 |
Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Gastrointestinal Agents; G | 2017 |
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biomarkers; Colitis, Ulcerative; Crohn Disease; Diges | 2018 |
Combination Therapy with Dose Optimized Thiopurine and Adalimumab in Crohn's Disease.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azathioprine; Combined Moda | 2017 |
Thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection: Strategy based on risk stratification.
Topics: Adolescent; Adult; Aged; Azathioprine; Cohort Studies; Colectomy; Crohn Disease; Female; Follow-Up S | 2018 |
Large atrial mass in a patient with Crohn's disease: organised thrombus mimicking a myxoma.
Topics: Adult; Azathioprine; Coronary Thrombosis; Crohn Disease; Diagnosis, Differential; Echocardiography, | 2017 |
Crohn's Disease: Hard to Swallow!
Topics: Adult; Azathioprine; Colectomy; Crohn Disease; Deglutition Disorders; Endoscopy, Digestive System; E | 2017 |
Hypersensitivity to azathioprine in a patient with Crohn's disease: a case report.
Topics: Azathioprine; Crohn Disease; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; Middle | 2017 |
Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease.
Topics: Adult; Azathioprine; Cohort Studies; Crohn Disease; Disease Progression; Female; Follow-Up Studies; | 2018 |
A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease.
Topics: Azathioprine; Crohn Disease; Female; Homozygote; Humans; Immunosuppressive Agents; Infant, Newborn; | 2018 |
Management of Postoperative Crohn's Disease: Missing Pieces of the Puzzle.
Topics: Adalimumab; Algorithms; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Monitoring; Endo | 2017 |
Visceral Leishmaniasis Infection in a Patient with Crohn's Disease Treated with Azathioprine.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Leishmaniasis, Visceral; Youn | 2017 |
Infliximab-induced acne and acute localized exanthematous pustulosis: Case report.
Topics: Acne Vulgaris; Acute Generalized Exanthematous Pustulosis; Adult; Azathioprine; Azithromycin; Clobet | 2017 |
Effects of Perianal Involvement on Clinical Outcomes in Crohn's Disease over 10 Years.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anus Diseases; Azathioprine; Crohn Disease; Disease Prog | 2018 |
Adalimumab trough levels predict Crohn's disease clinical course.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug The | 2018 |
Azathioprine-induce acute submandibular sialadenitis in a patient with Crohn's disease.
Topics: Acute Disease; Adult; Azathioprine; Budesonide; Crohn Disease; Drug Substitution; Humans; Immunosupp | 2018 |
Vulvar swelling as the first presentation of Crohn's disease in children-A report of three cases.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Endoscopy, Gastrointestinal; Female; Humans; Immunos | 2018 |
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply.
Topics: Antibodies, Monoclonal; Azathioprine; Biosimilar Pharmaceuticals; Crohn Disease; Gastrointestinal Ag | 2017 |
Clinical factors are associated with vitamin D levels in IBD patients: A retrospective analysis.
Topics: Azathioprine; Cholecalciferol; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Agents; Germany; | 2018 |
Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Drug Therapy, Combination; Female; Gastrointestinal | 2018 |
Role of thiopurines as disease-modifying agents in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine | 2018 |
Letter: addition of azathioprine to infliximab maintenance therapy in patients with anti-drug antibodies and subclinical inflammation.
Topics: Adalimumab; Antibody Formation; Azathioprine; Crohn Disease; Humans; Immunologic Factors; Immunosupp | 2018 |
Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease.
Topics: Adult; Antirheumatic Agents; Asymptomatic Diseases; Azathioprine; Capsule Endoscopy; Cohort Studies; | 2018 |
[Severe lymphopenia in a patient with Crohn's disease].
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; F | 2018 |
Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Biological Factors; Crohn Disease; Databases, Factual; | 2018 |
Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
Topics: Adolescent; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gastr | 2018 |
Mutilating male genital Crohn's without gastrointestinal involvement.
Topics: Azathioprine; Crohn Disease; Genital Diseases, Male; Humans; Immunosuppressive Agents; Male; Middle | 2018 |
Severe complication during remission of Crohn's disease: hemophagocytic lymphohistiocytosis due to acute cytomegalovirus infection.
Topics: Adult; Antiviral Agents; Azathioprine; Crohn Disease; Cytomegalovirus; Cytomegalovirus Infections; H | 2018 |
[Role of Rac1 signaling pathway of azathioprine and peptidoglycan in the regulation of monocyte-macrophage apoptosis in Crohn's disease].
Topics: Apoptosis; Azathioprine; Case-Control Studies; Crohn Disease; Humans; Inflammation; Intestinal Mucos | 2018 |
Letter: infliximab concentrations during induction therapy-one size does not fit all.
Topics: Azathioprine; Crohn Disease; Humans; Infliximab | 2018 |
6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease.
Topics: Adolescent; Adult; Australia; Azathioprine; Biomarkers; China; Crohn Disease; Cross-Sectional Studie | 2018 |
Effects of Anti-TNF
Topics: Adalimumab; Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Female; Flow Cytometry; Humans; In | 2018 |
Idiopathic Thrombocytopenic Purpura Responsive to Surgery for Crohn's Disease.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Male; Prognosis; Purpura, Thro | 2019 |
Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn's disease.
Topics: Azathioprine; Colectomy; Colonoscopy; Crohn Disease; Databases, Factual; Female; Follow-Up Studies; | 2018 |
Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.
Topics: Adult; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppre | 2018 |
Positioning biologics-A case-based discussion: Ustekinumab.
Topics: Adult; Antibodies, Monoclonal; Australia; Azathioprine; Biosimilar Pharmaceuticals; Crohn Disease; D | 2018 |
Positioning biologics-A case-based discussion: Vedolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Biosimilar Pharmaceuticals; Crohn Disease; F | 2018 |
Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biomarkers; Crohn Disease; Cross-Sectional Studies; D | 2019 |
Cerebral granulomatosis as a manifestation of Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Brain Diseases; Crohn Disease; Disease Progression; Fe | 2018 |
A risk score system to timely manage treatment in Crohn's disease: a cohort study.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Crohn Disease; Disease Progression; Female; Follow-Up | 2018 |
Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based Study.
Topics: Adolescent; Azathioprine; Biomarkers; Child; Child, Preschool; Cohort Studies; Colitis, Ulcerative; | 2019 |
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Topics: Adalimumab; Adult; Azathioprine; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Digestive Syste | 2019 |
Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Cholangit | 2019 |
Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Combined Modality Therapy; Crohn Disease; Drug Ad | 2018 |
Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Biological Products; Crohn Disease; Female | 2019 |
Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Adminis | 2019 |
Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease.
Topics: Adult; Age of Onset; Azathioprine; Crohn Disease; Deoxyuridine; Diagnosis, Differential; Female; Gas | 2019 |
Asymptomatic Macrocheilia in an Adult Woman.
Topics: Asymptomatic Diseases; Azathioprine; Biopsy, Needle; Cheilitis; Colonoscopy; Crohn Disease; Female; | 2019 |
An infiltrated vulvar plaque: Metastatic cutaneous Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Edema; Erythema; Female; Gluco | 2019 |
Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy.
Topics: Azathioprine; Bone Marrow; Crohn Disease; Humans; Immunosuppressive Agents; Mesenchymal Stem Cell Tr | 2018 |
Mean Corpuscular Volume to White Blood Cell Ratio for Thiopurine Monitoring in Pediatric Inflammatory Bowel Disease.
Topics: Adolescent; Area Under Curve; Azathioprine; C-Reactive Protein; Child; Colitis, Ulcerative; Crohn Di | 2019 |
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Topics: Adalimumab; Adult; Age Factors; Antibodies; Azathioprine; Cohort Studies; Crohn Disease; Drug Therap | 2019 |
Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.
Topics: Adult; Azathioprine; Cholelithiasis; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Fe | 2019 |
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; A | 2019 |
Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment.
Topics: Adrenal Cortex Hormones; Adult; Analysis of Variance; Anemia; Anti-Inflammatory Agents; Azathioprine | 2019 |
A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Lymphomatoid Granulomatosis; Male; Mi | 2019 |
Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Erythrocyte Indic | 2019 |
Diagnostic accuracy of intestinal ultrasound and magnetic resonance enterography for the detection of endoscopy-based disease activity in ileocolonic Crohn's disease.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Az | 2019 |
Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Azathioprine; Colorectal Neopl | 2020 |
Regression of a giant pseudopolyp in a patient with colonic Crohn's disease after therapy with infliximab.
Topics: Adult; Azathioprine; Colon, Transverse; Colonic Polyps; Colonoscopy; Crohn Disease; Female; Gastroin | 2019 |
Primary sclerosing cholangitis, Crohn's disease and HLA-B27 in black South African women.
Topics: Adult; Alkaline Phosphatase; Azathioprine; Back Pain; Black People; Cholagogues and Choleretics; Cho | 2012 |
Thiopurine treatment in patients with Crohn's disease leads to a selective reduction of an effector cytotoxic gene expression signature revealed by whole-genome expression profiling.
Topics: Adult; Antigens, CD; Azathioprine; Cells, Cultured; Chemokines; Crohn Disease; Female; Gene Expressi | 2013 |
Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: a single-center paired case-control study.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Case-Control Studies; Cohort Studies; Crohn Disease; Dr | 2014 |
Analysis of thiopurine S-methyltransferase phenotype-genotype in a Tunisian population with Crohn's disease.
Topics: Alleles; Azathioprine; Crohn Disease; DNA; Erythrocytes; Female; Gene Frequency; Genotype; Humans; I | 2013 |
Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Crohn Disease; | 2013 |
Tremor as dose dependent side-effect of azathioprine in remission patient with ileal Crohn's disease.
Topics: Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Age | 2013 |
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug-Related Side Effects and Adverse React | 2013 |
Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factors.
Topics: Adolescent; Adult; Azathioprine; Biomarkers, Tumor; Child; Child, Preschool; Crohn Disease; Female; | 2013 |
Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Asian People; Azathioprine; Chi-Square Distrib | 2013 |
Neutrophilic dermatosis after azathioprine exposure.
Topics: Aged, 80 and over; Azathioprine; Crohn Disease; Diagnosis, Differential; Drug Eruptions; Female; Hum | 2013 |
Clinical drug response to thiopurines is associated to a lower interferon-γ production by IBD patient's T lymphocytes.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Interferon-gamma; Male; T-Lym | 2013 |
Headache in a young male: the clot thickens.
Topics: Adult; Anticoagulants; Azathioprine; Brain Infarction; Cranial Sinuses; Crohn Disease; Headache; Hep | 2013 |
Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn's Disease.
Topics: Antibodies, Monoclonal; Azathioprine; Child; Colostomy; Crohn Disease; Endoscopy; Gastrointestinal A | 2013 |
Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine.
Topics: Adult; Antibodies, Monoclonal; Antifungal Agents; Azathioprine; Crohn Disease; Drug Therapy, Combina | 2013 |
Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease?
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Contraindications; Crohn Disease; Drug Monitoring | 2013 |
Longstanding Crohn's vulvitis successfully treated with combined anti-TNFα antibody and azathioprine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Crohn Disease; | 2013 |
Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Biopsy, Needle; Colectomy; Crohn | 2013 |
The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Huma | 2014 |
Infliximab versus azathioprine to prevent postoperative recurrence in Crohn's disease: are all controversial issues defined?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female | 2013 |
Reply to Dr. Kotze's and Dr. Yamamoto's letter.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female | 2013 |
Is there still a role for thiopurines in Crohn's disease?
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2013 |
Phenotypic features of Crohn's disease associated with failure of medical treatment.
Topics: Adalimumab; Adolescent; Adult; Alberta; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclo | 2014 |
Results from early therapy with azathioprine in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Diarrhea, Infantile; Feces; Female; Humans; Immunoglobulin Fragments; I | 2013 |
[How should azathioprine be dosed in Crohn's disease? a novel strategy of maximum dose-titration based on the lower limit of leukocyte count and tolerability].
Topics: Adolescent; Adult; Aged; Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Drug Dosage | 2013 |
[Azathioprine-induced hepatotoxicity in a patient with Crohn's disease].
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Crohn Disease; Humans; Immunosuppressiv | 2013 |
Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Ant | 2014 |
Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis.
Topics: Adolescent; Azathioprine; Biomarkers; Child; Colitis, Ulcerative; Crohn Disease; Female; Follow-Up S | 2013 |
[Crohn's disease: no advantage by azathioprine and 6-mercaptopurine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Controlled Clinical T | 2013 |
[Infliximab in the treatment of refractory gastroduodenal Crohn's disease].
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Resistance; | 2014 |
Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study.
Topics: Adolescent; Adult; Age Distribution; Aged; Antigens, Viral; Azathioprine; Cohort Studies; Colitis, U | 2013 |
Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Cohort Studies; Colitis, Ulcerative; Crohn | 2014 |
Low-dose azathioprine is effective in maintaining remission among Chinese patients with Crohn's disease.
Topics: Adolescent; Adult; Aged; Asian People; Azathioprine; China; Crohn Disease; Decision Making; Dose-Res | 2013 |
[Outcome of chronic hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive drugs and anti-TNF agents].
Topics: Adalimumab; Adenine; Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azathioprine; Crohn | 2014 |
Azathioprine-induced neuro-psychiatric disorders.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Male; Mental Disorders | 2014 |
[News on Azathioprine in IBD].
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug-Related Side Effects and Adverse Reactions; F | 2013 |
[Determining the dose of azathioprine based on the lower limit of leukocyte count in patients with Crohn’s disease].
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Leukocytes; Male | 2013 |
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2014 |
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2014 |
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2014 |
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2014 |
[A case of pleomorphic liposarcoma in a patient with Crohn's disease taking azathioprine].
Topics: Adult; Azathioprine; Colonoscopy; Combined Modality Therapy; Crohn Disease; Fluorodeoxyglucose F18; | 2013 |
Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn's disease: a long-term follow-up study in a regional and academic cohort.
Topics: Academic Medical Centers; Adolescent; Adult; Antibodies, Monoclonal; Azathioprine; Combined Modality | 2013 |
Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2014 |
American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Topics: Azathioprine; Crohn Disease; Gastroenterology; Humans; Mercaptopurine; Methotrexate; Remission Induc | 2013 |
Kaposi's sarcoma developing in a HIV-negative Crohn's disease patient shortly after azathioprine and corticosteroid treatment.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Male; Middle | 2014 |
No increase in Epstein-Barr virus viral load in a group of 30 asymptomatic patients with Crohn's disease.
Topics: Adult; Aged; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Huma | 2013 |
Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Co | 2014 |
The debated role for thiopurines in Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopur | 2014 |
Cytomegalovirus-associated hemophagocytic syndrome in a patient with Crohn's disease receiving azathioprine.
Topics: Adult; Anti-Infective Agents; Antiviral Agents; Azathioprine; Bone Marrow Examination; Crohn Disease | 2013 |
Long-term prognosis of crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Crohn Disease; Female; Follow-Up Studies; Hospitals; H | 2014 |
Commentary: Individual vs. weight-based dosing of azathioprine in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Prodrugs | 2014 |
6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Treatment Outcome | 2014 |
Azathioprine in early Crohn's disease: time to revisit patient selection and end points for clinical trials and/or azathioprine efficacy?
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2014 |
Get the best out of thiopurine therapy.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2014 |
Shrinking indications for azathioprine in Crohn's disease: a conclusion too premature?
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2014 |
Reply: To PMID 23644079.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2014 |
Reply: To PMID 23644079.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2014 |
Early use of azathioprine in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2014 |
The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010.
Topics: Adult; Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Female; Follow-Up Studies; | 2014 |
Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects.
Topics: Adult; Antirheumatic Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; | 2014 |
Neutrophilic eccrine hidradenitis in a patient with Crohn's disease and azathioprine hypersensitivity syndrome.
Topics: Aged; Azathioprine; Crohn Disease; Drug Hypersensitivity; Hidradenitis; Humans; Immunosuppressive Ag | 2014 |
Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011.
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents; Azathioprine; Child; Child, Preschool; Colectomy; | 2014 |
Letter: metabolite monitoring for thiopurines in Crohn's disease - still not fully understood.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Prodrugs | 2014 |
Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study.
Topics: Adolescent; Adult; Azathioprine; Case-Control Studies; Crohn Disease; Drug Therapy, Combination; End | 2014 |
A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing!
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Child, Preschool; Cohort Studies; Crohn Di | 2014 |
[A case of IgG4-related sclerosing mesenteritis associated with Crohn's disease].
Topics: Anti-Inflammatory Agents; Appendix; Azathioprine; Colonoscopy; Crohn Disease; Female; Humans; Immuno | 2014 |
Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.
Topics: Adult; Alleles; Azathioprine; Brazil; Colitis, Ulcerative; Crohn Disease; Female; Genetic Variation; | 2014 |
The great masquerader: Behcet's disease.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Azathioprine; Behcet Syndrome; Crohn Disease; Cyclop | 2014 |
[Postoperative recurrence: adalimumab is an effective standard medication].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Dise | 2014 |
[Value of adhesion molecules for evaluating the efficiency of therapy for ulcerative colitis and Crohn's disease].
Topics: Adult; Aged; Antibodies, Monoclonal; Azathioprine; Biomarkers; Cell Adhesion Molecules; Colitis, Ulc | 2014 |
[Combination biological therapy for fistular Crohn's disease: clinical demonstration].
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Combined Modality Therapy; Crohn Disease; Drug Therapy, | 2014 |
Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Enteral Nutrition; Female; Genotype; Humans; Immunos | 2014 |
Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression.
Topics: Adult; Azathioprine; Crohn Disease; Diagnostic Imaging; Disease Progression; Female; Humans; Immunos | 2014 |
Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monocl | 2014 |
Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; C-Reactive Protein; Cohort Studies; Crohn | 2014 |
Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antimetabolites; Azathioprin | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Ag | 2014 |
Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease.
Topics: Adolescent; Azathioprine; Chemical and Drug Induced Liver Injury; Child; Crohn Disease; Female; Guan | 2014 |
Use of azathioprine in IBD: modern aspects of an old drug.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Agents; Inflammatory Bow | 2014 |
Serum adipokines in inflammatory bowel disease.
Topics: Adipokines; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Biopsy; Case-Con | 2014 |
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Topics: Adalimumab; Adult; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; | 2014 |
Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Anal Canal; Azathioprine; Child; Child, Prescho | 2014 |
Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease.
Topics: Adult; Azathioprine; Blood Component Removal; Crohn Disease; Early Diagnosis; Granulocytes; Humans; | 2014 |
Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease.
Topics: Adult; Azathioprine; Brain Neoplasms; Crohn Disease; Female; Humans; Immunocompromised Host; Immunos | 2014 |
An unusual cutaneous manifestation in a patient with cystic fibrosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Biopsy; Budesonide; Colonoscopy; Crohn Disease; Cystic Fibro | 2014 |
Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents; Azathioprine; Child; Crohn Disease; Drug Monitori | 2014 |
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.
Topics: Adult; Age Factors; Aged; Azathioprine; Communicable Diseases; Crohn Disease; Drug Therapy, Combinat | 2015 |
Long-term prevention of postoperative Crohn's disease recurrence with azathioprine: the wolf in the sheep clothing.
Topics: Azathioprine; Colonoscopy; Crohn Disease; Humans; Male; Middle Aged; Postoperative Period; Recurrenc | 2015 |
How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort.
Topics: Adrenal Cortex Hormones; Age of Onset; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Admini | 2014 |
Response to Fujita.
Topics: Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Humans; Mercaptopurine | 2014 |
Level of evidence supporting the use of thiopurine in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Humans; Mercaptopurine | 2014 |
Azathioprine induced Epstein Barr virus-positive mucocutaneous ulcer arising in perianal fistula and abscess associated with Crohn's disease.
Topics: Abscess; Anus Diseases; Azathioprine; Crohn Disease; Herpesvirus 4, Human; Humans; Immunosuppressive | 2014 |
Unusual gingival swelling in a 4-year-old child.
Topics: Anti-Bacterial Agents; Azathioprine; Child, Preschool; Crohn Disease; Diagnosis, Differential; Drug | 2014 |
Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.
Topics: Anti-Inflammatory Agents; Azathioprine; Biomarkers; Colitis, Ulcerative; Crohn Disease; Cross-Sectio | 2015 |
Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.
Topics: Adolescent; Adult; Aged; Azathioprine; Behcet Syndrome; Colitis, Ulcerative; Comorbidity; Crohn Dise | 2015 |
Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; C-Reactive Protein; Crohn Disease; Drug Therapy, Combin | 2015 |
A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azathioprine; C-Reac | 2014 |
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
Topics: Adult; Azathioprine; C-Reactive Protein; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunos | 2014 |
Shortness of breath in a patient with inflammatory bowel disease.
Topics: Azathioprine; Crohn Disease; Cytomegalovirus; Cytomegalovirus Infections; Dyspnea; Humans; Immunocom | 2014 |
Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Double-Balloon | 2014 |
Funding a smoking cessation program for Crohn's disease: an economic evaluation.
Topics: Adult; Azathioprine; Benzazepines; Canada; Cost-Benefit Analysis; Crohn Disease; Directive Counselin | 2015 |
[Neutrophilic eccrine hidradenitis and azathioprine hypersensitivity syndrome].
Topics: Azathioprine; Crohn Disease; Diagnosis, Differential; Drug Hypersensitivity; Hidradenitis; Humans; I | 2014 |
[Treatment with immunosupressants in a patient with Crohn's disease and common variable immunodeficiency].
Topics: Adrenal Cortex Hormones; Azathioprine; Campylobacter Infections; Common Variable Immunodeficiency; C | 2015 |
How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Gastroenterology; Guideline Adherence; Huma | 2015 |
Is less more: does leukopenia predict remission in patients with inflammatory bowel disease receiving thiopurine treatment?
Topics: Azathioprine; Behcet Syndrome; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive | 2015 |
Editorial: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Mercaptopurine | 2015 |
[Sudden fever attacks in a young Crohn disease patient. Would you have considered the heart here?].
Topics: Adult; Aortic Valve; Azathioprine; Bicuspid Aortic Valve Disease; Crohn Disease; Diagnosis, Differen | 2014 |
Impact of timing and duration of thiopurine treatment on first perianal surgery in Crohn's disease: UK population-based study (1995-2009).
Topics: Adolescent; Adult; Anus Diseases; Azathioprine; Crohn Disease; Digestive System Surgical Procedures; | 2015 |
Letter: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Mercaptopurine | 2015 |
Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy.
Topics: Adult; Azathioprine; Biomarkers; C-Reactive Protein; Child; Cohort Studies; Colitis, Ulcerative; Com | 2015 |
Vulval Crohn's disease: a clinical study of 22 patients.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents; Azathioprine; Child; Crohn Disease; Drug Th | 2015 |
Asymptomatic pulmonary embolism in patient with fistulizing mild Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Digestive System Fistula; Heparin, Low-Molecular-Weight; Humans; | 2016 |
[Knowledge of adolescents with inflammatory bowel disease: Results of a multicenter cross-sectional survey].
Topics: Adolescent; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Feeding Behav | 2015 |
Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cerebrovascular Disorders; | 2015 |
Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Comparative Genomic Hybridization; Crohn Disease; DNA Copy | 2015 |
Indian Society of Gastroenterology consensus statements on Crohn's disease in India.
Topics: Administration, Ophthalmic; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; | 2015 |
Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.
Topics: Adolescent; Adult; Aged; Azathioprine; Body Mass Index; Colitis, Ulcerative; Crohn Disease; Drug Eru | 2015 |
Paediatric anogenital Crohn's disease 11 years after Lichen planus - same background for two different entities?
Topics: Anal Canal; Azathioprine; Child; Ciprofloxacin; Crohn Disease; Drug Therapy, Combination; Female; Ge | 2016 |
Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
Topics: Adolescent; Anti-Inflammatory Agents; Arylamine N-Acetyltransferase; Azathioprine; Biotransformation | 2015 |
[Bone marrow toxicity secondary to a primary Epstein-Barr infection in a patient with Crohn's disease on thiopurines treatment].
Topics: Adolescent; Azathioprine; Bone Marrow Diseases; Crohn Disease; Epstein-Barr Virus Infections; Humans | 2015 |
Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Female; F | 2015 |
Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; | 2015 |
Methotrexate is an efficient therapeutic alternative in children with thiopurine-resistant Crohn's disease.
Topics: Azathioprine; Child; Child, Preschool; Cohort Studies; Crohn Disease; Drug Resistance; Female; Follo | 2015 |
Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease.
Topics: Adolescent; Azathioprine; Child; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Drug Resistance | 2015 |
A case of molluscum contagiosum infection in a patient with Crohn's disease, receiving combination therapy with azathioprine and adalimumab.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Drug Therap | 2015 |
Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Azathioprin | 2015 |
Editorial: post hoc analysis of SONIC trial.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; Gastrointestinal Agents; Humans; Immuno | 2015 |
Editorial: post hoc analysis of SONIC trial--authors' reply.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; Gastrointestinal Agents; Humans; Immuno | 2015 |
Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
Topics: Adolescent; Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Interactions; Female; Gast | 2015 |
Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn's Disease.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Humans; Immunosuppressive Agents; Male; Mercaptopuri | 2015 |
Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
Topics: Adult; Azathioprine; Biomarkers; Body Mass Index; Colitis, Ulcerative; Crohn Disease; Drug Administr | 2015 |
Intestinal spirochetosis: an unusual cause of IBD flare-up during anti-TNF therapy.
Topics: Adult; Azathioprine; Colonoscopy; Crohn Disease; Female; Humans; Infliximab; Intestines; Spirochaeta | 2016 |
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Topics: Adult; Antibodies, Viral; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; JC | 2015 |
[What therapy for which patient?].
Topics: Azathioprine; Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Precision | 2015 |
NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Topics: Adult; Alopecia; Anti-Inflammatory Agents; Asian People; Azathioprine; Chi-Square Distribution; Coli | 2016 |
Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
Topics: Adolescent; Age Factors; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; | 2015 |
Prevalence and prognostic value of hepatic histological alterations in patients with Crohn's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Biopsy; Crohn Disease; Elasticity Imaging | 2015 |
Clinical predictors of thiopurine-related adverse events in Crohn's disease.
Topics: Adolescent; Adult; Age Factors; Alberta; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Fema | 2015 |
Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Drug Th | 2016 |
A Rare Case of Azathioprine-Induced Sweet's Syndrome in a Patient with Crohn's Disease.
Topics: Anti-Inflammatory Agents; Azathioprine; Biopsy; Crohn Disease; Gastrointestinal Agents; Humans; Male | 2015 |
Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Azathioprine; Crohn Disease; Di | 2015 |
Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease.
Topics: Adolescent; Adult; Azathioprine; Colon; Crohn Disease; Endoscopy, Gastrointestinal; Female; Follow-U | 2015 |
TPMT Testing Before Starting Azathioprine or Mercaptopurine: Surely Just Do It?
Topics: Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Gastrointestinal | 2015 |
Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Diseas | 2015 |
Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977-2013.
Topics: Adolescent; Adult; Aged; Azathioprine; Case-Control Studies; Child; Child, Preschool; Colitis, Ulcer | 2015 |
Varicella Complicated by Severe Pneumonia and Shock in an Immunosuppressed Crohn's Disease Patient Under Azathioprine and Anti-Tumour Necrosis Factor Alpha.
Topics: Azathioprine; Chickenpox; Crohn Disease; Drug Therapy, Combination; Humans; Immunocompromised Host; | 2015 |
Histologically confirmed case of cerebral vasculitis associated with Crohn's disease--a case report.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; | 2015 |
Editorial: preventing disease progression in Crohn's--can we shut the stable door before the horse bolts?
Topics: Animals; Azathioprine; Crohn Disease; Disease Progression; Humans; Immunologic Factors; Mesalamine; | 2015 |
A 29-year-old woman with Crohn disease considering pregnancy.
Topics: Adult; Azathioprine; Crohn Disease; Delivery, Obstetric; Drug Administration Schedule; Drug Therapy, | 2016 |
Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity.
Topics: Acute Disease; Adult; Age Distribution; Aged; Analysis of Variance; Azathioprine; Colitis, Ulcerativ | 2016 |
Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort.
Topics: Adult; Azathioprine; Body Mass Index; China; Crohn Disease; Drug Therapy, Combination; Female; Follo | 2015 |
Oral manifestations of Crohn's disease.
Topics: Azathioprine; Cheilitis; Crohn Disease; Glucocorticoids; Humans; Male; Oral Ulcer; Pain; Prednisolon | 2015 |
Thromboembolism as an important complication of inflammatory bowel disease.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2016 |
Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
Topics: Adult; Analysis of Variance; Azathioprine; Cohort Studies; Colectomy; Crohn Disease; Databases, Fact | 2016 |
Azathioprine is effective for oral involvement in Crohn's disease but not for orofacial granulomatosis alone.
Topics: Adult; Azathioprine; Crohn Disease; Female; Granulomatosis, Orofacial; Humans; Intestinal Diseases; | 2016 |
Dengue Hemorrhagic Fever in a Child With Early-Onset Fistulizing Crohn Disease Under Infliximab and Azathioprine Treatment.
Topics: Azathioprine; Child; Crohn Disease; Female; Gastrointestinal Agents; Humans; Immunocompromised Host; | 2016 |
NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
Topics: Age Factors; Alopecia; Asian People; Azathioprine; Crohn Disease; Female; Gastrointestinal Agents; G | 2016 |
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Therapy, | 2016 |
Placental involvement by non-Hodgkin lymphoma in a Crohn disease patient on long-term thiopurine therapy.
Topics: Adult; Azathioprine; Crohn Disease; Female; Fetal Death; Humans; Lymphoma, Non-Hodgkin; Placenta; Pl | 2016 |
Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease.
Topics: Adult; Anemia; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory Bowel | 2016 |
Does the intestinal microbial community of Korean Crohn's disease patients differ from that of western patients?
Topics: Acidobacteria; Actinobacteria; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Azathio | 2016 |
Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Crohn Disease; Enteral Nutrition; Humans; | 2016 |
Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion.
Topics: Adolescent; Azathioprine; Crohn Disease; Drug Substitution; Drug Therapy, Combination; Enteral Nutri | 2016 |
Case report of cheilitis granulomatosa and joint complaints as presentation of Crohn's disease.
Topics: Adolescent; Arthralgia; Azathioprine; Crohn Disease; Diagnosis, Differential; Drug Therapy, Combinat | 2016 |
Baseline Wall Thickness Is Lower in Mucosa-Healed Segments 1 Year After Infliximab in Pediatric Crohn Disease Patients.
Topics: Adolescent; Azathioprine; Child; Colon; Colonoscopy; Crohn Disease; Drug Therapy, Combination; Femal | 2017 |
Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn's Disease Under Combined Immunosuppression: Escalation versus Early Treatment.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Drug Administration Schedule; Drug Therapy, Combinat | 2016 |
Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients.
Topics: Adult; Azathioprine; Crohn Disease; Drug Monitoring; Erythrocytes; Female; Guanine Nucleotides; Huma | 2016 |
Abnormal Findings Lead to Surprising Diagnosis.
Topics: Azathioprine; Child; Crohn Disease; Diagnosis, Differential; Female; Gastrointestinal Agents; Genita | 2017 |
Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis.
Topics: Adult; Aged; Azathioprine; Crohn Disease; Female; France; Humans; Immunosuppressive Agents; Life Exp | 2016 |
Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites; Azathioprine; Blood Sedime | 2016 |
Coexistence of Celiac and Crohn's Disease in a Patient Presenting with Chronic Diarrhea.
Topics: Antirheumatic Agents; Azathioprine; Celiac Disease; Colonoscopy; Crohn Disease; Diarrhea; Diet, Glut | 2016 |
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
Topics: Adalimumab; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans | 2016 |
Severe perianal shingles during azathioprine and budesonide treatment for Crohn's disease-preventable with zoster vaccine?
Topics: Adult; Animals; Azathioprine; Budesonide; Crohn Disease; Glucocorticoids; Herpes Zoster; Herpes Zost | 2016 |
Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Mercaptopurine; | 2016 |
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi | 2016 |
Azathioprine hypersensitivity presenting as neutrophilic dermatosis and erythema nodosum.
Topics: Azathioprine; Crohn Disease; Drug Hypersensitivity; Erythema Nodosum; Humans; Immunosuppressive Agen | 2016 |
Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.
Topics: Adalimumab; Adult; Antirheumatic Agents; Azathioprine; Case-Control Studies; Cohort Studies; Colitis | 2016 |
Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema.
Topics: Adolescent; Adult; Aged; Anus Diseases; Azathioprine; Child; Crohn Disease; Genital Diseases, Male; | 2017 |
Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Me | 2016 |
Mercaptopurine and inflammatory bowel disease: the other thiopurine.
Topics: Adult; Aged; Azathioprine; Cohort Studies; Crohn Disease; Female; Humans; Immunosuppressive Agents; | 2017 |
Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.
Topics: Azathioprine; Blood Group Antigens; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Ag | 2017 |
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies; Antibody Formation; Azathioprine; Colitis, | 2017 |
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Disease; Dise | 2017 |
Vulvar inflammation: a presentation of Crohn's disease.
Topics: Adolescent; Adult; Antirheumatic Agents; Azathioprine; Biopsy; Colonoscopy; Crohn Disease; Disease P | 2017 |
Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Anus Diseases; Azathioprine; Biopsy, Needle; Crohn Disease; | 2016 |
Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.
Topics: Adalimumab; Adult; Antirheumatic Agents; Azathioprine; Biological Products; Crohn Disease; Digestive | 2017 |
Ganciclovir-induced ataxia and encephalopathy.
Topics: Antiviral Agents; Ataxia; Azathioprine; Brain Diseases; Crohn Disease; Cytomegalovirus Infections; F | 2016 |
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Topics: Adult; Azathioprine; C-Reactive Protein; Crohn Disease; Feces; Female; Gastrointestinal Agents; Huma | 2017 |
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathio | 2017 |
Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Biopsy; Crohn Disease; Drug Administra | 2016 |
Oesophageal presentation of Crohn's disease.
Topics: Azathioprine; Chest Pain; Crohn Disease; Deglutition Disorders; Endoscopy, Digestive System; Esophag | 2017 |
Methotrexate for Refractory Crohn's Disease Compared with Thiopurines: A Retrospective Non-head-to-head Controlled Study.
Topics: Adult; Azathioprine; Crohn Disease; Drug Resistance; Female; Humans; Immunosuppressive Agents; Induc | 2017 |
Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Cohort Studies; Colectomy; Colitis, Ulcerative; | 2017 |
Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study.
Topics: Adalimumab; Adolescent; Adult; Age of Onset; Azathioprine; Cohort Studies; Crohn Disease; Digestive | 2017 |
CSF-1 regulates the function of monocytes in Crohn's disease patients in remission.
Topics: Adult; Aged; Azathioprine; Case-Control Studies; Cell Differentiation; Cell Movement; Cells, Culture | 2017 |
Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age.
Topics: Adolescent; Azathioprine; Blood Cell Count; Crohn Disease; Erythrocyte Aging; Erythrocytes; Female; | 2008 |
Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy.
Topics: Adult; Anti-Infective Agents; Antibodies, Monoclonal; Azathioprine; Capsule Endoscopy; Cohort Studie | 2008 |
[Cutaneous manifestation of hypersensibility to azathioprine in a Crohn's disease patient].
Topics: Adolescent; Azathioprine; Crohn Disease; Drug Eruptions; Humans; Male | 2008 |
Early combined immunosuppression in Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Infliximab; R | 2008 |
Early combined immunosuppression in Crohn's disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Administration Sc | 2008 |
[Biological therapy as treatment of inflammatory bowel diseases].
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aza | 2008 |
Treatment of inflammatory bowel disease: a role for hypnotherapy?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2008 |
Azathioprine-induced Sweet's syndrome in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Sweet Syndrome | 2008 |
Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
Topics: Azathioprine; Child; Child, Preschool; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Factor An | 2008 |
Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab.
Topics: Adolescent; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Fema | 2008 |
Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Hyperse | 2008 |
Sweet syndrome as a manifestation of azathioprine hypersensitivity.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Hypersensitivity; Humans; Immuno | 2008 |
[Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease].
Topics: Ascites; Azathioprine; Blood Cell Count; Crohn Disease; Diagnosis, Differential; Fatigue; Focal Nodu | 2008 |
Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Body Heig | 2009 |
Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Az | 2008 |
Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Asian People; Azathioprine; Bone Marrow; Case-Control Studies; Colitis, Ulc | 2008 |
6-mercaptopurine as an alternative to azathioprine in azathioprine-induced hepatoxicity.
Topics: Adolescent; Azathioprine; Chemical and Drug Induced Liver Injury; Child; Crohn Disease; Humans; Immu | 2009 |
Association of idiopathic inflammatory myopathy and Crohn's disease.
Topics: Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease | 2009 |
Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Ciprof | 2009 |
Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus.
Topics: Adult; Azathioprine; Blood; Chickenpox; Crohn Disease; DNA, Viral; Fatal Outcome; Genotype; Herpesvi | 2009 |
Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Glucocorticoids; Humans | 2009 |
[Crohn's disease in association with IgA nephropathy].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antimetabo | 2008 |
[Which place for methotrexate in treatment of luminal Crohn's disease?].
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Methotrexate; Tumor Necrosis Factor-a | 2009 |
Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy.
Topics: Anti-Inflammatory Agents; Azathioprine; Behcet Syndrome; Colonoscopy; Crohn Disease; Humans; Male; M | 2008 |
[Bacillus cereus bacteremia in Crohn's disease with multiple ileal stricture on maintenance azathioprine therapy].
Topics: Adult; Azathioprine; Bacillus cereus; Bacteremia; Crohn Disease; Humans; Ileal Diseases; Ileum; Immu | 2009 |
[Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Age | 2008 |
Posterior reversible encephalopathy syndrome following infliximab infusion.
Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Brain Di | 2009 |
Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Crohn Disease; Drug Th | 2009 |
Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Fatal Outcome; Humans; Immunosupp | 2009 |
[Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Cortisone; Crohn Disease; Drug Thera | 2009 |
Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.
Topics: Adolescent; Adult; Aged; Asian People; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Hum | 2009 |
Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy; Humans; | 2009 |
Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Gastrointestinal Agents; Genetic Predisposition | 2009 |
[Inflammatory bowel disease. If a patient with Crohn's disease remains in remission for 4 years with azathioprine (or mercaptopurine), should the drug be withdrawn?].
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Remission Induction; | 2008 |
Cutaneous presentation of kwashiorkor due to infantile Crohn's disease.
Topics: Administration, Oral; Azathioprine; Crohn Disease; Diagnosis, Differential; Dose-Response Relationsh | 2010 |
Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.
Topics: Adult; Azathioprine; Bone Marrow Cells; Crohn Disease; Female; Genetic Testing; Humans; Methyltransf | 2009 |
[Perianal fistulas in Crohn's disease: treatment results at an interdisciplinary unit].
Topics: Abscess; Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; | 2009 |
[Mononucleosis syndrome of multiple etiologies in a patient with Crohn's disease and azathioprine treatment].
Topics: Adolescent; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Infectious Mononu | 2009 |
Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Erythema Infectiosum; Female; Humans; Immunosuppressive Agents; | 2009 |
Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Longitudinal Studie | 2009 |
[Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
Topics: Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Child; Crohn Disease; Dr | 2009 |
Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.
Topics: Administration, Oral; Adolescent; Azathioprine; Child; Crohn Disease; Drug Resistance; Drug Toleranc | 2009 |
Clinical spectrum of vulva metastatic Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Colon; Colonoscopy; Crohn Disease; Disease Progression; | 2009 |
Inflammatory bowel disease potpourri: a vignette-based discussion.
Topics: Adult; Allopurinol; Azathioprine; Clostridioides difficile; Colitis, Ulcerative; Crohn Disease; Drug | 2009 |
Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Recurrence; Remission I | 2010 |
Infliximab for postsurgical endoscopic recurrence of Crohn's disease: no trumpets yet.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr | 2009 |
Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.
Topics: Anti-Inflammatory Agents; Azathioprine; Body Mass Index; Colitis, Ulcerative; Crohn Disease; Drug Ad | 2010 |
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Budesonide; Cas | 2009 |
Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Chi-Square Distribution; Crohn Disease; Drug Therapy, C | 2010 |
Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Azathioprine; Crohn | 2009 |
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressi
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, R | 2010 |
Takayasu's aortitis and infliximab.
Topics: Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; H | 2009 |
Hepatocellular carcinoma occurring in a young Crohn's disease patient.
Topics: Adolescent; Adult; Age of Onset; Antibodies, Monoclonal; Azathioprine; Carcinoma, Hepatocellular; Cr | 2009 |
Azathioprine treatment during lactation.
Topics: Adult; Azathioprine; Breast Feeding; Crohn Disease; Female; Follow-Up Studies; Humans; Immunosuppres | 2009 |
Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.
Topics: Adult; Anus Diseases; Azathioprine; Biomarkers; Crohn Disease; Disease Progression; Female; Humans; | 2009 |
Acute lymphoid leukemia in a Crohn's disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aza | 2010 |
Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colit
Topics: Adolescent; Adult; Azathioprine; Biological Therapy; Colectomy; Colitis, Ulcerative; Crohn Disease; | 2010 |
Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride?
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Chi- | 2010 |
Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.
Topics: Adult; Azathioprine; Carcinogens; Cell Proliferation; Child; Child, Preschool; Colitis, Ulcerative; | 2009 |
Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease.
Topics: Adolescent; Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Crohn | 2010 |
Course of inflammatory bowel disease in patients infected with human immunodeficiency virus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiretroviral Therapy, Highly Active; Azathioprine; | 2010 |
Epstein-Barr virus and parvovirus B19 coinfection in a Crohn's disease patient under azathioprine.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Fluconazole; Gra | 2010 |
Immunomodulation with methotrexate: underused and undervalued?
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Immune Tolerance; Immunologic Factors | 2009 |
Azathioprine plus ribavirin treatment and pancytopenia.
Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Azathioprine; Crohn Disease; Drug Interactions; H | 2009 |
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, C | 2010 |
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, C | 2010 |
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, C | 2010 |
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, C | 2010 |
Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Azathi | 2010 |
The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
Topics: Adolescent; Adult; Age Distribution; Azathioprine; Cohort Studies; Colectomy; Crohn Disease; Female; | 2010 |
Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Colitis, | 2010 |
Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aza | 2009 |
Beyond these insights there are further applications and future challenges.
Topics: Azathioprine; Crohn Disease; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; Me | 2010 |
An infant with severe refractory Crohn's disease and homozygous MEFV mutation who dramatically responded to colchicine.
Topics: Azathioprine; Colchicine; Crohn Disease; Cyclosporine; Cytoskeletal Proteins; Drug Therapy, Combinat | 2012 |
Herpes simplex virus meningoencephalitis in a patient with Crohn's disease on azathioprine therapy.
Topics: Adult; Azathioprine; Crohn Disease; Encephalitis, Herpes Simplex; Female; Humans; Immunosuppressive | 2010 |
Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease.
Topics: Azathioprine; Biomarkers, Tumor; Chromosomal Instability; Colitis, Ulcerative; Colon; Colonic Neopla | 2010 |
[Significant changes of pharmacotherapy in gastroenterological rehabilitation of Crohn's disease].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2009 |
Efficacy of azathioprine in mild or moderate relapse in Crohn's disease: clinical and endoscopic evaluation.
Topics: Adult; Azathioprine; Crohn Disease; Endoscopy, Gastrointestinal; Erythrocyte Indices; Female; Humans | 2010 |
[A case of monozygotic twins with Crohn's disease].
Topics: Adolescent; Antimetabolites; Azathioprine; Colonoscopy; Crohn Disease; Diseases in Twins; Humans; Ma | 2010 |
A probable case of transfusion-transmitted hepatitis B virus infection in an immunosuppressed recipient caused by an occult HBV-infected donor with negative ID-NAT.
Topics: Acute Disease; Adult; Azathioprine; Blood Donors; Carrier State; Crohn Disease; DNA, Viral; False Ne | 2010 |
[Cytomegalovirus primary infection in a patient with Crohn's disease treated with azathioprine and anti-TNF alpha].
Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Azathioprine; Crohn Disease; Cytomegalovirus Infect | 2009 |
Thiopurine S-methyltransferase deficiency associated with a novel mutation.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Benzazepines; Crohn Disease; Heterozygote; Humans; Ma | 2010 |
Exacerbation of hereditary warfarin resistance by azathioprine.
Topics: Adult; Amino Acid Substitution; Anticoagulants; Antimetabolites; Azathioprine; Crohn Disease; Drug R | 2011 |
Acute myeloid leukemia after one month of azathioprine therapy in a Crohn's disease patient.
Topics: Adult; Azathioprine; Chromosomes, Human, Pair 21; Crohn Disease; Humans; Immunosuppressive Agents; I | 2010 |
Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimetabolites; Azathioprine; Crohn Disease; Female; Humans | 2010 |
Adverse reactions to azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Treatment Outcome | 2009 |
[Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr | 2010 |
Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha.
Topics: Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Humans; Immunosuppressive Age | 2010 |
Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Aorta, Abdominal; Aortitis; Azathioprine; Crohn Di | 2010 |
A population-based study of health-care resource use among infliximab users.
Topics: Adult; Analysis of Variance; Antibodies, Monoclonal; Azathioprine; Chi-Square Distribution; Crohn Di | 2010 |
Efficacy of early treatment with infliximab in pediatric Crohn's disease.
Topics: Adolescent; Antibodies, Monoclonal; Azathioprine; Child; Child, Preschool; Crohn Disease; Female; Hu | 2010 |
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Azathioprine; Cohort Studies; Confidence Intervals; Crohn | 2010 |
The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Exons; | 2010 |
Incidence, severity, and etiology of drug-induced acute pancreatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Cr | 2010 |
Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine.
Topics: Azathioprine; B-Lymphocytes; Child; Crohn Disease; Herpesvirus 4, Human; Humans; Immunosuppressive A | 2010 |
[Azathioprine: live long without probation?].
Topics: Adult; Azathioprine; C-Reactive Protein; Cohort Studies; Crohn Disease; Female; Follow-Up Studies; H | 2010 |
Nodular regenerative hyperplasia of the liver secondary to azathioprine in a patient with inflammatory bowel disease.
Topics: Azathioprine; Biopsy; Chemical and Drug Induced Liver Injury; Crohn Disease; Diagnosis, Differential | 2010 |
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Administ | 2010 |
Hepatocellular carcinoma occurring in a Crohn's disease patient.
Topics: Adult; Azathioprine; Carcinoma, Hepatocellular; Crohn Disease; Humans; Immunosuppressive Agents; Liv | 2010 |
Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Asian People; Azathioprine; Cohort Studies; Coliti | 2011 |
Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Crohn Disease; Di | 2010 |
Multifocal motor neuropathy with conduction block following treatment with infliximab.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Azathioprine; Crohn Disease; Electromyography; | 2010 |
Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Crohn Disease; Female; Humans; Hyperpla | 2011 |
Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agen | 2010 |
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Chromatography, High Pressure Liquid; Colitis, Ulcerative; Cr | 2011 |
Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Agents; M | 2011 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppre | 2010 |
EBV hepatitis in a young Crohn's disease patient on prolonged remission with azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Hepatitis; Herpesvirus 4, Human; | 2011 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis; Azathioprine; Crohn Disease; Drug Thera | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Cost-Benefit Analysis; Crohn Disease; Drug Therapy, Combinatio | 2010 |
Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease.
Topics: Adolescent; Azathioprine; Biomarkers, Pharmacological; Child; Chromatography, High Pressure Liquid; | 2010 |
Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn disease.
Topics: Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Epstein-B | 2011 |
Lymphoma with central nervous system involvement in a young patient with Crohn disease treated with azathioprine.
Topics: Adolescent; Azathioprine; Brain Neoplasms; Crohn Disease; Female; Humans; Immunosuppressive Agents; | 2010 |
Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?
Topics: Adolescent; Adult; Aged; Anastomotic Leak; Antibodies, Monoclonal; Azathioprine; Colectomy; Crohn Di | 2011 |
Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr | 2010 |
Facial basal cell carcinoma in a young patient with Crohn disease.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Carcinoma, Basal Cell; Crohn Disease; Facial Neoplasm | 2010 |
Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
Topics: Adult; Allopurinol; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Fem | 2010 |
Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA.
Topics: Adult; Anastomosis, Surgical; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Colonic Pou | 2011 |
[Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease].
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Crohn Disease; Humans; Hyperplasia; Hypertensi | 2011 |
Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Combined Modality Therapy; Crohn Disease; Drug Administration Sched | 2011 |
The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts.
Topics: Attitude of Health Personnel; Azathioprine; Crohn Disease; Drug Utilization; Epidemiologic Methods; | 2011 |
Internal iliac vein thrombosis in pediatric Crohn's disease.
Topics: Anticoagulants; Azathioprine; Child; Crohn Disease; Early Diagnosis; Female; Heparin; Humans; Iliac | 2011 |
Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease-the authors' response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agen | 2011 |
[To grow up with Crohn's disease].
Topics: Adolescent; Adrenal Cortex Hormones; Age of Onset; Anti-Inflammatory Agents; Azathioprine; Child; Cr | 2011 |
Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding.
Topics: Adult; Azathioprine; Breast Feeding; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Fe | 2011 |
Who wants to take a thiopurine holiday?
Topics: Adult; Azathioprine; Biomarkers; Blood Sedimentation; C-Reactive Protein; Crohn Disease; Diagnostic | 2011 |
Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2011 |
Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Cells, C | 2011 |
Low risk of Clostridium difficile infections in hospitalized patients with inflammatory bowel disease in a German tertiary referral center.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Azathiop | 2011 |
[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2011 |
Cytomegalovirus associated hemophagocytic lymphohistiocytosis in patients suffering from Crohn's disease treated by azathioprine: a series of four cases.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cytomegalovirus; Cytomegalovirus Infections | 2011 |
Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Anemia; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Ferritins; Fever; Hu | 2011 |
Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; C | 2011 |
[Hodgkin's lymphoma in a patient with Crohn's disease treated with azathioprine and antibodies anti tumor necrosis factor α].
Topics: Azathioprine; Crohn Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Tumor Necrosis | 2012 |
[Long term evolution of corticodependant and corticoresistant Crohn's disease patients treated by azzathioprine].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Crohn Disease; Drug Resistance; Fema | 2011 |
Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Cost-B | 2011 |
[Takayasu's disease associated with Crohn's disease: two identical diseases at different sites?].
Topics: Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Glucocorticoids; Humans; Immunosuppre | 2011 |
Treatment of refractory Crohn's disease by intensive granulocyte and monocyte adsorption apheresis: a report on two drug refractory cases.
Topics: Adsorption; Adult; Antibodies, Monoclonal; Azathioprine; Blood Component Removal; C-Reactive Protein | 2011 |
Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn's colitis: harmful cure?
Topics: Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Im | 2011 |
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2011 |
[Crohn's disease presenting with erythema nodosum as an early sign: a case report].
Topics: Adolescent; Anti-Inflammatory Agents; Azathioprine; Colonoscopy; Crohn Disease; Erythema Nodosum; Fe | 2011 |
[Biologicals first-line in chronic inflammatory bowel disease? No].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biological Products; Cost-Benefit An | 2011 |
Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Cost-Benefit Analysis | 2012 |
Tolerance and efficacy of azathioprine in pediatric Crohn's disease.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Cohort Studies; Crohn Disease; Enteral Nutrition; | 2011 |
Gut-liver axis plays a role in hepatocarcinogenesis of patients with Crohn's disease.
Topics: Azathioprine; Carcinoma, Hepatocellular; Crohn Disease; Humans; Immunosuppressive Agents; Liver Neop | 2011 |
Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antigens, CD; Antigens, Diff | 2012 |
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Decision Support Techniques; Drug Therap | 2012 |
Splenic littoral cell hemangioendothelioma in a patient with Crohn's disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immunosuppression.
Topics: Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemang | 2011 |
Uveitis preceding Crohn's disease by 8 years.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Child, Preschool; Crohn Disease; Drug | 2011 |
Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease.
Topics: Adult; Age Factors; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Dose-Response Relat | 2012 |
Surgical repair and biological therapy for fecal incontinence in Crohn's disease involving both sphincter defects and complex fistulas.
Topics: Abscess; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Anus Diseases; Azathioprine; Crohn | 2011 |
Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Az | 2011 |
Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acid; Anti-Inflammatory Agents; Anti-Inflammatory Age | 2011 |
Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry.
Topics: Azathioprine; Chromatography, High Pressure Liquid; Crohn Disease; Erythrocytes; Guanine Nucleotides | 2012 |
Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Chi-Square Dis | 2012 |
Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn's disease.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn | 2011 |
Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female | 2012 |
Is there any association between IgA nephropathy, Crohn's disease and Helicobacter pylori infection?
Topics: Azathioprine; Crohn Disease; Drug Therapy, Combination; Follow-Up Studies; Glomerulonephritis, IGA; | 2012 |
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Case-Control Studies; Child; Colitis, Ulcerative; Croh | 2012 |
[CED therapy with infliximab. Rapid and lasting remission - complete mucosal healing].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Crohn Disease; | 2011 |
[FAQs in chronic inflammatory bowel diseases. This way your patient stays in remission].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Colonoscopy; Cr | 2011 |
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, | 2012 |
Initiating azathioprine for Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Cytotoxins; Female; Humans; Immunosuppressive Agents; Methyltran | 2012 |
Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biomarkers; C-Reactive Protei | 2012 |
Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Azathioprine; Chemical and Drug Induced Liver Injury; C | 2012 |
Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; Drug Therapy, Com | 2012 |
Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aza | 2012 |
Spot diagnosis: eruptive melanocytic naevi during azathioprine therapy in Crohn's disease.
Topics: Azathioprine; Colonoscopy; Crohn Disease; Diagnosis, Differential; Dose-Response Relationship, Drug; | 2012 |
Endoscopic ultrasound for perianal Crohn's disease: disease and fistula characteristics, and impact on therapy.
Topics: Abscess; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Infective Agents; Anti-Inflammatory | 2012 |
[The effect of early immunosuppressive therapy on the rate of resections performed in patients with Chron's disease, in Veszprém county, Hungary, a population-based cohort study].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Cohort Studies; Colectomy; Crohn Disease; Digestive Sy | 2012 |
Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn's disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2012 |
Duodenal-pleural fistula in Crohn's disease: successful long-term medical management.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Duodenal Dise | 2013 |
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, M | 2013 |
Infliximab in the treatment of amyloidosis secondary to Crohn's disease.
Topics: Adult; Amyloidosis; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Deglutition Disorders; Drug | 2012 |
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.
Topics: Adalimumab; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclo | 2013 |
Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Cost-Benefit Analysis | 2013 |
A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn's disease patient on azathioprine, successfully treated with rituximab.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Crohn Disease; Epstein-Barr Virus | 2013 |
Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination.
Topics: Adalimumab; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antifungal Agents; | 2013 |
Resource utilization during pediatric to adult transfer of care in IBD.
Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathi | 2013 |
Mixed fortunes in the treatment of Crohn's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Crohn Disease; Female; Humans; Immunos | 2012 |
Growth in children receiving contemporary disease specific therapy for Crohn's disease.
Topics: Adolescent; Azathioprine; Body Height; Child; Child Development; Child, Preschool; Crohn Disease; Fe | 2012 |
Successful treatment with azathioprine of relapsing Rosai-Dorfman disease of the central nervous system.
Topics: Azathioprine; Central Nervous System Diseases; Comorbidity; Crohn Disease; Follow-Up Studies; Histio | 2012 |
Role of sex in the treatment and clinical outcomes of pediatric patients with inflammatory bowel disease.
Topics: Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Body Height; Body Mass I | 2012 |
The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Topics: Adult; Aged; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Human | 2013 |
Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease.
Topics: Abdominal Pain; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; | 2010 |
Vasculitis associated with tumor necrosis factor-α inhibitors.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2012 |
Use of exclusive enteral nutrition in paediatric Crohn's disease in The Netherlands.
Topics: Adolescent; Azathioprine; Child; Combined Modality Therapy; Crohn Disease; Enteral Nutrition; Female | 2013 |
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal | 2013 |
Immunosuppression in patients with Crohn's disease and neoplasia: an ongoing clinical dilemma.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Mercaptopu | 2012 |
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Cost-Benefit Analysis; Crohn Disease; Drug Therapy, Combinatio | 2013 |
Therapy-related acute myeloid leukemia in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male | 2013 |
Fever and pancytopenia in a patient with Crohn's disease.
Topics: Angiography; Antiviral Agents; Azathioprine; Cecum; Crohn Disease; Digestive System Surgical Procedu | 2013 |
Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.
Topics: Azathioprine; Bone Marrow Transplantation; Crohn Disease; Humans; Immunosuppressive Agents; Liver Ne | 2013 |
[Chemoprevention of colorectal cancer associated with IBD].
Topics: Azathioprine; Colorectal Neoplasms; Crohn Disease; Folic Acid; Humans; Inflammatory Bowel Diseases; | 2012 |
Long-term outcome of patients with Crohn's disease who respond to azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Mal | 2013 |
NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people.
Topics: Adolescent; Adult; Azathioprine; Child; Cost-Benefit Analysis; Crohn Disease; Disease Management; Fe | 2013 |
Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Endoscopy; Female; Humans; Immunosuppressive Agents; Intestinal | 2013 |
[A case of squamous cell carcinoma of the breast in a patient with Crohn's disease taking azathioprine].
Topics: Adult; Azathioprine; Breast Neoplasms; Carcinoma, Squamous Cell; Colonoscopy; Combined Modality Ther | 2012 |
[Myelotoxicity due to interaction between azathioprine and allopurinol in a patient with Crohn's disease].
Topics: Aged; Allopurinol; Azathioprine; Biotransformation; Bone Marrow Diseases; Crohn Disease; Drug Intera | 2013 |
Autoinoculation with Orf virus (ecthyma contagiosum).
Topics: Adult; Animals; Azathioprine; Crohn Disease; Ecthyma, Contagious; Humans; Immunosuppressive Agents; | 2014 |
Reassessing the risks and benefits of thiopurines in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male | 2013 |
The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Dose-R | 2013 |
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
Topics: Adolescent; Adult; Aged; Azathioprine; Biomarkers; Crohn Disease; Drug Administration Schedule; Drug | 2013 |
Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Colonic | 2013 |
TPMT in the treatment of Crohn's disease with azathioprine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Crohn Disease; Drug Interactions; | 2002 |
Protagonist: Crohn's disease recurrence can be prevented after ileal resection.
Topics: Anti-Bacterial Agents; Azathioprine; Colon; Crohn Disease; Humans; Ileum; Immunosuppressive Agents; | 2002 |
Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Erythrocytes; Female; Humans; Immunosuppressive Ag | 2002 |
Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Genotype; Humans; Immunosuppressive Agents; Methyl | 2002 |
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Genotype; Humans; Immunosuppr | 2002 |
Immunosuppressive treatment of Crohn's disease with fistulae.
Topics: Adult; Azathioprine; Crohn Disease; Cutaneous Fistula; Cyclosporine; Drug Therapy, Combination; Fema | 2002 |
Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Gastr | 2002 |
Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Female; Genotype; Humans; Immunosuppressive Agents; | 2002 |
Clonal marrow abnormalities after azathioprine and sulfasalazine exposure in Crohn's disease: a cautionary tale.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Male; Myelodysplastic Syndromes; Neutrophils; Sulfasalaz | 2002 |
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease.
Topics: Adolescent; Azathioprine; Child, Preschool; Crohn Disease; Female; Genotype; Humans; Immunosuppressi | 2002 |
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Drug Administration Schedule; Female; Humans; Immunosuppressive | 2003 |
Leukopenia and remission during azathioprine treatment.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Leukopenia; Retrospective Studies | 2003 |
Inflammatory bowel disease in pregnancy.
Topics: Aminosalicylic Acids; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Infertility, | 2003 |
[Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy].
Topics: Acyclovir; Adult; Aged; Antiviral Agents; Azathioprine; Chickenpox; Crohn Disease; Disease Susceptib | 2003 |
[Invasive cancer of the cervix in a patient undergoing chronic treatment with 6-mercaptopurine for Crohns disease].
Topics: Aged; Azathioprine; Carcinoma, Squamous Cell; Crohn Disease; Fatal Outcome; Female; Humans; Immunosu | 2003 |
[Acute episode].
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal | 2003 |
[Maintaining a remission].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2003 |
[Chronically active Crohn's disease].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Az | 2003 |
[Surgery -- fistulas].
Topics: Abdominal Abscess; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathiopr | 2003 |
[Follow up of Crohn's disease under therapy with hydro-MRI].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azathiopri | 2003 |
Neoplasia of the tongue in a patient with Crohn's disease treated with azathioprine: case report.
Topics: Adult; Antimetabolites; Azathioprine; Carcinoma in Situ; Crohn Disease; Humans; Male; Mouth Mucosa; | 2003 |
Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, | 2003 |
Consensus and controversy in the management of pediatric Crohn disease: an international survey.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Attitude o | 2003 |
Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease.
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Child; Crohn Disease; Humans; Immunosuppressive Agents; | 2003 |
Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; | 2003 |
TPMT in the treatment of inflammatory bowel disease with azathioprine.
Topics: Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Colonic Diseases, Functional; Crohn Dise | 2003 |
[Functional asplenia after severe varicella zoster-infection diagnosis by colour Doppler ultrasound].
Topics: Adult; Atrophy; Azathioprine; Crohn Disease; Drug Therapy, Combination; Follow-Up Studies; Herpes Zo | 2003 |
A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Azathioprine; Canada; Colitis; C | 2003 |
Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence?
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Gastrointestinal Agents; Humans; Immunos | 2003 |
Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine.
Topics: Adult; Azathioprine; Biopsy; Crohn Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressiv | 2003 |
Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Topics: Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Resistance; Female; Humans; Male; Mercapto | 2003 |
Pharmacological monitoring of azathioprine therapy.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Crohn Disease; Cross-Sectional Studies; Drug Monitoring; | 2003 |
Is there any remaining role for methotrexate for Crohn's disease?
Topics: Azathioprine; Crohn Disease; Enzyme Inhibitors; Female; Humans; Male; Methotrexate | 2003 |
Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anus Diseases; Azathioprine; Confidence Intervals; Crohn | 2003 |
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Case-Control Studies; Chemokines; Crohn Di | 2004 |
Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Axilla; Azathioprine; Crohn Disease; Female; Hi | 2003 |
Drug interaction between infliximab and azathioprine in patients with Crohn's disease.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antimetabolites; Azathioprine; Crohn Disease; Drug Intera | 2003 |
Bone density improves with disease remission in patients with inflammatory bowel disease.
Topics: Adult; Aged; Azathioprine; Bone Density; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies | 2003 |
[Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease].
Topics: Adolescent; Azathioprine; Crohn Disease; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immuno | 2003 |
Clinical features and management of Crohn's disease in Chinese patients.
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Child; Crohn Disease; Endoscopy, Gastrointestinal; Fe | 2004 |
Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hor | 2004 |
Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Evaluation; Drug Resistance; Drug T | 2004 |
Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy.
Topics: Azathioprine; Crohn Disease; DNA; Erythrocytes; Female; Humans; Immunosuppressive Agents; Interferon | 2004 |
Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays.
Topics: Adult; Aged; Azathioprine; Caco-2 Cells; Colitis, Ulcerative; Colon; Crohn Disease; DNA Primers; Fem | 2004 |
Side effects of azathioprine in patients with Crohn's disease.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents; Azathioprine; Chemical and Drug Induced Liver In | 2004 |
Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Erythrocytes; Female; Guanine Nucleotides; | 2004 |
Early diagnosis of subclinical multidrug-resistant tuberculosis.
Topics: Adult; Antigens, Bacterial; Azathioprine; Bronchoalveolar Lavage; Crohn Disease; Early Diagnosis; Fe | 2004 |
Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; | 2004 |
[Corticodependent Crohn's disease].
Topics: Adult; Azathioprine; Crohn Disease; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Predn | 2004 |
Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease.
Topics: Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Diagnosis, Differential; Humans; Immunocompro | 2004 |
Azathioprine dose escalation in inflammatory bowel disease.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, Drug; Drug Eval | 2004 |
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Azathioprine; Child; | 2004 |
Experience with the use of low-dose methotrexate for inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Drug Administratio | 2004 |
The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Topics: Adult; Azathioprine; Biomarkers; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Dose-Response R | 2004 |
[New research results give hope. Causal therapy of Crohn disease in sight].
Topics: Algorithms; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2004 |
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Digestive System Surgical Procedures; Humans; | 2004 |
Cytomegalovirus-associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine.
Topics: Antibodies, Viral; Azathioprine; Child; Crohn Disease; Cytomegalovirus; Cytomegalovirus Infections; | 2004 |
[Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].
Topics: Administration, Oral; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Female; Follow | 2004 |
Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease?
Topics: Adult; Azathioprine; Colon; Crohn Disease; Female; Gastrointestinal Agents; Humans; Ileum; Immunosup | 2004 |
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Gastrointestinal Agents; Humans; Immunos | 2004 |
Epstein-Barr virus-associated lymphoma in Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; DNA, Viral; Epstein-Barr Virus Infection | 2004 |
Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Gastrointestinal Agents; Humans; Immunos | 2004 |
Mucosal healing in pediatric Crohn's disease: the goal of medical treatment.
Topics: Age Factors; Antibodies, Monoclonal; Azathioprine; Child; Crohn Disease; Disease Progression; Drug R | 2004 |
Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases.
Topics: Acute Disease; Adult; Antimetabolites; Azathioprine; Crohn Disease; Female; Humans; Male; Middle Age | 2004 |
Crohn's disease with isolated esophagus and gastric involvement.
Topics: Adult; Anti-Ulcer Agents; Azathioprine; Biopsy; Crohn Disease; Endoscopy, Gastrointestinal; Esophage | 2004 |
[Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Female; Humans; Immunos | 2004 |
Immunomodulatory therapy for Crohn's disease resulting in acute liver failure.
Topics: Azathioprine; Crohn Disease; Diagnosis, Differential; Humans; Immunosuppressive Agents; Liver Failur | 2004 |
Azathioprine and 6 Mercaptopurine in postoperative maintenance of Crohn's disease remission: is no evidence of effect an evidence of no effect?
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Remission Induction | 2005 |
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
Topics: Adult; Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Drug Administration Schedu | 2005 |
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
Topics: Adult; Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Drug Administration Schedu | 2005 |
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
Topics: Adult; Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Drug Administration Schedu | 2005 |
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
Topics: Adult; Azathioprine; Crohn Disease; Digestive System Surgical Procedures; Drug Administration Schedu | 2005 |
Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Colectomy; Combined Modality Therapy; | 2004 |
Crohn's disease over 20 years after diagnosis in a referral population.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Az | 2004 |
Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Mesenteric Arter | 2005 |
Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: pro.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Child Welfare; Clinical Trials as T | 2005 |
Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con.
Topics: Azathioprine; Child; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Mer | 2005 |
Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance.
Topics: Azathioprine; Child; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Mer | 2005 |
Azathioprine-induced pancreatitis in Crohn's disease: a smoking gun or guilt by association.
Topics: Acute Disease; Aminosalicylic Acids; Antimetabolites; Azathioprine; Crohn Disease; Humans; Pancreati | 2005 |
ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Gen | 2005 |
Azathioprine-induced pancreatitis in Crohn's disease: a smoking gun or guilt by association. Author's reply.
Topics: Acute Disease; Antimetabolites; Azathioprine; Crohn Disease; Humans; Pancreatitis | 2005 |
6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Topics: Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Follow-Up Studies | 2005 |
6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine.
Topics: Adult; Azathioprine; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, | 2005 |
Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Arthralgia; Azathioprine; Crohn Disease; Disease Sus | 2005 |
Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Gastrointestinal Agents; Humans; Immunos | 2005 |
Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Dermoscopy; Female; Humans; Immunosuppression Therapy; Immunosup | 2005 |
Treatment of Crohn's disease: the "long" of it.
Topics: Azathioprine; Crohn Disease; Drug Administration Schedule; Humans; Immunosuppressive Agents; Patient | 2005 |
Azathioprine, 6-mercaptopurine and thiopurine S-methyltransferase.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Erythrocytes; Gene Frequency; Genetic Markers; Gen | 2005 |
Chorioamnionitis associated with Crohn's disease and azathioprine treatment: a case report.
Topics: Adult; Azathioprine; Chorioamnionitis; Crohn Disease; Female; Humans; Pregnancy; Treatment Outcome | 2005 |
Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; | 2005 |
Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine.
Topics: Adult; Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Merca | 2005 |
[Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease].
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Epstein-Barr Virus Infections; Fatal Outcom | 2005 |
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
Topics: Azathioprine; Community Health Services; Cost-Benefit Analysis; Crohn Disease; Dose-Response Relatio | 2005 |
6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Biomarkers; Crohn Disease; Erythrocytes; Guanine Nucleo | 2005 |
[Better to start from top?].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combina | 2005 |
Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Evidence-Based Medicine; Gastrointestinal Agents; | 2006 |
Re-introduction of azathioprine in previously intolerant patients.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Administration Schedule; Female; | 2006 |
Predictors of immunomodulator use as early therapy in pediatric Crohn's disease.
Topics: Adolescent; Azathioprine; Biomarkers; Chi-Square Distribution; Child; Child, Preschool; Crohn Diseas | 2006 |
Myelotoxicity and hepatotoxicity during azathioprine therapy.
Topics: Adult; Azathioprine; Biopsy; Blood Platelets; Bone Marrow; Crohn Disease; Guanine Nucleotides; Human | 2005 |
Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease.
Topics: Adolescent; Adrenal Cortex Hormones; Age Factors; Aminosalicylic Acids; Azathioprine; Child; Child, | 2006 |
RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine.
Topics: Adult; Azathioprine; Blood Cell Count; Crohn Disease; Erythrocyte Indices; Erythrocytes; Female; Gua | 2005 |
Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Antimetabolites; Azathioprine; Colitis, Ulcerative; Crohn Disease; Dose-Res | 2006 |
Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Topics: Adult; Aged; Azathioprine; Colectomy; Colitis, Ulcerative; Crohn Disease; Drug Resistance; Female; F | 2006 |
Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.
Topics: Azathioprine; Crohn Disease; Focal Nodular Hyperplasia; Humans; Immunosuppressive Agents; Magnetic R | 2006 |
Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Aza | 2006 |
Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Carcinoma, Hepatocellular; Crohn Disease; Female; Gastr | 2006 |
[Infliximab-induced hepatitis in a patient with Crohn's disease].
Topics: Acute Disease; Adult; Antibodies, Monoclonal; Azathioprine; Chemical and Drug Induced Liver Injury; | 2006 |
Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites.
Topics: Adult; Azathioprine; Crohn Disease; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; | 2006 |
Infliximab treatment of pediatric refractory Crohn's disease: a case report.
Topics: Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Admi | 2006 |
Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Imm | 2006 |
Severe muscular weakness: an unusual adverse effect of azathioprine therapy.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Hypersensitivity; Humans; Immunosuppre | 2006 |
Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Europe; Female; Glucocorticoids; Humans; Im | 2006 |
Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Drug Administration Schedule; Female; Humans; Male; | 2006 |
Next steps on the thiopurine methyltransferase 6-thioguanine nucleotide pathway.
Topics: Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Erythrocytes; Humans; Immunosuppressive Age | 2006 |
Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Erythr | 2006 |
Infliximab as first-line therapy in severe pediatric Crohn disease.
Topics: Abdominal Pain; Antibodies, Monoclonal; Azathioprine; Blood Sedimentation; Child; Colon; Colonoscopy | 2006 |
Natalizumab (Tysabri) returns.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Clinical Trials as Topic; C | 2006 |
Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Crohn Disease; Female; Humans; Male; Mercaptopurine; Middle A | 2006 |
Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Age | 2006 |
Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study.
Topics: Azathioprine; Child; Crohn Disease; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Mal | 2006 |
How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?
Topics: Adult; Antimetabolites; Azathioprine; Crohn Disease; Female; Humans; Longitudinal Studies; Male; Pat | 2007 |
Non-enteric salmonella spontaneous peritonitis--a new complication of an old immunosuppressant?
Topics: Adult; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Humans; Immunocompromised Host; Immun | 2007 |
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibody Formation; Azathioprine; Crohn Disease; Dr | 2007 |
Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Crohn Disease; Cross-Sectional Studies; Fe | 2007 |
MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2007 |
An unusual cause of azathioprine inefficacy.
Topics: Azathioprine; Catheterization; Colon; Colonoscopy; Crohn Disease; Drug Packaging; Female; Foreign Bo | 2006 |
[Advantages of different dosages of active metabolites in the follow-up of azathioprine treatment for Crohn disease].
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Crohn Disease; Female; Follow-Up Studies; Guanine | 2006 |
Gastroparesis in patients with inactive Crohn's disease: a case series.
Topics: Adrenal Cortex Hormones; Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Therapy, Combinat | 2007 |
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
Topics: Attitude of Health Personnel; Azathioprine; Crohn Disease; Dermatology; Dose-Response Relationship, | 2007 |
Development of hepatocellular carcinoma in a patient with Crohn's disease treated with azathioprine.
Topics: Adult; Azathioprine; Biopsy; Carcinoma, Hepatocellular; Crohn Disease; Diagnosis, Differential; Fata | 2007 |
Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; Humans; Immun | 2007 |
[Filgrastim in refractory Crohn's disease with an intra-abdominal abscess].
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Cell Differen | 2007 |
Perianal Crohn disease.
Topics: Adult; Anti-Bacterial Agents; Azathioprine; Cefotaxime; Crohn Disease; Female; Humans; Immunosuppres | 2006 |
Treatment response and colonic gene expression in patients with Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Cluster Analysis; Colon, Descending; Colonoscopy; Crohn Disease; Fe | 2007 |
Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Evaluation; Female; Humans; Inflixi | 2007 |
Infliximab at diagnosis: a sledgehammer to crack a walnut?
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Child; Crohn Disease; Female; Humans; Immunosuppressive | 2007 |
Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disea | 2007 |
Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
Topics: Adult; Azathioprine; Bone Marrow; Crohn Disease; Female; Genotype; Humans; Leukemia, Myeloid, Acute; | 2008 |
Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease.
Topics: Adult; Azathioprine; Central Nervous System Depressants; Crohn Disease; Ethanol; Glutathione; Humans | 2007 |
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents; Azathioprine; Child; Crohn Disease; Dose-Response | 2007 |
Mycophenolate mofetil therapy for refractory inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Follow-Up | 2007 |
Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile?
Topics: Adult; Aged; Azathioprine; Budesonide; Canada; Crohn Disease; Cross-Sectional Studies; Decision Supp | 2008 |
Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Dru | 2008 |
Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Black or African American; Cohort Studies; Colitis, Ulc | 2008 |
[Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Combined Modalit | 2007 |
Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Topics: Adult; Age Distribution; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Administration Sched | 2008 |
Severe Crohn disease of the lung following colectomy.
Topics: Anti-Inflammatory Agents; Azathioprine; Biopsy; Child, Preschool; Colectomy; Cough; Crohn Disease; D | 2007 |
[Azathioprine for prevention of postoperative recurrence in Crohn's disease].
Topics: Adult; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Mal | 2007 |
How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Data Collection; Gastroenterology; Humans; Immunos | 2008 |
Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Colectomy; Colonoscopy; Crohn Disease; Female; Follow- | 2008 |
Use of methotrexate in refractory Crohn's disease: the Edinburgh experience.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; Humans; Immunosuppre | 2008 |
Initial combination therapy in early Crohn's disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Combined Modality Therapy; Crohn Dise | 2008 |
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Child; Crohn Disease; Female; Gastroi | 2008 |
Medication adherence and quality of life in pediatric inflammatory bowel disease.
Topics: Adolescent; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Depression; | 2008 |
[Acute pancreatitis following azathioprine therapy of crohn's disease--a case report and the overview of the literature].
Topics: Acute Disease; Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Pancrea | 2008 |
Dysphagia and a skin rash.
Topics: Adult; Antirheumatic Agents; Azathioprine; Colonoscopy; Crohn Disease; Deglutition Disorders; Exanth | 2008 |
Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes.
Topics: Adult; Apgar Score; Azathioprine; Case-Control Studies; Cesarean Section; Colectomy; Colitis, Ulcera | 2008 |
[Portal vein hypertension during azathioprine therapy in patients with Crohn's disease--a frequent phenomenon?].
Topics: Azathioprine; Crohn Disease; Enbucrilate; Esophageal and Gastric Varices; Focal Nodular Hyperplasia; | 2008 |
Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease?
Topics: Adult; Autoantibodies; Azathioprine; Case-Control Studies; Crohn Disease; Female; Humans; Immunosupp | 2008 |
The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Utilization; Female; Humans; Immunosup | 2008 |
[Urethral fistula due to Crohn's disease: case report of successful conservative management].
Topics: Azathioprine; Ciprofloxacin; Crohn Disease; Cystoscopy; Cystostomy; Diagnosis, Differential; Drug Th | 2008 |
Azathioprine and 6-mercaptopurine for Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Mercaptopurine; Risk | 1980 |
Management of Crohn's disease: time for audit?
Topics: Azathioprine; Crohn Disease; Humans; Steroids; Sulfasalazine | 1980 |
Reflections on the treatment of Crohn's disease, the NCCDS report, and on randomized clinical trials.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Humans; Prednisone; Rand | 1980 |
The treatment of Crohn's disease.
Topics: Azathioprine; Bed Rest; Crohn Disease; Drug Therapy, Combination; Humans; Prednisone; Steroids; Sulf | 1980 |
Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Drug Synergism; Drug The | 1981 |
Medical therapy of inflammatory bowel disease.
Topics: Acute Disease; Adjuvants, Immunologic; Anus Diseases; Azathioprine; Colitis, Ulcerative; Crohn Disea | 1980 |
[Conservative treatment of ulcerative colitis and Crohn's disease in childhood].
Topics: Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Humans; Prednisone | 1981 |
The management of Crohn's disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antidiarrheals; Azathioprine; Crohn Disease; Humans; | 1981 |
[An approach to the medical management of inflammatory bowel disease (author's transl)].
Topics: Azathioprine; Colitis; Colitis, Ulcerative; Crohn Disease; Humans; Parenteral Nutrition, Total; Pred | 1981 |
[Evaluation of the results of radical surgical treatment of Crohn disease as related to a diversified postoperative treatment].
Topics: Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Postoperative Care; Postoperative Complicati | 1981 |
[Crohn disease and ulcerative colitis - current status: internal medicine aspects].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; | 1981 |
[Conservative therapy of Crohn disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Humans; Pancreatitis; Psychotherapy; Pyridazin | 1982 |
[Treatment of Crohn's disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Humans; Sulfasalazine | 1982 |
[Clinical features of inflammatory bowel disease (author's transl)].
Topics: Azathioprine; Bacterial Infections; Crohn Disease; Diarrhea; Drug Combinations; Fluid Therapy; Gluco | 1982 |
Anti-inflammatory drug treatment of Crohn's disease: a prospective evaluation of 100 consecutively treated patients.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Hum | 1980 |
Inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Colonoscopy; Crohn Disease; Drug Combinations; Glucosamine; Human | 1982 |
[Treatment of Crohn disease in childhood].
Topics: Adolescent; Azathioprine; Child; Child Development; Colectomy; Crohn Disease; Dose-Response Relation | 1982 |
Drug management of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Bacterial Agents; Antidiarrheals; Azathio | 1983 |
Current status of medical treatment for inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Mercaptopurine; M | 1983 |
[Immunomodulation treatment of inflammatory bowel disease].
Topics: Anti-Bacterial Agents; Antibody Formation; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Co | 1984 |
Impaired semen quality in Crohn's disease--drugs, ill health, or undernutrition?
Topics: Adult; Azathioprine; Crohn Disease; Humans; Male; Middle Aged; Nutrition Disorders; Oligospermia; Pr | 1983 |
Selected individual therapeutic problems in inflammatory bowel disease.
Topics: Adult; Azathioprine; Campylobacter Infections; Clostridium Infections; Colectomy; Colitis, Ulcerativ | 1984 |
[Crohn disease: when conservative, when surgical treatment?].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Colon; Crohn Disease; Dietary Carbohyd | 1984 |
[Therapy of chronic inflammatory bowel diseases].
Topics: Acute Disease; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Mercaptopurine; Methylpredn | 1983 |
Primary liver cell cancer occurring in association with Crohn's disease treated with prednisolone and azathioprine.
Topics: Adult; Azathioprine; Carcinoma, Hepatocellular; Crohn Disease; Female; Humans; Liver Neoplasms; Pred | 1983 |
A critical analysis of the use of azathioprine in clinical medicine.
Topics: Animals; Antibody Formation; Autoimmune Diseases; Azathioprine; Crohn Disease; Dogs; Humans; Immunit | 1983 |
Azathioprine-associated pulmonary dysfunction.
Topics: Adult; Allopurinol; Azathioprine; Crohn Disease; Humans; Inflammation; Kidney Calculi; Lung Diseases | 1983 |
Menetrier's disease in a patient with ileocolonic Crohn's disease.
Topics: Azathioprine; Cimetidine; Crohn Disease; Female; Gastritis; Gastritis, Hypertrophic; Humans; Middle | 1983 |
Escherichia coli osteomyelitis after sepsis in regional enteritis: report of a case.
Topics: Adult; Azathioprine; Crohn Disease; Escherichia coli Infections; Femur; Humans; Immunosuppression Th | 1982 |
The azathioprine controversy: J.E. Lennard-Jones vs John W. Singleton.
Topics: Azathioprine; Crohn Disease; Humans | 1981 |
Polyneuritis associated with azathioprine sensitivity reaction.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Male; Polyneuropathies | 1980 |
Isolated gastroduodenal Crohn's disease in a ten-year-old girl.
Topics: Azathioprine; Body Weight; Child; Crohn Disease; Duodenum; Female; Humans; Steroids; Stomach | 1980 |
Methotrexate for Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Mercaptopurine; Methotrexate; Prednisone; Remission Induction | 1995 |
Sweet's syndrome in association with Crohn's disease.
Topics: Azathioprine; Crohn Disease; Female; Humans; Middle Aged; Sweet Syndrome | 1995 |
Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients.
Topics: Azathioprine; Cholangitis, Sclerosing; Colitis, Ulcerative; Crohn Disease; Cyclophosphamide; Cyclosp | 1993 |
Hidradenitis suppurativa in Crohn's disease. A further support to this association.
Topics: Adult; Anti-Bacterial Agents; Azathioprine; Crohn Disease; Drug Therapy, Combination; Hidradenitis S | 1995 |
Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Fatal Outcome; Humans; Immunosuppression Therapy; Infectious Mon | 1995 |
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Fe | 1994 |
Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Lymphoma | 1994 |
Tumour-necrosis-factor antibody treatment in Crohn's disease.
Topics: Aminosalicylic Acids; Antibodies, Monoclonal; Azathioprine; Child; Crohn Disease; Female; Humans; Me | 1993 |
Azathioprine hypersensitivity mimicking sepsis in a patient with Crohn's disease.
Topics: Aged; Azathioprine; Crohn Disease; Diagnosis, Differential; Drug Hypersensitivity; Fever; Humans; In | 1993 |
Growth failure in pediatric inflammatory bowel disease.
Topics: Adolescent; Adrenal Cortex Hormones; Anthropometry; Azathioprine; Body Height; Child; Colitis, Ulcer | 1993 |
Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine.
Topics: Adolescent; Adult; Anal Canal; Anastomosis, Surgical; Azathioprine; Crohn Disease; Female; Humans; I | 1993 |
Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Topics: Adolescent; Adult; Attitude of Health Personnel; Azathioprine; Child; Colitis; Colitis, Ulcerative; | 1993 |
[Azathioprine in Crohn disease].
Topics: Azathioprine; Crohn Disease; Drug Therapy, Combination; Glucocorticoids; Humans | 1993 |
Cyclosporine and other immunosuppressive agents: current and future role in the treatment of inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Humans; Immunosuppressive Agents; In | 1993 |
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Humans; Immu | 1996 |
Perianal Crohn's disease--is it all bad news?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antimetabolites; Antitrichomona | 1996 |
Treatment of Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Mercaptopurine | 1996 |
Super turbo azathioprine: can Crohn's disease healing be accelerated?
Topics: Azathioprine; Crohn Disease; Drug Evaluation; Humans; Immunosuppressive Agents; Infusions, Intraveno | 1996 |
Regional enteritis complicating malignant lymphoma.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1996 |
Smoking, azathioprine, and clinical course in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Smoking | 1996 |
Polymyositis, alopecia universalis, and primary sclerosing cholangitis in a patient with Crohn's disease.
Topics: Adult; Alopecia; Anti-Inflammatory Agents; Antigens, CD; Azathioprine; Cholangiopancreatography, End | 1996 |
Crohn's disease and ulcerative colitis with onset in the same year in two sisters.
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Colitis, Ulcerative; Colonoscopy; Crohn Di | 1996 |
Purine analogues and Crohn's disease: learning more about the long-term.
Topics: Antimetabolites; Azathioprine; Crohn Disease; Humans; Mercaptopurine; Treatment Outcome | 1996 |
[3 pregnancies in 2 women after long-term azathioprine treatment for inflammatory bowel disease].
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Pregnancy | 1996 |
[Acute pancreatitis caused by azathioprine in patient with Crohn disease].
Topics: Acute Disease; Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Pancrea | 1996 |
[Crohn's disease and pregnancy. Two case reports].
Topics: Adult; Azathioprine; Cesarean Section; Crohn Disease; Female; Humans; Immunosuppressive Agents; Nutr | 1996 |
[Pancreatitis caused by azathioprine: immuno-allergy?].
Topics: Acute Disease; Adult; Azathioprine; Crohn Disease; Drug Hypersensitivity; Humans; Male; Pancreatitis | 1996 |
[Nephrotic syndrome as the initial symptom of Crohn disease].
Topics: Amyloidosis; Azathioprine; Biopsy; Cecum; Combined Modality Therapy; Crohn Disease; Humans; Immunosu | 1996 |
Anal lesions: any significant prognosis in Crohn's disease?
Topics: Adolescent; Adult; Aged; Anus Diseases; Azathioprine; Crohn Disease; Female; Fissure in Ano; Humans; | 1997 |
[Prevention of Crohn disease recurrence with azathioprine--for whom, how long?].
Topics: Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Immunosuppressive Agents; Long-Term Care; Me | 1997 |
Successful desensitization for azathioprine skin rash in a patient with severe Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Desensitization, Immunologic; Drug Eruptions; Female; Humans; Im | 1997 |
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Endoscopy; Female; Humans; Ileitis; Ileum; Immunosuppressive Age | 1997 |
6-MP metabolite levels: a potential guide to Crohn's disease therapy.
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Azathioprine; Chromatography, High Pressure Liquid | 1997 |
Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Cyclosporine; Dose-Response Relationship, Drug; Drug Administrat | 1997 |
Management of varicella infection during the course of inflammatory bowel disease.
Topics: Acyclovir; Adult; Anti-Inflammatory Agents; Antiviral Agents; Azathioprine; Cause of Death; Cephalex | 1997 |
[Recurrence-preventive (remission preserving) therapy of chronic inflammatory bowel diseases].
Topics: Anti-Inflammatory Agents; Antimetabolites; Azathioprine; Chronic Disease; Colitis, Ulcerative; Crohn | 1998 |
Immunomodulator therapy of inflammatory bowel disease.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Blood Component Removal; Colitis, Ulcerative; Crohn D | 1997 |
Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine.
Topics: Absorptiometry, Photon; Adult; Aged; Azathioprine; Bone Density; Colitis; Crohn Disease; Female; Hum | 1998 |
Oral cyclosporin in refractory inflammatory bowel disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyc | 1998 |
[Duodenal Crohn's disease: diagnostic and therapeutic complexity].
Topics: Adolescent; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Diagnosis, Differential; Duodenal | 1998 |
Summary of the workshop on 6-mercaptopurine/azathioprine pharmacology.
Topics: Adult; Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Drug Interactions; Drug Therapy, Com | 1998 |
[6-mercaptopurine levels and study of blood lymphocyte subsets during azathioprine treatment of Crohn's disease].
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunophenotyping; Immunosuppressive Agents; Kin | 1998 |
[Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
Topics: Administration, Oral; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Drug Administr | 1998 |
Postoperative outcome of Crohn's disease in 30 children.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Crohn Disease; Fema | 1998 |
[Pediatric Crohn's disease complications].
Topics: Abdominal Abscess; Adolescent; Azathioprine; Combined Modality Therapy; Crohn Disease; Humans; Immun | 1998 |
Mycophenolate mofetil in patients with Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myc | 1998 |
Methotrexate in refractory Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Drug Administration Schedule; Drug Resistance; Femal | 1999 |
Metastatic Crohn's disease in a 9-year-old boy.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Azathioprine; Child; Crohn Disease; Erythema; Human | 1999 |
A comparison of budesonide and mesalamine for active Crohn's disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn D | 1999 |
Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease.
Topics: Acute Disease; Adolescent; Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Drug Administrat | 1999 |
[Diffuse jejuno-ileitis of Crohn's disease: a separate form of the disease?].
Topics: Adolescent; Adult; Aging; Azathioprine; Crohn Disease; Enteritis; Female; Humans; Ileal Diseases; Je | 1999 |
[Gait disorders secondary to azathioprine treatment in 2 patients with Crohn's disease].
Topics: Adult; Azathioprine; Crohn Disease; Dyskinesia, Drug-Induced; Female; Humans; Male | 1999 |
[56-year-old patient with segmental florid colitis and colonic amyloidosis].
Topics: Amyloidosis; Azathioprine; Colitis; Colonic Diseases; Colonoscopy; Crohn Disease; Diagnosis, Differe | 1999 |
[A well hidden track].
Topics: Adrenal Cortex Hormones; Aged; Anemia, Hemolytic, Autoimmune; Azathioprine; Colonoscopy; Crohn Disea | 1999 |
[Pregnancy outcome in inflammatory bowel diseases].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Female; | 1999 |
[Agranulocytosis and transitory immune deficiency after fetal exposure to azathioprine and mesalazine].
Topics: Adult; Agammaglobulinemia; Agranulocytosis; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 1999 |
Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory A | 1999 |
Pneumatosis intestinalis and colocolic intussusception complicating Crohn's disease.
Topics: Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Diarrhea; Fluid Therapy; Humans; Immunosuppre | 2000 |
Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; IMP Dehydrogenase; Mal | 2000 |
Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children.
Topics: Adolescent; Anus Diseases; Azathioprine; Chi-Square Distribution; Child; Child, Preschool; Crohn Dis | 2000 |
Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Hypertension, Portal; Immunosuppressive Agents; | 2000 |
Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma.
Topics: Adolescent; Adult; Aged; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Incidence; L | 2000 |
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Azathioprine; Bone Marrow; Crohn Disease; DNA M | 2000 |
Steroids may prevent leukopenia, interfering with response to IV azathioprine in treatment of Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukopenia; | 2000 |
Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
Topics: Adolescent; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Agen | 2000 |
Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy.
Topics: Adult; Azathioprine; Carcinoma, Hepatocellular; Crohn Disease; Female; Glycogen; Humans; Immunosuppr | 2000 |
Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
Topics: Administration, Oral; Adult; Azathioprine; Biological Availability; Crohn Disease; Female; Humans; I | 2000 |
Medical management of major internal fistulae in Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Digestive System Fistula; Drug Therapy, Combin | 2000 |
[Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Female; Humans; Mesalam | 2000 |
Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine.
Topics: Amylases; Azathioprine; Biomarkers; Crohn Disease; Humans; Immunoenzyme Techniques; Immunosuppressiv | 2000 |
Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Multiple Scleros | 2000 |
[Aplasia after azathioprine administration: role of the thiopurine methyltransferase genetic polymorphism].
Topics: Adult; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Male; Methyltransferases; Poly | 2000 |
The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Age | 2000 |
Hepatitis related to cytomegalovirus infection in two patients with Crohn's disease treated with azathioprine.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Crohn Disease; Cytomegalovirus Infectio | 2000 |
Infliximab in Crohn's disease: first anniversary clinical experience.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Case-Control Studies; Crohn Disease; Female; Gastrointe | 2000 |
Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; Gastro | 2000 |
Lack of effect of intravenous azathioprine on time to respond for steroid treated Crohn's disease.
Topics: Administration, Oral; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Therapy, Combinati | 2001 |
[Therapy of chronic inflammatory intestinal disease].
Topics: Acute Disease; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Budesonide; Chronic D | 2000 |
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Topics: Adult; Azathioprine; Case-Control Studies; Crohn Disease; Drug Monitoring; Drug Therapy, Combination | 2001 |
[Fulminant infection caused by varicella herpes zoster in patient with Crohn disease undergoing treatment with azathioprine].
Topics: Adult; Azathioprine; Crohn Disease; Fatal Outcome; Female; Herpes Zoster; Humans; Immunosuppressive | 2001 |
[Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease].
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Female; Hum | 2000 |
Severe life-threatening diarrhea caused by azathioprine but not by 6-mercaptopurine.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; Female; Humans; Immunosuppressive | 2001 |
[Azathioprine and cavum carcinoma in a patient with autoimmune hepatitis and Crohn's disease].
Topics: Azathioprine; Carcinoma, Squamous Cell; Crohn Disease; Head and Neck Neoplasms; Hepatitis, Autoimmun | 2001 |
Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
Topics: Adult; Azathioprine; Chronic Disease; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; | 2001 |
[Chronic inflammatory bowel diseases. Immunosuppressive drugs--good alternatives to steroids].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Child; Colitis, Ulcerative; Crohn Disease; Humans; Imm | 2001 |
Mortality associated with infliximab.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Female; Gastrointestinal Agents; Humans; | 2001 |
Tuberculous pleurisy: an unusual complication during treatment of Crohn disease with azathioprine.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Male; Opportunistic Infections | 2001 |
Azathioprine hypersensitivity mimicking underlying inflammatory bowel disease.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; Drug Hypersensitiv | 2001 |
Azathioprine for prevention of postoperative recurrence in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Recurrence | 2001 |
Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study.
Topics: Adolescent; Adult; Azathioprine; Colectomy; Crohn Disease; Female; Humans; Immunosuppressive Agents; | 2001 |
Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug T | 2001 |
Steering azathioprine safely: lessons from pharmacogenetics.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Agents; Pharmacogenetics | 2001 |
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Age | 2002 |
[When is drug therapy with azathioprine indicated in Crohn's disease?].
Topics: Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Dose-Response Relationship, Drug; Genotype; H | 2002 |
[Pancreatic involvement in inflammatory bowel diseases in children].
Topics: Adolescent; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Colitis, Ulcerat | 2002 |
[Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
Topics: Adult; Anti-Inflammatory Agents; Antimetabolites; Azathioprine; Colitis, Ulcerative; Crohn Disease; | 2002 |
Ileal Crohn's disease is best treated by surgery.
Topics: Azathioprine; Budesonide; Crohn Disease; Glucocorticoids; Humans; Ileum; Mesalamine; Prednisolone | 2002 |
[Patient with abdominal pain].
Topics: Adult; Ampicillin; Azathioprine; Crohn Disease; Humans; Male; Parenteral Nutrition; Prednisone; Sulf | 1976 |
Crohn's disease of the distal large bowel.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Azathioprine; Colon, Sigmoid; Crohn Dis | 1976 |
[Inflammatory intestinal diseases: ulcerative colitis and Crohn's disease. Early diagnosis and treatment].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Endoscopy; Humans; Sulfas | 1976 |
Pharmacotherapy of inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Hydrocortisone; Sulfasalazine | 1976 |
Anti-inflammatory drug treatment in Crohn's disease.
Topics: Anti-Inflammatory Agents; Azathioprine; Colonic Diseases; Crohn Disease; Female; Humans; Intestinal | 1976 |
Inflammatory bowel diseases 1977.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cromolyn Sodium; Diet; Eye Diseases; Humans; Joint | 1977 |
Chronic inflammatory bowel disease.
Topics: Adolescent; Adult; Azathioprine; Bile Acids and Salts; Child; Cholestyramine Resin; Colitis, Ulcerat | 1977 |
[Management and prognosis of Crohn's disease].
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Female; Humans; Male; Prednisolone; Prognosis; Sulfa | 1977 |
Crohn's disease involving the colon: an audit of clinical management.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Azathioprine; Child; | 1977 |
[Chronic-inflammatory intestinal diseases. Clinical picture, complications, differential diagnosis and nonsurgical therapy].
Topics: Adrenal Cortex Hormones; Azathioprine; Chronic Disease; Colitis, Ulcerative; Crohn Disease; Diagnosi | 1977 |
The pediatric corner: the varied manifestations of Crohn's disease in children and adolescents.
Topics: Adolescent; Age Factors; Azathioprine; Child; Child, Preschool; Crohn Disease; Female; Hematocrit; H | 1978 |
Update '77.
Topics: Animals; Anus Neoplasms; Azathioprine; Colitis, Ulcerative; Colon; Colostomy; Condylomata Acuminata; | 1978 |
Crohn's disease of the colon.
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Azathioprine; Colectomy; Colitis, Ulcerative; | 1979 |
[Immunosuppressive drugs in intestinal diseases (author's transl)].
Topics: Acute Disease; Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Im | 1979 |
Radiographic findings of the National Cooperative Crohn's Disease Study.
Topics: Adult; Age Factors; Azathioprine; Colon; Crohn Disease; Duodenum; Female; Humans; Ileum; Intestinal | 1979 |
Inflammatory bowel disease. Part II.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Double-Blind Method; Evaluation Studies as Topic; | 1978 |
Place of azathioprine for Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Drug Evaluation; Follow-Up Studies; Humans; Re | 1976 |
[Enteritis regionalis (Crohn's disease) (proceedings)].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amyloidosis; Arthritis; Azathioprine; Child; Child | 1976 |
Drugs used in treatment of large bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antidiarrheals; Azathioprine; Cathartics; Colitis, U | 1979 |
[Letter: Crohn's disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Diet; Humans; Prednisone; Sulfasalazine | 1975 |
[Exceptional clinical courses of granulomatous colitis in children and adolescents (author's transl)].
Topics: Adolescent; Azathioprine; Child; Colitis, Ulcerative; Colostomy; Crohn Disease; Diarrhea; Female; Ga | 1978 |
The effect of azathioprine on cell-mediated immunity (CMI) to Candida albicans in Crohn's disease.
Topics: Adolescent; Adult; Aged; Antigens, Bacterial; Azathioprine; Candida albicans; Cell Migration Inhibit | 1977 |
[Conservative therapy of Crohn's disease].
Topics: Azathioprine; Crohn Disease; Humans; Methods; Prednisone; Remission, Spontaneous | 1979 |
[Long-term therapy in ulcerative colitis and Crohn's disease].
Topics: Aminosalicylic Acids; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Metronidazole; Patie | 1979 |
Adenocarcinoma of the small bowel complicating Crohn's disease in a patient treated with azathioprine.
Topics: Adenocarcinoma; Azathioprine; Crohn Disease; Female; Humans; Intestinal Neoplasms; Intestine, Small; | 1977 |
[Results of surgical treatment of Crohn's enterocolitis granulomatosa (author's transl)].
Topics: Adolescent; Adult; Azathioprine; Cecum; Colon, Sigmoid; Crohn Disease; Follow-Up Studies; Humans; Il | 1976 |
[Crohn's disease].
Topics: Appendicitis; Azathioprine; Cortisone; Crohn Disease; Diagnosis, Differential; Endoscopy; Female; Hu | 1977 |
[Surgical and medical treatment of Crohn's disease (author's transl)].
Topics: Acute Disease; Azathioprine; Chronic Disease; Crohn Disease; Drug Therapy, Combination; Female; Huma | 1977 |
Azathioprine-associated acute pancreatitis.
Topics: Acute Disease; Adult; Azathioprine; Crohn Disease; Granuloma; Humans; Male; Pancreatitis | 1977 |
[Diagnosis and therapy of Crohn's disease of the colon].
Topics: Azathioprine; Colonic Diseases; Cortisone; Crohn Disease; Humans | 1977 |
Metastatic Crohn's disease.
Topics: Adult; Azathioprine; Biopsy; Crohn Disease; Ear, External; Humans; Male; Rectal Fistula; Skin Diseas | 1976 |
An unusual case of Crohn's disease in a West Indian child.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Female; Humans; Hypertrophy; Perineum; Prednisolone; | 1976 |
[Immunosuppressive treatment of Crohn's disease].
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Prednisolone; Remissi | 1976 |
[Course studies in patients with Crohn's disease after surgery or immunosuppressive therapy].
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppression Therapy; Immunotherapy; Recurrence | 1976 |
T and B lymphocytes and cutaneous anergy in inflammatory bowel disease.
Topics: Azathioprine; B-Lymphocytes; Colitis, Ulcerative; Crohn Disease; Dinitrochlorobenzene; Humans; Hyper | 1976 |
Symposium. Crohn's disease. Discussion.
Topics: Animals; Azathioprine; Crohn Disease; Humans; Ileum; Perineum; Rectum; Skin Transplantation; Swine; | 1975 |
Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part II.
Topics: Adenocarcinoma; Arthritis; Azathioprine; Child; Chronic Disease; Colitis, Ulcerative; Colonic Neopla | 1975 |
[Collagen peptidase in Crohn's disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Collagen; Crohn Disease; Humans; Peptide Hydrolases; Sarcoido | 1976 |
Proceedings: Effect of azathioprine and cell-mediated immunity in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunity, Cellular | 1976 |
Azathioprine or 6-mercaptopurine therapy and colon carcinoma in Crohn's disease.
Topics: Adult; Azathioprine; Carcinoma; Colonic Neoplasms; Crohn Disease; Humans; Mercaptopurine | 1992 |
[Clinical study on inflammatory bowel diseases].
Topics: Anti-Bacterial Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; Hu | 1992 |
[Internistic therapy possibilities in therapy-resistant Crohn disease].
Topics: Anti-Bacterial Agents; Azathioprine; Crohn Disease; Cyclosporins; Drug Resistance; Drug Therapy, Com | 1992 |
Use of azathioprine in nine children with Crohn's disease.
Topics: Azathioprine; Child; Child, Preschool; Crohn Disease; Drug Therapy, Combination; Female; Humans; Mal | 1991 |
Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease.
Topics: Adult; Azathioprine; Blood Cell Count; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammat | 1991 |
[Crohn disease in children].
Topics: Age Factors; Azathioprine; Child; Colectomy; Crohn Disease; Female; Humans; Male; Prednisolone; Sulf | 1991 |
[Crohn's colitis and parenteral nutrition].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Par | 1991 |
[Treatment of Crohn disease].
Topics: Aminosalicylic Acids; Azathioprine; Crohn Disease; Humans; Palliative Care | 1991 |
Careful observations and flawed conclusions.
Topics: Azathioprine; Crohn Disease; Humans; Mercaptopurine | 1992 |
[Successful treatment of fulminant Crohn's colitis with azathioprine].
Topics: Adolescent; Azathioprine; Crohn Disease; Humans; Male; Radiography | 1991 |
Elemental diet in steroid-dependent and steroid-refractory Crohn's disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Crohn Disease; Drug Resistance; Drug Therapy, Combination; Fe | 1991 |
Kaposi's sarcoma of the colon in a young HIV-negative woman with Crohn's disease.
Topics: Adult; Azathioprine; Colonic Neoplasms; Crohn Disease; Female; HIV Seropositivity; Humans; Sarcoma, | 1991 |
Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Crohn Disease; Drug Administration S | 1991 |
[T-lymphocyte subpopulations in the peripheral blood of patients with Crohn disease].
Topics: Adrenal Cortex Hormones; Adult; Antigens, Differentiation, T-Lymphocyte; Azathioprine; Crohn Disease | 1990 |
Azathioprine in the treatment of children with inflammatory bowel disease.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Child, Preschool; Co | 1990 |
[Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases].
Topics: Actuarial Analysis; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Crohn Disease; F | 1990 |
[Therapy of Crohn disease].
Topics: Aminosalicylic Acids; Azathioprine; Colectomy; Crohn Disease; Diet; Glucocorticoids; Humans; Mercapt | 1989 |
Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine.
Topics: Adult; Alopecia; Azathioprine; Crohn Disease; Humans; Male | 1989 |
[Therapeutic experience with ulcerative colitis and Crohn disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Combinations; Drug T | 1985 |
[Crohn disease: initial experiences with cyclosporin A in an adolescent girl].
Topics: Adolescent; Azathioprine; Crohn Disease; Cyclosporins; Female; Humans; Lymphoma; Osteoporosis; Predn | 1985 |
Pregnancy, fertility, and inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Fe | 1985 |
Therapeutical experiments in ulcerative colitis and Crohn's disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Follow-Up Studies; Huma | 1985 |
[Crohn disease in childhood].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Child; Combined Modality Therapy; Crohn | 1986 |
[Therapy of amyloid nephrosis in Crohn disease: plasmapheresis plus azathioprine?].
Topics: Adult; Amyloidosis; Azathioprine; Combined Modality Therapy; Crohn Disease; Female; Glomerular Mesan | 1988 |
Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; Female; Humans; | 1988 |
Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squa | 1985 |
Further experience with azathioprine for Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Female; Humans; Intestinal Fistula; Klebsiella Infec | 1970 |
E.B.-virus antibody in Crohn's disease.
Topics: Adolescent; Adult; Aged; Antibodies; Azathioprine; Crohn Disease; Female; Fluorescent Antibody Techn | 1971 |
Treatment of Crohn's disease.
Topics: Age Factors; Azathioprine; Crohn Disease; Humans; Secondary Prevention | 1971 |
Treatment of Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Fistula; Humans; Recurrence | 1971 |
Letter: Larger doses of immunosuppressive drugs.
Topics: Arthritis, Rheumatoid; Azathioprine; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, | 1974 |
II. Medical treatment of inflammatory bowel disease.
Topics: Administration, Oral; Azathioprine; Colitis, Ulcerative; Crohn Disease; Enema; Glucocorticoids; Huma | 1973 |
[Regional enteritis Crohn (author's transl)].
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Different | 1973 |
The drug therapy of ulcerative colitis and of Crohn's disease.
Topics: Adrenocorticotropic Hormone; Atropine; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; D | 1974 |
Medical treatment of Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Humans; Sulfasalazine; Vitamin B 12 | 1974 |
[Regional enteritis (Crohn's disease). A follow-up and comparative study of 182 patients (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Child, Preschool; Crohn Disease; Erythema | 1974 |
[Study of the course of Crohn's disease under Imurel treatment].
Topics: Adult; Aged; Azathioprine; Blood Sedimentation; Crohn Disease; Female; Glucocorticoids; Hemoglobins; | 1974 |
Azathioprine for Crohn's disease.
Topics: Adult; Azathioprine; Child; Crohn Disease; Female; Humans; Male | 1969 |
Two first degree relatives with dilatation of the colon due to Crohn's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Azathioprine; Body Weight; Colectomy; Colitis, Ulcer | 1973 |
[Azathioprine therapy in regional enteritis (Crohn's disease)].
Topics: Adult; Azathioprine; Colon, Sigmoid; Crohn Disease; Female; Humans; Ileum; Intestinal Mucosa; Intest | 1970 |
[Treatment of autoimmune diseases].
Topics: Adrenal Cortex Hormones; Aged; Anemia, Hemolytic, Autoimmune; Antilymphocyte Serum; Autoimmune Disea | 1971 |
An evaluation of the rosette inhibition test in Crohn's disease.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Crohn Disease; Female; Humans; Immune Adherence | 1974 |
Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine.
Topics: Adolescent; Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cytotoxicity Tests, Immunologic | 1974 |
[Ulcerative colitis and Crohn's disease of the colon. Problems of diagnosis and therapy. Immunological aspects].
Topics: Antigens, Heterophile; Autoantibodies; Azathioprine; Colitis, Ulcerative; Colonic Diseases; Cortison | 1972 |
[Recent results of azathioprine treatment in hemorrhagic rectocolitis and colonic Crohn's disease].
Topics: Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Evaluation Studies as Top | 1972 |
Azathioprine in acute Crohn's disease.
Topics: Acute Disease; Azathioprine; Crohn Disease; Humans; Intestinal Obstruction; Male; Middle Aged | 1972 |
[Amyloidosis in Crohn's disease].
Topics: Amyloidosis; Azathioprine; Crohn Disease; Humans; Male; Nephrotic Syndrome | 1972 |
[Treatment of Crohn's disease with immunosuppressive agents].
Topics: Azathioprine; Crohn Disease; Humans | 1973 |
[Diagnosis and treatment of Crohn's disease].
Topics: Azathioprine; Colectomy; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; Humans; Ileost | 1973 |
Non-restorative surgery in the treatment of Crohn's disease of the large bowel.
Topics: Adolescent; Adult; Aged; Azathioprine; Barium Sulfate; Colectomy; Colostomy; Crohn Disease; Female; | 1973 |
[Therapy of enteritis regional Crohn using azathioprine].
Topics: Abscess; Azathioprine; Crohn Disease; Humans; Pancreatitis; Prospective Studies; Sepsis | 1973 |
Leucocyte migration studies with spleen preparations in Crohn's disease.
Topics: Adolescent; Adult; Aged; Antigens; Azathioprine; Cell Movement; Crohn Disease; Female; Humans; Leuko | 1973 |
Azathioprine-induced acute pancreatitis.
Topics: Acute Disease; Adolescent; Azathioprine; Crohn Disease; Female; Humans; Pancreatitis | 1973 |
Some aspects of Crohn's disease.
Topics: Adult; Aged; Anus Diseases; Azathioprine; Colitis; Colitis, Ulcerative; Colonic Diseases; Crohn Dise | 1973 |
[Immunosuppressive therapy of ulcerative colitis and Crohn's disease].
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppressive Agents | 1973 |
Immunosuppressive therapy.
Topics: Anemia, Hemolytic, Autoimmune; Antigen-Antibody Reactions; Arthritis, Rheumatoid; Azathioprine; Croh | 1973 |
Azathioprine in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Intestinal Fistula; Leukopenia; Nausea | 1973 |
[Medical treatment of regional enteritis].
Topics: Azathioprine; BCG Vaccine; Crohn Disease; Diet Therapy; Glucocorticoids; Humans | 1973 |
Crohn's disease in Transvaal blacks. A report of three cases with a review.
Topics: Acute Disease; Adult; Azathioprine; Black or African American; Black People; Crohn Disease; Diagnosi | 1974 |
Acute pancreatitis as a complication of Imuran therapy in regional enteritis.
Topics: Acute Disease; Amylases; Azathioprine; Crohn Disease; Female; Humans; Middle Aged; Pancreatitis; Tim | 1972 |
Immunosuppressants and Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine | 1972 |
Subphrenic abscess in a patient with Crohn's disease.
Topics: Adult; Anti-Bacterial Agents; Azathioprine; Crohn Disease; Drainage; Humans; Male; Subphrenic Absces | 1972 |
Intraabdominal abscesses due to azathioprine for Crohn's disease.
Topics: Abdomen; Abscess; Adolescent; Azathioprine; Blood Sedimentation; Crohn Disease; Humans; Male; Neutro | 1972 |
Immunosuppressive therapy for ulcerative colitis, ileitis, and granulomatous colitis.
Topics: Adult; Autoimmune Diseases; Azathioprine; Colitis, Ulcerative; Crohn Disease; Evaluation Studies as | 1972 |
[Treatment of chronic enteropathies using cytostatic agents].
Topics: Antineoplastic Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans | 1972 |
Azathioprine therapy for Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Colon; Crohn Disease; Female; Humans; Ileum; Male; Middle Aged; Rec | 1972 |
Crohn's disease of the appendix.
Topics: Appendicitis; Appendix; Azathioprine; Colon; Crohn Disease; Duodenum; Humans; Ileum; Meckel Divertic | 1972 |
Anorectal Crohn's disease.
Topics: Adult; Aged; Anus Diseases; Azathioprine; Biopsy; Crohn Disease; Female; Humans; Male; Middle Aged; | 1972 |
Crohn's disease and immunosuppressive therapy.
Topics: Animals; Azathioprine; Crohn Disease; Humans; Mice; Prednisolone; Recurrence | 1972 |
Azathioprine in the treatment of Crohn's disease.
Topics: Adolescent; Adult; Aged; Anus Diseases; Azathioprine; Barium Sulfate; Colon; Crohn Disease; Female; | 1972 |
[Immunosuppression in Crohn's disease].
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppression Therapy | 1971 |
Azathioprine (Imurel) therapy in Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Diarrhea; Humans; Male; Pain | 1971 |
[Imurel therapy in Crohn's disease].
Topics: Azathioprine; Crohn Disease; Humans | 1971 |
[Crohn's disease treated with azathioprine(Imurel)].
Topics: Azathioprine; Crohn Disease; Humans | 1971 |
[Combined surgical and clinical therapy of regional enteritis].
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Crohn Disease; Female; Follow-Up Stu | 1971 |
[Indication for antiphlogistic, antiproliferative therapy in Crohn's disease].
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Humans; Male; Prednisone | 1971 |
[Immunosuppressive agents in granulomatous ileo-colitis. 2 cases with favorable outcome].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Colectomy; Crohn Disease; Female; Humans; | 1970 |
Not so non-specific inflammatory disease of the colon.
Topics: Autoantibodies; Azathioprine; Colitis, Ulcerative; Colon; Crohn Disease; Diagnosis, Differential; Gl | 1970 |
Azathioprine: an adjunct to surgical therapy of granulomatous enteritis.
Topics: Adult; Azathioprine; Blood Proteins; Body Weight; Crohn Disease; Diarrhea; Diet Therapy; Feces; Fema | 1970 |
Azathioprine therapy for inflammatory bowel disease. A preliminary report.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Chronic Disease; Colitis, Ulcerative; | 1970 |
Immunosuppressive therapy of Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male | 1971 |
Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis.
Topics: Adolescent; Adult; Aged; Azathioprine; Carcinoma; Colectomy; Colitis, Ulcerative; Colonic Neoplasms; | 1971 |
Azathioprine in the treatment of Crohn's disease.
Topics: Azathioprine; Child; Child, Preschool; Crohn Disease; Female; Humans; Male | 1971 |
Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
Topics: Adalimumab; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colitis, Ulcerative; Crohn | 2020 |
Bone density in pediatric Crohn's disease: A cross-sectional observation from South India.
Topics: Absorptiometry, Photon; Adolescent; Body Mass Index; Bone Density; Child; Child, Preschool; Crohn Di | 2017 |
Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease.
Topics: Adult; Biological Therapy; Canada; Cost-Benefit Analysis; Crohn Disease; Decision Support Techniques | 2017 |
Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease.
Topics: Adalimumab; Adult; Crohn Disease; Feces; Female; Gastrointestinal Agents; Humans; Immunosuppressive | 2018 |
Positioning biological agents: Session two summary.
Topics: Adult; Antibodies, Monoclonal, Humanized; Crohn Disease; Digestive System Surgical Procedures; Femal | 2018 |
Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2013 |
Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease.
Topics: Adolescent; Adult; Age Factors; Chemical and Drug Induced Liver Injury; Cohort Studies; Crohn Diseas | 2013 |
Ustekinumab for Resistant Pediatric Crohn Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Crohn Disease; Drug Administration Schedule; Drug Mo | 2016 |
Risk factors for initial surgery in patients with Crohn's disease in Central China.
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Appendectomy; Child; China; Crohn Diseas | 2015 |
The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Cohort Studies; Colitis, Ulc | 2015 |
Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines.
Topics: Adolescent; Adult; Antibody Formation; Crohn Disease; Drug Therapy, Combination; Female; Humans; Imm | 2017 |
Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease.
Topics: Adult; Biological Availability; Case-Control Studies; Crohn Disease; Female; Humans; Immunosuppressi | 2008 |
Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2010 |
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2012 |
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2012 |
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2012 |
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2012 |
[Guidelines for the management of Crohn's disease].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Budesonide; Crohn | 2012 |
[Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Crohn Disease; Female; Gastrointestinal Dise | 2012 |
Adherence to thiopurine treatment in out-patients with Crohn's disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Crohn Disease; Female; Humans; Immunosuppressive | 2007 |
Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.
Topics: Adolescent; Chi-Square Distribution; Child; Crohn Disease; Female; Humans; Immunosuppressive Agents; | 2007 |